Nitrogen containing heterobicycles as factor Xa inhibitors

ABSTRACT

The present application describes nitrogen containing heterobicyclics and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.

[0001] This application is a divisional application of U.S. application Ser. No. 09/470,326 filed on Dec. 22, 1999 and now allowed, which claims the benefit of U.S. Provisional Application No. 60/113,628, filed on Dec. 23, 1998 and U.S. Provisional Application No. 60/127,633, filed on Apr. 2, 1999, the contents of which are hereby incorporated by reference.

FIELD OF THE INVENTION

[0002] This invention relates generally to nitrogen containing heterobicycles, which are inhibitors of trypsin-like serine protease enzymes, especially factor Xa, pharmaceutical compositions containing the same, and methods of using the same as anticoagulant agents for treatment and prevention of thromboembolic disorders.

BACKGROUND OF THE INVENTION

[0003] WO94/20460 describes angiotensin II compounds of the following formula:

[0004] wherein X can be a number of substituents and Het can be a nitrogen-containing heterobicycle. However, WO94/20460 does not suggest Factor Xa inhibition or exemplify compounds like those of the present invention.

[0005] WO96/12720 describes phosphodiesterase type IV and TNF production inhibitors of the following formula:

[0006] wherein X can be oxygen and R² and R³ can a number of substituents including heterocycle, heterocycloalkyl, and phenyl. However, the presently claimed compounds do not correspond to the compounds of WO96/12720. Furthermore, WO96/12720 does not suggest Factor Xa inhibition.

[0007] WO98/52948 describes inhibitors of ceramide-mediated signal transduction. One of the types of inhibitors described is of the following formula:

[0008] wherein Y₁ can be N—R₆, R₆ can be unsubstituted aryl-alkyl or unsubstituted heterocyclic-alkyl and R₁ can be a substituted aryl group. WO98/52948 does not mention factor Xa inhibition or show compounds like those of the present invention.

[0009] U.S. Pat. Nos. 3,365,459 and 3,340,269 illustrates anti-inflammatory inhibitors of the following formula:

[0010] wherein A is 2-3 carbon atoms, X can be O, and R¹ and R³ can be substituted or unsubstituted aromatic groups. Neither of these patents, however, exemplify compounds of the present invention.

[0011] Activated factor Xa, whose major practical role is the generation of thrombin by the limited proteolysis of prothrombin, holds a central position that links the intrinsic and extrinsic activation mechanisms in the final common pathway of blood coagulation. The generation of thrombin, the final serine protease in the pathway to generate a fibrin clot, from its precursor is amplified by formation of prothrombinase complex (factor Xa, factor V, Ca²⁺ and phospholipid). Since it is calculated that one molecule of factor Xa can generate 138 molecules of thrombin (Elodi, S., Varadi, K.: Optimization of conditions for the catalytic effect of the factor IXa-factor VIII Complex: Probable role of the complex in the amplification of blood coagulation. Thromb. Res. 1979, 15, 617-629), inhibition of factor Xa may be more efficient than inactivation of thrombin in interrupting the blood coagulation system.

[0012] Therefore, efficacious and specific inhibitors of factor Xa are needed as potentially valuable therapeutic agents for the treatment of thromboembolic disorders. It is thus desirable to discover new factor Xa inhibitors.

SUMMARY OF THE INVENTION

[0013] Accordingly, one object of the present invention is to provide novel nitrogen containing heterobicycles that are useful as factor Xa inhibitors or pharmaceutically acceptable salts or prodrugs thereof.

[0014] It is another object of the present invention to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt or prodrug form thereof.

[0015] It is another object of the present invention to provide a method for treating thromboembolic disorders comprising administering to a host in need of such treatment a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt or prodrug form thereof.

[0016] It is another object of the present invention to provide novel bicyclic compounds for use in therapy.

[0017] It is another object of the present invention to provide the use of novel bicyclic compounds for the manufacture of a medicament for the treatment of a thromboembolic disorder.

[0018] These and other objects, which will become apparent during the following detailed description, have been achieved by the inventors' discovery that the presently claimed bicyclic compounds, or pharmaceutically acceptable salt or prodrug forms thereof, are effective factor Xa inhibitors.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

[0019] [1] Thus, in a first embodiment, the present invention provides a novel compound selected from the group:

[0020] or a stereoisomer or pharmaceutically acceptable salt thereof, wherein compounds of the above formulas are substituted with 0-2 R³;

[0021] G is a group of formula I or II:

[0022] ring D is selected from —(CH₂)₃—, —(CH₂)₄—, —CH₂N═CH—, —CH₂CH₂N═CH—, and a 5-6 membered aromatic system containing from 0-2 heteroatoms selected from the group N, O, and S, provided that from 0-1 O and S atoms are present;

[0023] ring D, when present, is substituted with 0-2 R;

[0024] E is selected from phenyl, pyridyl, pyrimidyl, pyrazinyl, and pyridazinyl, substituted with 0-1 R;

[0025] R is selected from Cl, F, Br, I, OH, C₁₋₃ alkoxy, NH₂, NH(C₁₋₃alkyl), N(C₁₋₃ alkyl)₂, CH₂NH₂, CH₂NH(C₁₋₃ alkyl), CH₂N(C₁₋₃ alkyl)₂, CH₂CH₂NH₂, CH₂CH₂NH(C₁₋₃ alkyl), and CH₂CH₂N(C₁₋₃ alkyl)₂;

[0026] alternatively, ring D is absent;

[0027] when ring D is absent, ring E is selected from phenyl, pyridyl, pyrimidyl, pyrazinyl, and pyridazinyl, and ring E is substituted with R″ and R′;

[0028] R″ is selected from F, Cl, Br, I, OH, C₁₋₃ alkoxy, CN, C(═NR⁸)NR⁷R⁹, NHC(═NR⁸)NR⁷R⁹, NR⁸CH(═NR⁷), C(O)NR⁷R⁸, (CR⁸R⁹)_(t)NR⁷R⁸, SH, C₁₋₃ alkyl-S, S(O)R^(3b), S(O)₂R^(3a), S(O)₂NR²R^(2a), and OCF₃;

[0029] R′ is selected from H, F, Cl, Br, I, SR³, CO₂R³, NO₂, (CH₂)_(t)OR³, C₁₋₄ alkyl, OCF₃, CF₃, C(O)NR⁷R⁸, and (CR⁸R⁹)_(t)NR⁷R⁸;

[0030] alternatively, R″ and R′ combine to form methylenedioxy or ethylenedioxy;

[0031] Z is N or CR^(1a);

[0032] Z¹ is S, O, or NR³;

[0033] Z² is selected from H, C₁₋₄ alkyl, phenyl, benzyl, C(O)R³, and S(O)_(p)R^(3c);

[0034] R^(1a) is selected from H, —(CH₂)_(r)—R^(1′), —CH═CH—R^(1′), NHCH₂R^(1″), OCH₂R^(1″), SCH₂R^(1″), NH(CH₂)₂(CH₂)_(t)R^(1′), O(CH₂)₂(CH₂)_(t)R^(1′), and S(CH₂)₂(CH₂)_(t)R^(1′);

[0035] R^(1′) is selected from H, C₁₋₃ alkyl, F, Cl, Br, I, —CN, —CHO, (CF₂)_(r)CF₃, (CH₂)_(r)OR², NR²R^(2a), C(O)R^(2c), OC(O)R², (CF₂)_(r)CO₂R^(2c), S(O)_(p)R^(2b), NR²(CH₂)_(r)OR², C(═NR²C)NR²R^(2a), NR²C(O)R^(2b), NR²C(O)R³, NR²C(O)NHR^(2b), NR²C (O)₂R^(2a), OC(O)NR^(2a)R^(2b), C(O)NR²R^(2a), C(O)NR²(CH₂)_(r)OR², SO₂NR²R^(2a), NR²SO₂R^(2b), C₃₋₆ carbocyclic residue substituted with 0-2 R^(4a), and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R^(4a);

[0036] R^(1″) is selected from H, CH(CH₂OR²)₂, C(O)R^(2c), C(O)NR²R^(2a), S(O)R^(2b), S(O)₂R^(2b), and SO₂NR²R^(2a);

[0037] R², at each occurrence, is selected from H, CF₃, C₁₋₆ alkyl, benzyl, C₃₋₆ carbocyclic residue substituted with 0-2 R^(4b), a C₃₋₆ carbocyclic-CH₂— residue substituted with 0-2 R^(4b), and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R^(4b);

[0038] R^(2a), at each occurrence, is selected from H, CF₃, C₁₋₆ alkyl, benzyl, C₃₋₆ carbocyclic residue substituted with 0-2 R^(4b), and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R^(4b);

[0039] R^(2b), at each occurrence, is selected from CF₃, C₁₋₄ alkoxy, C₁₋₆ alkyl, benzyl, C₃₋₆ carbocyclic residue substituted with 0-2 R^(4b), and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R^(4b);

[0040] R^(2c), at each occurrence, is selected from CF₃, OH, C₁₋₄ alkoxy, C₁₋₆ alkyl, benzyl, C₃₋₆ carbocyclic residue substituted with 0-2 R^(4b), and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R^(4b);

[0041] alternatively, R² and R^(2a), together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R^(4b) and containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

[0042] R³, at each occurrence, is selected from H, C₁₋₄ alkyl, and phenyl;

[0043] R^(3a), at each occurrence, is selected from H, C₁₋₄ alkyl, and phenyl;

[0044] R^(3b), at each occurrence, is selected from H, C₁₋₄ alkyl, and phenyl;

[0045] R^(3c), at each occurrence, is selected from C₁₋₄ alkyl, and phenyl;

[0046] A is selected from:

[0047] C₃₋₁₀ carbocyclic residue substituted with 0-2 R⁴, and

[0048] 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R⁴;

[0049] B is selected from:

[0050] Y, X-Y, C(═NR²)NR²R^(2a), NR²C(═NR²)NR²R^(2a),

[0051] C₃₋₁₀ carbocyclic residue substituted with 0-2 R^(4a), and

[0052] 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R^(4a);

[0053] X is selected from C₁₋₄ alkylene, —CR²(CR²R^(2b)) (CH₂)_(t)—, —C(O)—, —C(═NR^(1″))—, —CR²(NR^(1″)R²)—, —CR²(OR²)—, —CR²(SR²)—, —C(O)CR²R^(2a)—, —CR²R^(2a)C(O) , —S(O)_(p)—, —S(O)_(p)CR²R^(2a)—, —CR²R^(2a)S(O)_(p)—, —S(O)₂NR²—, —NR²S(O)₂—, —NR²S(O)₂CR²R^(2a)—, —CR²R^(2a)S(O)₂NR²—, —NR²S(O)₂NR²—, —C(O)NR²—, —NR²C(O)—, —C(O)NR²CR²R^(2a)—, —NR²C(O)CR²R^(2a)—, —CR²R^(2a)C(O)NR²—, —CR²R^(2a)NR²C(O)—, —NR²C(O)O—, —OC(O)NR²—, —NR²C(O)NR²—, —NR²—, NR²CR²R^(2a)—, —CR²R^(2a)NR²—, O, —CR²R^(2a)O, and —OCR²R^(2a)—;

[0054] Y is selected from:

[0055] CH₂NR²R^(2a);

[0056] CH₂CH₂NR²R^(2a);

[0057] C₃₋₁₀ carbocyclic residue substituted with 0-2 R^(4a), and

[0058] 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R^(4a);

[0059] R⁴, at each occurrence, is selected from H, ═O, (CH₂)_(r)OR², F, Cl, Br, I, C₁₋₄ alkyl, —CN, NO₂, (CH₂)_(r)NR²R^(2a), (CH₂)_(r)C(O)R^(2c), NR²C(O)R^(2b), C(O)NR²R^(2a), NR²C(O)NR²R^(2a), C(═NR²)NR²R^(2a), C(═NS(O)₂R⁵)NR²R^(2a), NHC(═NR²)NR²R^(2a), C(O)NHC(═NR²)NR²R^(2a), SO₂NR²R^(2a), NR²SO₂NR²R^(2a), NR²SO₂—C₁₋₄ alkyl, NR²SO₂R⁵, S(O)_(p)R⁵, (CF₂)_(r)CF₃, NCH₂R^(1″), OCH₂R^(1″), SCH₂R^(1″), N(CH₂)₂(CH₂)_(t)R^(1′), O(CH₂)₂(CH₂)_(t)R^(1′), and S(CH₂)₂(CH₂)_(t)R^(1′);

[0060] alternatively, one R⁴ is a 5-6 membered aromatic heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;

[0061] R^(4a), at each occurrence, is selected from H, ═O, (CH₂)_(r)OR², (CH₂)_(r)—F, (CH₂)_(r)—Br, (CH₂)_(r)—Cl, Cl, Br, F, I, C₁₋₄ alkyl, —CN, NO₂, (CH₂)_(r)NR²R^(2a), (CH₂)_(r)C(O)R^(2c)C, NR²C(O)R^(2b), C(O)NR²R^(2a), (CH₂)_(r)N═CHOR³, C(O)NH(CH₂)₂NR²R^(2a), NR²C (O)NR²R^(2a), C(═NR²)NR²R^(2a), NHC(═NR²)NR²R^(2a), SO₂NR²R^(2a), NR²SO₂NR²R^(2a), NR²SO₂—C₁₋₄ alkyl, C(O)NHSO₂—C₁₋₄ alkyl, NR²SO₂R⁵, S(O)_(p)R⁵, and (CF₂)_(r)CF₃;

[0062] alternatively, one R^(4a) is a 5-6 membered aromatic heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-1 R⁵;

[0063] R^(4b), at each occurrence, is selected from H, ═O, (CH₂)_(r)OR³, F, Cl, Br, I, C₁₋₄ alkyl, —CN, NO₂, (CH₂)_(r)NR³R^(3a), (CH₂)_(r)C(O)R³, (CH₂)_(r)C(O)OR^(3c), NR³C(O)R^(3a), C(O)NR³R³a, NR³C(O)NR³R³a, C(═NR³)NR³R³a, NR³C(═NR³)NR³R³a, SO₂NR³R^(3a), NR³SO₂NR³R^(3a), NR³SO₂—C₁₋₄ alkyl, NR³SO₂CF₃, NR³SO₂-phenyl, S(O)_(p)CF₃, S(O)_(p)C₁₋₄ alkyl, S(O)_(p)-phenyl, and (CF₂)_(r)CF₃;

[0064] R⁵, at each occurrence, is selected from CF₃, C₁₋₆ alkyl, phenyl substituted with 0-2 R⁶, and benzyl substituted with 0-2 R⁶;

[0065] R⁶, at each occurrence, is selected from H, OH, (CH₂)_(r)OR², halo, C₁₋₄ alkyl, CN, NO₂, (CH₂)_(r)NR²R^(2a),(CH₂)_(r)C(O)R^(2b), NR²C(O)R^(2b), NR²C(O)NR²R^(2a), C(═NH)NH₂, NHC(═NH)NH₂, SO₂NR²R^(2a), NR²SO₂NR²R^(2a), and NR²SO₂C₁₋₄ alkyl;

[0066] R⁷, at each occurrence, is selected from H, OH, C₁₋₆ alkyl, C₁₋₆ alkylcarbonyl, C₁₋₆ alkoxy, C₁₋₄ alkoxycarbonyl, (CH₂)_(n)-phenyl, C₆₋₁₀ aryloxy, C₆₋₁₀ aryloxycarbonyl, C₆₋₁₀ arylmethylcarbonyl, C₁₋₄ alkylcarbonyloxy C₁₋₄ alkoxycarbonyl, C₆₋₁₀ arylcarbonyloxy C₁₋₄ alkoxycarbonyl, C₁₋₆ alkylaminocarbonyl, phenylaminocarbonyl, and phenyl C₁₋₄ alkoxycarbonyl;

[0067] R⁸, at each occurrence, is selected from H, C₁₋₆ alkyl and (CH₂)_(n)-phenyl;

[0068] alternatively, R⁷ and R⁸ combine to form a 5 or 6 membered saturated, ring which contains from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

[0069] R⁹, at each occurrence, is selected from H, C₁₋₆ alkyl and (CH₂)_(n)-phenyl;

[0070] n, at each occurrence, is selected from 0, 1, 2, and 3;

[0071] m, at each occurrence, is selected from 0, 1, and 2;

[0072] p, at each occurrence, is selected from 0, 1, and 2;

[0073] r, at each occurrence, is selected from 0, 1, 2, and 3;

[0074] s, at each occurrence, is selected from 0, 1, and 2; and,

[0075] t, at each occurrence, is selected from 0, 1, 2, and 3.

[0076] [2] In a preferred embodiment, the present invention provides a novel compound, wherein the compound is selected from the group:

[0077] wherein compounds of the above formulas are substituted with 0-2 R³;

[0078] G is selected from the group:

[0079] A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R⁴;

[0080] phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, benzofuranyl, benzothiofuranyl, indolyl, benzimidazolyl, benzoxazolyl, benzthiazolyl, indazolyl, benzisoxazolyl, benzisothiazolyl, and isoindazolyl;

[0081] B is selected from: Y, X—Y, C(═NR²)NR²R^(2a), and NR²C (═NR²)NR²R^(2a);

[0082] X is selected from C₁₋₄ alkylene, —C(O)—, —C(═NR)—, —CR²(NR²R^(2a))—, —C(O)CR²R^(2a)—, —CR²R^(2a)C(O), —C(O)NR²—, —NR²C(O)—, —C(O)NR²CR²R^(2a)—, —NR²C(O)CR²R^(2a)—, —CR²R^(2a)C(O)NR²—, —CR²R^(2a)NR²C(O)—, —NR²C(O)NR²—, —NR²—, —NR²CR²R^(2a)—, —CR²R^(2a)NR²—, O, —CR²R^(2a)O—, and —OCR²R^(2a)—;

[0083] Y is CH₂NR²R^(2a) or CH₂CH₂NR²R^(2a);

[0084] alternatively, Y is selected from one of the following carbocyclic and heterocyclic systems that are substituted with 0-2 R^(4a);

[0085] cyclopropyl, cyclopentyl, cyclohexyl, phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, isoxazolinyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, benzofuranyl, benzothiofuranyl, indolyl, benzimidazolyl, benzoxazolyl, benzthiazolyl, indazolyl, benzisoxazolyl, benzisothiazolyl, and isoindazolyl;

[0086] alternatively, Y is selected from the following bicyclic heteroaryl ring systems:

[0087] K is selected from O, S, NH, and N; and,

[0088] s is 0.

[0089] [3] In a more preferred embodiment, the present invention provides a novel compound, wherein the compound is selected from the group:

[0090] wherein compounds of the above formulas are substituted with 0-2 R³;

[0091] G is selected from the group:

[0092] [4] In an even more preferred embodiment, the present invention provides a novel compound, wherein:

[0093] G is selected from:

[0094] [5] In a still more preferred embodiment, the present invention provides a novel compound, wherein;

[0095] A is selected from phenyl, pyridyl, and pyrimidyl, and is substituted with 0-2 R⁴; and,

[0096] B is selected from X—Y, phenyl, pyrrolidino, morpholino, 1,2,3-triazolyl, and imidazolyl, and is substituted with 0-1 R^(4a);

[0097] R², at each occurrence, is selected from H, CH₃, CH₂CH₃, cyclopropylmethyl, cyclobutyl, and cyclopentyl;

[0098] R^(2a), at each occurrence, is H or CH₃;

[0099] alternatively, R² and R^(2a), together with the atom to which they are attached, combine to form pyrrolidine substituted with 0-2 R^(4b);

[0100] R⁴, at each occurrence, is selected from OH, (CH₂)_(r)OR², halo, C₁₋₄ alkyl, (CH₂)_(r)NR²R^(2a), and (CF₂)_(r)CF₃;

[0101] R^(4a) is selected from C₁₋₄ alkyl, CF₃, (CH₂)_(r)OR², (CH₂)_(r)NR²R^(2a), S(O)_(p)R⁵, SO₂NR²R^(2a), and 1-CF₃-tetrazol-2-yl;

[0102] R^(4b), at each occurrence, is selected from H, CH₃, and OH;

[0103] R⁵, at each occurrence, is selected from CF₃, C₁₋₆ alkyl, phenyl, and benzyl;

[0104] X is CH₂ or C(O);

[0105] Y is selected from pyrrolidino and morpholino; and,

[0106] r, at each occurrence, is selected from 0, 1, and 2.

[0107] [6] In a further preferred embodiment, the present invention provides a novel compound, wherein;

[0108] A is selected from the group: phenyl, 2-pyridyl, 3-pyridyl, 2-pyrimidyl, 2-Cl-phenyl, 3-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 2-methylphenyl, 2-aminophenyl, and 2-methoxyphenyl; and,

[0109] B is selected from the group: 2-(aminosulfonyl)phenyl, 2-(methylaminosulfonyl)phenyl, 1-pyrrolidinocarbonyl, 2-(methylsulfonyl)phenyl, 2-(N,N-dimethylaminomethyl)phenyl, 2-(N-pyrrolidinylmethyl)phenyl, 1-methyl-2-imidazolyl, 2-methyl-1-imidazolyl, 2-(dimethylaminomethyl)-1-imidazolyl, 2-(N-(cyclopropylmethyl)aminomethyl)phenyl, 2-(N-(cyclobutyl)aminomethyl)phenyl, 2-(N-(cyclopentyl)aminomethyl)phenyl, and 2-(N-(3-hydroxypyrrolidinyl)methyl)phenyl.

[0110] [7] In an even further preferred embodiment, the present invention provides a novel compound selected from:

[0111] 1-[4-Methoxyphenyl]-3-cyano-6-[2′-methylsulfonyl-3-fluoro-[1,1′]-biphen-4-yl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;

[0112] 1-[4-Methoxyphenyl]-3-(methoxycarbonyl)-6-[2′-aminosulfonyl-3-fluoro-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

[0113] 1-[4-Methoxyphenyl]-3-(aminocarbonyl)-6-[2′-aminosulfonyl-3-fluoro-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

[0114] 1-[4-Methoxyphenyl]-3-(methoxycarbonyl)-6-[2′-aminosulfonyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

[0115] 1-[4-Methoxyphenyl]-6-[2′-aminosulfonyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one-3-carboxylic acid;

[0116] 1-[4-Methoxyphenyl]-3-(aminocarbonyl)-6-[2′-aminosulfonyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

[0117] 1-[4-Methoxyphenyl]-3-cyano-6-[2′-aminosulfonyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

[0118] 1-[4-Methoxyphenyl]-3-(aminomethyl)-6-[2′-aminosulfonyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

[0119] 1-[4-Methoxyphenyl]-3-(ethoxycarbonyl)-6-[4-(2-methylimidazol-1′-yl)phenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

[0120] 1-[4-Methoxyphenyl]-3-(aminocarbonyl)-6-[4-(2-methylimidazol-1′-yl)phenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

[0121] 1-[4-Methoxyphenyl]-3-(ethoxycarbonyl)-6-[2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

[0122] 1-[4-Methoxyphenyl]-3-(ethoxycarbonyl)-6-[2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[4,3-d]-pyrimidin-7-one;

[0123] 1-[4-Methoxyphenyl]-3-(aminocarbonyl)-6-[2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

[0124] 1-[4-Methoxyphenyl]-3-cyano-6-[2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

[0125] 1-[4-Methoxyphenyl]-3-(ethoxycarbonyl)-6-[2-fluoro-4-(2-dimethylaminomethylimidazol-1′-yl)phenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

[0126] 1-[2-Aminomethylphenyl]-3-(ethoxycarbonyl)-6-[2′-methylsulfonyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

[0127] 1-[3-Aminoiminomethylphenyl]-3-methyl-6-[2′-aminosulfonyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;

[0128] 1-[2-Aminomethylphenyl]-3-methyl-6-[2′-aminosulfonyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;

[0129] 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-aminosulfonyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;

[0130] 1-[4-Methoxyphenyl]-3-cyano-6-[2′-N,N-dimethylaminomethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

[0131] 1-[4-Methoxyphenyl]-3-cyano-5-methyl-6-[2′-N,N-dimethylaminomethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

[0132] 1-[2-Aminomethylphenyl]-3-cyano-6-[2′-methylsulfonyl-3-fluoro-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

[0133] 1-[4-Methoxyphenyl]-3-trifluoromethyl-4-methyl-6-[2′-aminosulfonyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[3,4-d]-pyridazin-7-one;

[0134] 1-[4-Methoxyphenyl]-3-trifluoromethyl-4-methyl-6-[2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[3,4-d]-pyridazin-7-one,

[0135] 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[4-(1-methylimidazol-2′-yl)phenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

[0136] 1-[4-Methoxyphenyl]-3-(ethoxycarbonyl)-6-[2′-hydroxymethyl-3-fluoro-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

[0137] 1-[4-Methoxyphenyl]-3-(ethoxycarbonyl)-6-[2′-N-pyrrolidinylmethyl-3-fluoro-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d-pyrimidin-7-one;

[0138] 1-[4-Methoxyphenyl]-3-(aminocarbonyl)-6-[2′-N-pyrrolidinylmethyl-3-fluoro-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

[0139] 1-[4-Methoxyphenyl]-3-(aminocarbonyl)-6-[2′-(3-(R)-hydroxy-N-pyrrolidinylmethyl)-3-fluoro-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

[0140] 1-[4-Methoxyphenyl]-3-(N-formylaminomethyl)-6-[2′-methylsulfonyl-3-fluoro-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

[0141] 1-[3-Aminobenzisoxazol-5′-yl]-3-(ethoxycarbonyl)-6-[2′-hydroxymethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

[0142] 1-[3-Aminobenzisoxazol-5′-yl]-3-(ethoxycarbonyl)-6-[2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

[0143] 1-[4-Methoxyphenyl]-3-trifluoromethyl-7-[2′-methylsulfonyl-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one;

[0144] 1-[4-Methoxyphenyl]-3-trifluoromethyl-7-[2′-aminosulfonyl-3-fluoro-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one;

[0145] 1-[4-Methoxyphenyl]-3-trifluoromethyl-7-[2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one;

[0146] 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-7-[2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one;

[0147] 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-7-[2′-N-dimethylaminomethyl-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one;

[0148] 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-7-[2′-N-isopropylaminomethyl-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one;

[0149] 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-7-[2′-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one;

[0150] 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-7-[2′-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-3-fluoro-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one;

[0151] 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-7-[2′-N-pyrrolidinylmethyl-3-fluoro-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one;

[0152] 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-7-[2′-N-dimethylaminomethyl-3-fluoro-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one;

[0153] 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-7-[2′-N-isopropylaminomethyl-3-fluoro-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one;

[0154] 1-[4-Methoxyphenyl]-3-trifluoromethyl-7-[4-(2-dimethylaminomethylimidazol-1′-yl)-3-fluorophenyl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one;

[0155] 1-[4-Methoxyphenyl]-3-trifluoromethyl-7-[4-(imidazol-1′-yl)-3-fluorophenyl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one;

[0156] 1-[2-Aminomethylphenyl]-3-trifluoromethyl-7-[2′-methylsulfonyl-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one;

[0157] 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydro-7H-pyrazolo-[3,4-c]-pyridin-7-one;

[0158] 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-(3-(S)-hydroxy-N-pyrrolidinyl)methyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydro-7H-pyrazolo-[3,4-c]-pyridin-7-one;

[0159] 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-N-isopropylaminomethyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydro-7H-pyrazolo-[3,4-c]-pyridin-7-one;

[0160] 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-N,N-dimethylaminomethyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydro-7H-pyrazolo-[3,4-c]-pyridin-7-one;

[0161] 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-methylsulfonyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydro-7H-pyrazolo-[3,4-c]-pyridin-7-one;

[0162] 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-methylsulfonyl-3-fluoro-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydro-7H-pyrazolo- [3,4-c]-pyridin-7-one;

[0163] 1-[2-Aminomethylphenyl]-3-trifluoromethyl-6-[2′-methylsulfonyl-3-fluoro-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;

[0164] 1-[2-Aminomethylphenyl]-3-trifluoromethyl-6-[2′-aminosulfonyl-3-fluoro-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;

[0165] 1-[2-Aminomethylphenyl]-3-trifluoromethyl-6-[2′-methylsulfonyl-[1,1]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;

[0166] 1-[2-Aminomethylphenyl]-3-trifluoromethyl-6-[2′-N,N-dimethylaminomethyl-3-fluoro-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;

[0167] 1-[2-Aminomethylphenyl]-3-trifluoromethyl-6-[2′-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-3-fluoro-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;

[0168] 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-dimethylaminomethyl-3-fluoro-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;

[0169] 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-3-fluoro-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;

[0170] 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;

[0171] 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-isopropylaminomethyl-3-fluoro-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;

[0172] 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-N-(2-methylimidazol-1-yl)methyl-3-fluoro-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;

[0173] 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-N-pyrrolidinomethyl-3-fluoro-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;

[0174] 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-oximinomethyl-3-fluoro-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;

[0175] 1-[4-Methoxyphenyl]-3-trifluoromethyl-6-[2′-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-3-fluoro-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;

[0176] 1-[3-Aminomethylphenyl]-3-trifluoromethyl-6-[2′-methylsulfonyl-3-fluoro-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;

[0177] 1-[4-Methoxyphenyl]-3-[(imidazol-1-yl)methyl]-5-methyl-6-[(2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl)]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

[0178] 1-[4-Methoxyphenyl]-3-[(tetrazol-1-yl)methyl]-5-methyl-6-[(2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl)]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

[0179] 1-[4-Methoxyphenyl]-3-[(tetrazol-2-yl)methyl]-5-methyl-6-[(2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl)]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

[0180] 1-[3-Aminobenzisoxazol-5′-yl]-3,5-dimethyl-6-[2′-N-dimethylaminomethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

[0181] 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-N,N-dimethylaminomethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

[0182] 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-N-isopropylaminomethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

[0183] 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

[0184] 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[4-(4,5-dihydroimidazol-1′-yl)phenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

[0185] 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-N-(cyclopropylmethyl)aminomethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

[0186] 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

[0187] 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-(N-methyl-N-isopropyl)aminomethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

[0188] 1-[3-Aminobenzisoxazol-5′-yl]-3,5-dimethyl-6-[2′-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

[0189] 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-N,N-dimethylaminomethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

[0190] 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-N,N-dimethylaminomethyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[4,3-d]-pyrimidin-7-one;

[0191] 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1′-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[4,3-d]-pyrimidin-7-one;

[0192] 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-(3-(S)-hydroxy-N-pyrrolidinyl)methyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;

[0193] 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-N-(pyrrolindinyl)methyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;

[0194] 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-N-(morpholino)methyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;

[0195] 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-N,N-dimethylaminomethyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;

[0196] 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-7-[(3′-N-dimethylaminomethyl)-3-fluoro-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]azepin-8-one;

[0197] 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-7-[(3′-N-pyrrolidinylmethyl)-3-fluoro-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]azepin-8-one;

[0198] 1-[4-Methoxyphenyl]-3-trifluoromethyl-7-[(3′-N-pyrrolidinylmethyl)-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]azepin-8-one;

[0199] 1-[4-Methoxyphenyl]-3-trifluoromethyl-7-[(3′-N-dimethylaminomethyl)-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]azepin-8-one;

[0200] 1-[4-Methoxyphenyl]-3-trifluoromethyl-7-[4-benzimidazol-1′-yl-3-fluorophenyl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]azepin-8-one;

[0201] 1-[3-Aminobenzisoxazo-5′-yl]-3-trifluoromethyl-7-[(2′-N-pyrrolidinylmethyl)-3-fluoro-[1,1′]-biphen-4-yl]-6,7-dihydropyrazolo-[3,4-c]azepin-8-one;

[0202] 1-[3-Aminobenzisoxazo-5′-yl]-3-trifluoromethyl-7-[(2′-N-dimethylaminomethyl)-3-fluoro-[1,1′]-biphen-4-yl]-6,7-dihydropyrazolo-[3,4-c]azepin-8-one;

[0203] 1-[3-Aminobenzisoxazo-5′-yl]-3-trifluoromethyl-7-[(2′-N-(R)-3-hydroxypyrrolidinylmethyl)-3-fluoro-[1,1′]-biphen-4-yl]-6,7-dihydropyrazolo-[3,4-c]azepin-8-one;

[0204] 1-[3-Aminobenzisoxazo-5′-yl]-3-trifluoromethyl-7-[(2′-N-(R)-3-hydroxypyrrolidinylmethyl)-[1,1′]-biphen-4-yl]-6,7-dihydropyrazolo-[3,4-c]azepin-8-one;

[0205] 1-[3-Aminobenzisoxazo-5′-yl]-3-trifluoromethyl-7-[(2′-N-dimethylaminomethyl)-[1,1′]-biphen-4-yl]-6,7-dihydropyrazolo-[3,4-c]azepin-8-one;

[0206] 1-[4-Methoxyphenyl]-3-trifluoromethyl-7-[(2′-N-pyrrolidinylmethyl)-[1,1′]-biphen-4-yl]-6,7-dihydropyrazolo-[3,4-c]azepin-8-one;

[0207] 1-[4-Methoxyphenyl]-3-trifluoromethyl-7-[(2′-N,N-dimethylaminomethyl)-[1,1′]-biphen-4-yl]-6,7-dihydropyrazolo-[3,4-c]azepin-8-one;

[0208] 1[4-Methoxyphenyl]-3-trifluoromethyl-6-[(4-aminomethyl)phenyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]pyridin-7-one;

[0209] 1-[3-Aminomethylphenyl]-3-methyl-6-[(2′-N-((3-(S)-hydroxy)pyrrolidinyl)methyl-[1,1′]-biphen-4-yl)]-1,4,5,6-tetrahydro-7H-pyrazolo-[3,4-c]-pyridin-7-one;

[0210] 1-[3-Aminomethylphenyl]-3-methyl-6-[(2′-methylsulfonyl-[1,1′]-biphen-4-yl)]-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one;

[0211] 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[(3-fluoro-2′-N-(3(S)-hydroxy)pyrrolidinylmethyl-[1,1′]-biphen-4-yl)]-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one;

[0212] 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[(3-fluoro-2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl)]-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one;

[0213] 1-[1-Aminoisoquinolin-7′-yl]-3-trifluoromethyl-6-[4-(2-methylimidazol-1′-yl)phenyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;

[0214] 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[4-(2-methylimidazol-1′-yl)phenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

[0215] 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[4-(2-(dimethylaminomethyl)imidazol-1′-yl)-2-fluorophenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

[0216] 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[4-(2-(dimethylaminomethyl)imidazol-1′-yl)phenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; and,

[0217] 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[4-(2-(dimethylaminomethyl)imidazol-1′-yl)-2-fluorophenyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;

[0218] or a pharmaceutically acceptable salt form thereof.

[0219] In another embodiment, the present invention provides novel pharmaceutical compositions, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt form thereof.

[0220] In another embodiment, the present invention provides a novel method for treating or preventing a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt form thereof.

Definitions

[0221] The compounds herein described may have asymmetric centers. Compounds of the present invention containing an asymmetrically substituted atom may be isolated in optically active or racemic forms. It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis from optically active starting materials. Many geometric isomers of olefins, C═N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms. All chiral, diastereomeric, racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated. All processes used to prepare compounds of the present invention and intermediates made therein are considered to be part of the present invention.

[0222] The term “substituted,” as used herein, means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound. When a substituent is keto (i.e., ═O), then 2 hydrogens on the atom are replaced. Keto substituents are not present on aromatic moieties.

[0223] The present invention is intended to include all isotopes of atoms occurring in the present compounds. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include tritium and deuterium. Isotopes of carbon include C-13 and C-14.

[0224] When any variable (e.g., R⁶) occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with 0-2 R⁶, then said group may optionally be substituted with up to two R⁶ groups and R⁶ at each occurrence is selected independently from the definition of R⁶. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.

[0225] When a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then such substituent may be bonded to any atom on the ring. When a substituent is listed without indicating the atom via which such substituent is bonded to the rest of the compound of a given formula, then such substituent may be bonded via any atom in such substituent. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.

[0226] As used herein, “alkyl” is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms. C₁₋₁₀ alkyl, is intended to include C₁, C₂, C₃, C₄, C₅, C₆, C₇, C₈, C₉, and C₁₀ alkyl groups. Examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, and s-pentyl. “Haloalkyl” is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, substituted with 1 or more halogen (for example —CVFW where v=1 to 3 and w=1 to (2v+1)). Examples of haloalkyl include, but are not limited to, trifluoromethyl, trichloromethyl, pentafluoroethyl, and pentachloroethyl. “Alkoxy” represents an alkyl group as defined above with the indicated number of carbon atoms attached through an oxygen bridge. C₁₋₁₀ alkoxy, is intended to include C₁, C₂, C₃, C₄, C₅, C₆, C₇, C₈, C₉, and C₁₀ alkoxy groups. Examples of alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy, n-pentoxy, and s-pentoxy. “Cycloalkyl” is intended to include saturated ring groups, such as cyclopropyl, cyclobutyl, or cyclopentyl. C₃₋₇ cycloalkyl is intended to include C₃, C₄, C₅, C₆, and C₇ cycloalkyl groups. Alkenyl” is intended to include hydrocarbon chains of either straight or branched configuration and one or more unsaturated carbon-carbon bonds that may occur in any stable point along the chain, such as ethenyl and propenyl. C₂₋₁₀ alkenyl is intended to include C₂, C₃, C₄, C₅, C₆, C₇, C₈, C₉, and C₁₀ alkenyl groups. “Alkynyl” is intended to include hydrocarbon chains of either straight or branched configuration and one or more triple carbon-carbon bonds that may occur in any stable point along the chain, such as ethynyl and propynyl. C₂₋₁₀ Alkynyl is intended to include C₂, C₃, C₄, C₅, C₆, C₇, C₈, C₉, and C₁₀ alkynyl groups.

[0227] “Halo” or “halogen” as used herein refers to fluoro, chloro, bromo, and iodo; and “counterion” is used to represent a small, negatively charged species such as chloride, bromide, hydroxide, acetate, and sulfate.

[0228] As used herein, “carbocycle” or “carbocyclic residue” is intended to mean any stable 3, 4, 5, 6, or 7-membered monocyclic or bicyclic or 7, 8, 9, 10, 11, 12, or 13-membered bicyclic or tricyclic, any of which may be saturated, partially unsaturated, or aromatic. Examples of such carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclooctyl, [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4.0]bicyclodecane, [2.2.2]bicyclooctane, fluorenyl, phenyl, naphthyl, indanyl, adamantyl, and tetrahydronaphthyl.

[0229] As used herein, the term “heterocycle” or “heterocyclic system” is intended to mean a stable 5, 6, or 7-membered monocyclic or bicyclic or 7, 8, 9, or 10-membered bicyclic heterocyclic ring which is saturated, partially unsaturated or unsaturated (aromatic), and which consists of carbon atoms and 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, NH, O and S and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The nitrogen and sulfur heteroatoms may optionally be oxidized. The heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure. The heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. A nitrogen in the heterocycle may optionally be quaternized. It is preferred that when the total number of S and O atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to one another. It is preferred that the total number of S and O atoms in the heterocycle is not more than 1. As used herein, the term “aromatic heterocyclic system” or “heteroaryl” is intended to mean a stable 5, 6, or 7-membered monocyclic or bicyclic or 7, 8, 9, or 10-membered bicyclic heterocyclic aromatic ring which consists of carbon atoms and 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, NH, O and S. It is to be noted that total number of S and O atoms in the aromatic heterocycle is not more than 1.

[0230] Examples of heterocycles include, but are not limited to, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzoxazolinyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isatinoyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, methylenedioxyphenyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxindolyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, piperidonyl, 4-piperidonyl, piperonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, and xanthenyl. Also included are fused ring and spiro compounds containing, for example, the above heterocycles.

[0231] The phrase “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

[0232] As used herein, “pharmaceutically acceptable salts” refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.

[0233] The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound that contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418, the disclosure of which is hereby incorporated by reference.

[0234] Since prodrugs are known to enhance numerous desirable qualities of pharmaceuticals (e.g., solubility, bioavailability, manufacturing, etc . . . ) the compounds of the present invention may be delivered in prodrug form. Thus, the present invention is intended to cover prodrugs of the presently claimed compounds, methods of delivering the same and compositions containing the same. “Prodrugs” are intended to include any covalently bonded carriers that release an active parent drug of the present invention in vivo when such prodrug is administered to a mammalian subject. Prodrugs the present invention are prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound. Prodrugs include compounds of the present invention wherein a hydroxy, amino, or sulfhydryl group is bonded to any group that, when the prodrug of the present invention is administered to a mammalian subject, it cleaves to form a free hydroxyl, free amino, or free sulfhydryl group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups in the compounds of the present invention. Preferred prodrugs are amidine prodrugs wherein D is C(═NR⁷)NH₂ or its tautomer C(═NH)NHR⁷ and R⁷ is selected from OH, C₁₋₄ alkoxy, C₆₋₁₀ aryloxy, C₁₋₄ alkoxycarbonyl, C₆₋₁₀ aryloxycarbonyl, C₆₋₁₀ arylmethylcarbonyl, C₁₋₄ alkylcarbonyloxy C₁₋₄ alkoxycarbonyl, and C₆₋₁₀ arylcarbonyloxy C₁₋₄ alkoxycarbonyl. More preferred prodrugs are where R⁷ is OH, methoxy, ethoxy, benzyloxycarbonyl, methoxycarbonyl, and methylcarbonyloxymethoxycarbonyl.

[0235] “Stable compound” and “stable structure” are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.

[0236] “Substituted” is intended to indicate that one or more hydrogens on the atom indicated in the expression using “substituted” is replaced with a selection from the indicated group(s), provided that the indicated atom's normal valency is not exceeded, and that the substitution results in a stable compound. When a substituent is keto (i.e., ═O) group, then 2 hydrogens on the atom are replaced.

[0237] “Therapeutically effective amount” is intended to include an amount of a compound of the present invention or an amount of the combination of compounds claimed effective to inhibit factor Xa. The combination of compounds is preferably a synergistic combination. Synergy, as described, for example, by Chou and Talalay, Adv. Enzyme Regul. 1984, 22:27-55, occurs when the effect (in this case, inhibition of factor Xa) of the compounds when administered in combination is greater than the additive effect of the compounds when administered alone as a single agent. In general, a synergistic effect is most clearly demonstrated at sub-optimal concentrations of the compounds. Synergy can be in terms of lower cytotoxicity, increased antiviral effect, or some other beneficial effect of the combination compared with the individual components.

Synthesis

[0238] The compounds of the present invention can be prepared in a number of ways known to one skilled in the art of organic synthesis. The compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or by variations thereon as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those described below. The reactions are performed in a solvent appropriate to the reagents and materials employed and suitable for the transformations being effected. It will be understood by those skilled in the art of organic synthesis that the functionality present on the molecule should be consistent with the transformations proposed. This will sometimes require a judgment to modify the order of the synthetic steps or to select one particular process scheme over another in order to obtain a desired compound of the invention. It will also be recognized that another major consideration in the planning of any synthetic route in this field is the judicious choice of the protecting group used for protection of the reactive functional groups present in the compounds described in this invention. An authoritative account describing the many alternatives to the trained practitioner is Greene and Wuts (Protective Groups In Organic Synthesis, Wiley and Sons, 1991). All references cited herein are hereby incorporated in their entirety herein by reference.

[0239] The compounds of the present invention represented by Formula I consist of a group “D—E—G—(CH₂)_(s)—” and a group “—A—B” attached to a [5,6]- or [5,7]-heterobicyclic core structure of varying composition. The five-membered ring can be pyrazole, triazole, isoxazole or isothiazole and this ring can be fused to a variety of six- or seven membered rings including but not limited to piperidinone, pyridinone, pyrimidinone, pyrimidinedione, pyranone, diazepinone, diazepinedione. The following discussion and schemes will describe methods for the syntheses of the heterobicyclic cores and attachment to the groups “G—(CH₂)_(s)—” and “—A—B”.

[0240] The 4-aminopyrazole-5-carboxylate V is a useful intermediate for the preparation of many of the pyrazole fused compounds of Formula I wherein the “G—(CH₂)_(s)—” residue is attached to a nitrogen atom of the pyrazole (Scheme I). This intermediate can be prepared in a variety of ways from hydrazines I. Hydrazines I are readily available starting materials. Aromatic hydrazines (G is aryl, s=0) are conveniently prepared from the corresponding aniline by diazotization with NaNO₂ in acidic media followed by reduction of the resulting diazonium ion with a suitable reducing agent, with SnCl₂ being a preferred reagent. Non-aromatic hydrazines represented by I are readily prepared by a variety of methods, such as by displacement of a suitable halogen compound with hydrazine or with a protected hydrazine followed by deprotection. Condensation of hydrazines I with a suitable hemiacetal or aldehyde followed by halogenation with NBS or NCS leads to hydrazidoyl halides II. Alternatively, the hydrazines I can be acylated with an acid chloride and converted to hydrazidoyl halides II by carbon tetrahalide/triphenylphosphine. The hydrazidoyl halides II are versatile intermediates for pyrazole synthesis (Shawali, A. S.; et. al. J. Het. Chem. 1980, 17, 833). The halide can be displaced with cyanide ion to afford cyanide III. Cyano compounds of this type (where G is aryl and s=0) can also be prepared more directly by diazotization of aniline IV followed by direct reaction with a cyano-containing active methylene compound, where R^(1a) can include a variety of groups such as ester, ketone, cyano, trifluoromethyl, sulfone, aryl, etc. (Butler, R. N.; et. al. J. Chem. Soc. Chem. Commun. 1992, 20, 1481). Treatment of III with a bromoacetate in the presence of a suitable base such as carbonate or trialkylamine results in N-alkylation followed by ring closure to give the 4-aminopyrazole-5-carboxylate V. Alternatively, treatment of II with a nitropyruvate in the presence of a base such as alkoxide provides a 4-nitropyrazole by displacement of the halide followed by ring closure of the nitrogen onto the carbonyl group. Reduction of the nitro group can be accomplished by a variety of reducing agents, a preferred one of which is SnCl₂, to give the 4-aminopyrazole-5-carboxylate V. The hyrazidoyl halide II can also be reacted with a ketoester where R′ represents a masked ester, preferably a 2-furyl residue, to give a pyrazole-4-carboxylate VI. Ester hydrolysis, conversion to an acyl azide, either via the acid chloride or anhydride, heating to generate an isocyanate via Curtius rearrangement, and finally treatment with water affords the 4-aminopyrazole VII. Alternatively, the amino can be masked as an appropriate carbamate by using an alcohol instead of water in the Curtius rearrangement. When R′=2-furyl, the furan can be oxidatively cleaved under a variety of conditions, such as sodium periodate with catalytic ruthenium trichloride, or KMnO₄, to afford a carboxylic acid which can be esterified to afford the 4-aminopyrazole-5-carboxylate V.

[0241] Another route to the 4-aminopyrazole V involves condensation of the hydrazine I with an appropriate diketone or monoprotected diketone to form a 3,5-disubstituted pyrazole in which the 5-substituent is a carboxylic ester. With proper choice of the G group, this pyrazole can be selectively nitrated at the 4-position with nitrating agents such as nitric acid or ammonium nitrate/trifluoroacetic anhydride. Reduction of the nitro group under a variety of conditions, such as with tin (II) chloride or catalytic hydrogenation, affords the 4-aminopyrazole V. This route can also be carried out using a diketone with a 2-furyl group as a latent carboxylate, giving initially a 3,5-disubstituted pyrazole in which the 5-substituent is the 2-furyl group. Oxidative cleavage of the furyl group to a carboxylate, nitration of the pyrazole 4-position, esterification and nitro reduction then affords 4-aminopyrazole V. It will be recognized by those skilled in the art that the synthetic route chosen to v will depend on additional functionality present in the molecule of interest and the route may require additional protection/ deprotection sequences as well as modifications in the order of synthetic steps.

[0242] In Scheme II is shown how the 4-aminopyrazole-5-carboxylate V can be utilized to prepare a variety of structures described by Formula I where the A-B residue is connected to a nitrogen atom of the bicyclic core. The 4-amino group can be protected as a suitable carbamate (see Greene and Wuts, Protective Groups in Organic Synthesis, Wiley and Sons, 1991) or as an azide group (NaNO₂, acid, NaN₃). In some cases it may not be necessary to protect the amino functionality, as will be recognized by those skilled in the art. Unmasking of the ester residue involves either basic hydrolysis (R═Me, Et), hydrogenolysis (R═Bn) or trifluoroacetic acid (R=t-Bu). Coupling of the resulting acid with the appropriate amine H₂N—A—B can be accomplished by a wide variety of methods known to those skilled in the art, including dicyclohexylcarbodiimide and N,N-dimethylaminopyridine, the mixed anhydride method, the BOP reagent, and many others. Alternatively, the amide bond can be formed directly from the ester (R═Me, Et) by reacting the ester with an aluminum reagent prepared from the amine H₂N—A—B and trimethylaluminum. Deprotection of the amino group, if required, provides compounds VIII. Treating this amino amide with carbonyl diimidazole or other phosgene equivalent, such as triphosgene, provides pyrazolopyrimidinediones IX. Alternatively, aminocarboxylate V can be converted to pyrazolopyrimidinediones IX in a single step by heating with an appropriate isocyanate OCN—A—B in the presence of a base such as sodium hydride. Treating VIII with a substituted bromoacetyl chloride or bromide in the presence of a base such as triethylamine affords the pyrazolodiazepinediones X. Refluxing VIII in the presence of formic acid provides the pyrazolopyrimidinones XI (R³═H). Substituted derivatives XI can be obtained by refluxing VIII in the presence of triethylorthoacetate (R³═Me) or other orthoesters. Reduction of XI with catalytic hydrogenation, sodium borohydride in acidic medium or other reducing agent can provide compounds of type XII. Additionally, V can be treated with a bromoacetate in the presence of a base such as carbonate or sodium hydride to provide XIII. Selective hydrolysis of either ester of XIII followed by standard coupling with H₂N—A—B and subsequent heating affords compounds XIV, which are regioisomeric with X. Oxygen analogs of XIV are prepared by converting the amino group of V to a hydroxy group via a diazonium ion. Coupling with the amine H₂N—A—B by any of a wide variety of procedures yields XV. O-alkylation of XV with a bromoacetate in the presence of a base such as sodium hydride leads to XVI, the oxygen analogs of XIV. In the cases of compounds IX, X, XII and XIV the nitrogen atom can be further functionalized to provide additional analogs, such as by treating with methyl iodide in the presence of a base to afford the N-methyl derivatives.

[0243] The 4-aminopyrazole-5-carboxylate can be used to prepare pyrazolopyranone and pyrazolopyridinone derivatives, in which the A—B residue is attached to a carbon atom of the bicyclic core, as shown in Scheme III. N-protection of V as described previously can be followed by straightforward conversion of the ester residue to an acid chloride. Treatment of this acid chloride with a zinc cuprate reagent derived from Br—CH₂—A—B (A=aryl) will afford the ketone XVII after N-deprotection. Heating XVII with dimethylformamide dimethylacetal or with an orthoester can provide the pyrazolopyridinone compounds XVIII. Conversion of the 4-amino residue of XVII to a hydroxyl group via the diazonium ion will lead to XIX, which will provide the pyrazolopyranone derivatives XX under similar cyclization conditions. Alternatively, treatment of the acid chloride XXI, obtained as described above where N—PG can represent a carbamate protected nitrogen or can represent conversion of the amino group to an azide group as described previously, with a suitable enamine in the presence of a base such as triethylamine can afford the ketone XXII. N-deprotection followed by heating will afford the pyrazolopyridinones XXIII (XVIII where R═H). Also, the ketone XVII can be prepared from the cyano compound III by treatment with a suitable bromoketone in the presence of a base such as carbonate or triethylamine. The required bromoketone is readily available by treating an appropriate acid chloride with diazomethane followed by HBr. It will be recognized by those skilled in the art that the syntheses of the compounds described in Scheme III may require additional protection/deprotection steps or modifications in the order of carrying out the steps, depending on additional functionality present in the compounds of interest.

[0244] Additional oxygen-containing bicyclic systems can be prepared as shown in Scheme IV. The 4-amino-5-carboxylate V can be converted to its 4-hydroxy derivative via the diazonium ion to give XXIV. Ester deprotection and amide bond formation with an appropriate H₂N—A—B as described in Scheme II will afford the amide XXV. Alternatively, the amide bond can be formed directly from the ester by addition of the aluminum reagent derived from H₂N—A—B and trimethylaluminum. The 4-hydroxy substituent can be easily protected if required by any of a number of protecting groups, such as with t-butyldimethylsilyl ether (TBS), and then deprotected following amide bond formation. Treating the hydroxy amide XXV with carbonyl diimidazole or other phosgene equivalent, such as triphosgene, can provide the bicyclic core XXVI. Heating XXV in the presence of paraformaldehyde in the presence of a suitable acid such as p-toluenesulfonic acid will provide XXVII (R³═H). Alternatively, XXV can be treated with dibromomethane in the presence of a suitable base such as carbonate to afford XXVII (R³—H). Other aldehydes and substituted dibromomethanes can provide substituted derivatives of XXVII where R³ is not hydrogen.

[0245] Additional bicyclic systems in which the A—B residue is substituted on a carbon atom can be prepared as shown in Scheme V. N-protection of 4-aminopyrazole-5-carboxylate V can be followed by manipulation of the ester to afford an acid chloride or an N-methoxy-N-methyl amide. Addition of an enolate derived from RO₂CCH₂—A—B and a base such as lithium diisopropylamide or lithium hexamethyldisilazide provides XXVIII. The N-methoxy-N-methyl amide is the preferred reaction partner for this addition, as this functionality prevents the formation of overaddition products. Alternatively, the enolate addition reaction could be done on the ester as well. N-deprotection of the 4-amino substituent allows it to close onto the ester residue and provides the pyrazolopiperidinedione XXIX. Manipulation of the ester residue of XXVIII can lead to XXX where X represents a suitable leaving group such as a bromide or mesylate residue. A variety of methods can be utilized for the transformation of XXVIII to XXX, such as ketone protection, reduction of the ester to a primary alcohol, ketone deprotection and conversion of the primary alcohol to a bromide using CBr₄/PPh₃ or to a mesylate using methanesulfonyl chloride and a base such as triethylamine. Alternatively, the ester can be hydrolyzed to the acid that can be reduced to the primary alcohol with borane and converted to a leaving group as just described. N-deprotection liberates the 4-amino group, which provides compounds of structure XXXI upon heating or treatment with base. The corresponding oxygen derivative is also available from XXVIII. N-deprotection, diazotization with NaNO₂ in acidic medium and treatment with sulfuric acid produces the 4-hydroxy derivative XXXII. Protection of the alcohol functionality, for example as the TBS ether, followed by ester manipulation as described above and subsequent alcohol deprotection, produces XXXIII. Treatment of XXXIII with a suitable base such as carbonate leads to ring closure to afford compounds XXXIV. Alternatively, compounds XXXIII where X═OH can be closed to XXXIV via a Mitsunobu reaction by treatment with diethylazodicarboxylate and triphenylphosphine.

[0246] In scheme VI is shown how to make additional bicyclic systems in which the A—B residue is substituted on a carbon atom and the ring is substituted with an R³ group. Ester XXVIII can be converted under standard conditions to the N-methoxy-N-methyl amide XXXV. Addition of an appropriate Grignard reagent R³MgBr produces a ketone, which upon N-deprotection and heating in acidic conditions leads to the substituted pyridones XXXVI. Hydride reduction, with REDAL for example, will produce the piperidone XXXVII. Alternatively, diisobutylaluminum hydride reduction of the N-methoxy-N-methyl amide gives an aldehyde which will add a suitable Grignard reagent R³MgBr to afford XXXVIII. Conversion of the alcohol to a leaving group, for example by making the mesylate with methanesulfonyl chloride and a trialkylamine base, followed by N-deprotection leads to ring closure to piperidones XXXVII. The alcohol XXXVIII can also be prepared from enamine XXII from Scheme III by hydrolysis to the corresponding aldehyde followed by addition of the appropriate Grignard reagent R³MgBr.

[0247] Preparation of a bicyclic system containing a seven-membered ring in which the A—B residue is attached to a carbon atom is described in Scheme VII. N-protection of aminoketone XVII, where N—PG represents preferably an N-protected nitrogen wherein both N—H groups are masked, such as by conversion to an azide group, is followed by formation of a ketone enolate, with a base such as lithium diisopropylamide, and reaction with a bromoacetate to afford XXXIX. N-deprotection followed by heating of the resulting amino ester affords XL. Alternatively, the ester can be converted by straightforward means to a more reactive species prior to ring closure, such as a mixed anhydride or acid chloride. Treatment of XVII with bromoacetyl bromide and a base such as triethylamine gives the acylamine XLI that can be cyclized by formation of the ketone enolate with a base such as lithium diisopropylamide.

[0248] Additional seven-membered ring-containing bicyclic systems can be prepared as shown in Scheme VIII. The hydrazidoyl halide II, prepared as shown in Scheme I, can be cyclized with a cyanopyruvate in the presence of a base such as alkoxide to afford 4-cyanopyrazole XLII. Ester deprotection and coupling with H₂N—A—B as described in previous schemes yields cyanoamide XLIII. Reduction of the nitrile can be accomplished by various methods, such as by catalytic hydrogenation or by reduction with sodium borohydride in the presence of cobalt chloride. Cyclization of the resulting aminoamide using carbonyl diimidazole or other phosgene equivalent as described previously affords compounds XLIV. For the corresponding compound wherein the A—B residue is attached to carbon, the ester XLII can be converted to the N-methoxy-N-methyl amide as described previously. Treatment of this amide with the enolate derived from RO₂CH₂A—B yields the ketone XLV. Catalytic hydrogenation of the nitrile affords an amine that upon heating undergoes cyclization to afford XLVI. The oxygen containing analog corresponding to XLIV is obtained from ester VI, prepared as described in Scheme I. The group R′ represents preferably a 2-furyl residue as a masked carboxylic acid. Reduction of the ester group of VI with a hydride reducing agent such as diisobutylaluminum hydride is followed by protection of the resulting primary alcohol, such as by a TBS ether. When R′ is 2-furyl, the carboxylic acid can be unmasked by oxidation by a variety of reagents, including ozone, potassium permanganate, and sodium periodate in the presence of ruthenium trichloride. Coupling with a suitable with H₂N—A—B as described in previous schemes yields the amide XLVII. Deprotection of the alcohol affords a hydroxy amide, which can be cyclized using carbonyl diimidazole as described previously to afford compounds XLVIII.

[0249] Bicyclic compounds of Formula I containing a carbon atom at the pyrazole 4-position are prepared by a [3+2] cycloaddition strategy as shown in Scheme IX (for a review of [3+2] cycloadditions, see 1,3-Dipolar Cycloaddition Chemistry (Padwa, ed.), Wiley, New York, 1984).

[0250] Treatment of unsaturated lactone XLIX, which is readily available by standard procedures known to those skilled in the art, with an aluminum reagent prepared from an appropriate amine H₂N—A—B and trimethylaluminum affords the ring-opened amide L. Conversion of the primary alcohol under standard conditions to a suitable leaving group, such as a bromide or mesylate, and subjection to basic conditions affords the required unsaturated lactam LI. Treatment of hydrazidoyl halide II, prepared as shown in Scheme I where X═Cl or Br, with triethylamine generates a 1,3-dipolar intermediate LII, which can undergo a [3+2] cycloaddition with the olefin LI to produce the bicyclic pyrazolidine LIII as the predominant regioisomer. Mild oxidation with reagents such as chloranil or nickel peroxide will produce the pyrazolopiperidones LIV. Further oxidation, such as with DDQ, can produce the unsaturated derivatives LV. These steps can be reversed such that initial complete oxidation to LV can be followed by reduction, such as by catalytic hydrogenation, to produce LIV. The ketone derivatives can be prepared by condensation of an appropriate amine H₂N—A—B with the cyclic anhydride LVI to give LVII. Alternatively, a saturated derivative of LVI can be condensed with an appropriate amine H₂N—A—B followed by oxidation to the unsaturated derivative LVII, such as by treatment with LDA/PhSeSePh and subsequent oxidative selenoxide elimination. The olefin LVII undergoes similar [3+2] cycloaddition to give a pyrazolidine intermediate that is readily oxidized to the pyrazolopiperidinedione derivatives LVIII by a variety of oxidizing agents.

[0251] An alternative preparation of compound LIV is also described. A standard alkylation/acylation sequence on the amine H₂N—A—B affords amide ester LIX, which contains a protected ketone functionality. A variety of reaction conditions can be employed for these transformations, which are known to those skilled in the art. Deprotection of the ketone followed by Dieckmann condensation under basic conditions affords the cyclic diketoamides LX. Condensation of LX with an appropriate hydrazine is readily accomplished by heating in a solvent such as acetic acid or ethanol to afford the previously described LIV.

[0252] Pyrazolopiperidone compounds LXVI (where n=1) wherein the pyrazole 4-substituent R^(1a) is a trifluoromethyl group can be prepared via the method outlined in Scheme X. Coupling of the acid LXI with amines H₂N—A—B can be accomplished under a variety of conditions, such as via the acid chloride, giving amide LXII. A straightforward sequence involving cleavage of the tetrahydrofuran ring and intramolecular cyclization on the amide nitrogen affords the ketolactam LXIII. This compound can also be prepared from the lactam LXIV by introduction of sulfur substituents and subsequent oxidation to the ketolactam LXIII. Formation of the morpholine or related enamine followed by reaction with trifluoroacetic anhydride leads to the trifluoroacetylated intermediate LXV. Alternatively, dichlorination of lactam LXIV with PCl₅ or analogous reagents, heating with excess morpholine or related amine, and reacting the enamine derived in this way with trifluoroacetic anhydride also yields the trifluoroacetylated intermediate LXV. This compound can be readily condensed with an appropriate hydrazine to afford the pyrazolopiperidone compounds LXVI. Analogous chemistry can be utilized to afford [5,7]-fused ring systems (where n=2).

[0253] Unsaturated analogs of the above compounds can be prepared as shown in the bottom of Scheme X. Bromination of LXVII, prepared as described in Scheme IX and the top of Scheme X, affords bromo analog LXVIII. Elimination of HBr by treatment with any of a variety of bases, such as DBU, will afford the unsaturated bicylic analogs LXIX. Additional analogs can be prepared by displacement of the bromide LXVIII by any of a wide variety of nitrogen-, oxygen- and sulfur-based nucleophiles.

[0254] Additional [5,7]-fused bicyclic systems which contain an additional heteroatom in the seven-membered ring can be prepared as shown in Scheme XI. Compounds LXXI where X is O or S can be prepared from commercially available tetrahydro-4H-pyran-4-one and tetrahydrothiopyran-4-one. Photoinduced Schmidt rearrangement of (triisopropylsilyl)azidohydrin (Evans, P. A. and Modi, D. P. J. Org. Chem. 1995, 60, 6662-6663), which is formed from tetrahydro-4H-pyran-4-one and tetrahydrothiopyran-4-one, provides tetrahydro-1,4-oxazepin-5(2H)-one and tetrahydro-1,4-thiazepin-5(2H)-one. Compounds LXXI where X is NH or NR can be prepared by Schmidt rearrangement of 4-piperidone monohydrate hydrochloride or protected 4-piperidone (Groves, J. T. and Chambers, R. R. Jr. J. Am. Chem. Soc. 1984, 106, 630-638). Ullmann coupling of the lactam with I(Br)—A—B provides the lactam LXXII with an A—B residue. Dichloronation with phosphorus pentachloride or related reagent affords a dichlorinated intermediate which can react with morpholine to give the enamine LXXIII. Reaction of LXXIII with DMAP and an appropriate acid chloride or acid anhydride provides the acylenamine intermediate LXXIV which can be condensed with an appropriate hydrazine in acetic acid to afford the [5,7]-fused bicyclic compounds LXXV.

[0255] Bicyclic compounds of Formula I which contain a carbon atom at the pyrazole 4-position and wherein the A—B residue is attached to a carbon atom are also prepared by a [3+2] cycloaddition strategy as shown in Scheme XII. Unsaturated cyclic ketones LXXVI are readily available by standard synthetic methods known to those skilled in the art. The [3+2] cycloaddition with the 1,3-dipole generated from II as described previously gives a pyrazolidine intermediate that can be readily oxidized to the pyrazolocyclohexanone LXXVII. Introduction of a double bond, such as by treating with LDA and PhSeSePh followed by oxidative selenoxide elimination, gives the unsaturated derivative LXXVIII. Incorporation of a residue such as a protected alcohol into the unsaturated ketone, represented by LXXIX, leads to pyrazolocyclohexanone LXXX following [3+2] cycloaddition and subsequent oxidation. Deprotection of the alcohol and oxidation by a variety of reagents affords the pyrazolocyclohexanedione LXXXI.

[0256] Additional bicyclic compounds of Formula I containing a carbon atom at the pyrazole 4-position are described in Scheme XIII. Condensation of hydrazidoyl halide II with a diketoester in the presence of a base such as alkoxide affords pyrazoles LXXXII. Heating this ketoester in the presence of readily available hydrazines A—B—NHNH₂ affords the pyrazolopyridazinones LXXXIII. For preparation of pyrazolopyridazinones where R³ is hydrogen, the hydrazidoyl halide II can be cyclized with a furyl ketoester in the presence of alkoxide base to afford LXXXIV. Standard functional group manipulations, involving ester reduction and protection, furyl oxidation and esterification leads to LXXXV, although not necessarily in that order. Those skilled in the art will be able to determine a proper order and appropriate reagents for achieving these transformations. Alcohol deprotection and oxidation, such as by manganese dioxide, affords an aldehyde ester which readily produces LXXXVI upon heating in the presence of a hydrazine A—B—NHNH₂. Appropriate functional group manipulation of LXXXIV, of which many methods are available, can also afford ester acids LXXXVII. Activation of the carboxylic acid, such as by formation of the acid chloride with oxalyl chloride, followed by heating in the presence of a hydrazine A—B—NHNH₂ affords the pyrazolopyridazinedione LXXXVIII.

[0257] The preparation of the compounds of Formula I where the five-membered ring is triazole is accomplished using azide intermediates. Azides readily undergo [3+2] cycloaddition reactions with a variety of olefins and alkynes, and the application of this reaction to the synthesis of the triazole-fused bicyclic compounds of Formula I is shown in Scheme XIV. As described for the pyrazole-fused compounds previously, the 4-amino-1,2,3-triazole-5-carboxylate XCII is a particularly useful intermediate for the preparation of many of the triazole-fused bicyclic systems. The required azides LXXXIX are readily available. Aliphatic azides are easily prepared from the corresponding bromide by displacement with sodium azide in solvents such as dimethylformamide and dimethyl sulfoxide. Where “G—(CH₂)_(s)—” represents an aryl azide (G is aryl, s=0), the azides are readily available from the corresponding aniline by diazotization with NaNO₂ in acidic medium followed by displacement of the diazonium ion with sodium azide. The [3+2] cycloaddition of azides LXXXIX with nitroolefins XC (R′═Me, 2-furyl) affords the triazoles XCI as the major product, in which initial cyclization to a triazoline intermediate is followed by autooxidation to the triazole products (Cailleux, P.; et. al. Bull. Soc. Chim. Belg. 1996, 105, 45). These reactions can be performed in refluxing benzene or similar solvents at similar temperatures. Conversion of XCI to the 4-amino-1,2,3-triazole-5-carboxylate XCII is straightforward. When R′ is methyl, oxidation of the methyl group with an oxidant such as KMnO₄ gives the carboxylic acid which can be esterified to an appropriate ester. Reduction of the nitro group by any of a variety of reducing agents, preferably SnCl₂ or catalytic hydrogenation, gives XCII. When R′ is 2-furyl, the carboxylic acid can be unmasked by a variety of oxidizing agents, including ozone, KMnO₄ and sodium periodate/ruthenium trichloride, to give the carboxylic acid which can be esterified and reduced as described above to afford XCII. The 4-hydroxy-1,2,3-triazole-5-carboxylates can be obtained via the diazonium ion of XCII as described for the pyrazole series to afford XCIV.

[0258] The reaction of azides LXXXIX with active methylene compounds is also illustrated in Scheme XIV. Treating LXXXIX with cyano- or nitropyruvates in the presence of a base such as alkoxide affords triazoles XCIII. The triazole-4-carboxylate derivatives can be prepared by treating LXXXIX with a furyl ketoester in the presence of alkoxide base to afford XCV. These reactions are analogous to those described in Scheme I for the pyrazole derivatives. The triazole-containing bicyclic systems having a carbon atom at the 4-position of the triazole can be prepared by [3+2] cycloaddition of an appropriate azide LXXXIX with an unsaturated lactam LI or an unsaturated cyclic ketone LXXVI. These cycloadditions are performed by heating in an appropriate solvent, such as benzene or toluene. The resulting triazoline intermediates are readily oxidized to the fused triazoles using chloroanil, nickel peroxide or other mild oxidant to give XCVI and XCVII, respectively. The triazole intermediates XCI, XCII, XCIII, XCIV, XCV, XCVI and XCVII can be transformed into the final triazole-containing bicyclic compounds described by Formula I following the procedures described for the corresponding pyrazole derivatives in Schemes II-XI. The nitro group present in XCI and XCIII can correspond to the “N—PG” residue described in Schemes II-VIII, or alternatively, the nitro group can be reduced at an appropriate time and further protected as a suitable carbamate derivative or as an azido group.

[0259] The preparation of the compounds of Formula I where the five-membered ring is isoxazole is accomplished as shown in Scheme XV. The hydroximinoyl chloride XCIX is a useful intermediate for the preparation of isoxazole-fused compounds. This intermediate is readily available from appropriate aldehydes XCVIII by oxime formation with hydroxylamine followed by chlorination with N-chlorosuccinimide. Treatment of XCIX with a cyanoacetate in the presence of a base such as carbonate results in cyclization to give a 5-aminoisoxazole-4-carboxylate C. The amino residue of C can be readily converted into the corresponding hydroxy or cyano derivatives CI and CII, respectively, via the diazonium ion, as described earlier for the pyrazole and triazole compounds.

[0260] The isoxazole-5-carboxylates are available from cyclization of XCIX with a furan ketoester to give CIII. Oxidation of the furan to a carboxylic acid residue is accomplished by a variety of oxidizing agents as described earlier.

[0261] The hydroxyiminoyl chloride XCIX can also be treated with a base such as triethylamine to generate a nitrile oxide intermediate, which can undergo [3+2] cycloaddition reactions with appropriate olefins or alkynes. This is a convenient method by which to prepare bicyclic compounds containing a carbon atom at the 5-position of the isoxazole ring. For example, cycloaddition with the unsaturated lactam LI leads to formation of a fused isoxazoline intermediate which is readily oxidized with reagents such as nickel peroxide, chloranil or DDQ to afford CIV. Cycloaddition with unsaturated cyclic ketone and oxidation under the same conditions affords the ketone analog CV. The isoxazole-fused intermediates C, CI, CII, CIII, CIV and CV can be transformed into the final isoxazole-containing bicyclic compounds described by Formula I following the procedures described for the corresponding pyrazole derivatives in Schemes II-XI.

[0262] The preparation of the compounds of Formula I where the five-membered ring is isothiazole is accomplished as shown in Scheme XVI. One method for preparing the 5-aminoisothiazole-4-carboxylate intermediate CVIII proceeds from readily available acid chloride CVI. Condensation of CVI with a cyanoacetate in the presence of a base such as a magnesium alkoxide followed by treatment with ammonia in an alcoholic solvent gives an aminonitrile CVII. Treatment with hydrogen sulfide in the presence of a base such as triethylamine affords a thioamide that can undergo an oxidative cyclization to CVIII upon treatment with hydrogen peroxide or bromine. As described in previous schemes, the amino residue can easily be converted into the corresponding hydroxyl or cyano derivatives CIX or CX, respectively.

[0263] Another useful intermediate for the preparation of isothiazole compounds of the present invention is the nitrile sulfide CXIII. This intermediate can be generated conveniently from heterocycle CXII, which itself can be prepared from amides CXI either by treating with chlorocarbonylsulfenyl chloride or by treating with trichloromethanesulfenyl chloride followed by aqueous sodium hydroxide. Thermolysis of heterocycle CXII affords the nitrile sulfide CXIII, which can undergo many of the same reactions as the corresponding nitrile oxide intermediates. For example, [3+2] cycloaddition of CXIII with olefins LI and LXXVI can afford, after subsequent mild oxidation as described previously, the isothiazole-fused compounds CXIV and CXV, respectively. Isothiazole intermediates CVIII, CIX, CX, CXIV and CXV can be transformed into the final isothiazole-containing bicyclic compounds described by Formula I following the procedures described for the corresponding pyrazole derivatives in Schemes II-XI.

[0264] Formula I also describes pyrazole-fused bicyclic compounds in which the “G—(CH₂)_(s)—” group resides on a carbon atom of the pyrazole ring. These compounds can be prepared as shown in Scheme XVII. Condensation of acid chlorides CVI with cyanoacetates in the presence of a base such as magnesium methoxide affords an enol derivative that is converted to the enol ether CXVI (X═OMe) with diazomethane or to the chloro derivative CXVI (X═Cl) with POCl₃. Heating with hydrazine (R′═H) or a substituted hydrazine affords 5-amino-4-carboxylate CXVII. The amino residue of CXVII can be converted to the hydroxyl or cyano derivative CXVIII or CXIX, respectively via the diazonium ion as described previously.

[0265] The 5-carboxylate derivatives can be prepared by condensing a substituted hydrazine with a hemiacetal or related derivative represented by CXX. Chlorination or bromination with NCS or NBS, respectively, affords the hydrazidoyl halides CXXI. Reaction of CXXI with the anion of a furyl ketoester affords the 5-carboxylate CXXII, the furan residue of which can be oxidized to a carboxylic acid residue by methods described previously.

[0266] The hydrazidoyl halides CXXI can also participate in [3+2] cycloadditions as described previously to afford, after oxidation of the intermediate pyrazolines, the pyrazole-fused compounds CXXIII and CXXIV. The intermediates CXVII, CXVIII, CXIX, CXXII, CXXIII and CXXIV can be transformed into the final C-linked pyrazole-containing bicyclic compounds described by Formula I following the procedures described for the corresponding N-linked pyrazole derivatives in Schemes II-XI.

[0267] Bicyclic compounds of the present invention in which the five membered ring is pyrrole and the G-containing group is attached to a carbon atom can be prepared as shown in Scheme XVIII. For compounds of this type wherein a nitrogen atom is required at the pyrrolo 2-position, the 2-aminopyrrole CXXVI is a useful intermediate. This compound can be prepared by condensation of readily obtained aminocarbonyl compounds CXXV with an appropriate cyanoacetate. This condensation can be carried out under basic conditions or by heating with azeotropic removal of water. The 2-aminopyrroles CXXVI can be diazotized and subsequently converted into the 2-cyano- and 2-hydroxypyrroles CXXVII, which are suitable intermediates for a variety of the bicyclic compounds of this invention. Pyrrole 2,3-dicarboxylates can also be prepared from aminocarbonyl compounds CXXV. Michael addition under basic conditions with acetylenedicarboxylate esters is followed by in situ ring closure to afford the pyrrole 2,3-dicarboxylate diester. Selective hydrolysis of one of the esters, typically the 2-ester, affords the pyrrole 2-carboxylic acid CXXVIII. Curtius rearrangement of CXXVIII affords another route to the 2-aminopyrrole CXXVI. Also, the carboxylic acid can be reduced to the alcohol CXXIX using borane or by sodium borohydride reduction of the derived mixed anhydride. Following procedures described in Schemes II-VIII and Scheme XIII, the intermediates CXXVI, CXXVII, CXXVIII and CXXIX can be converted to the final pyrrolo-fused bicyclic compounds of Formula I. Other procedures not described here are also known to those skilled in the art and can be used to prepare the pyrrolo-fused bicyclic compounds of Formula I.

[0268] Bicyclic compounds of the present invention in which the five membered ring is furan and the G-containing group is attached to a carbon atom can be prepared as shown in Scheme XIX. For compounds of this type wherein a nitrogen atom is required at the furyl 2-position, the 2-aminofuran CXXXI is a useful intermediate. These compounds can be prepared analogously to the pyrrole analogs described in Scheme XVIII. Thus, condensation of readily obtained hydroxycarbonyl compounds CXXX with an appropriate cyanoacetate affords the 2-aminofurans CXXXI. This condensation can be carried out under basic conditions or by heating with azeotropic removal of water. The 2-aminofurans CXXXI can be diazotized and subsequently converted into the 2-cyano- and 2-hydroxyfurans CXXXII, which are suitable intermediates for a variety of the bicyclic compounds of this invention. Furan 2,3-dicarboxylates can also be prepared from hydroxycarbonyl compounds CXXX, analogously to the pyrrole analogs described in Scheme XVIII. Michael addition of CXXX under basic conditions with acetylenedicarboxylate esters is followed by in situ ring closure to afford the furan 2,3-dicarboxylate diester. Selective hydrolysis of one of the esters, typically the 2-ester, affords the furan 2-carboxylic acid CXXXIII. Curtius rearrangement of CXXXIII affords another route to the 2-aminofurans CXXXI. Also, the carboxylic acid can be reduced to the alcohol CXXXIV using borane or by sodium borohydride reduction of the derived mixed anhydride. Following procedures described in Schemes II-VIII and Scheme XIII, the intermediates CXXXI, CXXXII, CXXXIII and CXXXIV can be converted to the final furan-fused bicyclic compounds of Formula I. Other procedures not described here are also known to those skilled in the art and can be used to prepare the furan-fused bicyclic compounds of Formula I.

[0269] Bicyclic compounds of the present invention in which the five membered ring is thiophene and the G-containing group is attached to a carbon atom can be prepared as shown in Scheme XX. For compounds of this type wherein a nitrogen atom is required at the thiophene 2-position, the 2-aminothiophene CXXXVI is a useful intermediate. These compounds can be prepared analogously to the pyrrole analogs described in Scheme XVIII. Thus, condensation of readily obtained mercaptocarbonyl compounds CXXXV with an appropriate cyanoacetate affords the 2-aminothiophenes CXXXVI. This condensation can be carried out under basic conditions or by heating with azeotropic removal of water. Alternatively, condensation of the cyanoacetate with ketone CXXXVIII affords olefin CXXXIX. In a subsequent step, CXXXIX can be converted into 2-aminothiophenes CXXXVI by treatment with S₈ and a base such as triethylamine. The 2-aminothiophenes CXXXVI can be diazotized and subsequently converted into the 2-cyano- and 2-hydroxythiophenes CXXXVII, which are suitable intermediates for a variety of the bicyclic compounds of this invention. Thiophene 2,3-dicarboxylates can be prepared from alkali-metal acetylenethiolates CXL. These compounds react with acetylenedicarboxylate esters in a [3+2] cycloaddition to afford thiophene 2,3-dicarboxylate diesters. Selective hydrolysis of one of the esters, typically the 2-ester, affords the thiophene 2-carboxylic acid CXLI. Curtius rearrangement of CXLI affords another route to the 2-aminothiophenes CXXXVI. Also, the carboxylic acid can be reduced to the alcohols CXLII using borane or by sodium borohydride reduction of the derived mixed anhydride. Following procedures described in Schemes II-VIII and Scheme XIII, the intermediates CXXXVI, CXXXVII, CXLI and CXLII can be converted to the final thiophene-fused bicyclic compounds of Formula I. Other procedures not described here are also known to those skilled in the art and can be used to prepare the thiophene-fused bicyclic compounds of Formula I.

[0270] Bicyclic compounds of the present invention in which the five membered ring is imidazole and the G-containing group is attached to a nitrogen atom can be prepared as shown in Scheme XXI. These compounds CXLIII through CLXIV, where the R group may be alkyl, aryl or a protecting group PG, are available either from commercial sources or through known prior art and can be represented generically by CLXV. Suitable protection of the imidazole nitrogen affords compounds of the type CLXVI, which are further elaborated via a cupric mediated coupling of appropriate A—B containing boronic acid to yield CLXVII. Subsequent removal of the imidazole-protecting group PG affords compounds such as CLXVIII. The introduction of a substituent G is accomplished as before by the coupling of a G-containing boronic acid in a manner such that the G-group is transferred to the imidazole nitrogen as depicted by CLVIX.

[0271] The A—B moieties can be prepared by methods known to those of skill in the art. The following publications, the contents of which are incorporated herein by reference, describe and exemplify means of preparing A—B moieties: WO97/23212, WO97/30971, WO97/38984, WO98/06694, WO98/01428, WO98/28269, and WO98/28282.

[0272] Other features of the invention will become apparent in the course of the following descriptions of exemplary embodiments that are given for illustration of the invention and are not intended to be limiting thereof.

EXAMPLES Example 1 1-[4-methoxyphenyl]-3-cyano-6-[2′-methylsulfonyl-3-fluoro-[1,1′]-biphen-4-yl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione

[0273]

[0274] Part A. □,□-Dicyano-4-methoxyphenyl hydrazine imine

[0275] Anisidine (18.84 g, 152.99 mmol) was dissolved in 225 mL of water followed by the addition of 32.7 mL (392.4 mmol) of concentrated HCl and then the mixture was cooled in an ice bath. NaNO₂ (13.72 g, 198.89 mmol) was dissolved in 45 mL of water and added in several portions. The solution was stirred for 10 minutes and poured into a flask containing a solution of 10.10 g (152.99 mmol) of malononitrile and sodium acetate (27.61 g, 336.59 mmol) in 36 mL of methanol and 75 mL of water. A heavy yellow precipitate immediately formed (29.9 g, 97%) and was isolated as the title compound by suction filtration. LRMS (NH₃—CI): 218.2 (M+NH₄)⁺.

[0276] Part B. Methyl (1-[4-Methoxyphenyl]-3-cyano-4-amino)pyrazole-5-carboxylate

[0277] □,□-Dicyano-4-methoxyphenyl hydrazine imine (20.00 g, 99.92 mmol), methyl bromoacetate (16.81 g, 109.90 mmol), 4-N,N-dimethyl pyridine (1.22 g, 9.99 mmol) and potassium carbonate (34.52 g, 249.79 mmol) were dissolved in N,N-dimethyl formamide and heated to 100° C. for several hours. The solution was diluted with ethyl acetate and washed 4 times with brine. The organics were dried over MgSO₄, filtered through a pad of silica gel and the volatiles were removed. The title compound was purified by dissolving in hot diethyl ether and collecting the solids (9.18 g, 34%) that formed upon cooling by filtration. LRMS (ES+): 273.2 (M+H)⁺.

[0278] Part C. Methyl (1-[4-Methoxyphenyl]-3-cyano-4-azido)pyrazole-5-carboxylate

[0279] Methyl (1-[4-Methoxyphenyl]-3-cyano-4-amino)pyrazole-5-carboxylate (3.36 g, 12.34 mmol) was dissolved in TFA and cooled to 0° C. followed by the addition of NaNO₂ (0.94 g, 13.57 mmol) and then the reaction was stirred at that temperature for 45 min. NaN₃ (0.80 g, 12.34 mmol) was dissolved in a minimal amount of water and added in portions to the TFA solution. The solution was allowed to stir at 0° C. for 45 min and added slowly to a saturated water solution of NaHCO₃. The solution was diluted with ethyl acetate and washed twice with brine. The organics were dried over MgSO₄, filtered through a plug of silica gel and the volatiles were removed to give the title compound as a tan solid (1.0 g, 57%). LRMS (NH₃—CI) : 316.3 (M+NH₄)⁺.

[0280] Part D. 1-[4-methoxyphenyl]-3-cyano-4-azido-5-[2′-methylsulfonyl-3-fluoro-[1,1′]-biphen-4-yl]aminocarbonyl]pyrazole

[0281] [2′-methylsulfonyl-3-fluoro-[1,1′]-biphen-4-yl]amine hydrochloride (1.00 g, 3.31 mmol) was dissolved in anhydrous methylene chloride followed by the addition of trimethylaluminum (9.94 mL. 19.88 mmol) as 2.0 M solution in toluene. The solution was stirred at ambient temperature until gas evolution ceased. Methyl (1-[4-Methoxyphenyl]-3-cyano-4-azido)pyrazole-5-carboxylate (0.988 g, 3.31 mmol) was added and the solution stirred overnight at room temperature and refluxed for an additional 2 hrs. The solution was allowed to cool to room temperature and the solution slowly quenched with a saturated solution of ammonium chloride. The reaction was diluted with ethyl acetate and washed twice with a 5% solution of citric acid. The organics were dried over MgSO₄ and filtered through a plug of silica gel. The title compound was purified by column chromatography eluting with 1:1 hexane/ethyl acetate (0.09 g, 5%). LRMS (ES−): 530.1 (M−H)⁻.

[0282] Part E. 1-[4-methoxyphenyl]-3-cyano-4-amino-5-[2′-methylsulfonyl-3-fluoro-[1,1′]-biphen-4-yl]aminocarbonyl]pyrazole

[0283] 1-[4-methoxyphenyl]-3-cyano-4-azido-5-[2′-methylsulfonyl-3-fluoro-[1,1′]-biphen-4-yl]aminocarbonyl]pyrazole (0.09 g, 0.169 mmol) was dissolved in methanol followed by the addition of SnCl₂.2 H₂O (0.321 g, 1.69 mmol) and the solution refluxed for 1 hr. The volatile were removed under reduced pressure and the residue stirred in TFA, filtered through a pad of Celite® and the residue purified by preparative HPLC chromatography to yield the title compound as a white solid (30 mg 19%). LRMS (ES+): 506.3 (M+H)⁺.

[0284] Part F. 1-[4-methoxyphenyl]-3-cyano-6-[2′-methylsulfonyl-3-fluoro-[1,1′]-biphen-4-yl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione

[0285] 1-[4-methoxyphenyl]-3-cyano-4-amino-5-[2′-methylsulfonyl-3-fluoro-[1,1′]-biphen-4-yl]aminocarbonyl]pyrazole (0.02 g, 0.032 mmol) was dissolved in THF followed by the addition of carbonyl diimidazole (0.010 g, 0.064 mmol) and the solution was stirred at room temperature for 48 hrs. and then at reflux for 0.5 hrs. The volatiles were removed under reduced pressure and the product purified by preparative HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and lyophilized to afford the title compound of Example 1 as a white powder (1.9 mg, 11%). LRMS (ES−): 530.2 (M−H)⁻

Example 2 1-[4-methoxyphenyl]-3-(methoxycarbonyl)-6-[2′-aminosulfonyl-3-fluoro-[1,1′-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one

[0286]

[0287] Part A. (1-[4-Methoxyphenyl]-3-cyano-4-azido)pyrazole-5-carboxylic acid

[0288] Methyl (1-[4-Methoxyphenyl]-3-cyano-4-azido)pyrazole-5-carboxylate (5.9 g, 19.78 mmol) was dissolved in a 1:1:1 mixture of MeOH/H₂O/THF followed by the addition of NaOH (1.58 g, 39.56 mmol) and the reaction was allowed to stir at room temperature until all of the starting material was consumed by TLC. The solution was acidified with 10% HCl and the product was extracted with ethyl acetate. The organic layer was washed twice with brine and the solvent was dried over MgSO₄, filtered and the volatiles were removed under reduced pressure to yield the title compound as a tan solid (4.00, 71%). LRMS (ES−): 539.0 (M−H—CO₂)⁻.

[0289] Part B. 1-[4-methoxyphenyl]-3-cyano-4-azido-5-[2-fluoro-4-bromophenyl)aminocarbonyl]pyrazole

[0290] 1-[4-methoxyphenyl]-3-cyano-4-azidopyrazole-5-carboxylic acid (4.00 g, 14.07 mmol) was dissolved in CH₂Cl₂ followed by the addition of oxalyl chloride (1.84 mL, 21.11 mmol) and 1 drop of DMF. The mixture was allowed to stir at room temperature for 2 hrs. The volatiles were removed under reduced pressure and the residue dried under high vacuum for 1 hr. The residue was dissolved in CH₂Cl₂ followed by the addition of DMAP (3.44 g, 28.15 mmol) and 2-fluoro-4-bromo-aniline (2.67 g, 14.07 mmol) and the solution stirred overnight at room temperature. The volatiles were removed under vacuum and the product purified by trituration of the residue with ether/hexanes to afford the title compound (1.50 g, 23%). LRMS (ES−): 454.0 (M−H)⁻.

[0291] Part C. 1-[4-methoxyphenyl]-3-(methoxycarbonyl)-4-amino-5-[2-fluoro-4-bromophenyl)aminocarbonyl]pyrazole

[0292] 1-[4-methoxyphenyl]-3-cyano-4-azido-5-[2-fluoro-4-bromophenyl)aminocarbonyl]pyrazole (1.50 g, 3.28 mmol) was dissolved in MeOH followed by the addition of tin (II) chloride dihydrate (6.23, 32.88 mmol) and the solution refluxed for 2 hrs. The solution was dissolved in EtOAc and basified by the addition of 10% NaOH solution. The organics were washed twice with brine and dried over MgSO₄ filtered through a pad of silica gel and dried under vacuum to give the title compound (0.55 g, 39%). LRMS (ES+): 463.1 (M+H)⁺.

[0293] Part D. 1-[4-methoxyphenyl]-3-(methoxycarbonyl)-6-[2-fluoro-4-bromophenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one

[0294] 1-[4-methoxyphenyl]-3-methoxycarbonyl-4-amino-5-[2-fluoro-4-bromophenyl)aminocarbonyl]pyrazole (0.55 g, 1.27 mmol) was dissolved in 25 mL of 96% formic acid and refluxed for 3 hrs. The volatile were removed and the residue dissolved in EtOAc and washed with a saturated solution of NaHCO₃. The organics were dried over a solution of MgSO₄, filtered through a plug of silica gel and the volatiles were removed to yield the title compound as a white solid (0.30 g, 50%). LRMS (ES+): 473.1 (M+H)⁺.

[0295] Part E. 1-[4-methoxyphenyl]-3-(methoxycarbonyl)-6-[2′-aminosulfonyl-3-fluoro-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one

[0296] 1-[4-methoxyphenyl]-3-(methoxycarbonyl)-6-[2-fluoro-4-bromophenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one (0.30 g, 0.633 mmol), TBAB (0.02 g, 0.06 mmol), aqueous Na₂CO₃ (2M , 0.7 mL, 0.88 mmol), and 2-(N-tert-butyl)phenylsulfonamide boronic acid (0.22 g, 0.88 mmol) were dissolved in 100 mL of benzene and degassed with nitrogen for 30 minutes. Following the purge, tetrakis(triphenylphosphine)palladium(0) (0.036 g, 0.03 mmol) was added and the solution stirred overnight at reflux. The solution was diluted with EtOAc and washed twice with brine and the organics dried over MgSO₄, filtered and the volatiles were removed under reduced pressure. Purification by column chromatography, eluting with 1:1 hexane/EtOAc, afforded 0.20 g (52%) of a tert-butyl sulfonamide. This compound (0.20 g, 0.33 mmol) was dissolved in 25 mL of TFA and refluxed for 1 hour. The volatiles were removed under reduced pressure and the product was purified by reverse phase HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and lyophilized to afford the title compound of Example 2 as a white solid. LRMS (ES+): 550.2 (M+H)⁺.

Example 3 1-[4-methoxyphenyl]-3-(aminocarbonyl)-6-[2′-aminosulfonyl-3-fluoro-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one

[0297]

[0298] Part A. (1-[4-Methoxyphenyl]-3-cyano-4-azido)pyrazole-5-carboxylic acid

[0299] Methyl (1-[4-Methoxyphenyl]-3-cyano-4-azido)pyrazole-5-carboxylate from Example 1, Part C (14.0 gr, 46.94 mmol) was dissolved in a 1:1 solution of THF/H₂O followed by the addition of lithium hydroxide monohydrate (5.90 g, 140.84 mmol) and the solution stirred at room temperature for 4 hours. The solution was acidified with HCl, the organics were extracted with EtOAc and washed with brine. The organic layer was dried over MgSO₄, filtered through a plug of silica gel and the volatiles removed under reduced pressure to yield 8.72 g (65%) of the title compound as a tan solid. LRMS (ES−): 283.1 (M−H)⁻.

[0300] Part B. 1-[4-methoxyphenyl]-3-cyano-4-azido-5-[(2-fluoro-4-bromophenyl)aminocarbonyl]pyrazole

[0301] To a solution of (1-[4-Methoxyphenyl]-3-cyano-4-azido)pyrazole-5-carboxylic acid (8.22 g, 28.92 mmol) in CH₂Cl₂ was added oxallyl chloride (3.78 mL, 43.38 mmol) and 1 drop of DMF. The mixture was allowed to stir at room temperature for 2 hours. The volatiles were removed under reduced pressure and the residue dried under high vacuum for 1 hour. The residue was dissolved in CH₂Cl₂ followed by the addition of DMAP (7.06 g, 57.84 mmol) and 2-fluoro-4-bromoaniline (5.49 g, 28.92 mmol) and the solution stirred overnight at room temperature. The volatiles were removed under vacuum and the product was purified by trituration of the residue with hexane/ether to give 7.9 g (60%) of the title compound as a solid. LRMS (ES−): 454.0/456.0 (M−H)⁻.

[0302] Part C. 1-[4-methoxyphenyl]-3-(aminocarbonyl)-4-azido-5-[(2-fluoro-4-bromophenyl)aminocarbonyl]pyrazole

[0303] A solution of 1-[4-methoxyphenyl]-3-cyano-4-azido-5-[(2-fluoro-4-bromophenyl)aminocarbonyl]pyrazole (1.00 g, 2.32 mmol) in a 1:1 mixture of MeOH:MeOAc was cooled in an ice/water bath. Gaseous HCl was bubbled through the cooled solution for 15 minutes and the solution was stirred, with warming to room temperature, overnight. The volatiles were removed under reduced pressure followed by the addition of 25 mL of MeOH and 20 mL of 1 M HCl and the resulting solution was stirred at room temperature for 2 hours. The solution was diluted with EtOAc, washed with brine, the organics were dried over MgSO₄, filtered through a pad of silica gel and the volatiles were removed under reduced pressure to give 0.99 g (95%) of the title compound as a tan solid. LRMS (ES+): 458.1/460.1 (M+H)⁺.

[0304] Part D. 1-[4-methoxyphenyl]-3-(aminocarbonyl)-6-[2-fluoro-4-bromophenyl]-1,6-dihyropyrazolo-[4,3-d]-pyrimidin-7-one

[0305] To a solution of 1-[4-methoxyphenyl]-3-(aminocarbonyl)-4-azido-5-[(2-fluoro-4-bromophenyl)aminocarbonyl]pyrazole (0.99 g, 2.20 mmol) in methanol was added tin (II) chloride dihydrate (6.23, 32.88 mmol) and the solution refluxed for 2 hrs. The solution was dissolved in EtOAc and basified by the addition of 10% NaOH solution. The organics were washed twice with brine and dried over MgSO₄ filtered through a pad of silica gel and dried under vacuum. The residue was dissolved in 50 mL of 95% formic acid was stirred at reflux for 2 hours. The volatiles were removed under reduced pressure and the residue was heated in methanol and filtered to afford 0.69 g (68%) of the title compound as a solid. LRMS (ES+): 458.1/460.1 (M+H)⁺.

[0306] Part E. 1-[4-methoxyphenyl]-3-(aminocarbonyl)-6-[2′-N-tert-butylaminosulfonyl-3-fluoro-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one

[0307] 1-[4-Methoxyphenyl]-3-(aminocarbonyl)-6-[2-fluoro-4-bromophenyl]-1,6-dihyropyrazolo-[4,3-d]-pyrimidin-7-one (0.69 g, 1.50 mmol), TBAB (0.048 g, 0.15 mmol), aqueous Na₂CO₃ (2M , 3.0 mL, 6.0 mmol) and 2-(tert-butylaminosulfonyl)phenylboronic acid (0.54 g, 2.1 mmol) were dissolved in 100 mL of benzene and degassed with nitrogen for 30 minutes. Following the purge, tetrakis(triphenylphosphine)palladium(0) (0.087 g, 0.075 mmol) was added and the solution stirred overnight at reflux. The solution was diluted with EtOAc and washed twice with brine and the organics dried over MgSO₄, filtered and the volatiles removed under reduced pressure. The title compound was purified by column chromatography eluting with 1:1 hexane/EtOAc to afford 0.26 g (29%) of the title compound. LRMS (ES+): 573.3 (M+H)⁺.

[0308] Part F. 1-[4-methoxyphenyl]-3-(aminocarbonyl)-6-[2′-aminosulfonyl-3-fluoro-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one

[0309] A solution of 1-[4-methoxyphenyl]-3-(aminocarbonyl)-6-[2′-N-tert-butylaminosulfonyl-3-fluoro-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one (0.26 g, 0.44 mmol) in 25 mL of TFA was refluxed for 1 hour. The volatiles were removed under reduced pressure and the product purified by reverse phase HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and lyophilized to afford the title compound of Example 3 as a white solid. LRMS (ES+): 535.2 (M+H)⁺.

Example 4 1-[4-methoxyphenyl]-3-(methoxycarbonyl)-6-[2′-aminosulfonyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one

[0310]

[0311] Part A. □-Cyano-□-(methoxycarbonyl)-4-methoxyphenyl hydrazine imine

[0312] Anisidine (55.0 g, 446.57 mmol) was dissolved in 675 mL of water followed by the addition of 98.1 mL (1.1 mol) of concentrated HCl and the mixture cooled in an ice bath. NaNO₂ (40.05 g, 580.54 mmol) was dissolved in 100 mL of water and added in several portions. The solution was stirred for 10 minutes and poured into a flask containing a solution of 44.25 g (446.57 mmol) of methyl cyanoacetate and sodium acetate trihydrate (133.69 g, 446.57 mmol) in a solution of methanol and water (108:225 mL). A heavy yellow precipitate immediately formed and was isolated by suction filtration and dried on a lyophilizer to give 82.0 g (79%) of the title compound as a yellow solid. LRMS (ES+): 232.1 (M−H)⁻.

[0313] Part B. tert-Butyl (1-[4-Methoxyphenyl]-3-(methoxycarbonyl)-4-amino)pyrazole-5-carboxylate

[0314] □-Cyano-□-(methoxycarbonyl)-4-methoxyphenyl hydrazine imine (105.7 g, 455.2 mmol), tert-butyl bromoacetate (106.5 g, 546.2 mmol), and potassium carbonate (157.3 g, 1.13 mol) were dissolved in N,N-dimethylformamide and heated to 100° C. for several hours. The solution was diluted with ethyl acetate and washed 4 times with brine. The organics were dried over MgSO₄, filtered through a pad of silica gel and the volatiles removed. The title compound was obtained as a dark viscous liquid and used without any further purification (136.7 g, 86%). LRMS (NH₃—CI): 348.3 (M+H)⁺.

[0315] Part C. (1-[4-Methoxyphenyl]-3-(methoxycarbonyl)-4-azido)pyrazole-5-carboxylic acid

[0316] To a solution of tert-butyl (1-[4-Methoxyphenyl]-3-(methoxycarbonyl)-4-amino)pyrazole-5-carboxylate (16.89 g, 48.62 mmol) in 100 mL of TFA at 0° C. was added NaNO₂ (4.02 g, 58.34 mmol) and the mixture was stirred for 45 min. NaN₃ (3.79 g, 58.34 mmol) was dissolved in a minimal amount of water and added in portions to the TFA solution. The solution was allowed to sir at 0° C. for 45 min. and added slowly to a saturated aqueous solution of NaHCO₃. The solution was diluted with ethyl acetate and washed three times with water. The aqueous layer was acidified with 10% aqueous HCl and extracted with EtOAc. The organics were dried over MgSO₄, filtered through a plug of silica gel. The product was obtained by flushing the silica gel with 1:1 EtOAc:MeOH. The volatiles were removed under reduced pressure to give 3.0 g (32%) of the title compound as a tan solid. LRMS (ES−): 316.1 (M−H)⁻

[0317] Part D. 1-[4-methoxyphenyl]-3-(methoxycarbonyl)-4-azido-5-[4-bromophenylaminocarbonyl]pyrazole

[0318] To a solution of (1-[4-Methoxyphenyl]-3-(methoxycarbonyl)-4-azido)pyrazole-5-carboxylic acid (3.00 g, 9.45 mmol) in 20 mL of CH₂CO₂ was added oxallyl chloride (1.24 mL, 14.18 mmol) and 1 drop of DMF. The mixture was allowed to stir at room temperature for 2 hours. The volatiles were removed under reduced pressure and the residue dried under high vacuum for 1 hour. The residue was dissolved in CH₂Cl₂ followed by the addition of DMAP (4.0 g, 33.1 mmol) and 4-bromoaniline (1.62 g, 9.45 mmol) and the solution stirred overnight at room temperature. The volatiles were removed under vacuum and the product purified by trituration of the residue with ether/hexanes to afford the title compound (1.5 g, 33%). LRMS (ES−): 454.0 (M−H)⁻

[0319] Part E. 1-[4-methoxyphenyl]-3-(methoxycarbonyl)-6-[4-bromophenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one

[0320] To a solution of 1-[4-methoxyphenyl]-3-(methoxycarbonyl)-4-azido-5-[4-bromophenylaminocarbonyl]pyrazole (1.5 g, 3.18 mmol) in isopropanol was added tin (II) chloride dihydrate (0.43 g, 2.28 mmol) and the solution was warmed for 5 minutes. The solution was filtered through a pad of silica gel and the silica rinsed with EtOAc. The volatiles were removed under reduced pressure and the residue was refluxed for 2 hours in 95% formic acid. The volatiles were removed under reduced pressure and the solid residue was washed with cold EtOAc and collected by suction filtration to afford 1.44 g (93%) of the title compound as a solid. LRMS (ES+): 455.1/457.1 (M+H)⁺

[0321] Part F. 1-[4-methoxyphenyl]-3-(methoxycarbonyl)-6-[2′-aminosulfonyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one

[0322] A solution of 1-[4-methoxyphenyl]-3-(methoxycarbonyl)-6-[4-bromophenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one (0.60 g, 1.32 mmol), TBAB (0.04 g, 0.13 mmol), aqueous Na₂CO₃ (2M, 2.6 mL, 5.28 mmol), and 2-(tert-butylaminosulfonyl)phenylboronic acid (0.47 g, 1.84 mmol) in 100 mL of benzene was degassed with a stream of nitrogen for 30 minutes. Following the purge, tetrakis(triphenylphosphine)palladium(0) (0.076 g, 0.066 mmol) was added and the solution was stirred overnight at reflux. The solution was diluted with EtOAc and washed twice with brine and the organics dried over MgSO₄, filtered and the volatiles removed under reduced pressure. The residue was purified by column chromatography (elution with 1:1 hexane/EtOAc) to afford 0.2 g (52%) of a t-butylsulfonamide. A portion of this compound (0.08 g, 0.136 mmol) was dissolved in 30 mL of TFA and refluxed for 1 hour. The volatiles were removed under reduced pressure and the product was purified by reverse phase HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and lyophilized to afford the title compound of Example 4 as a white solid. LRMS (ES+): 532.2 (M+H)⁺.

Example 5 1-[4-methoxyphenyl]-6-[2′-aminosulfonyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one-3-carboxylic acid

[0323]

[0324] To a solution of 1-[4-methoxyphenyl]-3-(methoxycarbonyl)-6-[2′-aminosulfonyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one from Example 4, Part F (150 mg, 0.28 mmol) in a 1:1 mixture of MeOH:H₂O was added LiOH (120 mg, 2.82 mmol) and the reaction was followed by TLC. The solution was quenched by the addition of 10% HCl until acidic to litmus and the product purified by reverse phase HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and lyophilized to afford the title compound of Example 5 as a white solid. LRMS (ES): 516.1 (M−H)⁻

Example 6 1-[4-methoxyphenyl]-3-(aminocarbonyl)-6-[2′-aminosulfonyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one

[0325]

[0326] To a solution of 1-[4-methoxyphenyl]-3-(methoxycarbonyl)-6-[2′-aminosulfonyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one from Example 4, Part F (1.00 gr, 1.70 mmol) in 20 mL of 1,4-dioxane was added 25 mL of aqueous (28%) ammonia and the reaction was stirred at room temperature overnight. The solution was diluted with EtOAc and washed with 100 mL of brine. The organics were dried over MgSO₄, filtered through a plug of silica gel and the volatiles removed under reduced pressure. The residue (0.08 g, 0.139 mmol) was dissolved in 30 mL of TEA and refluxed for 1 hour. The volatiles were removed under reduced pressure and the product purified by reverse phase HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and lyophilized to afford the title compound of Example 6 as a white solid. LRMS (ES+): 535.1 (M+H)⁺.

Example 7 1-[4-methoxyphenyl]-3-cyano-6-[2′-aminosulfonyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one

[0327]

[0328] To a solution of 1-[4-methoxyphenyl]-3-(aminocarbonyl)-6-[2′-aminosulfonyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one from Example 6, Part A (0.25 g, 0.436 mmol) in 50 mL of anhydrous benzene was added phosphorous oxychloride (0.33 g, 2.18 mmol) and the reaction was allowed to reflux for 3 hours. The solution was quenched with H₂O and the product extracted with EtOAc, dried over MgSO₄, filtered through a plug of silica gel and the volatiles removed under reduced pressure. The residue was dissolved in 30 mL of TFA and refluxed for 1 hour. The volatiles were removed under reduced pressure and the product purified by reverse phase HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and lyophilized to afford the title compound of Example 7 as a white solid. LRMS (ES+): 499.2 (M+H)⁺.

Example 8 1-[4-methoxyphenyl]-3-(aminomethyl)-6-[2′-aminosulfonyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one trifluoroacetic acid salt

[0329]

[0330] To a solution of 1-[4-methoxyphenyl]-3-cyano-6-[2′-aminosulfonyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one from Example 7, Part A (0.50 g, 1.00 mmol) in 75 mL of absolute EtOH containing 1 mL of TFA was added 10% Pd/C (50 mg) and the reaction was stirred overnight under a balloon of H₂ gas. The solution was filtered through a pad of Celite® and the volatiles were removed under reduced pressure and the product purified by reverse phase HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and lyophilized to afford the title compound of Example 8 as a white solid. LRMS (ES+): 503.3 (M+H)⁺.

Example 9 1-[4-methoxyphenyl]-3-(ethoxycarbonyl)-6-[4-(2-methylimidazol-1′-yl)phenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one

[0331]

[0332] Part A. □-Cyano-.□-(ethoxycarbonyl)-4-methoxyphenyl hydrazine imine

[0333] Anisidine (110 g, 0.89 mol) was dissolved in 1 L of water followed by the addition of 196 mL (2.35 mol) of concentrated HCl and then the mixture was cooled in an ice bath. NaNO₂ (67.8 g, 0.98 mol) was dissolved in 250 mL of water and added in several portions. The solution was stirred for 15 minutes and then poured into a flask containing a solution of ethyl cyanoacetate (111 g, 0.98 mol) and sodium acetate trihydrate (267 g, 1.96 mol) in 215 mL of methanol and 450 mL of water at 0° C. A heavy yellow precipitate immediately formed. After 30 minutes 187 g (84%) of the title compound was isolated by suction filtration and was used without further purification.

[0334] Part B. 3-Ethyl-5-methyl (1-[4-Methoxyphenyl]-4-amino)pyrazole-3,5-dicarboxylate

[0335] □-Cyano-.□-(ethoxycarbonyl)-4-methoxyphenyl hydrazine imine (81.8 g, 331 mmol), methyl bromoacetate (55.7 g, 364 mmol) and potassium carbonate (114 g, 827 mmol) were dissolved in N,N-dimethyl formamide and heated to 100° C. for several hours. The solution was diluted with ethyl acetate and washed 4 times with brine. The organics were dried over MgSO₄, filtered through a pad of silica gel and the volatiles were removed. The title compound was purified by dissolving in hot diethyl ether and collecting the solids (24.3 g, 23%) that formed upon cooling by filtration. This material was used without further purification.

[0336] Part C. 3-Ethyl-5-methyl (1-[4-Methoxyphenyl]-4-azido)pyrazole-3,5-dicarboxylate

[0337] 3-Ethyl-5-methyl (1-[4-Methoxyphenyl]-4-amino)pyrazole-3,5-dicarboxylate (41.0 g, 128.4 mmol) was dissolved in TFA and cooled to 0° C. followed by the portionwise addition of NaNO₂ (10.6 g, 154.1 mmol) and then the reaction was stirred at that temperature for 45 min. NaN₃ (10.0 g, 154.1 mmol) was dissolved in a minimal amount of water and added in portions to the TFA solution. The solution was allowed to stir at 0° C. for 45 min and added slowly to a saturated aqueous solution of NaHCO₃. The solution was diluted with ethyl acetate and washed twice with brine. The organics were dried over MgSO₄, filtered through a plug of silica gel and the volatiles were removed. The residue was recrystallized from ether/hexanes to give the title compound as a tan solid (39.9 g, 90%). LRMS (ES+): 346.1 (M+H)⁺.

[0338] Part D. (1-[4-Methoxyphenyl]-3-(ethoxycarbonyl)-4-azido)pyrazole-5-carboxylic acid

[0339] To a solution of 3-ethyl-5-methyl (1-[4-Methoxyphenyl]-4-azido)pyrazole-3,5-dicarboxylate (14.0 g, 40.5 mmol) in 50 mL of tetrahydrofuran and 50 mL of water was added lithium hydroxide (0.97 g, 40.5 mmol) and the reaction was stirred at ambient temperature for several hours. The reaction was diluted with water and hexanes and made basic with saturated aqueous sodium bicarbonate. The organic layer was separated. The aqueous layer was acidified with aqueous HCl and then was extracted with ethyl acetate. The organics were washed with brine, dried over MgSO₄, and concentrated to afford 10.1 g (75%) of the title compound that was used without purification. LRMS (ES+): 332.1 (M+H)⁺.

[0340] Part E. 1-[4-methoxyphenyl]-3-(ethoxycarbonyl)-6-[4-(2-methylimidazol-1′-yl)phenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one

[0341] To a solution of (1-[4-Methoxyphenyl]-3-(ethoxycarbonyl)-4-azido)pyrazole-5-carboxylic acid (1.50 g, 4.52 mmol) in 20 mL of CH₂Cl₂ was added oxallyl chloride (0.60 mL, 6.80 mmol) and 1 drop of DMF. The mixture was allowed to stir at room temperature for 2 hours. The volatiles were removed under reduced pressure and the residue dried under high vacuum for 1 hour. The residue was dissolved in CH₂Cl₂ followed by the addition of DMAP (1.38 g, 11.3 mmol) and 4-(2-methylimidazol-1′-yl)aniline (0.78 g, 4.52 mmol) and the solution stirred overnight at room temperature. The volatiles were removed under vacuum and the residue was taken up in ethyl acetate and filtered through a plug of silica gel. The product was obtained by flushing the silica gel with methanol. The volatiles were removed under vacuum and the residue was used without further purification. The crude product was dissolved in ethanol and then there was added tin (II) chloride dihydrate (2.57 g, 13.6 mmol) and the solution was warmed for 15 minutes. The solution was diluted with ethyl acetate, washed with 10% aqueous sodium hydroxide and brine, dried MgSO₄) and the volatiles were removed under reduced pressure. The residue was refluxed for 2 hours in 95% formic acid. The volatiles were removed under reduced pressure and the residue was purified by reverse phase HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and lyophilized to afford 0.16 g of the title compound of Example 9 as a white solid. LRMS (ES+): 471.2 (M+H)⁺.

Example 10 1-[4-methoxyphenyl]-3-(aminocarbonyl)-6-[4-(2-methylimidazol-1′-yl)phenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one

[0342]

[0343] To a solution of 1-[4-methoxyphenyl]-3-(ethoxycarbonyl)-6-[4-(2-methylimidazol-1′-yl)phenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one from Example 9, Part E (0.50 g, 0.85 mmol) in 20 mL of 1,4-dioxane was added 20 mL of aqueous (28%) ammonia and the reaction was stirred at room temperature overnight. The solution was diluted with EtOAc and washed with 100 mL of brine. The organics were dried over MgSO₄ and the volatiles removed under reduced pressure. The residue was purified by reverse phase HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and lyophilized to afford the title compound of Example 10 as a white solid. LRMS (ES+): 442.1 (M+H)⁺.

Examples 11 and 12 1-[4-methoxyphenyl]-3-(ethoxycarbonyl)-6-[2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one trifluoroacetic acid salt (Example 11) and 1-[4-methoxyphenyl]-3-(ethoxycarbonyl)-6-[2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[4,3-d]-pyrimidin-7-one trifluoroacetic acid salt (Example 12)

[0344]

[0345] Part A. 1-[4-methoxyphenyl]-3-(ethoxycarbonyl)-4-azido-5-[4-bromophenylaminocarbonyl]pyrazole

[0346] To a solution of (1-[4-Methoxyphenyl]-3-(ethoxycarbonyl)-4-azido)pyrazole-5-carboxylic acid from Example 9, Part D (3.6 g, 10.9 mmol) in 40 mL of CH₂Cl₂ was added oxallyl chloride (1.42 mL, 16.3 mmol) and 1 drop of DMF. The mixture was allowed to stir at room temperature for 2 hours. The volatiles were removed under reduced pressure and the residue dried under high vacuum for 1 hour. The residue was dissolved in CH₂Cl₂ followed by the addition of DMAP (3.32 g, 27.2 mmol) and 4-bromoaniline (1.86 g, 10.9 mmol) and the solution stirred overnight at room temperature. The volatiles were removed under vacuum and the product purified by trituration of the residue with ether/hexanes to afford the title compound (2.6 g, 49%). LRMS (ES+): 485.0/487.0 (M+H)⁺.

[0347] Part B. 1-[4-methoxyphenyl]-3-(ethoxycarbonyl)-6-[4-bromophenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one

[0348] To a solution of 1-[4-methoxyphenyl]-3-(ethoxycarbonyl)-4-azido-5-[4-bromophenylaminocarbonyl]pyrazole (2.62 g, 5.40 mmol) in ethanol was added tin (II) chloride dihydrate (3.07 g, 16.2 mmol) and the solution was warmed for 15 minutes. The solution was filtered through a pad of silica gel and the silica rinsed with EtOAc. The volatiles were removed under reduced pressure and the residue was refluxed for 2 hours in 95% formic acid. The volatiles were removed under reduced pressure and the solid residue was washed with cold EtOAc and collected by suction filtration to afford 1.1 g (44%) of the title compound as a solid. LRMS (ES+): 469.0/471.0 (M+H)⁺.

[0349] Part C. 1-[4-methoxyphenyl]-3-(ethoxycarbonyl)-6-[2′-formyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one

[0350] A solution of 1-[4-methoxyphenyl]-3-(ethoxycarbonyl)-6-[4-bromophenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one (1.1 g, 2.34 mmol), TBAB (0.07 g, 0.23 mmol), aqueous Na₂CO₃ (2M, 5.0 mL, 9.3 mmol), and 2-formylphenylboronic acid (0.49 g, 3.28 mmol) in 30 mL of benzene was degassed with a stream of nitrogen for 15 minutes. Following the purge, tetrakis(triphenylphosphine)palladium(0) (0.14 g, 0.12 mmol) was added and the solution was stirred overnight at reflux. The solution was diluted with EtOAc, washed twice with brine and dried over MgSO₄, filtered through a pad of silica gel and the volatiles were removed under reduced pressure to afford the title compound that was used without further purification. LRMS (ES+): 495.1 (M+H)⁺.

[0351] Part D. 1-[4-methoxyphenyl]-3-(ethoxycarbonyl)-6-[2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one trifluoroacetic acid salt (Example 11) and 1-[4-methoxyphenyl]-3-(ethoxycarbonyl)-6-[2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[4,3-d]-pyrimidin-7-one trifluoroacetic acid salt (Example 12)

[0352] To a solution of 1-[4-methoxyphenyl]-3-(ethoxycarbonyl)-6-[2′-formyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one (2.68 g, 5.42 mmol) in 20 mL of dimethyl formamide was added pyrrolidine (0.77 g, 10.8 mmol) and acetic acid dropwise until pH was about 5-6. Then there was added sodium cyanoborohydride (0.68 g, 10.8 mmol) and the resulting solution was allowed to sir for 18 h. The reaction mixture was quenched with water and was partitioned between saturated aqueous sodium bicarbonate and ethyl acetate. The organics were washed with water and brine, dried (MgSO₄) and the volatiles were removed under vacuum. The residue was purified by prep HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) to afford 0.3 g (10%) of the title compound of Example 11 and 0.5 g (17%) of the title compound of Example 12. Example 11 LRMS (ES+): 550.2 (M+H)⁺. Example 12 LRMS (ES+): 552.2 (M+H)⁺.

Example 13 1-[4-methoxyphenyl]-3-(aminocarbonyl)-6-[2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one trifluoroacetic acid salt

[0353]

[0354] To a solution of 1-[4-methoxyphenyl]-3-(ethoxycarbonyl)-6-[2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one trifluoroacetic acid salt from Example 11, Part D (0.32 g, 0.48 mmol) in 20 mL of 1,4-dioxane was added 20 mL of aqueous (28%) ammonia and the reaction was stirred at room temperature overnight. The solution was diluted with EtOAc and washed with 100 mL of brine. The organics were dried over MgSO₄ and the volatiles removed under reduced pressure. The residue was purified by reverse phase HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and lyophilized to afford the title compound of Example 13 as a white solid. LRMS (ES+): 521.1 (M+H)⁺.

Example 14 1-[4-methoxyphenyl]-3-cyano-6-[2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one trifluoroacetic acid salt

[0355]

[0356] To a solution of 1-[4-methoxyphenyl]-3-(aminocarbonyl)-6-[2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one from Example 13 (0.20 g, 32 mmol) in 10 mL of anhydrous benzene was added phosphorous oxychloride (0.24 g, 1.57 mmol) and the reaction was allowed to reflux for 4 hours. The solution was quenched with H₂O and the volatiles were removed under reduced pressure. The residue was purified by reverse phase HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and lyophilized to afford the title compound of Example 14 as a white solid. LRMS (ES+): 503.1 (M+H)⁺.

Example 15 1-[4-methoxyphenyl]-3-(ethoxycarbonyl)-6-[2-fluoro-4-(2-dimethylaminomethylimidazol-1′-yl)phenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one trifluoroacetic acid salt

[0357]

[0358] Following the procedures described in Example 9, Part E, the title compound of Example 15 was prepared. LRMS (ES+): 532.1 (M+H)⁺.

Example 16 1-[2-aminomethylphenyl]-3-(ethoxycarbonyl)-6-[2′-methylsulfonyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one trifluoroacetic acid salt

[0359]

[0360] Part A. □-Cyano-.□-(ethoxycarbonyl)-2-methylphenyl hydrazine imine.

[0361] To a solution of o-toluidine (20.0 g, 187 mmol) in 320 mL of water at 0° C. was added of 44 mL of concentrated HCl followed by sodium nitrite (16.7 g, 243 mmol) portionwise. The solution was stirred for 15 minutes and then poured into a flask containing a solution of ethyl cyanoacetate (21.1 g, 187 mmol) and sodium acetate trihydrate (55.9 g, 410 mmol) in 100 mL of methanol and 200 mL of water at 0° C. A heavy yellow precipitate immediately formed. After 30 minutes the solid was filtered, washed with water and dried under vacuum to afford 32.4 g (75%) of the title compound, that was used without further purification. ¹H NMR (CDCl₃): □ 9.29 (broad s, 1H), 7.63 (d, 1H), 7.28 (t, 1H), 7.20 (d, 1H), 7.11 (t, 1H), 4.40 (q, 2H), 2.40 (s, 3H), 1.40 (t, 3H).

[0362] Part B. 3-Ethyl-5-methyl 1-(2-methylphenyl)-4-aminopyrazole-3,5-dicarboxylate

[0363] □-Cyano-.□-(ethoxycarbonyl)-2-methylphenyl hydrazine imine (14.0 g, 60 mmol), methyl bromoacetate (8.6 mL, 91 mmol) and potassium carbonate (31.3 g, 226 mmol) were dissolved in 150 mL of N,N-dimethyl formamide and heated to 100° C. for several hours. The solution was diluted with ethyl acetate and washed 4 times with brine. The organics were dried over MgSO₄, filtered through a pad of silica gel and the volatiles were removed. The residue was purified by flash chromatography (elution with 3:1 hexanes/ethyl acetate) to afford 5.15 g (28%) of the title compound. ¹H NMR (CDCl₃): □ 7.30-7.15 (m, 4H), 5.25 (broad s, 2H), 4.40 (q, 2H), 3.67 (s, 3H), 2.01 (s, 3H), 1.38 (t, 3H).

[0364] Part C. 1-(2-methylphenyl)-3-(ethoxycarbonyl)-4-azidopyrazole-5-carboxylic acid

[0365] 3-Ethyl-5-methyl 1-(2-methylphenyl)-4-aminopyrazole-3,5-dicarboxylate (5.2 g, 17.0 mmol) was dissolved in 100 mL of TFA and cooled to 0° C. followed by the addition of NaNO₂ (1.4 g, 20.4 mmol) and then the reaction was stirred at that temperature for 45 min. Sodium azide (1.3 g, 20.4 mmol) was dissolved in a minimal amount of water and added in portions to the TFA solution. The solution was allowed to stir at 0° C. for 45 min and added slowly to a saturated aqueous solution of NaHCO₃. The solution was diluted with ethyl acetate and washed twice with brine. The organics were dried over MgSO₄, filtered through a plug of silica gel and the volatiles were removed. The residue was triturated with ether to afford a crude azide that was used without purification.

[0366] To a solution of 1.0 g (3.0 mmol) of the residue in 20 mL of tetrahydrofuran and 20 mL of water was added lithium hydroxide (60 mg, 2.7 mmol) and the reaction was stirred at ambient temperature for several hours. The reaction was diluted with water and hexanes and made basic with saturated aqueous sodium bicarbonate. The organic layer was separated. The aqueous layer was acidified with aqueous HCl and then was extracted with ethyl acetate. The organics were washed with brine, dried over MgSO₄, and concentrated to afford 0.65 g (69%) of the title compound that was used without purification. LRMS (ES−): 314.2 (M−H)⁺.

[0367] Part D. 1-(2-methylphenyl)-3-(ethoxycarbonyl)-4-azido-5-[2′-methylsulfonyl-[1,1′-biphen-4-yl]aminocarbonyl]pyrazole

[0368] To a solution of 1-(2-methylphenyl)-3-(ethoxycarbonyl)-4-azidopyrazole-5-carboxylic acid (0.69 g, 2.2 mmol) in 50 mL of CH₂Cl₂ was added oxallyl chloride (0.29 mL, 3.3 mmol) and 1 drop of DMF. The mixture was allowed to stir at room temperature for 2 hours. The volatiles were removed under reduced pressure and the residue dried under high vacuum for 1 hour. The residue was dissolved in CH₂Cl₂ followed by the addition of DMAP (0.81 g, 6.6 mmol) and [2′-methylsulfonyl-[1,1′]-biphen-4-yl]amine hydrochloride (0.62 g, 2.2 mmol) and the solution was stirred overnight at room temperature. The volatiles were removed under vacuum and the residue was taken up in ethyl acetate, washed with saturated aqueous sodium bicarbonate and brine, dried (MgSO₄) and filtered through a plug of silica gel. The volatiles were removed under vacuum to afford 1.0 g (83%) of the title compound that was used without further purification. LRMS (ES−): 543.1 (M−H)⁻.

[0369] Part E. 1-(2-methylphenyl)-3-(ethoxycarbonyl)-6-[2′-methylsulfonyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one

[0370] To a solution of 1-(2-methylphenyl)-3-(ethoxycarbonyl)-4-azido-5-[2′-methylsulfonyl-[1,1′]-biphen-4-yl]aminocarbonyl]pyrazole (0.98 g, 1.8 mmol) in absolute ethanol was added tin (II) chloride dihydrate (1.22 g, 5.4 mmol) and the solution was warmed for 15 minutes. The solution was filtered through a pad of silica gel and the silica rinsed with EtOAc. The volatiles were removed under reduced pressure and the residue was refluxed for 2 hours in 95% formic acid. The volatiles were removed under reduced pressure and the solid residue was purified by flash chromatography (elution with 1:1 hexanes/ethyl acetate) to afford 0.21 g (22%) of the title compound as a solid. LRMS (ES+): 529.2 (M+H)⁺.

[0371] Part F. 1-[2-bromomethylphenyl]-3-(ethoxycarbonyl)-6-[2′-methylsulfonyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one

[0372] To a solution of 1-(2-methylphenyl)-3-(ethoxycarbonyl)-6-[2′-methylsulfonyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one (0.21 g, 0.4 mmol) in 50 mL of carbon tetrachloride was added N-bromosuccinimide (0.08 g, 0.44 mmol) and a small amount of AIBN. The reaction was stirred at reflux for 5 h and then was cooled and diluted with ethyl acetate. The organics were washed with brine, dried (MgSO₄) and concentrated in vacuo to afford 0.24 g (99%) of the title compound that was used without purification. LRMS (ES+): 607.0/609.0 (M+H)⁺.

[0373] Part G. 1-[2-aminomethylphenyl]-3-(ethoxycarbonyl)-6-[2′-methylsulfonyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one trifluoroacetic acid salt

[0374] To a solution of 1-[2-bromomethylphenyl]-3-(ethoxycarbonyl)-6-[2′-methylsulfonyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one (0.24 g, 0.4 mmol) in 20 mL of dimethyl formamide was added sodium azide (0.04 g, 0.6 mmol) and the reaction was stirred at ambient temperature for 3 h. The reaction was poured into water and extracted with ethyl acetate. The organics were washed with brine, dried (MgSO₄) and concentrated in vacuo to afford 0.21 g (91%) of an azide that was used without further purification. This azide was taken up in 20 mL of absolute ethanol and 10 mL of tetrahydrofuran and then there was added tin (II) chloride dihydrate (0.061 g, 0.27 mmol). The reaction was allowed to stir at reflux for 18 h. The voltiles were removed in vacuo and the residue was purified by prep HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and lyophilized to afford the title compound of Example 16 as a white solid. LRMS (ES+): 544.2 (M+H)⁺.

Example 17 1-[3-aminoiminomethylphenyl]-3-methyl-6-[2′-aminosulfonyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one trifluoroacetic acid salt

[0375]

[0376] Part A. 1-[4-bromophenyl]-4-acetyl-2,3-dioxopiperidine

[0377] This intermediate was prepared in four steps in 10% overall yield by the following sequence of reactions. Commercially available 4-bromoaniline was treated with commercially available 5-chloro-2-pentanone ethylene ketal in dimethylformamide in the presence of potassium carbonate for three days. The crude alkylated aniline was treated with ethyloxalyl chloride in THF the presence of triethylamine. Hydrolysis of the ketal was accomplished by treating with aqueous HCl and the resulting material was subjected to Dieckmann cyclization conditions (NaOMe, methanol). The crude dioxopiperidine was purified by flash chromatography (elution with 4:1 hexanes/ethylacetate) to afford the title compound. ¹H NMR (dmso d6): □ 7.56 (d, 2H, J=8 Hz), 7.26 (d, 2H, J=8 Hz), 3.60 (t, 2H), 3.28 (t, 2H), 2.30 (s, 3H). LRMS (ES+): 281.0 (M+H)⁺.

[0378] Part B. 1-[3-aminoiminomethylphenyl]-3-methyl-6-[2′-aminosulfonyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one trifluoroacetic acid salt

[0379] To a solution of 1-[4-bromophenyl]-4-acetyl-2,3-dioxopiperidine in glacial acetic acid was added 3-cyanophenyl hydrazine. The reaction mixture was stirred at reflux for 3 h and then was cooled to ambient temperature. The volatiles were removed and the residue was taken up in ethyl acetate. The organics were washed with saturated aq sodium bicarbonate and brine, dried (MgSO₄) and concentrated.

[0380] The residue was dissolved in benzene and then there was added tetrabutylammonium bromide, aqueous Na₂CO₃ and 2-(tert-butylaminosulfonyl)phenylboronic. This solution was degassed with a stream of nitrogen for 30 minutes. Following the purge, tetrakis(triphenylphosphine)palladium(0) was added and the solution was stirred overnight at reflux. The solution was diluted with EtOAc and washed twice with brine and the organics dried over MgSO₄, filtered and the volatiles removed under reduced pressure. The residue was purified by column chromatography (elution with 1:1 hexane/EtOAc) to afford an intermediate biphenyl compound.

[0381] This material was dissolved in 50 mL of anhydrous methanol and was cooled to 0° C. Anhydrous HCl gas was bubbled through the solution for about 30 min (until solution saturated). The flask was then sealed and allowed to stand for 16 h at 0° C. The reaction mixture was concentrated in vacuo. The resulting solid was dissolved in anhydrous methanol and ammonium carbonate was added and the mixture was allowed to stir at room temperature for 24 h. The reaction mixture was concentrated in vacuo. The residue was dissolved in trifluoroacetic acid and stirred at reflux for 20 minutes. The volatiles were removed in vacuo and the residue was purified by prep HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and lyophilized to afford the title compound of Example 17 as a white powder. ¹H NMR (dmso d6): □ 9.40 (broad s, 1.5H), 9.28 (broad s, 1.5H), 8.04 (ds, 2H), 7.94 (d, 1H), 7.81 (d, 1H), 7.78-7.48 (m, 4H), 7.40-7.30 (m, 4H), 4.18 (t, 2H), 2.95 (t, 2H), 2.30 (s, 3H). LRMS (ES+): 501.0 (M+H)⁺.

Example 18 1-[2-aminomethylphenyl]-3-methyl-6-[2′-aminosulfonyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one trifluoroacetic acid salt

[0382]

[0383] Part A. 1-[2-trifluoroacetamidomethylphenyl]-3-methyl-6-[4-bromophenyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one

[0384] To solution of 2-(trifluoroacetamidomethyl)aniline (6.5 g, 0.029 mol), prepared from 2-(aminomethyl)aniline and ethyl trifluoroacetate, was added conc. HCl (50 mL) with cooling in an ice bath. The temperature was maintained between 0° C. and 10° C. and sodium nitrite (2 g, 0.029 mol) in water (40 mL) was added. The diazonium was stirred cold for 2 h, then stannous chloride dihydrate (15.4 g, 0.069 mol) in conc. HCl (5 mL) and water (50 mL) was added slowly. The reaction was stirred 0.5 h, saturated with NaCl, extracted with ether, dried (Na₂SO₄) and concentrated. A portion of the crude hydrazine tin salt (2 g) was combined with 1-[4-bromophenyl]-4-acetyl-2,3-dioxopiperidine from Example 17, Part A (0.46 g, 1.5 mmol) and acetic acid (20 mL) and heated to reflux for 8 h. The reaction was concentrated, taken up in ethyl acetate, washed successively with sat'd NaHCO₃ and sat'd NaCl, dried (Na₂SO₄) and concentrated. The residue was purified by flash chromatography (elution with 1:1 hexanes/ethyl acetate) to afford 0.24 g (32%) of the title compound as a yellow oil. LRMS (ES+): 507/509 (M+H)⁺.

[0385] Part B. 1-[2-aminomethylphenyl]-3-methyl-6-[2′-aminosulfonyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one trifluoroacetic acid salt

[0386] To a solution of 1-[2-trifluoroacetamidomethylphenyl]-3-methyl-6-[4-bromophenyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (0.24 g, 0.47 mmol) in dioxane (15mL) was added 2-tert-butylsulfonamide benzeneboronic acid (0.16 g,0.62 mmol), potassium phosphate tribasic (0.3 g, 1.4 mmol), and the mixture was degassed with N₂ for 0.5 h. Tetrakis(triphenylphosphine)palladium(0) (50 mg) was added and the reaction was heated to reflux for 4 h. The reaction was filtered through Celite® and the filtrate concentrated. Trifluoroacetic acid (10 mL) was added to the crude residue and the mixture was heated to reflux for 0.25 h. The reaction was concentrated and the residue was purified by flash chromatography (elution with 2:1 hexanes/ethyl acetate) to afford 0.13 g (49%) of the trifluoroacetamide as a tan foam. The trifluoroacetamide was placed in MeOH (10 mL), water (2 mL) and K₂CO₃ (0.15 g) and heated to reflux for 4 h. The reaction was concentrated, acidified with TFA, purified by prep HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and lyophilized to afford the title compound of Example 18 as a white powder. ¹H NMR (DMSO-d6) □ 8.19 (broad s, 2H), 8.05 (dd, J=1.1, 7.4 Hz, 1H), 7.65-7.28 (m, 13H), 4.17 (t, J=6.6 Hz, 2H), 3.88 (m, 2H), 3.01 (t, J=6.2, 2H), 2.31 (s, 3H). LRMS (ES+): 488.3 (M+H)⁺.

Example 19 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-aminosulfonyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one

[0387]

[0388] Part A. 1-[3-cyano-4-fluorophenyl]-3-methyl-6-[4-bromophenyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one

[0389] To 1-[4-bromophenyl]-4-acetyl-2,3-dioxopiperidine from Example 17, Part A (0.3 g, 0.97 mmol) in acetic acid (20mL) was added 3-cyano-4-fluorophenylhydrazine stannyl chloride hydrochloride (0.39 g, 1.16 mmol) and the mixture was heated to reflux for 8 h. The reaction was concentrated, taken up in ethyl acetate, washed successively with sat'd NaHCO₃ and sat'd NaCl, dried (Na₂SO₄) and concentrated. Purification by silica gel chromatography using 1:1 hexanes/ethyl acetate as eluent afforded 0.31 g (76%) of the title compound as a white solid. ¹H NMR (CDCl₃) □ 7.88 (m, 2H), 7.53 (d, J=8.4 Hz, 2H), 7.25 (m, 1H), 7.21 (d, J=8.4 Hz, 2H),4.13 (t, J=7.0 Hz, 2H), 2.98 (t, J=6.6 Hz, 2H), 2.35 (s, 3H). LRM (ES+): 425.1/427.1 (M+H)⁺.

[0390] Part B. 1-[3-cyano-4-fluorophenyl]-3-methyl-6-[2′-tert-butylaminosulfonyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one

[0391] To a solution of 1-[3-cyano-4-fluorophenyl]-3-methyl-6-[4-bromophenyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (0.31 g, 0.73 mmol) in 15 mL of dioxane was added 2-tert-butylsulfonamide benzeneboronic acid (0.24 g, 0.95 mmol), potassium phosphate tribasic (0.47 g, 2.2 mmol), and the mixture was degassed with N₂ for 0.5 h. Tetrakis(triphenylphosphine)palladium(0) (60mg) was added and the reaction was heated in a 70-80° C. bath for 18 h. The reaction was filtered through Celite® and the filtrate concentrated. Purification by silica gel chromatography using 1:1 hexanes/ethyl acetate as eluent afforded 0.24 g (59%) of a yellow solid. ¹H NMR (CDCl₃) □ 8.18 (dd, J=1.4, 7.7 Hz, 1H), 7.91 (m, 2H), 7.59 (m, 4H), 7.42 (d, J=8.4 Hz, 2H), 7.32 (dd, J=1.5, 7.5 Hz, 1H), 7.24 (d, J=8.8 Hz, 1H), 4.19 (t, J=6.5 Hz, 2H), 3.68 (s, 1H), 3.68 (t, J=6.9 Hz, 2H), 2.36 (3H, s), 1.04 (s, 9H). LRMS (ES+): 580.3 (M+Na)⁺.

[0392] Part C. 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-aminosulfonyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one

[0393] Trifluoroacetic acid (10 mL) was added to 1-[3-cyano-4-fluorophenyl]-3-methyl-6-[2′-tert-butylaminosulfonyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one and the mixture was heated to reflux for 0.25 h. The reaction was concentrated and the residue dried in vacuo for 2 h. To the crude residue was added DMF (5 mL), K₂CO₃ (0.18 g, 1.3 mmol), and acetohydroxamic acid (97 mg, 1.3 mmol) and the reaction was stirred at ambient temperature. After 0.25 h excess K₂CO₃ and acetohydroxamic acid were added to counter residual TFA and the rection was stirred 18 h. Water (10 mL) was added and the precipitate filtered off. The solid was acidifed in TFA/CH₃CN, concentrated and purified by prep HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and lyophilized to afford the title compound of Example 19 as a white powder. LRMS (ES+): 515.2 (M+H)⁺, 537 (M+Na)⁺.

Example 20 1-[4-methoxyphenyl]-3-cyano-6-[2′-N,N-dimethylaminomethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one trifluoroacetic acid salt

[0394]

[0395] Part A. 1-[4-methoxyphenyl]-3-cyano-4-azido-5-[4-bromophenylaminocarbonyl]pyrazole

[0396] 1-[4-Methoxyphenyl]-3-cyano-4-azidopyrazole-5-carboxylic acid from Example 2, Part A (2.92 g, 10.3 mmol) was dissolved in CH₂Cl₂ followed by the addition of oxalyl chloride (1.34 mL, 15.4 mmol) and 2 drops of DMF. The mixture was allowed to stir at room temperature for 2 hrs. The volatiles were removed under reduced pressure and the residue dried under high vacuum for 1 hr. The residue was dissolved in CH₂Cl₂ followed by the addition of DMAP (3.78 g, 30.9 mmol) and 4-bromo-aniline (1.77 g, 10.3 mmol) and the solution stirred overnight at room temperature. The reaction mixture was diluted with ethyl acetate, washed sequentially with 10% aqueous HCl, saturated aqueous sodium bicarbonate and brine, dried (MgSO₄) and filtered through a plug of silica gel. The volatiles were removed under vacuum to afford 3.9 g (87%) of the title compound that was used without further purification. ¹H NMR (CDCl₃) 8.41 (broad s, 1H), 7.43 (app s, 4H), 7.31 (d, 2H), 6.98 (d, 2H), 3.86 (s, 3H).

[0397] Part B. 1-[4-methoxyphenyl]-3-cyano-4-amino-5-[4-bromophenyl)aminocarbonyl]pyrazole

[0398] To a solution of 1-[4-methoxyphenyl]-3-cyano-4-azido-5-[4-bromophenylaminocarbonyl]pyrazole (3.9 g, 8.9 mmol) in 30 mL of isopropanol was added tin (II) chloride dihydrate (8.0 g, 35.6 mmol) and the solution was stirred at 80° C. for 2 hrs. The solution was cooled, dissolved in EtOAc, washed with 10% aqueous NaOH solution and brine, dried over MgSO₄, filtered through a pad of silica gel and dried under vacuum to give the title compound (3.0 g, 82%). ¹H NMR (dmso-D6) □ 10.26 (s, 1H), 7.46 (app s, 4H), 7.35 (d, 2H), 6.98 (d, 2H), 5.46 (broad s, 2H), 3.74 (s, 3H).

[0399] Part C. 1-[4-methoxyphenyl]-3-cyano-6-[4-bromophenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one

[0400] 1[4-methoxyphenyl]-3-cyano-4-amino-5-[4-bromophenylaminocarbonyl]pyrazole (0.60 g, 1.45 mmol) was dissolved in 5 mL of N,N-dimethylformamide dimethyl acetal and stirred at 100° C. for 1 h. The volatiles were removed and the residue was dissolved in 95% formic acid and stirred at 100° C. for 1 h. The volatiles were removed in vacuo and the residue was dissolved in EtOAc and washed with saturated NaHCO₃ and brine. The organics were dried over MgSO₄, filtered through a plug of silica gel and the volatiles were removed to yield the title compound as an off-white solid (0.56 g, 91%). ¹H NMR (dmso-D6) □ 8.45 (s, 1H), 7.75 (app d, 2H), 7.62 (app d, 2H), 7.45 (app d, 2H), 7.05 (app d, 2H), 3.79 (s, 3H).

[0401] Part D. 1-[4-methoxyphenyl]-3-cyano-6-[2′-formyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one

[0402] To a solution of 1-[4-methoxyphenyl]-3-cyano-6-[4-bromophenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one (0.40 g, 0.95 mmol) in 10 mL of 1,4-dioxane was added 2-formylphenylboronic acid (0.22 g, 1.43 mmol) and potassium phosphate tribasic (0.71 g, 3.33 mmol). This mixture was degassed with a stream of nitrogen for 15 minutes. Following the purge, tetrakis(triphenylphosphine)palladium(0) (0.04 g, 0.035 mmol) was added and the solution was stirred overnight at 100° C. The solution was cooled, diluted with EtOAc, washed twice with brine and the organics were dried over MgSO₄, filtered through a pad of silica gel and concentrated to afford 0.30 g (71%) of the title compound that was sufficiently pure to be used without purification. ¹H NMR (CDCl₃) □ 10.02 (s, 1H), 8.21 (s, 1H), 8.06 (dd, 1H), 7.70-7.40 (m, 9H), 7.00 (app d, 2H), 3.86 (s, 3H).

[0403] Part E. 1-[4-methoxyphenyl]-3-cyano-6-[2′-hydroxymethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one

[0404] To a solution of 1-[4-methoxyphenyl]-3-cyano-6-[2′-formyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one (0.30 g, 0.67 mmol) in 10 mL of 1:1 DMF/THF was added sodium borohydride (38 mg, 1.0 mmol) and the reaction was stirred at ambient temperature for 1 h. The reaction was quenched with 10% aqueous HCl and then diluted with ethyl acetate. The organics were washed with water and brine, dried (MgSO₄) and concentrated. The residue was purified by flash chromatography (elution with 2:1 hexanes/ethyl acetate) to afford 150 mg (50%) of the title compound. ¹H NMR (dmso-D6) □ 8.53 (s, 1H), 7.65 (app d, 2H), 7.62-7.54 (m, 5H), 7.42-7.30 (m, 2H), 7.23 (dd, 1H), 7.07 (app d, 2H), 5.19 (t, 1h), 4.39 (s, 2H), 3.80 (s, 3H).

[0405] Part F. 1-[4-methoxyphenyl]-3-cyano-6-[2′-N,N-dimethyaminomethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one trifluoroacetic acid salt

[0406] To a solution of 1-[4-methoxyphenyl]-3-cyano-6-[2′-hydroxymethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one (120 mg, 0.27 mmol) in 5 mL of CH₂Cl₂ was added phosphorous tribromide (144 mg, 0.53 mmol) and the reaction mixture was allowed to stir at ambient temperature for 1 h. The reaction was diluted with ethyl acetate, washed with brine, dried (MgSO₄), filtered through a pad of silica gel and concentrated to afford 115 mg of a crude bromide. To a portion of this residue (65 mg, 0.13 mmol) in 2 mL of acetonitrile was added dimethylamine (0.13 mL of a 2M solution in methanol, 0.26 mmol). The reaction was allowed to stir at ambient temperature for 2 h. The reaction was concentrated and the residue was purified by prep HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and lyophilized to afford 38 mg (50%) of the title compound of Example 20 as a white powder. ¹H NMR (dmso-D6) □ 9.68 (broad s, 1H), 8.48 (s, 1H), 7.72-7.50 (m, 9H), 7.36 (dd, 1H), 7.07 (app d, 2H), 4.30 (broad s, 2H), 3.80 (s, 3H), 2.55 (s, 6H). LRMS (ES+): 477.3 (M+H)⁺.

Example 21 1-[4-methoxyphenyl]-3-cyano-5-methyl-6-[2′-N,N-dimethylaminomethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one trifluoroacetic acid salt

[0407]

[0408] Part A. 1-[4-methoxyphenyl]-3-cyano-5-methyl-6-[4-bromophenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one

[0409] 1-[4-methoxyphenyl]-3-cyano-4-amino-5-[4-bromophenyl)aminocarbonyl]pyrazole from Example 20, Part B (1.0 g, 2.4 mmol) was dissolved in 5 mL of N,N-dimethylacetamide dimethyl acetal and stirred at 100° C. for 1 h. The volatiles were removed and the residue was dissolved in glacial acetic acid and stirred at 100° C. for 1 h. The volatiles were removed in vacuo and the residue was dissolved in EtOAc and washed with saturated NaHCO₃ and brine. The organics were dried over MgSO₄, filtered through a plug of silica gel and the volatiles were removed to yield the title compound as an off-white solid (0.95 g, 90%). ¹H NMR (dmso-D6) □ 7.75 (app d, 2H), 7.58 (app d, 2H), 7.37 (app d, 2H), 7.04 (app d, 2H), 3.78 (s, 3H), 2.15 (s, 3H).

[0410] Part B. 1-[4-methoxyphenyl]-3-cyano-5-methyl-6-[2′-formyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one

[0411] To a solution of 1-[4-methoxyphenyl]-3-cyano-6-[4-bromophenyl]-1,6-dihydropyrazolo-[4,3-d]-5-methyl-pyrimidin-7-one (0.24 g, 0.55 mmol) in 10 mL of 1,4-dioxane was added 2-formylphenylboronic acid (0.12 g, 0.83 mmol) and potassium phosphate tribasic (0.41 g, 1.93 mmol). This mixture was degassed with a stream of nitrogen for 15 minutes. Following the purge, tetrakis(triphenylphosphine)palladium(0) (0.025 g) was added and the solution was stirred at 100° C. for 4 h. The solution was cooled, diluted with EtOAc, washed twice with brine and the organics were dried over MgSO₄, filtered through a pad of silica gel and concentrated. The residue was purified by flash chromatography (elution with 2:1 hexanes/ethyl acetate) to afford 0.10 g (40%) of the title compound. ¹H NMR (CDCl₃) □ 10.02 (s, 1H), 8.05 (dd, 1H), 7.69 (td, 1H), 7.65-7.55 (m, 5H), 7.46 (dd, 1H), 7.36 (app d, 2H), 6.98(app d, 2H), 3.83 (s, 3H), 2.38 (s, 3H).

[0412] Part C. 1-[4-methoxyphenyl]-3-cyano-5-methyl-6-[2′-N,N-dimethylaminomethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one trifluoroacetic acid salt

[0413] To a solution of 1-[4-methoxyphenyl]-3-cyano-6-[2′-formyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-5-methyl-pyrimidin-7-one (80 mg, 0.17 mmol) in 5 mL of THF was added dimethylamine (0.34 mL of a 2M solution in methanol, 0.68 mmol) and then sodium triacetoxyborohydride (73 mg, 0.35 mmol) and 2 drops of glacial acetic acid. The reaction was allowed to stir at ambient temperature for 3 h. The reaction was quenched with water and diluted with ethyl acetate and saturated aqueous NaHCO₃. The organics were washed with brine, dried (MgSO₄) and concentrated. The residue was purified by prep HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and lyophilized to afford 45 mg (44%) of the title compound of Example 21 as a white powder. ¹H NMR (dmso-D6) □ 9.60 (broad S, 1H), 7.70 (m, 1H), 7.60 (app d, 2H), 7.65-7.48 (m, 6H), 7.39 (m, 1H), 7.05 (app d, 2H), 4.31 (broad s, 2H), 3.79 (s, 3H), 2.53 (s, 6H), 2.24 (s, 3H). LRMS (ES+): 491.3 (M+H)⁺.

Example 22 1-[2-aminomethylphenyl]-3-cyano-6-[2′-methylsulfonyl-3-fluoro-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one trifluoroacetic acid salt

[0414]

[0415] Part A. □.□-Dicyano-2-methylphenyl hydrazine imine

[0416] To a solution of o-toluidine (10.0 g, 93.3 mmol) in 160 mL of water at 0° C. was added of 22 mL of concentrated HCl followed by sodium nitrite (8.4 g, 121 mmol) portionwise. The solution was stirred for 15 minutes and then poured into a flask containing a solution of malononitrile (6.2 g, 93.3 mmol) and sodium acetate trihydrate (28 g, 205 mmol) in 50 mL of methanol and 100 mL of water at 0° C. A heavy yellow precipitate immediately formed. After 30 minutes the solid was filtered, washed with water and dried under vacuum to afford 16 g (93%) of the title compound, that was used without further purification. ¹H NMR (CDCl₃): □ 9.60 (broad s, 1H), 7.53 (d, 1H), 7.31 (t, 1H), 7.22 (m, 2H), 2.40 (s, 3H).

[0417] Part B. Methyl 1-(2-methylphenyl)-3-cyano-4-aminopyrazole-5-carboxylate

[0418] □.□-Dicyano-2-methylphenyl hydrazine imine (12.0 g, 65.1 mmol), methyl bromoacetate (9.3 mL, 97.7 mmol) and potassium carbonate (22.5 g, 163 mmol) were dissolved in 100 mL of N,N-dimethyl formamide and heated to 100° C. for 3 h. The solution was cooled, diluted with ethyl acetate and washed 2 times with brine. The organics were dried over MgSO₄, filtered through a pad of silica gel and the volatiles were removed. The residue was purified by flash chromatography (elution with 3:1 hexanes/ethyl acetate) to afford 5.1 g (31%) of the title compound. ¹H NMR (CDCl₃): □ 7.39 (t, 1H), 7.28 (m, 2H), 7.17 (d, 1H), 3.71 (s, 3H), 2.04 (s, 3H). LRMS (ESI): 255.1 (M−H)⁻.

[0419] Part C. 1-(2-methylphenyl)-3-cyano-4-azidopyrazole-5-carboxylic acid

[0420] To a solution of methyl 1-(2-methylphenyl)-3-cyano-4-aminopyrazole-5-carboxylate (5.1 g, 19.9 mmol) in 100 mL of TFA at 0° C. was added NaNO₂ (1.65 g, 23.9 mmol) and then the reaction was stirred at that temperature for 45 min. Sodium azide (1.55 g, 23.9 mmol) was dissolved in a minimal amount of water and added in portions to the TFA solution. The solution was allowed to stir at 0° C. for 45 min and added slowly to a saturated aqueous solution of NaHCO₃. The solution was diluted with ethyl acetate and washed twice with brine. The organics were dried over MgSO₄, filtered through a plug of silica gel and the volatiles were removed to afford 5.26 g of crude azide that was used without purification. To a solution of crude azide (5.26 g, 18.6 mmol) in 100 mL of tetrahydrofuran and 50 mL of water at 0° C. was added lithium hydroxide (0.53 g, 22.3 mmol) and the reaction was stirred at ambient temperature for 3 h. The reaction was diluted with water and ethyl acetate and made basic with saturated aqueous sodium bicarbonate. The organic layer was separated. The aqueous layer was acidified with aqueous HCl and then was extracted with ethyl acetate. The organics were washed with brine, dried over MgSO₄, and concentrated to afford 5.18 g of the title compound that was used without purification. ¹H NMR (CDCl₃): □ 9.56 (broad s, 1H), 7.42 (t, 1H), 7.30 (m, 2H), 7.15 (d, 1H), 2.03 (s, 3H).

[0421] Part D. 1-(2-methylphenyl)-3-cyano-4-azido-5-[2′-methylsulfonyl-3-fluoro-[1,1′]-biphen-4-yl]aminocarbonyl]pyrazole

[0422] To a solution of 1-(2-methylphenyl)-3-cyano-4-azidopyrazole-5-carboxylic acid (2.25 g, 8.37 mmol) in 50 mL of CH₂Cl₂ was added oxalyl chloride (1.1 mL, 12.6 mmol) and 2 drops of DMF. The mixture was allowed to stir at room temperature for 2 hours. The volatiles were removed under reduced pressure and the residue dried under high vacuum for 1 hour. The residue was dissolved in CH₂Cl₂ followed by the addition of DMAP (3.07 g, 25.1 mmol) and [2′-methylsulfonyl-3-fluoro-[1,1′]-biphen-4-yl]amine hydrochloride (2.53 g, 8.37 mmol) and the solution was stirred overnight at room temperature. The volatiles were removed under vacuum and the residue was taken up in ethyl acetate, washed with 10% aqueous HCl, saturated aqueous sodium bicarbonate and brine, dried (MgSO₄) and filtered through a plug of silica gel. The volatiles were removed under vacuum to afford 4.1 g (95%) of the title compound that was used without further purification. ¹H NMR (CDCl₃): □ 8.94 (d, 1H), 8.30 (t, 1H), 8.20 (dd, 1H), 7.64 (td, 1H), 7.57 (td, 1H), 7.46 (t, 1H), 7.37-7.30 (m, 4H), 7.23 (m, 1H), 7.13 (d, 1H), 2.68 (s, 3H), 2.08 (s, 3H).

[0423] Part E. 1-(2-methylphenyl)-3-cyano-6-[2′-methylsulfonyl-3-fluoro-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one

[0424] To a solution of 1-(2-methylphenyl)-3-cyano-4-azido-5-[2′-methylsulfonyl-3-fluoro-[1,1′]-biphen-4-yl]aminocarbonyl]pyrazole (2.06 g, 4.0 mmol) in absolute ethanol was added tin (II) chloride dihydrate (2.71 g, 12.0 mmol) and the solution was stirred at reflux for 2 h. The reaction was cooled and concentrated. The residue was taken up in ethyl acetate, washed with dilute aqueous sodium hydroxide and brine, dried (MgSO₄) and concentrated. The residue was dissolved in 25 mL of N,N-dimethylformamide dimethyl acetal and stirred at 100° C. for 2 h. The reaction was cooled and concentrated in vacuo. The residue was taken up in 95% formic acid and stirred at 100° C. for 2 h. The reaction was cooled and concentrated. The residue was diluted with ethyl acetate and washed with saturated NaHCO₃ and brine, dried (MgSO₄) and concentrated to afford 0.60 g (30%) of the title compound that was used without purification. ¹H NMR (CDCl₃): □ 8.23 (dd, 1H), 8.13 (s, 1H), 7.67 (symm m, 2H), 7.50-7.30 (m, 8H), 2.76 (s, 3H), 2.17 (s, 3H).

[0425] Part F. 1-[2-aminomethylphenyl]-3-cyano-6-[2′-methylsulfonyl-3-fluoro-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one trifluoroacetic acid salt

[0426] To a solution of 1-(2-methylphenyl)-3-cyano-6-[2′-methylsulfonyl-3-fluoro-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one (0.30 g, 0.60 mmol) in 50 mL of 1,2-dichloroethane was added N-bromosuccinimide (0.13 g, 0.72 mmol) and a small amount of AIBN. The reaction was stirred at reflux for 16 h and then was cooled and diluted with ethyl acetate. The organics were washed with brine, dried (MgSO₄) and concentrated in vacuo to afford 0.35 g of a 4:1 mixture of desired bromide/starting material that was used without purification.

[0427] To this residue in 20 mL of dimethyl formamide was added sodium azide (0.06 g, 0.9 mmol) and the reaction was stirred at ambient temperature for 16 h. The reaction was poured into water and extracted with ethyl acetate. The organics were washed with brine, dried (MgSO₄) and concentrated in vacuo to afford 0.21 g (91%) of an azide that was used without further purification. This azide was taken up in 20 mL of isopropanol and 10 mL of tetrahydrofuran and then there was added tin (II) chloride dihydrate (0.41 g, 1.8 mmol). The reaction was allowed to stir at reflux for 18 h. The volatiles were removed in vacuo and the residue was purified by prep HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and lyophilized to afford the title compound of Example 22 as a white solid. ¹H NMR (dmso-D6) □ 8.66 (s, 1H), 8.21 (broad s, 3H), 8.09 (dd, 1H), 7.80-7.50 (m, 8H), 7.42 (m, 2H), 3.99 (broad s, 2H), 2.94 (s, 3H). LRMS (ES+): 515.1 (M+H)⁺.

Example 23 1-[4-methoxyphenyl]-3-trifluoromethyl-4-methyl-6-[2′-aminosulfonyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[3,4-d]-pyridazin-7-one

[0428]

[0429] Part A. Ethyl 1-[4-methoxyphenyl]-3-trifluoromethyl-4-acetylpyrazole-5-carboxylate

[0430] To a solution of □bromo-.□-trifluoromethyl-4-methoxyphenyl hydrazine imine (2.0 g, 6.7 mmol) in 200 mL of absolute ethanol was added ethyl 2,4-dioxovalerate (2.33 g, 14.7 mmol) and sodium ethoxide (5.0 mL of a 21% wt solution in ethanol, 13.4 mmol). The reaction mixture was stirred at ambient temperature overnight. The ethanol was removed and the residue was diluted with ethyl acetate, washed sequentially with 10% aq HCl, sat'd aq NaHCO₃ and brine, dried (MgSO₄) and concentrated. The residue was purified by flash chromatography (elution with 4:1 hexanes/ethyl acetate) to afford 0.48 g (20%) of the title compound. ¹H NMR (CDCl₃): □ 7.37 (d, 2H) , 6.97 (d, 2H) , 4.27 (q, 2H) , 3.85 (s, 3H), 2.57 (s, 3H), 1.22 (t, 3H).

[0431] Part B. 1-[4-methoxyphenyl]-3-trifluoromethyl-4-methyl-6-[4-bromophenyl]-1,6-dihydropyrazolo-[3,4-d]-pyridazin-7-one

[0432] To a solution of ethyl 1-[4-methoxyphenyl]-3-trifluoromethyl-4-acetylpyrazole-5-carboxylate (1.5 g, 4.2 mmol) in 100 mL of absolute ethanol was added 4-bromophenyl hydrazine hydrochloride (0.94 g, 4.2 mmol) and the resulting mixture was stirred at reflux overnight. Upon cooling a solid fell out of solution. The mixture was filtered and the solid was dried in vacuo to afford 0.77 g (38%) of the title compound. ¹H NMR (CDCl₃): □ 7.60-7.45 (m, 6H), 7.00 (d, 2H), 3.85 (s, 3H), 2.69 (s, 3H).

[0433] Part C. 1-[4-methoxyphenyl]-3-trifluoromethyl-4-methyl-6-[2′-aminosulfonyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[3,4-d]-pyridazin-7-one

[0434] To a solution of 1-[4-methoxyphenyl]-3-trifluoromethyl-4-methyl-6-[4-bromophenyl]-1,6-dihydropyrazolo-[3,4-d]-pyridazin-7-one (0.10 g, 0.21 mmol) in 20 mL of benzene was added 2-(tert-butylaminosulfonyl)phenyl boronic acid (0.08 g, 0.29 mmol), tetrabutylammonium bromide (7 mg, 0.02 mmol), sodium carbonate (0.07 g, 0.63 mmol) and 1 mL of water. This mixture was degassed with a stream of nitrogen for 15 minutes and then there was added tetrakis (triphenylphosphine) palladium (0.02 g, 0.02 mmol). The reaction mixture was stirred at reflux for 16 h. The mixture was cooled, diluted with ethyl acetate and washed with sat'd aq NaHCO₃ and brine, dried (MgSO₄) and concentrated. The residue was taken up in 10 mL of trifluoroacetic acid and stirred at reflux for 30 min and concentrated in vacuo. The residue was purified by prep HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and lyophilized to afford the title compound of Example 23 as a white solid. ¹H NMR (dmso-D6) □ 8.01 (dd, 1H), 7.64-7.56 (m, 3H), 7.49 (m, 4H), 7.34 (m, 2H), 7.05 (d, 2H), 3.80 (s, 3H), 2.58 (s, 3H). LRMS (ES+): 556.0 (M+H)₊

Example 24 1-[4-methoxyphenyl]-3-trifluoromethyl-4-methyl-6-[2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[3,4-d]-pyridazin-7-one, trifluoroacetic acid salt

[0435]

[0436] To a solution of 1-[4-methoxyphenyl]-3-trifluoromethyl-4-methyl-6-[4-bromophenyl]-1,6-dihydropyrazolo-[3,4-d]-pyridazin-7-one from Example 23, Part B (0.10 g, 0.21 mmol) in 10 mL of toluene and 10 mL of water was added 2-formylphenylboronic acid (0.04 g, 0.29 mmol) and potassium fluoride (0.02 g, 0.42 mmol). This mixture was degassed with a stream of nitrogen for 15 minutes and then there was added tetrakis (triphenylphosphine) palladium (0.02 g, 0.02 mmol). The reaction mixture was stirred at reflux for 16 h. The mixture was cooled, diluted with ethyl acetate and washed with sat'd aq NaHCO₃ and brine, dried (MgSO₄) and concentrated to give 0.11 g of an aldehyde. This aldehyde was dissolved in 10 mL of DMF and then there was added pyrrolidine (0.02 mL, 0.26 mmol). This mixture was allowed to stir at ambient temperature for 1 h. The pH was adjusted to 6 by addition of acetic acid and then there was added sodium cyanoborohydride (0.03 g, 0.42 mmol). The reaction was allowed to stir at ambient temperature overnight. The reaction was quenched with dilute aq HCl, diluted with ethyl acetate, washed with brine, dried (MgSO₄) and concentrated. The residue was purified by prep HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and lyophilized to afford the title compound of Example 24 as a white solid. ¹H NMR (dmso-D6) □ 7.72 (m, 1H), 7.70-7.60 (m, 4H), 7.51 (m, 2H), 7.46 (d, 2H), 7.35 (m, 1H), 7.06 (d, 2H), 4.39 (broad s, 2H), 3.81 (s, 3H), 3.35 (m, 2H), 2.80 (m, 2H), 2.58 (s, 3H), 1.77 (m, 4H). LRMS (ES+): 560.2 (M+H)⁺.

Example 25 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[4-(1-methylimidazol-2′-yl)phenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one trifluoroacetic acid salt

[0437]

[0438] Part A. 1-[3-cyano-4-fluorophenyl]-3-trifluoromethyl-4-nitropyrazole-5-carboxylate

[0439] To a solution of 1-[3-cyano-4-fluorophenyl]-3-trifluoromethylpyrazole-5-carboxylate (2.30 g, 7.7 mmol) in 70 mL of trifluoroacetic acid was added ammonium nitrate (0.92 g, 11.6 mmol). Stirred for 15 minutes and then cooled to 0° C. and added trifluoroacetic anhydride (5.4 mL, 38.5 mmol). The reaction was allowed to stir overnight with warming to room temperature. The reaction was concentrated, poured into water, diluted with ethyl acetate, washed with saturated NaHCO₃ and brine, dried (MgSO₄) and concentrated. The residue was a mixture of nitrated compound and starting material. It was dissolved in warm water and remaining solid was filtered (starting material). Pure title compound (0.65 g, 25%) was obtained by extracting the water with ethyl acetate, drying (MgSO₄) and concentrating. ¹H NMR (CD₃OD): □ 8.12 (dd, 1H), 8.00 (m, 1H), 7.58 (t, 1H).

[0440] Part B. 1-[3-cyano-4-fluorophenyl]-3-trifluoromethyl-4-nitro-5-[4-(1-methylimidazol-2′-yl)aminocarbonyl]pyrazole

[0441] To a solution of 1-[3-cyano-4-fluorophenyl]-3-trifluoromethyl-4-nitropyrazole-5-carboxylate (0.76 g, 2.2 mmol) in 100 mL of methylene chloride was added oxalyl chloride (0.29 mL, 3.3 mmol) and 2 drops of DMF. The reaction was allowed to stir at ambient temperature for 3 h, at which time gas evolution had ceased. The reaction was concentrated in vacuo. The residue was taken up in 100 mL of methylene chloride and then there was added 4-dimethylaminopyridine (0.81 g, 6.6 mmol) and 4-(1-methylimidazol-2′-yl)aniline (0.38 g, 2.2 mmol). The reaction was allowed to stir at ambient temperature overnight. The reaction was diluted with ethyl acetate, washed with 10% aq HCl, sat'd aq NaHCO₃ and brine, dried (MgSO₄) and concentrated. The residue was purified by flash chromatography to afford 0.45 g (41%) of the title compound. ¹H NMR (CD₃OD): □ 8.12 (dd, 1H), 8.03 (m, 1H), 7.70-7.50 (m, 5H), 7.13 (d, 1H), 6.98 (d, 1H), 3.72 (s, 3H). LRMS (ES+): 500.1 (M+H)⁺.

[0442] Part C. 1-[3-cyano-4-fluorophenyl]-3-trifluoromethyl-6-[4-(1-methylimidazol-2′-yl)phenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one

[0443] To a solution of 1-[3-cyano-4-fluorophenyl]-3-trifluoromethyl-4-nitro-5-[4-(1-methylimidazol-2′-yl)aminocarbonyl]pyrazole (113 mg, 0.23 mmol) in 20 mL of methanol was added copper (I) chloride (0.27 g, 2.7 mmol) and potassium borohydride (0.17 g, 3.2 mmol). The reaction was allowed to stir at ambient temperature for 2 h. The reaction was diluted with ethyl acetate, washed with sat'd ammonium chloride and brine, dried (MgSO₄) and concentrated. The residue was taken up in 10 mL of 95% formic acid and stirred at 100° C. for 2 h. The reaction was cooled and concentrated, diluted with ethyl acetate, washed with saturated NaHCO₃ and brine, dried (MgSO₄) and concentrated to afford the title compound that was used without purification. LRMS (ES+): 480.2 (M+H)⁺.

[0444] Part D. 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[4-(1-methylimidazol-2′-yl)phenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one trifluoroacetic acid salt

[0445] To a solution of 1-[3-cyano-4-fluorophenyl]-3-trifluoromethyl-6-[4-(1-methylimidazol-2′-yl)phenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one (53 mg, 0.11 mmol) in 5 mL of DMF and 1 mL of water was added N-acetylhydroxylamine (0.02 g, 0.33 mmol) and potassium carbonate (0.06 g, 0.44 mmol). The reaction was allowed to stir at ambient temperature overnight. The reaction was diluted with ethyl acetate, washed with brine, dried (MgSO₄) and concentrated. The residue was purified by prep HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and lyophilized to afford the title compound of Example 25 as a white solid. LRMS (ES+): 493.3 (M+H)⁺.

Example 26 1-[4-methoxyphenyl]-3-(ethoxycarbonyl)-6-[2′-hydroxymethyl-3-fluoro-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one

[0446]

[0447] To a solution of 1-[4-Methoxyphenyl]-3-(ethoxycarbonyl)-4-azidopyrazole-5-carboxylic acid (5.77 g, 17.44) in a 1:1 mixture of tetrahydrofuran and methylene chloride (200 mL) was added oxalyl chloride (1.90 mL, 21.81 mmol) and 1 drop of N,N-dimethylformamide. The solution was allowed to stir at ambient temperature for several hours. The volatiles were removed under reduced pressure and the residue dried under high vacuum for several hours. The residue was then dissolved in 200 mL of methylene chloride followed by the addition of 4-dimethylamino pyridine (4.44 g, 36.35 mmol) and [2′-tert-butyldimethyl-siloxymethyl-3-fluoro-[1,1′]-biphen-4-yl]amine (4.82 g, 14.54 mmol) and the solution allowed to stir at ambient temperature overnight. The solution was filtered though a pad of silica gel and the volatiles were removed in vacuum. The residue was purified by column chromatography using 1:1 hexane/ethyl acetate to give the title compound as a white solid (7.51 g, 67%). LRMS (ESI): 643.2 (M−H)⁻.

[0448] Part B. 1-[4-methoxyphenyl]-3-(ethoxycarbonyl)-6-[2′-hydroxymethyl-3-fluoro-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one

[0449] (1-[4-Methoxyphenyl]-3-(ethoxycarbonyl)-4-azido)-5-[(2′-tert-butyldimethylsiloxymethyl-3-fluoro-[1,1′]-biphen-4-yl)aminocarbonyl]pyrazole (7.51 g, 11.64 mmol) was dissolved in 300 mL of ethanol followed by the addition of stannous chloride dihydrate (5.52 g, 29.12 mmol) and the solution was warmed gently for 2 minutes. The solution was poured through a plug of silica gel and the volatiles removed. The crude product was dissolved in 100 mL of 95% formic acid and refluxed for 1 hr. The volatiles were removed under vacuum and the residue dried overnight. The product was then dissolved in 200 mL of ethanol and cooled in an ice/water bath followed by the addition of lithium hydroxide (1.26 g, 3.3 mmol) in 30 mL of water and the reaction stirred at ambient temperature for 2 hours. The solution was diluted with ethyl acetate and washed with brine. The organics were dried over magnesium sulfate and the residue was purified by prep HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and lyophilized to afford the title compound of Example 26 as a white solid. LRMS (ESI): 515.1 (M+H)⁺.

Example 27 1-[4-methoxyphenyl]-3-(ethoxycarbonyl)-6-[2′-N-pyrrolidinylmethyl-3-fluoro-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one, trifluoroacetic acid salt

[0450]

[0451] To a solution of 1-[4-methoxyphenyl]-3-(ethoxycarbonyl)-6-[2′-hydroxymethyl-3-fluoro-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one from Example 26, Part B (0.20 g, 0.39 mmol) in 150 mL of methylene chloride was added phosphorous tribromide (0.074 mL, 0.77 mmol) and the reaction was stirred at ambient temperature overnight. The solution was slowly quenched with water and the organics extracted with ethyl acetate. The organics were dried over magnesium sulfate, filtered and the volatiles were removed under reduced pressure. The crude benzyl bromide (0.22 g, 0.39 mmol) was dissolved in 50 mL of acetonitrile followed by the addition of pyrrolidine (0.11 mL, 1.34 mmol) and stirred at ambient temperature overnight. The volatiles were removed under reduced pressure and the residue was purified by prep HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and lyophilized to afford the title compound of Example 27 as a white solid. LRMS (ESI): 568.2 (M+H)⁺.

Example 28 1-[4-methoxyphenyl]-3-(aminocarbonyl)-6-[2′-N-pyrrolidinylmethyl-3-fluoro-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one, trifluoroacetic acid salt

[0452]

[0453] 1-[4-methoxyphenyl]-3-(ethoxycarbonyl)-6-[(2′-N-pyrrolidinylmethyl-3-fluoro-[1,1′]-biphen-4-yl)aminocarbonyl]pyrazole (0.60 g, 0.92 mmol) was dissolved in 200 mL of methanol followed by the addition of 50 mL of a 28% ammonium hydroxide solution and allowed the reaction to stir overnight at ambient temperature. The reaction was concentrated and the residue was purified by prep HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and lyophilized to afford the title compound of Example 28 as a white solid. LRMS (ESI): 539.1 (M+H)⁺.

Example 29 1-[4-methoxyphenyl]-3-(aminocarbonyl)-6-[2′-(3-(R)-hydroxy-N-pyrrolidinylmethyl)-3-fluoro-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one, trifluoroacetic acid salt

[0454]

[0455] 1-[4-methoxyphenyl]-3-(ethoxycarbonyl)-6-[2′-hydroxymethyl-3-fluoro-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one (0.85 g, 1.71 mmol) was dissolved in 150 mL of methylene chloride followed by the addition of phosphorous tribromide (0.32 mL, 3.42 mmol) and stirred at ambient temperature overnight. The solution was slowly quenched with water and the organics extracted with ethyl acetate. The organics were dried over magnesium sulfate, filtered and the volatiles removed under reduced pressure. The crude benzyl bromide (0.42 g, 0.75 mmol) was dissolved in 50 mL of acetonitrile followed by the addition of 3-(R)-pyrrolidinol hydrochloride (0.55 mL, 4.50 mmol) and stirred at ambient temperature overnight. The volatiles were removed under reduced pressure and the residue was purified by prep HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and lyophilized to afford 0.2 g (17%) of the title compound as a white solid. LRMS (ESI): 566.3 (M+H)⁺.

[0456] Part B. 1-[4-methoxyphenyl]-3-(aminocarbonyl)-6-[2′-(3-(R)-hydroxy-N-pyrrolidinylmethyl)-3-fluoro-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one, trifluoroacetic acid salt

[0457] 1-[4-methoxyphenyl]-3-(ethoxycarbonyl)-6-[2′-(3-(R)-hydroxy-N-pyrrolidinylmethyl)-3-fluoro-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one (0.120 g, 0.20 mmol) was dissolved in 200 mL of methanol followed by the addition of 50 mL of a 28% ammonium hydroxide solution and allowed the reaction to stir overnight at ambient temperature. The reaction was concentrated and the residue was purified by prep HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and lyophilized to afford the title compound of Example 29 as a white solid. LRMS (ESI): 537.2 (M+H)⁺

Example 30 1-[4-methoxyphenyl]-3-(N-formylaminomethyl)-6-[2′-methylsulfonyl-3-fluoro-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one

[0458]

[0459] 1-[4-methoxyphenyl]-3-cyano-4-amino-5-[2′-methylsulfonyl-3-fluoro-[1,1′]-biphen-4-yl]aminocarbonyl]pyrazole (0.30 g, 0.59 mmol) was dissolved in 100 mL of ethanol followed by the addition of 5 mL of trifluoroacetic acid and a catalytic amount of 10% palladium on carbon (0.03 g) and the reaction was stirred overnight at ambient temperature under a balloon of hydrogen gas. The solution was filtered through a plug of Celite® and the volatiles were removed to give the title product as a grey/white solid (0.30 g, 99%). LRMS (ESI): 510.1 (M+H)⁺.

[0460] Part B. 1-[4-methoxyphenyl]-3-(N-formylaminomethyl)-6-[2′-methylsulfonyl-3-fluoro-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one

[0461] 1-[4-Methoxyphenyl]-3-aminomethyl-4-amino-5-[2′-methylsulfonyl-3-fluoro-[1,1′]-biphen-4-yl]aminocarbonyl}pyrazole (0.30 g, 0.59 mmol) was refluxed for 3 hours in 75 mL of 95% formic acid. The volatiles were removed under vacuum and the residue was purified by prep HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and lyophilized to afford the title compound of Example 30 as a white solid. LRMS (ESI): 548.1 (M+H)⁺.

Example 31 1-[3-Aminobenzisoxazol-5′-yl]-3-(ethoxycarbonyl)-6-[2′-hydroxymethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one

[0462]

[0463] Part A. □-Cyano-.□-ethoxycarbonyl-[4-fluoro-3-cyano)phenyl]hydrazine imine

[0464] To a solution of 4-fluoro-3-cyanoaniline (11.78 g, 86.5 mmol) in concentrated HCl (20.2 mL, 173.0 mmol) was added 131 mL of water and the entire reaction was cooled in an ice/water bath. Sodium nitrite (6.5 g, 95.20 mmol) was dissolved in 20 mL of water and slowly added to the reaction mixture. After stirring for 30 minutes, the diazonium solution was poured into a solution of ethyl cyanoacetate (7.60 mL, 95.20 mmol) and sodium acetate trihydrate (25.91 g, 190.40 mmol) in a mixture of 21 mL of methanol and 44 mL of water at 0° C. The reaction was stirred at 0° C. for 20 minutes during which time a heavy yellow precipitate of the title compound formed. The product was isolated and dried by suction filtration to afford 8.9 g (39%) of bright yellow product.

[0465] Part B. 3-Ethyl-5-methyl 1-(4-fluoro-3-cyano)phenyl-4-aminopyrazole-3,5-dicarboxylate

[0466] □-Cyano-.□-ethoxycarbonyl-[4-fluoro-3-cyano)phenyl]hydrazine imine (4.00 g, 15.37 mmol), methyl bromoacetate, (1.85 mL, 19.98 mmol) and potassium carbonate (5.31 g, 38.43 mmol) were dissolved in N,N-dimethyl formamide and heated to 100° C. for several hours. The solution was diluted with ethyl acetate and washed 2 times with brine. The organics were dried over MgSO₄, filtered through a pad of silica gel and the volatiles were removed. The title compound was purified by dissolving in hot diethyl ether and collecting the solids (2.82 g, 55%).

[0467] Part C. 3-Ethyl-5-methyl 1-(4-fluoro-3-cyano)phenyl-4-azidopyrazole-3,5-dicarboxylate

[0468] 3-Ethyl-5-methyl 1-(4-fluoro-3-cyano)phenyl-4-aminopyrazole-3,5-dicarboxylate (2.82 g, 8.48 mmol) was dissolved in TFA and cooled to 0° C. followed by the addition of NaNO₂ (0.70 g, 10.18 mmol) and then the reaction was stirred at that temperature for 45 min. NaN₃ was dissolved in a minimal amount of water and added in portions to the TFA solution. The solution was allowed to stir at 0° C. for 45 min and added slowly to a saturated solution of NaHCO₃. The organics were dried over MgSO₄, filtered through a plug of silica gel and the volatiles were removed to give the title compound as a tan solid (0.13 g, 4.2%).

[0469] Part D. 1-(4-fluoro-3-cyano)phenyl-3-(ethoxycarbonyl)-4-azidopyrazole-5-carboxylic acid

[0470] 3-Ethyl-5-methyl 1-(4-fluoro-3-cyano)phenyl-4-azidopyrazole-3,5-dicarboxylate (0.40 g, 1.11 mmol) was dissolved in a 1:1 mixture of 1,4-dioxane/water and cooled in an ice water bath. Lithium hydroxide (0.04 g, 1.67 mmol) was predissolved in a minimal amount of water and added to the stirring solution in one portion. The reaction was allowed to warm to ambient temperature and the reaction was followed by thin layer chromatography. The solution was extracted with water, the aqueous layer acidified with 10% hydrochloric acid and the product extracted with ethyl acetate to yield the title compound as a white solid (0.35 g, 92%) LRMS (ESI): 687.2 (2M−H)⁻. 1-(4-fluoro-3-cyano)phenyl-3-(ethoxycarbonyl)-4-azidopyrazole-5-carboxylic acid (0.35 g, 1.0 mmol) was dissolved in a 1:1 mixture of tetrahydrofuran and methylene chloride (200 mL) followed by the addition of oxalyl chloride (0.130 mL, 17.58 mmol) and 1 drop of N,N-dimethylformamide. The solution was allowed to stir at ambient temperature for several hours. The volatiles were removed under reduced pressure and the residue dried under high vacuum for several hours. The residue was then dissolved in 200 mL of methylene chloride followed by the addition of N,N-dimethylaminopyridine (3.58 g, 29.31 mmol) and [2′-tert-butyldimethylsiloxymethyl-3-fluoro-[1,1′]-biphen-4-yl]amine (3.88 g, 11.72 mmol) and the solution allowed to stir at ambient temperature overnight. The solution was filtered though a pad of silica gel and the volatiles were removed in vacuum. The residue was used without further purification (0.55 g, 86%). LRMS (ESI): 508.1 (M—OSi (t-Bu)Me₂+H)⁺.

[0471] Part F. 1-(4-fluoro-3-cyano)phenyl-3-(ethoxycarbonyl)-6-[2′-formylhydroxymethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one

[0472] (1-(4-fluoro-3-cyano)phenyl-3-(ethoxycarbonyl)-4-azido-5-[2′-tert-butyldimethylsiloxy)methyl-[1,1′]-biphen-4-yl]aminocarbonyl]pyrazole (0.55 g, 0.86 mmol) was dissolved in 100 mL of ethanol followed by the addition of stannous chloride dihydrate (0.49 g, 2.57 mmol) and the solution warmed gently for several minutes. The solution was then filtered through a pad of silica gel and the volatiles removed under reduced pressure. The residue was dissolved in 100 mL of 96% formic acid and refluxed for 2 hours. The volatiles were removed under reduced pressure and the residue dissolved in ethylacetate and the solution filtered through a pad of silica gel and the volatiles removed under reduced pressure. The title product was purified by column chromatography using 1:1 hexane:ethylacetate and isolated as a white solid (0.40 g, 86%), LRMS (ESI): 560.1 (M+Na)⁺.

[0473] Part G. 1-[3-Aminobenzisoxazol-5′-yl]-3-(ethoxycarbonyl)-6-[2′-hydroxymethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one

[0474] 1-(4-fluoro-3-cyano)phenyl-3-(ethoxycarbonyl)-6-[2′-formylhydroxymethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one (0.40 g, 0.74 mmol) was dissolved in N,N-dimethylformamide followed by the addition of acetohydroxamic acid (0.22 g, 2.97 mmol) and potassium carbonate (0.41 g, 2.97 mmol) and stirred overnight at ambient temperature. Potassium carbonate in 10 mL of ethanol was added to the solution and heated to 80° C. for 1 hour. The solution was diluted with water and the product immediately precipitated out and was isolated by filtration. The residue was purified by prep HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and lyophilized to afford the title compound of Example 31 as a white solid. LRMS (ESI): 523.1 (M+H)⁺.

Example 32 1-[3-Aminobenzisoxazol-5′-yl]-3-(ethoxycarbonyl)-6-[2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one, trifluoroacetic acid salt

[0475]

[0476] 1-[3-Aminobenzisoxazol-5′-yl]-3-(ethoxycarbonyl)-6-[2′-N-hydroxymethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one (0.05 g, 0.08 mmol) was dissolved in 10 mL of methylene chloride followed by the addition of phosphorous tribromide (0.022 mL, 0.23 mmol) and stirred at ambient temperature overnight. The solution was slowly quenched with water and the organics extracted with ethyl acetate. The organics were dried over magnesium sulfate, filtered and the volatiles removed under reduced pressure. The crude benzyl bromide was dissolved in 10 mL of acetonitrile followed by the addition of pyrrolidine (0.04 mL, 0.47 mmol) and stirred at ambient temperature overnight. The volatiles were removed under reduced pressure and the residue was purified by prep HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and lyophilized to afford the title compound of Example 32 as a white solid. LRMS (ESI): 576.3 (M+H)⁺.

Example 33 1-[4-Methoxyphenyl]-3-trifluoromethyl-7-[2′-methylsulfonyl-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one

[0477]

[0478] Part A. N-[4-bromophenyl]caprolactam

[0479] 4-Bromoaniline (20.0 g, 11.62 mmol)and triethylamine (17.8 mL, 12.78 mmol) were dissolved in 250 mL of methylene chloride. 6-Bromohexanoyl chloride (19.6 mL, 12.78 mmol) was added dropwise via an addition funnel. The reaction mixture was stirred under N₂ for ½ h after the addition was completed. It was diluted with methylene chloride and washed with water, 1N aqueous HCl, 1N aqueous NaOH, and brine. It was then dried over MgSO₄ and concentrated to a white solid (37.20 g).

[0480] A solution of the above solid in 100 mL of DMF was added dropwise at room temperature to a mixture of NaH (5.00 g of 60% dispersion, 12.47 mmol) in 150 mL of DMF. The reaction mixture was stirred at room temperature for 2 h under N₂. It was then poured into 500 mL of water and extracted with EtOAc. The combined organic mixture was washed with brine, dried over MgSO₄, and concentrated to colorless oil. The title compound was then purified by chromatography on silica gel eluted with methylene chloride to give 24.5 g of white solid (78%). LRMS (ES+): 268.0, 270.0 (M+H)⁺. ¹H NMR (CDCl₃): δ 7.49 (d, 2H), 7.12 (d, 2H), 3.73 (m, 2H), 2.69 (m, 2H), 1.82 (m, 6H).

[0481] Part B. N-[4-bromophenyl]-3-oxocaprolactam

[0482] N,N-Diisopropylamine (11.0 mL, 78.4 mmol) was dissolved in 20 mL of dry THF and cooled at 0° C. n-BuLi (29.4 mL of 2.5 M solution in hexane) was added. The mixture was stirred at 0° C. under N₂ for 30 minutes and then cooled to −78° C. It was then cannulated to a solution of N-[4-bromophenyl]caprolactam (6.57 g, 24.5 mmol) in 100 mL of THF at −78° C. The mixture was stirred at −78° C. under N₂ for 1 h, and methyl methanethiosulfonate (8.1 mL, 78.4 mmol) was added. The cooling bath was removed, the mixture was allowed to warm up to room temperature and stirred for 12 h. It was quenched with H₂O and the THF was removed in vacuo. The residue was dissolved in EtOAc and washed with water and brine. It was then dried over MgSO₄ and concentrated. Chromatography on silica gel with 20% EtOAc in hexane gave 1.40 g of N-[4-bromophenyl]-3-bis(thiomethoxy)caprolactam and 4.42 g of N-[4-bromophenyl]-3-mono(thiomethoxy)caprolactam. The N-[4-bromophenyl]-3-mono(thiomethoxy)caprolactam isolated was resubjected to the above conditions, and a total of 6.38 g of N-[4-bromophenyl]-3-bis(thiomethoxy)caprolactam was isolated. LRMS (AP⁺): 361.9, (M+H)⁺.

[0483] N- [4-bromophenyl]-3-bis(thiomethoxy)caprolactam from above was dissolved in 100 mL of CH₃CN and 25 mL of H₂O was added. Ceric ammonium nitrate (38.86 g, 70. 89 mmol) was then added. After stirring for five minutes, water (300 mL) was added and the mixture was extracted with EtOAc. The combined organic mixture was washed with water and brine. It was dried over MgSO₄ and concentrated. The desired product was purified by chromatography on silica gel eluted with 30% EtOAc in hexane to give 1.25 g of light yellow oil (18%). LRMS (AP⁺): 283.9, (M+H)⁺. ¹H NMR (CDCl₃): δ 7.56 (d, 2H), 7.22 (d, 2H), 3.77 (t, 2H), 2.67 (t, 2H), 2.09 (m, 2H), 1.98 (m, 2H).

[0484] Part C. 1-[4-methoxyphenyl]-3-trifluoromethyl-7-[4-bromophenyl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one

[0485] N-[4-bromophenyl]-3-oxocaprolactam (0.37 g, 1.13 mmol), morpholine (0.25 mL, 2.81 mmol), and p-toluenesulfonic acid (catalytic amount) were refluxed with 30 mL benzene using a Dean Stark apparatus under N₂ for 12 h. The solvent was removed in vacuo and the residue was dried under vacuum to give 1,5,6,7-tetrahydro-1-[4-bromophenyl]-3-(morpholin-4-yl)-2H-azepin-2-one. LRMS (AP⁺): 351.0, 353.0, (M+H)⁺.

[0486] 4-Dimethylaminopyridine (0.13 g, 1.13 mmol) was dissolved in 5 mL of methylene chloride and cooled in an ice-bath. Trifluoroacetic anhydride (0.16 mL, 1.13 mmol) was added. The mixture was stirred at 0° C. for ½ h, and a solution of 1,5,6,7-tetrahydro-1-[4-bromophenyl]-3-(morpholin-4-yl)-2H-azepin-2-one in 5 mL of methylene chloride was added. The ice-bath was removed, and the reaction mixture was stirred at room temperature under N₂ for 12 h. The reaction mixture was diluted with methylene chloride and washed with water and brine. After drying over MgSO₄, it was concentrated to give 1,5,6,7-tetrahydro-1-[4-bromophenyl]-3-(morpholin-4-yl)-4-trifluoroacetyl-2H-azepin-2-one as brown oil. LRMS (AP⁺) 446.0, 448.0, (M+H)⁺.

[0487] The brown oil above and p-methoxyphenylhydrazine hydrochloride (0.20 g, 1.13 mmol) were refluxed with 50 mL of acetic acid under N₂ for 20 h. The solvent was removed, the residue was dissolved in EtOAc and washed with water, Saturated NaHCO₃, and brine. It was dried over MgSO₄, concentrated, and chromatographed on silica gel with 15-20% EtOAc in hexane to give 0.24 g of the desired product (40%) and 0.17 g of the regioisomer (28%). LRMS (ES⁺): 528.0, (M+H)⁺. ¹H NMR (CDCl₃) δ 7.71 (d, 2H) , 7.39 (d, 2H) , 7.06 (d, 2H), 6.92 (d, 2H), 3.89 (t, 2H), 3.82 (s, 3H), 3.04 (t, 2H), 2.22 (m, 2H).

[0488] Part D. 1-[4-methoxyphenyl]-3-trifluoromethyl-7-[2′-aminosulfonyl-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one

[0489] 1-[4-Methoxyphenyl]-3-trifluoromethyl-7-[4-bromophenyl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one (0.12 g, 0.23 mmol), 2-(tert-butylaminosulfonyl)phenylboronic acid (63.0 mg, 0.25 mmol), tetrabutylammonium bromide (4 mg, 5 mol %), tetrakis(triphenylphosphine)palladium(0) (13 mg, 5 mol %) were refluxed with 20 mL of benzene under N₂ for 12 h. The reaction was cooled. It was filtered through Celite® and washed with EtOAc. The mixture was washed with water and brine, dried over MgSO₄, concentrated, and chromatographed on silica gel with 15-30% EtOAc in hexane to give 26 mg of the desired product (18%) and 96 mg of the starting material. LRMS (ES⁺): 613.4, (M+H)⁺.

[0490] The product above was refluxed with 10 mL of trifluoroacetic acid for ½ h. The solvent was removed. It was purified by prep HPLC (C18 reverse phase column, eluted with a H₂O/CH₃CN gradient with 0.05% TFA) and lyophilized to afford 5.7 mg of the title compound of Example 33 as a white powder (24%). LRMS (ES⁺) 557.3, (M+H)⁺. ¹H NMR (CDCl₃): δ 8.12 (d, 1H), 7.59 (t, 1H), 7.51 (m, 3H), 7.38 (m, 4H), 7.29 (d, 1H), 6.82 (d, 2H), 4.51 (s, 2H), 4.00 (t, 2H), 3.82 (s, 3H), 3.10 (t, 2H), 2.31 (m, 2H).

Example 34 1-[4-Methoxyphenyl]-3-trifluoromethyl-7-[2′-aminosulfonyl-3-fluoro-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one

[0491]

[0492] The title compound was prepared by the same procedures as shown for Example 1 using 4-bromo-2-fluoroaniline as starting material. LRMS (ES⁺): 575.2, (M+H)⁺. ¹HNMR (CDCl₃) δ 8.15 (d, 1H), 7.57 (m, 2H), 7.39 (t, 2H), 7.32 (d, 2H), 7.27 (d, 2H), 6.93 (d, 2H), 4.51 (s, 2H), 3.93 (t, 2H), 3.82 (s, 3H), 3.11 (t, 2H), 2.27 (m, 2H).

Example 35 1-[4-Methoxyphenyl]-3-trifluoromethyl-7-[2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one, trifluoroacetic acid salt

[0493]

[0494] Part A. 1-[4-methoxyphenyl]-3-trifluoromethyl-7-[2′-formyl-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one

[0495] 1-[4-Methoxyphenyl]-3-trifluoromethyl-7-[4-bromophenyl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one from Part C of Example 33 (0.17 g, 0.32 mmol), 2-formylphenylboronic acid (97.0 mg, 0.64 mmol), potassium phosphate (273.0 mg, 1.28 mmol) and tetrakis(triphenylphosphine)palladium(0) (19 mg) were refluxed with 20 mL of dioxane under N₂ for 12 h. It was filtered through Celite® and washed with EtOAc. The mixture was washed with water and brine, dried over MgSO₄, concentrated, and chromatographed on silica gel with 10-15% EtOAc in hexane to give 0.10 g of the desired product (62%). LRMS (ES⁺): 506.4, (M+H)⁺. ¹H NMR (CDCl₃): δ 10.02 (s, 1H) , 8.02 (d, 1H), 7.64 (t, 1H), 7.52 (t, 1H), 7.42 (m, 6H), 6.83 (d, 2H), 3.99 (t, 2H), 3.82 (s, 3H), 3.10 (t, 2H), 2.29 (m, 2H).

[0496] Part B. 1-[4-methoxyphenyl]-3-trifluoromethyl-7-[2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one, trifluoroacetic acid salt

[0497] The product from Part A was dissolved in 15 mL of MeOH. Pyrrolidine (0.049 mL, 0.59 mmol) and NaBH₄ (13 mg, 0.40 mmol) were added. The mixture was stirred at room temperature under N₂ for 12 h. It was quenched with water, extracted with methylene chloride, dried over MgSO₄, concentrated, and purified by prep HPLC (C18 reverse phase column, eluted with a H₂O/CH₃CN gradient with 0.05% TFA) and lyophilized to afford 24 mg of the title compound of Example 35 as a TFA salt (18%). LRMS (ES⁺): 557.3, (M+H)⁺. ¹H NMR (CD₃OD) δ 7.66 (m, 1H) , 7.35-7.56 (m, 9H) , 6.98 (d, 2H), 4.40 (s, 2H), 4.01 (t, 2H), 3.81 (s, 3H), 3.32 (m, 2H), 3.08 (t, 2H), 2.80 (m, 2H), 2.29 (m, 2H), 1.88 (m, 4H).

Example 36 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-7-[2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one, trifluoroacetic acid salt

[0498]

[0499] Part A. 1-[3-Cyano-4-fluorophenyl]-3-trifluoromethyl-7-[4-bromophenyl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one

[0500] N-[4-bromophenyl]-3-oxocaprolactam (1.31 g, 4.63 mmol), morpholine (1.60 mL, 18.52 mmol), and p-toluenesulfonic acid (catalytic amount) were refluxed with 50 mL benzene using a Dean Stark apparatus under N₂ for 12 h. The solvent was then removed in vacuo and the residue was dried under vacuum to give 1,5,6,7-tetrahydro-1-[4-bromophenyl]-3-(morpholin-4-yl)-2H-azepin-2-one as a yellow solid. LRMS (AP⁺): 351.0, 353.0, (M+H)⁺.

[0501] 4-Dimethylaminopyridine (0.68 g, 5.56 mmol) was dissolved in 20 mL of methylene chloride and cooled in an ice-bath. Trifluoroacetic anhydride (0.79 mL, 5.56 mmol) was added. The mixture was stirred at 0° C. for ½ h, and a solution of the solid formed above in 20 mL of methylene chloride was added. The ice-bath was removed, and the reaction mixture was stirred at room temperature under N₂ for 12 h. It was diluted with methylene chloride and washed with water and brine. After dried over MgSO₄, it was concentrated to give 1,5,6,7-tetrahydro-1-[4-bromophenyl]-3-(morpholin-4-yl)-4-trifluoroacetyl-2H-azepin-2-one as brown oil. LRMS (AP⁺): 446.0, 448.0, (M+H)⁺.

[0502] The brown oil above and 3-cyano-4-fluorophenylhydrazine hydrochloride (1.31 g, 6.95 mmol) were refluxed with 100 mL of acetic acid under N₂ for 20 h. The solvent was removed, the residue was dissolved in EtOAc and washed with water, saturated NaHCO₃, and brine. It was dried over MgSO₄, concentrated, and chromatographed on silica gel with 15-20% EtOAc in hexane to give 1.06 g of the desired product (46%). LRMS (ES⁺): 493.1, (M+H)⁺. ¹H NMR (CDCl₃): δ 7.77 (m, 2H), 7.54 (d, 2H), 7.28 (m, 3H), 7.15 (d, 2H), 3.91 (t, 2H), 3.10 (t, 2H), 2.28 (m, 2H).

[0503] Part B. 1-[3-Cyano-4-fluorophenyl]-3-trifluoromethyl-7-[2′-formyl-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one

[0504] 1-[3-Cyano-4-fluorophenyl]-3-trifluoromethyl-7-[4-bromophenyl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one (1.06g, 2.15 mmol), 2-formylphenylboronic acid (0.65 g, 4.30 mmol), potassium phosphate (1.83 g, 8.60 mmol), tetrakis(triphenylphosphine)palladium (0) (124 mg) were refluxed with 80 mL of dioxane under N₂ for 12 h. It was filtered through Celite® and washed with EtOAc. The mixture was washed with water and brine, dried over MgSO₄, concentrated, and chromatographed on silica gel with 15-25% EtOAc in hexane to give 0.90 g of the desired product (81%). LRMS (ES⁺): 519.3, (M+H)⁺. ¹H NMR (CDCl₃): δ 10.02 (s, 1H), 8.04 (d, 1H), 7.80 (m, 2H), 7.68 (t, 1H), 7.54 (t, 1H), 7.43 (m, 4H), 7.30 (m, 1H), 4.02 (m, 2H), 3.12 (t, 2H), 2.32 (m, 2H).

[0505] Part C. 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-7-[2′-hydroxymethyl-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one

[0506] 1-[3-Cyano-4-fluorophenyl]-3-trifluoromethyl-7-[2′-formyl-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one (0.90 g, 1.74 mmol) was dissolved in 20 mL of methanol and cooled at 0° C. NaBH₄ (76.0 mg, 2.00 mmol) was added. After stirring for ½ h at 0° C., it was quenched with water. The solvent was removed. The residue was partitioned between methylene chloride and water. The aqueous layer was extracted with methylene chloride. The combined organic solution was washed with brine, dried over MgSO₄, concentrated to yellow foam. The alcohol formed such was used in the next step without further purification.

[0507] N-Acetylhydroxylamine (0.39 g, 5.22 mmol) was dissolved in 10 mL of DMF. Potassium carbonate (0.96 g, 6.96 mmol) was added, followed by 2 mL of water. After stirring for ½ h, a solution of the alcohol from above in 5 mL of DMF was added. The reaction mixture was stirred at room temperature under N₂ for 12 h. Water was added, the precipitate was filtered and dried to give 0.90 g of the desired product (97%). LRMS (AP⁺) : 534.2, (M+H)⁺. ¹H NMR (CDCl₃): δ 7.67 (m, 2H) , 7.50 (m, 1H), 7.42-7.20 (m, 8H), 4.52 (s, 2H), 3.97 (m, 2H), 3.10 (t, 2H), 2.30 (m, 2H), 2.06 (bs, 1H).

[0508] Part D. 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-7-[2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one, trifluoroacetic acid salt

[0509] 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-7-[2′-hydroxymethyl-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one (0.15 g, 0.28 mmol) was dissolved in 6 mL of dry methylene chloride. PBr₃ (0.037 mL, 0.39 mmol) was added and the mixture was stirred at room temperature under N₂ for 30 minute. The reaction mixture was quenched with water and extracted with methylene chloride. The methylene chloride extract was washed with brine, dried over MgSO₄, and concentrated to yellow foam.

[0510] The foam was then dissolved in 10 mL of CH₃CN, and pyrrolidine (0.070 mL, 0.84 mmol) was added. The mixture was stirred at room temperature for 12 h. It was concentrated, and purified by prep HPLC (C18 reverse phase column, eluted with a H₂O/CH₃CN gradient with 0.05% TFA) and lyophilized to afford 0.11 of the title compound of Example 36 as a TFA salt (56%). LRMS (ES⁺): 587.3, (M+H)⁺. ¹H NMR (CD₃OD): δ 7.96 (m, 1H), 7.73-7.60 (m, 3H), 7.58-7.34 (m, 7H), 4.38 (s, 2H), 4.04 (t, 2H), 3.33 (m, 2H), 3.14 (t, 2H), 2.78 (m, 2H), 2.32 (m, 2H) , 1.86 (m, 4H).

Example 37 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-7-[2′-N-dimethylaminomethyl-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one, trifluoroacetic acid salt

[0511]

[0512] The title compound of Example 37 was prepared by the same methods described in Example 36. LRMS (ES⁺): 561.4, (M+H)⁺. ¹H NMR (CD₃OD): δ 7.96 (d, 1H) , 7.71 (dd, 1H) , 7.63 (m, 1H), 7.55 (m, 2H), 7.50 (m, 2H), 7.40 (m, 4H), 4.34 (s, 2H), 4.07 (t, 2H), 3.15 (t, 2H), 2.60 (S, 6H), 2.34 (m, 2H).

Example 38 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-7-[2′-N-isopropylaminomethyl-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one, trifluoroacetic acid salt

[0513]

[0514] The title compound of Example 38 was prepared by the same methods described in Example 36. LRMS (ES⁺): 575.4, (M+H)⁺. ¹H NMR (CD₃OD): δ 7.97 (s, 1H), 7.71 (m, 1H) , 7.62 (m, 1H), 7.53-7.36 (m, 8H), 4.18 (s, 2H), 4.07 (t, 2H), 3.20 (m,1H), 3.15 (t, 2H), 2.33 (t, 2H), 1.14 (d, 6H).

Example 39 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-7-[2′-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one, trifluoroacetic acid salt

[0515]

[0516] The title compound of Example 39 was prepared by the same methods described in Example 36. LRMS (ES⁺): 603.4, (M+H)⁺. ¹H NMR (CD₃OD): δ 7.98 (d, 1H), 7.70 (m, 2H), 7.58-7.37 (m, 8H), 4.58-4.30 (m, 3H), 4.08 (t, 2H), 3.60-3.35 (m, 1H), 3.15 (t, 2H), 3.00-2.78 (m, 2H), 2.34 (m, 2H), 2.20-1.79 (m, 2H).

Example 40 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-7-[2′-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-3-fluoro-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one, trifluoroacetic acid salt

[0517]

[0518] Part A. N-(4-Bromo-2-fluorophenyl)caprolactam

[0519] 4-Bromo-2-fluoroaniline (11.80 g, 62.1 mmol) and triethylamine (9.00 mL, 64.6 mmol) were dissolved in 200 mL of methylene chloride. 6-Bromohexanoyl chloride (13.26 g, 62.1 mmol) was added dropwise via an addition funnel. The reaction mixture was stirred under N₂ for ½ h after the addition was completed. It was diluted with methylene chloride and washed with water, 1N aqueous HCl, 1N aqueous NaOH, and brine. It was the dried over MgSO₄ and concentrated to a white solid (21.75 g).

[0520] A solution of the above solid in 200 mL of DMF was added dropwise at room temperature to a mixture of NaH (2.85 g of 60% dispersion, 71.3 mmol) in 100 mL of DMF. The reaction mixture was stirred at room temperature for 2 h under N₂. It was then poured into 500 mL of water and extracted with EtOAc. The combined organic mixture was washed with brine, dried over MgSO₄, and concentrated to orange oil. The title compound was then purified by chromatography on silica gel eluted with 10-50% EtOAc in hexane to give 16.27 g of orange oil (92%). LRMS (ES⁺): 286.1, 288.1 (M+H)⁺. ¹H NMR (CDCl₃): δ 7.29 (m, 2H), 7.09 (t, 1H), 3.65 (t, 2H), 2.71 (t, 2H), 1.82 (m, 6H).

[0521] Part B. N-(4-Bromo-2-fluorophenyl)-3,3-dichlorocaprolactam

[0522] N-[4-bromo-2-fluorophenyl]caprolactam (6.96 g, 24.33 mmol) and phosphorus pentachloride (15.20 g, 72.99 mmol) were added together with 200 mL of benzene and refluxed under N₂ for 2 h. The reaction mixture was cooled and quenched with water and saturated aqueous NaHCO₃. It was diluted with EtOAc and washed with water and brine. The organic mixture was then dried over MgSO₄, concentrated, and chromatographed on silica gel eluted with 10% EtOAc in hexane to give 4.97 g of the desired product (58%). LRMS (ES⁺): 355.9 (M+H)⁺. ¹H NMR (CDCl₃): δ 7.32 (m, 2H), 7.10 (t, 1H), 3.84 (m, 2H), 2.75 (t, 2H), 2.10 (m, 2H), 1.82 (m, 2H).

[0523] Part C. 1-[3-Cyano-4-fluorophenyl]-3-trifluoromethyl-7-[4-bromo-2-fluorophenyl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one

[0524] N-[4-bromo-2-fluorophenyl]-3,3-dichlorocaprolactam (0.49 g, 1.38 mmol) was refluxed with 10 mL of morpholine under N₂ for 1 h. The solvent was then removed in vacuo. Toluene was added and the solid was filtered off. The filtrate was concentrated and dried under vacuum to give 1,5,6,7-tetrahydro-1- [4-bromo-2-fluorophenyl]-3-(morpholin-4-yl)-2H-azepin-2-one as brown oil (0.55 g). LRMS (AP⁺): 369.0, 371.0, (M+H)⁺.

[0525] 4-Dimethylaminopyridine (0.22 g, 1.79 mmol) was dissolved in 5 mL of methylene chloride and cooled in an ice-bath. Trifluoroacetic anhydride (0.0.42 mL, 2.98 mmol) was added. The mixture was stirred at 0° C. for ½ h, and a solution of 1,5,6,7-tetrahydro-1-[4-bromo-2-fluorophenyl]-3-(morpholin-4-yl)-2H-azepin-2-one in 15 mL of methylene chloride was added. The ice-bath was removed, and the reaction mixture was stirred at room temperature under N₂ for 12 h. It was diluted with methylene chloride and washed with water and brine. After drying over MgSO₄, it was concentrated to give 1,5,6,7-tetrahydro-1-[4-bromo-2-fluorophenyl]-3-(morpholin-4-yl)-4-trifluoroacetyl-2H-azepin-2-one as brown oil. LRMS (AP⁺) 465.0.0, 467.0, (M+H)⁺.

[0526] 1,5,6,7-Tetrahydro-1-[4-bromo-2-fluorophenyl]-3-(morpholin-4-yl)-4-trifluoroacetyl-2H-azepin-2-one formed above and 3-cyano-4-fluorophenylhydrazine hydrochloride (0.42 g, 2.24 mmol) were refluxed with 25 mL of acetic acid under N₂ for 20 h. The solvent was removed, the residue was dissolved in EtOAc and washed with water, saturated NaHCO₃, and brine. It was dried over MgSO₄, concentrated, and chromatographed on silica gel with 25% EtOAc in hexane to give 0.15 g of the desired product (19%). LRMS (AP⁺): 511.0, 513.0, (M+H)⁺. ¹H NMR (CDCl₃): δ 7.76 (m, 2H), 7.36 (m, 2H), 7.28 (m, 1H), 7.17 (m, 1H), 3.85 (t, 2H), 3.12 (t, 2H), 2.26 (m, 2H).

[0527] Part D. 1-[3-Cyano-4-fluorophenyl]-3-trifluoromethyl-7-[2′-formyl-3-fluoro-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one

[0528] 1-(3-Cyano-4-fluoro)phenyl-3-trifluoromethyl-7-[4-bromo-2-fluorophenyl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one (0.15 g, 0.29 mmol), 2-formylphenylboronic acid (88.0 mg, 0.58 mmol), potassium phosphate (0.25 g, 1.16 mmol), tetrakis(triphenylphosphine)palladium (0) (34 mg) were refluxed with 20 mL of dioxane under N₂ for 12 h. It was filtered through Celite® and washed with EtOAc. The mixture was washed with water and brine, dried over MgSO₄, concentrated, and chromatographed on silica gel with 25% EtOAc in hexane to give 93.0 mg of the desired product (60%). LRMS (AP⁺): 537.1, (M+H)⁺. ¹H NMR (CDCl₃): δ 10.02 (s, 1H), 8.04 (d, 1H), 7.80 (m, 2H), 7.68 (t, 1H), 7.54 (t, 1H), 7.40-7.20 (m, 6H), 3.97 (m, 2H), 3.15 (t, 2H), 2.33 (m, 2H).

[0529] Part E. 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-7-[2′-hydroxymethyl-3-fluoro-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one

[0530] 1-(3-Cyano-4-fluoro)phenyl-3-trifluoromethyl-7-[2′-formyl-3-fluoro-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one (93.0 mg, 0.17 mmol) was dissolved in 10 mL of THF and cooled at 0° C. NaBH₄ (17 mg, 0.45 mmol) was added. After stirred for ½ h at 0° C., it was quenched with water and extracted with EtOAc. The combined organic solution was washed with brine, dried over MgSO₄, concentrated. The alcohol formed such was used in the next step without further purification.

[0531] N-Acetylhydroxylamine (38 mg, 0.51 mmol) was dissolved in 2 mL of DMF. Potassium carbonate (94 mg, 0.68 mmol) was added, followed by 2 drops of water. After stirred for ½ h, a solution of the alcohol from above in 3 mL of DMF was added. The reaction mixture was stirred at room temperature under N₂ for 12 h. Water was added, the milky mixture was extracted with EtOAc. The combined organic solution was washed with brine, dried over MgSO₄, concentrated and dried to give 89 mg of the desired product (95%). LRMS (AP⁺): 552.2, (M+H)⁺. ¹H NMR (CDCl₃): δ 8.01 (s, 1H), 7.76 (d, 1H), 7.63 (dd, 1H), 7.54 (dd, 1H), 7.47-7.20 (m, 6H), 4.55 (s, 2H), 4.47 (s, 2H), 3.83 (t, 2H), 3.13 (t, 2H), 2.30 (m, 2H), 1.68 (bs, 1H).

[0532] Part F. 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-7-[2′-N-pyrrolidinylmethyl-3-fluoro-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one, trifluoroacetic acid salt

[0533] 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-7-[2′-hydroxymethyl-3-fluoro-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one (89 mg, 0.16 mmol) was dissolved in 10 mL of dry methylene chloride. PBr₃ (0.021 mL, 0.22 mmol) was added and the mixture was stirred at room temperature under N₂ for 30 minute. The reaction mixture was quenched with water and extracted with methylene chloride. The methylene chloride extract was washed with brine, dried over MgSO₄, and concentrated to yellow foam.

[0534] The foam was then dissolved in 10 mL of CH₃CN, and (R)-3-pyrrolidinol (0.050 mL, 0.60 mmol) was added. The mixture was stirred at room temperature for 12 h. It was concentrated, and purified by prep HPLC (C18 reverse phase column, eluted with a H₂O/CH₃CN gradient with 0.05% TFA) and lyophilized to afford 49 mg of the title compound of Example 40 as a TFA salt (42%). LRMS (ES⁺): 621.3, (M+H)⁺. ¹H NMR (CD₃OD): δ 7.96 (d, 1H) , 7.64 (m, 2H), 7.58-7.36 (m, 5H), 7.25 (m, 2H), 4.58-4.30 (m, 3H), 4.02 (t, 2H), 3.60-3.35 (m, 1H), 3.15 (t, 2H), 3.00-2.78 (m, 2H), 2.34 (m, 2H), 2.20-1.79 (m, 2H).

Example 41 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-7-[2′-N-pyrrolidinylmethyl-3-fluoro-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one, trifluoroacetic acid salt

[0535]

[0536] The title compound of Example 41 was prepared by the same methods described in Example 40. LRMS (ES⁺): 605.3, (M+H)⁺. ¹H NMR (CD₃OD) δ 7.97 (d, 1H) , 7.67 (m, 2H) , 7.57 (m, 3H), 7.50 (d, 1H), 7.42 (m, 1H), 7.27 (dd, 2H), 4.41 (s, 2H), 4.03 (t, 2H), 3.36 (m, 1H), 3.15 (t, 2H), 2.82 (m, 2H), 2.33 (m, 2H), 1.90 (m, 4H).

Example 42 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-7-[2′-N-dimethylaminomethyl-3-fluoro-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one, trifluoroacetic acid salt

[0537]

[0538] The title compound of Example 42 was prepared by the same methods described in Example 40. LRMS (ES⁺): 579.3, (M+H)⁺. ¹H NMR (CD₃OD) : δ 7.97 (d, 1H) , 7.68 (dd, 1H) , 7.62 (m, 1H), 7.57 (m, 3H), 7.47 (t, 1H), 7.42 (m, 1H), 7.25 (dd, 2H), 4.34 (s, 2H), 4.04 (t, 2H), 3.15 (t, 2H), 2.62 (6, 6H), 2.32 (m, 2H).

Example 43 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-7-[2′-N-isopropylaminomethyl-3-fluoro-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one, trifluoroacetic acid salt

[0539]

[0540] The title compound of Example 43 was prepared by the same methods described in Example 40. LRMS (ES⁺): 593.3, (M+H)⁺. ¹H NMR (CD3OD) δ 7.97 (d, 1H), 7.66 (dd, 1H) , 7.59 (m, 1H), 7.53 (m, 3H), 7.47 (d, 1H), 7.40 (m, 1H), 7.28 (m, 2H), 4.18 (s, 2H), 4.02 (t, 2H), 3.24 (m, 1H), 3.15 (t, 2H), 2.32 (m, 2H), 1.16 (d, 6H).

Example 44 1-[4-Methoxyphenyl]-3-trifluoromethyl-7-[4-(2-dimethylaminomethylimidazol-1′-yl)-3-fluorophenyl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one, trifluoroacetic acid salt

[0541]

[0542] 1-[4-Methoxyphenyl]-3-trifluoromethyl-7-[2-fluoro-4-iodophenyl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one (prepared by the procedures described in Example 40) (0.22 g, 0.40 mmol), 2-(N,N-dimethylaminomethyl)imidazole (61 mg, 0.48 mmol), potassium carbonate (61 mg, 0.44 mmol), CuI (12 mg), and 1,10-phenanthroline (11 mg) were heated with 8 mL of DMSO at 130° C. under N₂ for 12 h. The reaction mixture was cooled and 14% aqueous NH₄OH was added. It was extracted with EtOAc, washed with brine, dried over MgSO₄, concentrated, and chromatographed on silica gel eluted with 5% MeOH in CH₂Cl₂. Final purification by prep HPLC (C18 reverse phase column, eluted with a H₂O/CH₃CN gradient with 0.05% TFA) afforded 53.2 mg of the title compound of Example 44 as a TFA salt (20%). LRMS (ES⁺): 543.3, (M+H)⁺. ¹H NMR (CD₃OD): δ 7.68 (t, 1H), 7.54-7.36 (m, 5H), 7.27 (d, 1H), 6.98 (d, 2H), 4.42 (s, 2H), 3.87 (t, 2H), 3.80 (s, 3H), 3.08 (t, 2H), 2.83 (s, 6H), 2.25 (m, 2H).

Example 45 1-[4-Methoxyphenyl]-3-trifluoromethyl-7-[4-(imidazol-1′-yl)-3-fluorophenyl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one, trifluoroacetic acid salt

[0543]

[0544] The title compound of Example 45 was prepared by the same methods described in Example 44. LRMS (ES⁺): 485.4, (M+H)⁺. ¹H NMR (CD₃OD): δ 9.50 (s, 1H), 8.12 (s, 1H), 7.82-7.66 (m, 4H), 7.43 (d, 2H), 7.00 (d, 2H), 3.97 (t, 2H), 3.82 (s, 3H), 3.10 (t, 2H), 2.28 (m, 2H).

Example 46 1-[2-Aminomethylphenyl]-3-trifluoromethyl-7-[2′-methylsulfonyl-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one, trifluoroacetic acid salt

[0545]

[0546] Part A. 1-[2-Trifluoroacetamidomethylphenyl]-3-trifluoromethyl-7-[4-bromophenyl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one

[0547] To a solution of 2-(trifluoroacetamidomethyl)aniline (0.64 g, 2.94 mmol) in 5 mL of acetic acid at 0° C. was added 5 mL concentrated HCl, followed by sodium nitrite (220 mg, 3.19 mmol) in 5 mL of H₂O. After stirred at 0° C. for 2 h, stannous chloride dihydrate (1.53 g, 6.73 mmol) in 3 mL of concentrated HCl and 3 mL of H₂O was slowly added. After stirring at 0° C. for 1 h, a solution of 1,5,6,7-tetrahydro-1-[4-bromophenyl]-3-(morpholin-4-yl)-4-trifluoroacetyl-2H-azepin-2-one (prepared in Part C of Example 33) (0.57 g, 1.18 mmol) in 20 mL of MeOH was added. The mixture was heated at 70° C. for 3 h. The solvent was removed. The residue was dissolved in EtOAc and washed with water, saturated NaHCO₃, and brine. It was dried over MgSO₄, concentrated, and chromatographed on silica gel with 10-30% EtOAc in hexane to give 0.13 g of the desired product (19%). LRMS (AP⁺): 575.1, (M+H)⁺.

[0548] Part B. 1-[2-Trifluoroacetamidomethylphenyl]-3-trifluoromethyl-7-[2′-thiomethyl-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one

[0549] 1-[2-Trifluoroacetamidomethylphenyl])-3-trifluoromethyl-7-[4-bromophenyl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one (0.132 g, 0.23 mmol), 2-thiomethylphenylboronic acid (79 mg, 0.46 mmol), potassium phosphate (0.19 g, 0.92 mmol), tetrakis(triphenylphosphine)palladium (0) (13 mg) were refluxed with 20 mL of dioxane under N₂ for 12 h. It was filtered through Celite® and washed with EtOAc. The mixture was washed with water and brine, dried over MgSO₄, concentrated, and chromatographed on silica gel with 25% EtOAc in hexane to give 80.0 mg of the desired product (56%). LRMS (AP⁺): 619.1, (M+H)⁺.

[0550] Part C. 1-[2-Trifluoroacetamidomethylphenyl]-3-trifluoromethyl-7-[2′-methylsulfonyl-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one

[0551] To a solution of 1-[2-trifluoroacetamidomethylphenyl]-3-trifluoromethyl-7-[2′-thiomethyl-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one (80 mg, 0.13 mmol) in 10 mL of CH₂Cl₂ was added MCPBA (111 mg, 0.33 mmol) at 0° C. The mixture was allowed to warm up to room temperature and stirred for 12 h. It was diluted with CH₂Cl₂ and washed with saturated aqueous NaHCO₃ and brine. It was dried over MgSO₄, concentrated, chromatographed on silica gel eluted with 50% EtOAc in hexane to give 25 mg of white solid. LRMS (AP⁻): 649.1, (M−H)⁻.

[0552] Part D. 1-[2-Aminomethylphenyl]-3-trifluoromethyl-7-[2′-methylsulfonyl-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one, trifluoroacetic acid salt

[0553] 1-[2-Trifluoroacetamidomethylphenyl]-3-trifluoromethyl-7-[2′-methylsulfonyl-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one (25 mg, 0.039 mmol) and potassium carbonate (11 mg) were stirred with 6 mL of MeOH and a few drops of H₂O under N₂ for 12 h. It was concentrated and purified by prep HPLC (C18 reverse phase column, eluted with a H₂O/CH₃CN gradient with 0.05% TFA) afforded 5 mg of the title compound of Example 46 as a TFA salt. LRMS (ES⁺): 555.3, (M+H)⁺.

Example 47 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-N-pyrrolidinyl methyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydro-7H-pyrazolo-[3,4-c]-pyridin-7-one trifluoroacetic acid salt

[0554]

[0555] Part A. 1-[4-bromophenyl]-3-hydroxy-4-acetyl-5,6-dihydropyridin-2-one

[0556] Levulinic acid (10 g, 86.1 mmol) in CH₂Cl₂ (100 mL) was cooled to 0° C. and oxalyl chloride (90.4 mmol, 11.48 g) and a few drops of DMF were added. The reaction was allowed to warm to ambient temperature and stirred 18 h. The reaction was evaporated and the residue dissolved in CH₂Cl₂ (50 mL) and added dropwise to a solution of 4-bromoaniline (81.1 mmol, 13.95 g), Et₃N (100 mmol, 10.12 g) and DMAP (81.1 mmol, 9.9 g) in CH₂Cl₂ (100 mL) at 0° C. The reaction was allowed to warm to ambient temperature and stirred 18 h. The reaction was filtered, washed with 1N HCl (3×) and 1N NaOH (3×), dried (MgSO₄) and evaporated. There was obtained 9.4 g of N-[4-bromophenyl]-4-oxopentamide. Crystallization from EtOAc gave material with mp 156.2° C.

[0557] N-[4-bromophenyl]-4-oxopentamide (18.5 mmol, 5 g) was added dropwise to a suspension of LiAlH₄ (74 mmol, 2.8 g) in THF (50 mL). When the addition was completed, the reaction mixture was heated at reflux for 1 h. The reaction was cooled to ambient temperature and water (2.8 mL), 1N NaOH (2.8 mL) and water (8.4 mL) were carefully added sequentially to the reaction mixture. Low resolution mass spectroscopy (LRMS), showed only product, N-[4-bromophenyl]-4-hydroxypentylamine, (M+H)⁺: 258.0/260.0 m/z.

[0558] This solution was cooled to 0° C., then 4-methylmorpholine (37 mmol, 3.75 g) and ethyl oxalyl chloride (37 mmol, 5.1 g) were added. The reaction was allowed to warm to ambient temperature and stirred 3 h. LRMS showed the major portion of the product mixture to be the mono-acylation product [M+H)+: 358.0/360.0 m/z] and a small amount of the di-acylation product [M+H)⁺: 458.0/460.0 m/z]. The reaction mixture was evaporated, dissolved in EtOAc, and washed with 1N HCl (3×), 1N NaOH (2×), dried (MgSO₄) and evaporated. There was obtained 4.34 g of material.

[0559] The product mixture from above was dissolved in MeOH (100 mL), cooled to 0° C. and a freshly prepared solution of NaOMe in MeOH (ca. 0.2 g of Na metal in 10 mL of MeOH) added. The reaction was stirred at 0° C. for 2 h whereupon all of the diacylation product was consumed and the ethyl ester in the monoacylation product was transesterified to the methyl ester. The reaction was evaporated, dissolved in CHCl₃ and washed with 1N HCl, dried (MgSO₄) and evaporated to give 3.9 g of methyl N-[4-bromophenyl]-N-(4-hydroxypentyl)oxalyl amide; LRMS (M+H)⁺: 344.0/346.0 m/z.

[0560] DMSO (74 mmol, 5.8 g) was added dropwise to a solution of oxalyl chloride (34 mmol, 17 mL of a 2M solution in CH₂Cl₂) in CH₂Cl₂ (50 mL) at −63° C. (dry ice/AcCN bath). The reaction was maintained at −63° C. for 15 min then methyl N-[4-bromophenyl]-N-(4-hydroxypentyl)oxalyl amide (3.9 g, 11.3 mmol) in CH₂Cl₂ (50 mL) was added dropwise. After 3 h at −63° C., Et₃N (96.4 mmol, 9.75 g) was added and the cooling bath removed. After the reaction warmed to ambient temperature and stirred for 1 h, water was added (150 mL), the layers were separated, washed with 1N HCl (2×) and brine, dried (MgSO₄) and evaporated. There was obtained 3.4 g (9.8 mmol) of methyl N-[4-bromophenyl]-N-(4-oxopentyl)oxalyl amide; LRMS (M+H)⁺ 342.0/344.0 m/z.

[0561] Methyl N-[4-bromophenyl]-N-(4-oxopentyl)oxalyl amide (9.8 mmol, 3.4 g) was added to a solution of NaOMe in MeOH (from 0.53 g of Na metal (23 mg atom) in 20 mL of MeOH). This mixture was stirred at ambient temperature for 1 h, then 10 mL of 3N HCl was added. This suspension was diluted further by the addition of more water (100 mL) and the product collected by filtration and air-dried. There was obtained 1.72 g (5.6 mmol) of 1-[4-bromophenyl]-3-hydroxy-4-acetyl-5,6-dihydropyridin-2-one; LRMS (M+H)⁺: 310.2/312.2 m/z.

[0562] Part B. 1-[3-Cyano-4-fluorophenyl]-3-methyl-6-[4-bromophenyl]-1,4,5,6-tetrahydro-7H-pyrazolo-[3,4-c]-pyridin-7-one

[0563] 3-Cyano-4-fluoroaniline (3.7 mmol, 0.5 g) in conc. HCl (4 mL) was cooled to 0° C. and NaNO₂ (4.4 mmol, 0.3 g) in water (3 mL). This was stirred at 0° C. for 30 min, then acetic acid (1.3 mL) was added. SnCl₂.(H₂O)₂ (8.5 mmol, 1.9 g) in 1:1 water:conc. HCl (3 mL) was added dropwise to the cold solution and stirred for an additional 30 min. To this mixture 1-[4-bromophenyl]-3-hydroxy-4-acetyl-5,6-dihydropyridin-2-one (3.9 mmol, 1.2 g) was slurried in MeOH (20 mL) and added with the aid of additional MeOH (6 mL). The suspension was heated at 50° C. for 3 h, then cooled at 10° C. for 18 h. The product, 1-[3-cyano-4-fluorophenyl]-3-methyl-6-[4-bromophenyl]-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one, was isolated by filtration. There was obtained 1.34 g (3.2 mmol) of product; mp 237.6° C., LRMS (M+H)⁺: 425.2/427.1 m/z.

[0564] Part C. 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-formyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydro-7H-pyrazolo-[3,4-c]-pyridin-7-one

[0565] 1-[3-Cyano-4-fluorophenyl]-3-methyl-6-[4-bromophenyl]-1,4,5,6-tetrahydro-7H-pyrazolo-[3,4-c]-pyridin-7-one (1.34 g, 3.2 mmol), 2-formylphenylboronic acid (0.68 g, 4.5 mmol) and Bu₄NBr (0.06 g) in C₆H₆ (50 mL) and 2N Na₂CO₃ (10 mL) was purged with a stream of N₂ gas. Palladium tetrakis(triphenyl)phosphine (0.19 g, 5 mol %) was added and the mixture heated at reflux for 18 h. To the cooled reaction mixture, brine and EtOAc was added and the layers separated. The organic layer was dried (MgSO₄) and evaporated to give 1.58 g (3.2 mmol) of 1-[3-cyano-4-fluorophenyl]-3-methyl-6-[2′-formyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one; LRMS (M+Na)⁺: 473.3 m/z.

[0566] 1-[3-Cyano-4-fluorophenyl]-3-methyl-6-[2′-formyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydro-7H-pyrazolo-[3,4-c]-pyridin-7-one (3.4 g, 7.5 mmol) was cooled to 0° C. in MeOH (75 mL) and NaBH₄ (0.43 g, 11.3 mmol) added. After 3 h, 1N HCl (50 mL) was added, the reaction was evaporated and EtOAc added. The organic layer was washed with 1N HCl, dried (MgSO₄) and evaporated to give 2.48 g (5.5 mmol) of 1-[3-cyano-4-fluorophenyl]-3-methyl-6-[2′-hydroxymethyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydro-7H-pyrazolo-[3,4-c]-pyridin-7-one.

[0567] The product from above (2.48 g, 5.5 mmol), N-acetylhydroxylamine (1.24 g, 16.4 mmol) and K₂CO₃ (4.54 g, 33 mmol) in DMF (75 mL) and water (7.5 mL) were stirred at ambient temperature for 18 h. The solvent was removed by distillation and the residue applied to a flash silica gel column (200 g) and eluted with a gradient of 2:1 to 1:1 hexane:EtOAc. There was obtained 1.65 g of 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-hydroxymethyl-[1,1′]-biphenyl-4-yl)-1,4,5,6-tetrahydro-7H-pyrazolo-[3,4-c]-pyridin-7-one; LRMS (M⁻) 464.0 m/z.

[0568] 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-hydroxymethyl-[1,1′]-biphenyl-4-yl)-1,4,5,6-tetrahydro-7H-pyrazolo-[3,4-c]-pyridin-7-one (0.1 g, 0.22 mmol) in acetone (5 mL) and CH₂Cl₂ (20 mL) was stirred with activated MnO₂ (0.3 g, 3.3 mmol). After 3 h the suspension was filtered through a pad of Celite® and evaporated to give 0.09 g of 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-formyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydro-7H-pyrazolo-[3,4-c]-pyridin-7-one; LRMS (M+H)⁺: 464.2 m/z.

[0569] Part D. 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydro-7H-pyrazolo-[3,4-c]-pyridin-7-one trifluoroacetic acid salt

[0570] To 0.09 g of 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-formyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydro-7H-pyrazolo-[3,4-c]-pyridin-7-one (0.22 mmol) in 1:1 CHCl₃ THF (40 mL) was added pyrrolidine (0.064 g, 0.88 mmol), acetic acid (0.44 mmol) and sodium triacetoxyborohydride (0.094 g, 0.44 mmol). After 18 h at ambient temperature more CHCl₃ was added (100 mL) and the organics washed with water, dried (MgSO₄) and evaporated. The residue (0.11 g) was purified by HPLC on a C₁₈ column by elution with a gradient of water (0.05% TFA, solvent A) and acetonitrile (0.05% TFA, solvent B). There was obtained 0.066 g of 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-N-pyrrolidinylmethyl)-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydro-7H-pyrazolo-[3,4-c]-pyridin-7-one trifluoroacetic acid salt with a purity of >99%; mp 108.9° C., HRMS (C₃₁H₃₁O₂N₆)⁺: 519.2517 m/z.

Example 48 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-(3-(S)-hydroxy-N-pyrrolidinyl)methyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydro-7H-pyrazolo-[3,4-c]-pyridin-7-one trifluoroacetic acid salt

[0571]

[0572] This compound was prepared and purified by the same procedure outlined in Example 47, Part D from a mixture of 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-formyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydro-7H-pyrazolo-[3,4-c]-pyridin-7-one and 3-(S)-hydroxypyrrolidine. There was obtained 0.047 g of the title compound of Example 48 with a purity >98%; mp 137.7° C.; HRMS (C₃₁H₃₁N₆O₃)⁺: 535.2452.

Example 49 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-N-isopropylaminomethyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydro-7H-pyrazolo-[3,4-c]-pyridin-7-one trifluoroacetic acid salt

[0573]

[0574] This compound was prepared and purified by the same procedure outlined in Example 47, Part D from a mixture of 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-formyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydro-7H-pyrazolo-[3,4-c]-pyridin-7-one and isopropylamine. There was obtained 0.065 g of the title compound of Example 49 with a purity >95%; mp 71.5° C.; HRMS (C₃₀H₃₁N₆O₂)⁺: 507.2501.

Example 50 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-N,N-dimethylaminomethyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydro-7H-pyrazolo-[3,4-c]-pyridin-7-one trifluoroacetic acid salt

[0575]

[0576] This compound was prepared and purified by the same procedure outlined in Example 47, Part D from a mixture of 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-formyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydro-7H-pyrazolo-[3,4-c]-pyridin-7-one and a 2M THF solution of dimethylamine. There was obtained 0.040 g of the title compound of Example 50 with a purity >95%; mp 51.6° C.; HRMS (C₂₉H₂₉N₆O₂)⁺: 493.2355.

Example 51 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-methylsulfonyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydro-7H-pyrazolo-[3,4-c]-pyridin-7-one trifluoroacetic acid salt

[0577]

[0578] Part A. 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-thiomethyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydro-7H-pyrazolo-[3,4-c]-pyridin-7-one

[0579] 1-[3-Cyano-4-fluorophenyl]-3-methyl-6-[4-bromophenyl]-1,4,5,6-tetrahydro-7H-pyrazolo-[3,4-c]-pyridin-7-one (Example 47, Part B; 0.23 g, 0.54 mmol), 2-thiomethylphenylboronic acid (0.13 g, 0.76 mmol) and Bu₄NBr (0.011 g) in C₆H₆ (20 mL) and 2N Na₂CO₃ (4 mL) was purged with a stream of N₂ gas. Palladium tetrakis(triphenyl)phosphine (0.032 g, 0.028 mmol) was added and the mixture heated at reflux for 18 h. To the cooled reaction mixture, brine and EtOAc was added and the layers separated. The organic layer was dried (MgSO₄) and evaporated then the residue was purified by silica gel chromatography (100 g of SiO₂, eluted with 1:1 hexane EtOAc) to give 0.17 g (3.2 mmol) of 1-[3-cyano-4-fluorophenyl]-3-methyl-6-[2′-thiomethyl)-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydro-7H-pyrazolo-[3,4-c]-pyridin-7-one; LRMS (M+H)⁺: 469.0 m/z.

[0580] The product from above (0.17 g, 0.36 mmol), N-acetylhydroxylamine (0.08 g, 1.09 mmol) and K₂CO₃ (0.30 g, 2.2 mmol) in DMF (5 mL) and water (0.5 mL) were stirred at ambient temperature for 18 h. The reaction was diluted with EtOAc and washed with water (5×), dried (MgSO₄) and evaporated. The residue was applied to a flash silica gel column (50 g) and eluted with 1:1 hexane:EtOAc. There was obtained 0.09 g of 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-thiomethyl)-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydro-7H-pyrazolo-[3,4-c]-pyridin-7-one.

[0581] A mixture of 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-thiomethyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydro-7H-pyrazolo-[3,4-c]-pyridin-7-one (0.09 g, 0.19 mmol) and m-chloroperbenzoic acid (0.10 g, 0.56 mmol) in CH₂Cl₂ were stirred for 18 h. Saturated NaHCO3 was added and the layers separated. The basic layer was extracted into CH₂Cl₂, then the organic layers were combined, dried (MgSO₄) and evaporated. The residue was purified by HPLC on a C18 column by elution with a gradient of water (0.05% TFA, solvent A) and acetonitrile (0.05% TFA, solvent B). There was obtained 0.036 g of 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-methylsulfonyl)-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydro-7H-pyrazolo-[3,4-c]-pyridin-7-one trifluoroacetic acid salt with a purity of >96%; mp 274.5° C., HRMS (C₂₇H₂₄O₄N₅S)⁺: 514.1527 m/z.

Example 52 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-methylsulfonyl-3-fluoro-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydro-7H-pyrazolo-[3,4-c]-pyridin-7-one trifluoroacetic acid salt

[0582]

[0583] The title compound was prepared by the same methods disclosed for Example 51. After HPLC purification there was obtained 0.24 g of 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-methylsulfonyl-3-fluoro-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydro-7H-pyrazolo-[3,4-c]-pyridin-7-one trifluoroacetic acid salt with a purity of >96%; mp 250.3° C., CHN for C₂₇H₂₂N₅O₄FS.¼C₂F₃O₂H: Calcd. %C: 58.98,%H: 4.00,%N: 12.50, Found. %C: 59.02,%H: 4.17,%N: 12.56; HRMS (C₂₇H₂₃O₄N₅SF)⁺: 532.1471 m/z.

Examples 53 and 54 1-[2-Aminomethylphenyl]-3-trifluoromethyl-6-[2′-methylsulfonyl-3-fluoro-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one trifluoroacetic acid salt (Example 53) and cyclized byproduct (Example 54).

[0584]

[0585] Part A. 1,5,6-Trihydro-1-[4-bromo-2-fluorophenyl]-3-(morpholin-4-yl)-pyridin-2-one

[0586] To DMSO (16.6 mL) in CH₂Cl₂ (200 mL) at −60° C. was added dropwise trifluoroacetic anhydride (29.9 mL, 0.21 mol). This mixture was stirred 15 min then 1-[4-bromo-2-fluorophenyl]-3-hydroxypiperidin-2-one (21 g, 0.073 mol, prepared following the procedures in Marinelli et. al. Tetrahedron 1996, 11176) in CH₂Cl₂ (100 mL) was added dropwise. After 2 h triethylamine (61.2 mL, 0.44 mol) was slowly added. The reaction was stirred 1.5 h then poured into 1N HCl and the CH₂Cl₂ layer was separated and concentrated. The residue was taken up in EtOAc and washed with water, saturated aq NaHCO₃ and brine, dried (Na₂SO₄) and concentrated. The dione was placed in a Dean-Stark apparatus in benzene (200 mL) with morpholine (13 mL) and p-toluenesulfonic acid (50 mg) and heated to reflux 18 h. The reaction was concentrated and purification by chromatography on silica with (2:1) hexanes/EtOAc as eluent afforded 17.2 g (66%) of a pale yellow foam. ¹H NMR (CDCl₃): □ 7.41-7.12 (m, 3H), 5.68 (t, j=4.7, 1H), 3.83 (4H, j=4.4 Hz, 4H), 3.71 (t, j=6.6 Hz, 2H), 2.93 (t, j=4.8 Hz, 4H), 2.55 (dd, j=4.8, 6.6 Hz, 2H).

[0587] Part B. 1-[2-Trifluoroacetamidomethylphenyl]-3-trifluoromethyl-6-[4-bromo-2-fluorophenyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one

[0588] To DMAP(0.5 g, 4.1 mmol) in CH₂Cl₂ (25 mL) at 0° C. was added TFAA (0.58 mL, 4.1 mmol). After 30 minutes 1,5,6-trihydro-1-[4-bromophenyl]-3-[morpholin-4-yl]-pyridin-2-one (1.2 g, 3.3 mmol) in CH₂Cl₂ (20 mL) was added. The reaction was stirred 24 h at rt. The solvent was removed and purification by chromatography on silica with (2:1) hexanes/EtOAc as eluent afforded 0.79 g (52%) of a yellow solid. LRMS (ES−): 449-450.9 (M−H)⁻. The compound was heated to reflux for 3 h in THF (45 mL) containing 20% HCl (15 mL). The reaction was cooled and extracted with diethyl ether, washed successively with NaHCO₃, brine and dried (Na₂SO₄). The trione intermediate was obtained as a green-yellow foam (0.64 g, 90%). LRMS (ES+): 783-785 (2M+Na). To this product (0.62 g, 1.6 mmol) was added 2-hydrazino benzyltrifluoroacetamide hydrochloride (1.0 g, 3.7 mmol) and acetic acid (20 mL) and the mixture was heated to reflux 24 h. The acetic acid was removed and the residue dissolved in EtOAc, washed successively with NaHCO₃, brine and dried (Na₂SO₄). Purification by chromatography on silica with (4:1) hexanes/EtOAc as eluent afforded 0.3 g (32%) of the title compound. LRMS (ES−): 577-579.1 (M−H)⁻.

[0589] Part C. 1-[2-Aminomethylphenyl]-3-trifluoromethyl-6-[2′-methylsulfonyl-3-fluoro-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one trifluoroacetic acid salt

[0590] 1-[2-Trifluoroacetamidomethylphenyl]-3-trifluoromethyl-7-[4-bromophenyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (0.3 g, 0.052 mmol) was coupled with 2-thiomethylphenyl boronic acid (0.113 g, 0.06 mmol) via standard Suzuki coupling procedures with Pd°. Purification by chromatography on silica with (2:1) hexanes/EtOAc as eluent afforded 0.35 g of the desired thiomethyl intermediate. The thiomethyl intermediate was dissolved in CH₂Cl₂, cooled to 0° C. and oxidized with m-chloroperbenzoic acid (0.39 g, 1.3 mmol). After stirring for 2.5 h the reaction mixture was washed successively with sat'd sodium bisulfate, brine and dried (MgSO₄). Purification by chromatography on silica with (1:1) hexanes/EtOAc as eluent afforded 0.2 g of a foam. LRMS (ES−): 653.1 (M−H)⁻. The trifluoroacetamide group was removed by heating to reflux the previous compound in a mixture of MeOH (10 mL), water (3 mL), and K₂CO₃ (0.17 g, 1.2 mmol) for 3 h. The reaction was cooled, acidified with TFA, concentrated and purified via HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) to afford two products. First the desired ortho-benzyl amine (Example 53), 0.064 mg (32% from sulfone) was recovered: Mass Spec m/z (ESI) (M+H)⁺ 559.1; HRMS (M+H)⁺ for C₂₇H₂₃F₄N₄O₃S₁: 599.1427; ¹H NMR (DMSO) □ 8.23 (s, 2H), 8.12 (dd, j=1.1, 7.7 Hz, 1H) 7.82 (dt, j=1.5, 7.3 Hz, 1H), 7.74 (dt, j=1.5, 7.7 Hz, 1H), 7.67 (m, 2H), 7.55 (m, 2H), 7.53 (d, j=8 Hz, 1H), 7.42 (m, 2H), 7.32 dd, j=1.8, 8 Hz, 1H), 4.18 (t, j=6.6 Hz, 2H), 3.88 (q, j=5.8 Hz, 2H), 3.23 (t, j=6.2 Hz, 2H), 2.91 (s, 3H). A second byproduct the cyclic lactam (Example 54), 25 mg (12% from sulfone), was recovered: HRMS (M+H)⁺ for C₂₇H₂₃F₄N₄O₃S₁: 599.1429; ¹H NMR (DMSO) □ 8.21 (dd, j=1.1, 7.7 Hz, 1H), 7.86 (d, j=8 Hz, 1H), 7.65 (m, 2H), 7.56 (m, 2H), 7.45 (dt, j=1.1, 7.3 Hz, 1H), 7.36 (m, 2H), 7.16 (dd, j=2.2, 12.5 Hz, 1H), 7.06 (dd, j=1.5, 8.4 Hz, 1H), 6.81 (t, j=8.7 Hz, 1H), 4.25 (d, j=5.9 Hz, 2H), 3.59 (t, j=6.2 Hz, 2H), 3.30 (m, 2H), 2.74 (s+m, 4H).

Example 55 1-[2-Aminomethylphenyl]-3-trifluoromethyl-6-[2′-aminosulfonyl-3-fluoro-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one trifluoroacetic acid salt

[0591]

[0592] The product from Example 53, Part B (0.33 g, 0.057 mmol) was coupled with 2-(tert-butylaminosulfonyl)phenyl boronic acid (0.22 g, 0.08 mmol) via the Suzuki procedure. Purification by chromatography on silica with (2:1) hexanes/EtOAc as eluent afforded 0.23 g(56%) of a pale yellow solid. LRMS (ES−): 710.2 (M−H)⁻. The protecting groups were removed sequentially by, first, stirring the previous compound in a mixture of MeOH (30 mL), water (10 mL), and K₂CO₃ (0.086 g, 0.6 mmol) for 18 h. The reaction was acidified with TFA and heated to reflux for 10 min. The reaction was concentrated and purified by HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and freeze-dried to afford 92 mg (44%) of the title compound of Example 55. HRMS (M+H)⁺ for C₂₆H₂₂F₄N₅O₃S₁: 560.1377. ¹H NMR (DMSO-d6) □ 8.21 (2H, s), 8.04 (dd, j=2.2, 5.1 Hz, 1H), 7.67 (m, 4H), 7.55 (m, 2H), 7.49 (t, j=8.1 Hz, 1H), 7.39 (s, 2H), 7.35 (m, 2H), 7.28 (dd, j=1.8, 8 Hz, 1H), 4.16 (t, j=6.3 Hz, 2H), 3.89 (q, j=5.9 Hz, 2H), 3.23 (t, j=6.2 Hz, 2H). Analysis calc'd for C₂₆H₂₂F₄N₅O₃S₁ (TFA) (H₂O)2: C: 47.39; H:3.69; N:9.87; found C:47.35; H:3.22; N:9.55.

Example 56 1-[2-Aminomethylphenyl]-3-trifluoromethyl-6-[2′-methylsulfonyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one trifluoroacetic acid salt

[0593]

[0594] The title compound of Example 56 was prepared in a similar fashion to that described for example 53. LRMS (ES+): 541.3 (M+H)⁺. ¹H NMR (DMSO-d6): 8.18 (bm, 2H), 8.09 (dd, 2H), 7.78-7.64 (cp, 6H), 7.54 (m, 2H), 7.38 (m, 2H), 4.22 (t, 2H), 3.86 (m, 2H), 3.35 (bm, 1H), 3.20 (t, 2H), 2.83 (s, 3H).

Example 57 1-[2-Aminomethylphenyl]-3-trifluoromethyl-6-[2′-N,N-dimethylaminomethyl-3-fluoro-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one trifluoroacetic acid salt

[0595]

[0596] Part A. 1-[2-Trifluoroacetamidomethylphenyl]-3-trifluoromethyl-6-[2′-formyl-3-fluoro-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one

[0597] The product from Example 53, Part B above (0.8 g, 1.4 mmol) was coupled with 2-formylphenylboronic acid (0.311 g, 2.1 mmol) via standard Suzuki methodology. Purification by chromatography on silica with (2:1) hexanes/EtOAc as eluent afforded 0.5 g (59%) of the aldehyde intermediate. LRMS (ES−): 603.2 (M−H)⁻.

[0598] Part B. 1-[2-Aminomethylphenyl]-3-trifluoromethyl-6-[2′-N,N-dimethylaminomethyl-3-fluoro-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one trifluoroacetic acid salt

[0599] The aldehyde from part A (0.16 g, 0.26 mmol) was hydrogenated at 40 psi in EtOH with 5% Pd/C (35 mg) and excess dimethylamine hydrochloride (50mg) for 6 h. The incomplete reaction was filtered through Celite®, concentrated and purification by chromatography on silica with 10% MeOH/CH₂Cl₂ as eluent afforded 77 mg (32%) of the trifluoroacetamide. The protecting group was removed in a mixture of MeOH (15 mL), water (8 mL), and K₂CO₃ (34 mg, 0.2 mmol) for 18 h. The reaction was acidified with TFA, concentrated, combined with another 60 mg of additional crude product and purified via HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) to afford 94 mg (67%) of the title compound of Example 57. HRMS (M+H)⁺ for C₃₄H₂₉F₃N₂O 538.2234; ¹H NMR (DMSO-d6) .□8.26 (s, 2H), 7.73 (m, 1H), 7.67 (m, 2H), 7.58 (m, 5H), 7.41 (dd, j=1.9, 11.4 Hz, 1H), 7.36 (m, 1H), 7.26 (dd, j=1.4, 8 Hz, 1H), 4.31 (d, j=4.4 Hz, 2H), 4.17 (t, j=6.2 Hz, 2H), 3.88 (q, j=5.5 Hz, 2H), 3.24 (t, j=6.6 Hz, 2H), 2.58 (s, 3H), 2.56 (s, 3H).

Example 58 1-[2-Aminomethylphenyl]-3-trifluoromethyl-6-[2′-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-3-fluoro-[1,1′ -biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one trifluoroacetic acid salt

[0600]

[0601] The aldehyde from Example 57, Part A (0.225 g, 0.37 mmol) was reductively aminated, with (S)-3-pyrrolidinol (100 mg, 1.1 mmol) and then deprotected with K₂CO₃/MeOH/water, as in Example 57. Purification by HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and freeze-drying afforded 80 mg (27%) of the title compound of Example 58 as a white solid: HRMS (M+H)⁺ for C₃₁H₃₀F₄N₅O₂: 580.2313; ¹H NMR (DMSO-d6) □ 8.27 (m, 2H), 7.78 (m, 1H), 7.67 (m, 2H), 7.55 (m, 5H), 7.40 (dd, j=1.8, 11.4 Hz, 1H), 7.33 (m, 1H), 7.27 (dd, j=1.4, 8 Hz, 1H), 4.46 (m, 3H), 4.16 (t, j=5.5 Hz, 2H), 3.87 (q, j=5.5 Hz, 2H), 3.50 m, 1H), 3.24 (t, j=6.6 Hz, 2H), 3.10-2.51 (m, 3H), 2.10-1.60 (m, 3H). Analysis calc'd for C₃₁H₃₀F₄N₅O₂ (TFA)₂(H₂O)_(1.5); C: 50.37; H: 4.11; N: 8.39; found C: 50.05; H: 3.78; N:8.01.

Example 59 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-dimethylaminomethyl-3-fluoro-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one trifluoroacetic acid salt

[0602]

[0603] Part A. 1-[3-Cyano-4-fluorophenyl]-3-trifluoromethyl-6-[4-bromo-2-fluorophenyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one

[0604] The trione intermediate from Example 53, Part B (4.1 g, 11 mmol) was condensed with 3-cyano-4-fluorophenyl hydrazine (4.5 g, 13 mmol) in refluxing AcOH (60 mL) for 18 h. The reaction was cooled, concentrated and the residue taken up in EtOAc. The organic layer was washed successively with NaHCO₃, brine and dried (Na₂SO₄). Purification by chromatography on silica with (4:1) hexanes/EtOAc as eluent afforded 3.68 g (67%) of the title compound as a foam. LRMS (ES−): 497-499 (M−H)⁻.

[0605] Part B. 1-[3-Cyano-4-fluorophenyl]-3-trifluoromethyl-6-[2′-formyl-3-fluoro-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one

[0606] 1-[3-Cyano-4-fluorophenyl]-3-trifluoromethyl-6-[4-bromo-2-fluorophenyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (3.6 g, 7 mmol) was coupled with 2-formyl phenyl boronic acid (1.6 g, 10.9 mmol) via Suzuki methodology. Purification by chromatography on silica with (2:1) hexanes/EtOAc as eluent afforded 2.7 g (71.4%) of the title compound as a yellow foam. LRMS (ES−): 520.9 (M−H)⁻; 635 (M−H+TFA).

[0607] Part C. 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-hydroxymethyl-3-fluoro-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one

[0608] To the aldehyde from Part B (3.68 g, 7.1 mmol) in MeOH (25 mL) at 0° C. was added NaBH₄ (0.31 g, 8 mmol) and the reaction was stirred 20 min. The MeOH was removed and the crude alcohol dissolved in CH₂Cl₂, washed with water, brine and dried (MgSO₄). To N-acetylhydroxylamine (1.6 g, 21 mmol) in DMF (15 mL) and water (1 mL) was added K₂CO₃ (3.9 g, 28 mmol). After 30 min. the above alcohol in DMF (15 mL) was added and the reaction was stirred 6 h. Water (75 mL) was added and the precipitated product filtered off, dried in vacuo and used in the next step. LRMS (ES−): 536.1 (M−H)⁻.

[0609] Part D. 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-dimethylaminomethyl-3-fluoro-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one trifluoroacetic acid salt

[0610] To a suspension of the alcohol from Part C (2.99 g, 5.6 mmol) in CH₂Cl₂ (100 mL) was added PBr₃ (0.74 mL, 7.8 mmol). After 30 min. the reaction was quenched with ice water. The aqueous layer was extracted with CH₂Cl₂, washed with brine and dried (Na₂SO₄) to afford 3.6 g. The crude bromide was used in the next step. To a portion of this intermediate bromide (0.5 g, 0.8 mmol) in CH₃CN (15 mL) was added excess 40% aqueous dimethylamine (1 mL, 9 mmol). After 24 h the reaction was concentrated and purification by HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and freeze-drying afforded 257 mg (45%) of the title compound of Example 59 as a white solid: HRMS (M+H)⁺ for C₂₉H₂₅F₄N₆O₂: 565.1967; ¹H NMR (DMSO-d6) □ 9.50 (m, 2H), 8.11 (d, j=2.2 Hz, 1H), 7.79 (dd, j=2.2, 8.8 Hz, 1H), 7.72 (m, 1H), 7.59 (m, 4H), 7.41 (m, 2H), 7.26 (dd, j=1.4, 8 Hz, 1H), 4.32 (d, j=5.1 Hz, 2H), 4.17 (t, j=6.2 Hz, 2H), 3.23 (t, j=6.6 Hz, 2H), 2.58 (s, 3H), 2.57 (s, 3H).

Example 60 1-[3-Aminobenzisoxazol-5′-yl-3-trifluoromethyl-6-[2′-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-3-fluoro-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one trifluoroacetic acid salt

[0611]

[0612] To the intermediate bromide from Example 59, Part D (0.5 g, 0.8 mmol) in CH₃CN (15 mL) was added (R)-3-pyrrolidinol (0.22 g, 2.5 mmol). After 24 h the reaction was concentrated and purification by HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and freeze-drying afforded 283 mg (47%) of the title compound of Example 60 as a white solid: HRMS (M+H)⁺ for C₃₁H₂₇F₄N₆O₃: 607.2075; ¹H NMR (DMSO-d6) □ 8.11 (d, j=1.8 Hz, 1H), 7.79 (dd, j=2.2, 8.8 Hz, 2H), 7.60 (m, 4H), 7.40 (m, 2H), 7.27 (dd, j=1.4, 8 Hz, 1H), 4.48 (d, j=5.5 Hz, 1H), 4.38 (m, 1H), 4.31 (m, 1H), 4.15 (t, j=6.2 Hz, 2H), 3.40 (m, 2H), 3.22 (t, j=6.3 Hz, 2H), 3.15-2.70 (m, 4H), 2.20-1.70 (m, 3H).

Example 61 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one trifluoroacetic acid salt

[0613]

[0614] The title compound of Example 61 was prepared in a similar fashion to that described above. HRMS (M+H)+ for C₃₁H₂₈F₃O₃N₆ 589.216 ¹H NMR (DMSO-d6): 8.11 (d, j=1.8 Hz, 1H), 8.81-7.65 (m, 2H), 7.58-7.45 (m, 5H), 7.40-7.31 (m, 3H), 6.60 (b, 1H), 4.48 (d, j=5.5 Hz, 1H), 4.38 (m, 1H), 4.31 (m, 1H), 4.15 (t, j=6.2 Hz, 2H), 3.40 (m, 2H), 3.22 (t, j=6.3 Hz, 2H), 3.15-2.70 (m, 4H), 2.20-1.70 (m, 3H).

Example 62 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-isopropylaminomethyl-3-fluoro-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one trifluoroacetic acid salt

[0615]

[0616] To the intermediate bromide from Example 59, Part D (0.62 g, 1.3 mmol) in CH₃CN (25 mL) was added isopropylamine (0.52 mL, 6.2 mmol). After 24 h the reaction was concentrated and purification by HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and freeze-drying afforded 308 mg (43%) of the title compound of Example 62 as a white solid: HRMS (M+H)⁺ for C₃₀H₂₇F₄N₆O₂: 579.2158; ¹H NMR (DMSO-d6) □ 8.73 (m, 2H), 8.12 (d, j=1.8 Hz, 1H), 7.79 (dd, j=2.2, 8.8 Hz, 1H), 7.72 (dd, j=1.8, 7.3 Hz, 1H), 7.63-7.49 (m, 4H), 7.43 (m+s, 2H), 7.31 (dd, j=1.4, 8 Hz, 1H), 6.60 (m, 1H), 4.16 (t, j=6.2 Hz, 2H), 4.11 (m, 2H), 3.26 (m, 1H), 3.20 (t, j=6.2 Hz, 2H), 1.14 (d, j=6.6 Hz, 6H).

Example 63 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-N-(2-methylimidazol-1-yl)methyl-3-fluoro-[1,1′′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one trifluoroacetic acid salt

[0617]

[0618] To the intermediate bromide from Example 59, Part D (0.2 g, 0.3 mmol) in CH₃CN (15 mL) was added 2-methylimidazole (0.11 mL, 1.3 mmol). After 24 h the reaction was concentrated and purification by HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and freeze-drying afforded 80 mg (34%) of the title compound of Example 63 as a white solid: HRMS (M+H)⁺ for C₃₁H₂₄F₄N₇O₂: 602.1908; ¹H NMR (DMSO-d6) □ 8.12 d, j=1.8 Hz, 1H), 7.79 dd, j=2.1, 9.1 Hz, 1H), 7.60 (m, 2H), 7.48 (dt, j=2.2, 4.7 Hz, 1H), 7.43-7.33 (m, 4H), 7.31 (d, j=1.8 Hz, 1H), 7.28 (dd, j=1.8, 8.1 Hz, 1H), 7.12 (dd, j=8.2 Hz, 1H), 6.58 (m, 2H), 5.35 (s, 2H), 4.15 (t, j=6.6 Hz, 2H), 3.22 (t, j=6.3 Hz, 2H), 2.31 (s, 3H). HRMS (M+H)⁺ for C₃₁H₂₄F₄N₇O₂: 602.1908.

Example 64 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-N-pyrrolidinomethyl-3-fluoro-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one trifluoroacetic acid salt

[0619]

[0620] To the intermediate bromide from Example 59, Part D (0.27 g, 0.45 mmol) in CH₃CN (20 mL) was added pyrrolidine (0.17 g, 2.7 mmol). After 18 h the reaction was concentrated and purification by HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and freeze-drying afforded 113 mg (36%) of the title compound of Example 64 as a white solid. HRMS (M+H)⁺ for C₃₁H₂₇F₄N₆O₂: 591.2141; ¹H NMR (DMSO-d6) □ 8.11 (d, j=2.2 Hz, 1H), 7.79 (dd, j=2.1, 9.1 Hz, 1H), 7.74 m, 1H), 7.58 (m, 4H), 7.42 (m, 2H), 7.28 (dd, j=1.5, 8.1 Hz, 1H), 6.58 (m, 2H), 4.39 (d, j=5.5 Hz, 2H), 4.16 (t, j=6.6 Hz, 2H), 3.35 m, 2H), 3.22 (t, j=6.2 Hz, 2H), 2.82 (m, 2H) , 1.81 (m, 4H).

Example 65 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-oximinomethyl-3-fluoro-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one trifluoroacetic acid salt

[0621]

[0622] 1-[3-Cyano-4-fluorophenyl]-3-trifluoromethyl-6-[2′-formyl-3-fluoro-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one from Example 59, Part B (2 g, 3.8 mmol) was reacted with N-acetylhydroxylamine (0.57 g, 7.6 mmol) and K₂CO₃ (1.6 g,11.5 mmol) in DMF (15 mL). The reaction was stirred 18 h, then extracted with EtOAc , washed with water, brine and dried (MgSO₄). Purification through silica using (2:1) hexanes/EtOAc as eluent afforded 1.6 g of a white solid. A portion (100 mgs) of this solid was further purified by HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and freeze-dried to afford 48 mg of the title compound of Example 65. HRMS (M+H)⁺ for C₂₇H₁₉F₄N₆O₃: 551.1436; Analysis calc'd for C₂₇H₁₈F₄N₆O₃ (TFA) 0.6: C:54.73;H:3.03;N:13.58; found C:54.71;H:3.10;N:13.55

Example 66 1-[4-Methoxyphenyl]-3-trifluoromethyl-6-[2′-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-3-fluoro-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one trifluoroacetic acid salt

[0623]

[0624] Part A. 1-[4-Methoxyphenyl]-3-trifluoromethyl-6-[4-bromo-2-fluorophenyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one

[0625] The trione intermediate from Example 53, Part B (0.49 g, 1.3 mmol) and 4-methoxyphenylhydrazine hydrochloride (0.29 g, 1.7 mmol) were heated to reflux in a mixture of MeOH (30 mL) and AcOH (10 mL) for 18 h. The reaction was cooled, concentrated and dissolved in EtOAc. The EtOAc layer was washed with NaHCO₃, brine, and dried (Na₂SO₄). Purification through silica using (4:1) hexanes/ EtOAc as eluent afforded 0.22 g (35%)of the title compound as a yellow oil. LRMS (ES+): 484-486 (M+H)⁺.

[0626] Part B. 1-[4-Methoxyphenyl]-3-trifluoromethyl-6-[2′-hydroxymethyl-3-fluoro-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one

[0627] 1-[4-Methoxyphenyl]-3-trifluoromethyl-6-[4-bromo-2-fluorophenyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (0.22 g, 0.45 mmol) was coupled with 2-formylphenyl boronic acid (0.102 g, 0.6 mmol) via Suzuki procedure. After 18h the reaction was filtered, concentrated, and the crude aldehyde used in next step. LRMS (ES−): 508 (M−H)⁻. To the aldehyde in MeOH (10 mL) at 0° C. was added NaBH₄ (21 mg, 0.5 mmol). After 2 h the reaction was quenched with water, extracted with EtOAc and dried (MgSO₄). Purification by chromatography on silica with (2:1) hexanes/EtOAc as eluent afforded 0.1 g (43%) of the title compound as a clear oil: ¹H NMR (CDCl₃) □ 7.54 (m, 1H), 7.51 (d, j=9.1 Hz, 2H), 7.44-7.33 (m, 3H), 7.26-7.18 (m, 4H), 6.95 (d, j=9.2 Hz, 2H), 4.59 (s, 2H), 4.13 (m, 2H), 3.82 (s, 3H), 3.23 (t, j=6.6 Hz, 2H).

[0628] Part C. 1-[4-Methoxyphenyl]-3-trifluoromethyl-6-[2′-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-3-fluoro-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one trifluoroacetic acid salt

[0629] To a solution of 1-[4-methoxyphenyl]-3-trifluoromethyl-6-[2′-hydroxymethyl-3-fluoro-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (0.1 g,0.19 mmol) in CH₂Cl₂ (20 mL) was added PBr₃ (0.026 mL, 0.27 mmol) and the reaction was stirred 2 h. After quenching with ice water, the bromide was extracted with CH₂Cl₂, washed with brine and dried (Na₂SO₄). Acetonitrile (20 mL) and R-(3)-pyrrolidinol (85 mg, 0.97 mmol) were added to the crude bromide and the reaction was stirred 72 h. The reaction was concentrated and purification by HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and freeze-drying afforded 90 mg (66%) of the title compound of Example 66 as a white solid: HRMS (M+H)⁺ for C₃₁H₂₉F₄N₄O₃: 581.2191; ¹H NMR (DMSO-d6) □ 7.78 (m, 1H), 7.58 ( m, 3H), 7.53 (d, j=8.7 Hz, 2H), 7.41 (m, 2H), 7.27 (dd, j=8.1, 1.9 Hz, 1H), 7.05 (d, j=9.2 Hz, 2H), 4.49 (d, j=5.5 Hz, 1H), 4.38 (m, 2H), 4.13 t, j=5.5 Hz, 2H), 3.81 (s, 3H), 3.74-3.38 (m, 3H), 3.18 (t, j=6.2 Hz, 2H), 2.94 (m, 2H), 2.1-1.75 (m, 2H).

Example 67 1-[3-Aminomethylphenyl]-3-trifluoromethyl-6-[2′-methylsulfonyl-3-fluoro-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one trifluoroacetic acid salt

[0630]

[0631] Part A. 1-[3-Cyanophenyl]-3-trifluoromethyl-6-[4-bromo-2-fluorophenyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one

[0632] The trione intermediate from Example 53, Part B (1.8 g, 4.7 mmol) and 3-cyanophenylhydrazine HCl (1 g, 6.1 mmol) were heated to reflux in MeOH (60 mL) and ACOH (15 mL) for 18 h. The solvents were removed and CH₂Cl₂/water added. The product was extracted with CH₂Cl₂, washed with brine and dried (Na₂SO₄). Purification by chromatography on silica with (2:1) hexanes/EtOAc as eluent afforded 1.26 g (56%) of the title compound. LRMS (ES−): 476.9-478 (M−H)⁻.

[0633] Part B. 1-[3-Cyanophenyl]-3-trifluoromethyl-6-[2′-methylsulfonyl-3-fluoro-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one

[0634] 1-[3-Cyanophenyl]-3-trifluoromethyl-6-[4-bromo-2-fluorophenyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (1.2 g, 2.5 mmol) was coupled with 2-thiomethylphenyl boronic acid (1 g, 5.9 mmol) via Suzuki procedure. Purification by chromatography on silica with (2:1) hexanes/EtOAc as eluent afforded 1 g of a yellow foam. The thiomethyl intermediate was dissolved in CH₂Cl₂, cooled to 0° C. and oxidized with m-chloroperbenzoic acid (1.4 g, 4.6 mmol). After stirring for 24 h the reaction mixture was washed successively with sat'd sodium bisulfate, brine and dried (MgSO₄) to afford 0.73 g (52%) of the title compound as a yellow foam.

[0635] Part C. 1-[3-Aminomethylphenyl]-3-trifluoromethyl-6-[2′-methylsulfonyl-3-fluoro-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one trifluoroacetic acid salt

[0636] 1-[3-Cyanophenyl]-3-trifluoromethyl-6-[2′-methylsulfonyl-3-fluoro-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (0.7 g, 1.3 mmol) was hydrogenated on the Parr at 45 psi in EtOH (30 mL) and TFA (2 mL) for 24 h. The reaction was filtered through Celite®, concentrated and purification by HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and freeze-drying afforded 225 mg (26%) of the title compound of Example 67 as a white solid: HRMS (M+H)⁺ for C₂₇H₂₃F₄N₄O₃S: 559.1449; ¹H NMR (CDCl₃) □ 8.23 (s, 2H), 8.13 (dd, j=1.1, 7.7 Hz), 7.79-7.67 (m, 3H), 7.66-7.65 (m, 1H), 7.58 (s, 1H, +m, 2H), 7.44 (m, 2H), 7.33 (dd, j=1.8, 8 Hz, 1H), 4.17 (m, 4H), 3.18 (t, j=6.2 Hz, 2H), 2.94 (s, 3H).

Example 68 1-[4-Methoxyphenyl]-3-[(imidazol-1-yl)methyl]-5-methyl-6-[(2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl)]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one, bis-trifluoroacetic acid salt

[0637]

[0638] Part A. 1-(4-Methoxyphenyl)-3-(ethoxycarbonyl)-5-methyl-6-[(4-bromophenyl)]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one

[0639] To a solution of 1-(4-Methoxyphenyl)-3-(ethoxycarbonyl)-4-azido-5-[(4-bromophenyl)aminocarbonyl]pyrazole from Example 11, Part A (2.00 g, 4.12 mmol) in ethanol was added tin (II) chloride dihydrate (3.7 g, 16.5 mmol) and the solution was stirred at reflux for 1 h. The solution was filtered through a pad of silica gel and the silica rinsed with EtOAc. The volatiles were removed under reduced pressure and the residue was taken up in ethyl acetate, washed with 1N sodium hydroxide and brine, dried (MgSO₄) and concentrated. The residue was refluxed for 2 hours in 10 mL of N,N-dimethylacetamide dimethyl acetal. The volatiles were removed under reduced pressure and the solid residue was taken up in 20 mL of glacial acetic acid and stirred at reflux for 2 h. The reaction was cooled and concentrated, and the residue was taken up in ethyl acetate, washed with saturated sodium bicarbonate and brine, dried (MgSO₄) and concentrated to afford 1.5 g (75%) of the title compound as a solid. LRMS (ES+): 483.0/485.0 (M+H)+.

[0640] Part B. 1-(4-Methoxyphenyl)-3-(hydroxymethyl)-5-methyl-6-[(4-bromophenyl)]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one

[0641] To a solution of 1-(4-Methoxyphenyl)-3-(ethoxycarbonyl)-5-methyl-6-[(4-bromophenyl)]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one (0.74 g, 1.53 mmol) in 20 mL of 1:1:1 methanol/THF/water was added potassium hydroxide (94 mg, 1.68 mmol) and the reaction was stirred at reflux for 2 h. The reaction was cooled to ambient temperature, diluted with water and extracted with hexanes/ethyl acetate (1:1). The aqueous layer was acidified with 1N HCl and extracted with ethyl acetate. This extract was washed with brine, dried (MgSO₄) and concentrated to afford 0.57 g (81%) of the carboxylic acid. This acid (0.57 g, 1.25 mmol) was taken up in THF at 0° C. and then there was added N-methylmorpholine (0.19 mL, 1.38 mmol) and isobutyl chloroformate (0.18 mL, 1.38 mmol). After stirring for 20 min there was added sodium borohydride (95 mg, 2.5 mmol) and the reaction was allowed to stir for 2 h. The reaction was quenched with excess 1N HCl and diluted with ethyl acetate. The organics were washed with brine, dried (MgSO₄) and concentrated. The residue was purified by flash chromatography (elution with 2:1 hexanes/ethyl acetate) to afford 0.40 g (73%) of the title compound.

[0642] Part C. 1-(4-Methoxyphenyl)-3-[(imidazol-1-yl)methyl]-5-methyl-6-[(4-bromophenyl)]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one

[0643] To a solution of 1-(4-Methoxyphenyl)-3-(hydroxymethyl)-5-methyl-6-[(4-bromophenyl)]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one (0.19 g, 0.43 mmol) in 10 mL of methylene chloride was added phosphorous tribromide (0.23 g, 0.86 mmol) and the solution was allowed to stir at ambient temperature for 3 h. The reaction was quenched with water, diluted with ethyl acetate, washed with brine, dried (MgSO₄) and concentrated to afford a crude bromide, which was used without purification. This residue (0.17 g, 0.34 mmol) was taken up in 5 mL of DMF and then there was added imidazole (0.046 g, 0.67 mmol). The reaction was allowed to stir at ambient temperature for 16 h. The reaction was diluted with ethyl acetate, washed with brine, dried (MgSO₄) and concentrated to afford 160 mg (76%) of the title compound, which was sufficiently pure to be used without purification. LRMS (ES+): 491.1/493.1 (M+H)+.

[0644] Part D. 1-[4-Methoxyphenyl]-3-[(imidazol-1-yl)methyl]-5-methyl-6-[(2′-formyl-[1,1′]-biphen-4-yl)]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one

[0645] To a solution of 1-(4-Methoxyphenyl)-3-[(imidazol-1-yl)methyl]-5-methyl-6-[(4-bromophenyl)]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one (0.16 g, 0.33 mmol) in 10 mL of 1,4-dioxane was added 2-formylphenylboronic acid (0.073 g, 0.49 mmol) and potassium phosphate tribasic (0.24 g, 1.15 mmol). This mixture was degassed with a stream of nitrogen for 15 minutes. Following the purge, tetrakis(triphenylphosphine)palladium (0) (0.038 g) was added and the solution was stirred at 100° C. for 4 h. The solution was cooled, diluted with EtOAc, washed twice with brine and the organics were dried over MgSO₄, filtered through a pad of silica gel and concentrated. The residue was purified by flash chromatography (elution with 2:1 hexanes/ethyl acetate) to afford 0.08 g (47%) of the title compound. LRMS (ES+): 517.2 (M+H)+.

[0646] Part E. 1-[4-Methoxyphenyl]-3-[(imidazol-1-yl)methyl]-5-methyl-6-[(2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl)]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one, bis-trifluoroacetic acid salt

[0647] To a solution of 1-[4-Methoxyphenyl]-3-[(imidazol-1-yl)methyl]-5-methyl-6-[(2′-formyl-[1,1′]-biphen-4-yl)]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one (80 mg, 0.15 mmol) in 5 mL of THF was added pyrrolidine (0.05 mL, 0.60 mmol) and then sodium triacetoxyborohydride (64 mg, 0.3 mmol) and 2 drops of glacial acetic acid. The reaction was allowed to stir at ambient temperature for 3 h. The reaction was quenched with water and diluted with ethyl acetate and saturated aqueous NaHCO₃. The organics were washed with brine, dried (MgSO₄) and concentrated. The residue was purified by prep HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and lyophilized to afford 28 mg (24%) of the title compound of Example 68. LRMS (ES+): 572.4 (M+H)⁺.

Examples 69 and 70 1- [4-Methoxyphenyl]-3-[(tetrazol-1-yl)methyl]-5-methyl-6-[(2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl)]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one, trifluoroacetic acid salt (Example 69) and 1-[4-Methoxyphenyl]-3-[(tetrazol-2-yl)methyl]-5-methyl-6-[(2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl)]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one, trifluoroacetic acid salt (Example 70)

[0648]

[0649] Part A. 1-(4-Methoxyphenyl)-3-[(tetrazol-1-yl)methyl]-5-methyl-6-[(4-bromophenyl)]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one and 1-(4-Methoxyphenyl)-3-[(tetrazol-2-yl)methyl]-5-methyl-6-[(4-bromophenyl)]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one

[0650] To a solution of 1-(4-Methoxyphenyl)-3-(hydroxymethyl)-5-methyl-6-[(4-bromophenyl)]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one (0.20 g, 0.45 mmol) in 10 mL of methylene chloride was added phosphorous tribromide (0.25 g, 0.90 mmol) and the solution was allowed to stir at ambient temperature for 3 h. The reaction was quenched with water, diluted with ethyl acetate, washed with brine, dried (MgSO₄) and concentrated to afford a crude bromide, which was used without purification. This residue was taken up in 5 mL of DMF and then there was added tetrazole (0.032 g, 0.45 mmol) and potassium carbonate (0.12 g, 0.90 mmol). The reaction was allowed to stir at ambient temperature for 16 h. The reaction was diluted with ethyl acetate, washed with water and brine, dried (MgSO₄) and concentrated to afford 180 mg (81%) of an approximately 1:1 mixture of the title compounds, which was sufficiently pure to be used without purification.

[0651] Part B. 1-[4-Methoxyphenyl]-3-[(tetrazol-1-yl)methyl]-5-methyl-6-[(2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl)]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one, trifluoroacetic acid salt (Example 69) and 1-[4-Methoxyphenyl]-3-[(tetrazol-2-yl)methyl]-5-methyl-6-[(2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl)]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one, trifluoroacetic acid salt (Example 70)

[0652] Following the procedures described in Example 68, Parts D and E, 1-(4-Methoxyphenyl)-3-[(tetrazol-1-yl)methyl]-5-methyl-6-[(4-bromophenyl)]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one and 1-(4-Methoxyphenyl)-3-[(tetrazol-2-yl)methyl]-5-methyl-6-[(4-bromophenyl)]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one were converted into the title compounds of Examples 69 and 70. The final products were separated by prep HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and lyophilized to afford 11 mg of the title compound of Example 69 and 5 mg of the title compound of Example 70. Example 69: LRMS (ES+): 574.3 (M+H)⁺. Example 70: LRMS (ES+): 574.3 (M+H)⁺.

Example 71 1-[3-Aminobenzisoxazol-5′-yl]-3,5-dimethyl-6-[2′-N-dimethylaminomethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one, trifluoroacetic acid salt

[0653]

[0654] Part A. Ethyl [1-(3-cyano-4-fluoro)phenyl]-3-methyl-4-nitropyrazole-5-carboxylate

[0655] Ethyl [1-(3-cyano-4-fluoro)phenyl]-3-methylpyrazole-5-carboxylate (32.3 g, 118.21 mmol) was dissolved in 200 ml of trifluoroacetic acid followed by the addition of trifluoroacetic acid anhydride (116.9 ml, 827.48 mmol) and the resulting solution was cooled to 0° C. Ammonium nitrate (18.92, 236.42 mmol) was added slowly in 4 portions and allowed to stir overnight with warming to ambient temperature. The solution was neutralized with aq K₂CO₃ and the product was extracted with EtOAc. The organics were dried over MgSO₄, filtered through a plug of silica gel and the volatiles removed in vacuo to afford 35.0 g (93%) of the title compound. LRMS (NH₃-DCI): 336.2 (M+NH₄)⁺.

[0656] Part B. [1-(3-cyano-4-fluoro)phenyl]-3-methyl-4-nitropyrazole-5-carboxylic acid

[0657] Ethyl 1-(3-cyano-4-fluoro)phenyl-3-methyl-4-nitropyrazole-5-carboxylate (17.5 g, 54.99 mmol) was dissolved in 250 ml of methanol and cooled to 0° C. followed by the addition of lithium hydroxide (1.31 g, 54.99 mmol) that was pre-dissolved in a minimum amount of water. The solution was allowed to warm to RT. The reaction was followed by TLC and was complete within 2 hrs. The product was extracted with water and acidified with dilute HCl. The product was extracted with EtOAc and dried over MgSO₄, and the volatiles were removed in vacuo to afford 12.5 g (78%) of the title compound. LRMS (ES−): 579.2 (2M−H)⁻.

[0658] Part C. [1-(3-cyano-4-fluoro)phenyl]-3-methyl-4-nitro-5-[(4-bromophenyl)aminocarbonyl]pyrazole

[0659] [1-(3-Cyano-4-fluoro)phenyl]-3-methyl-4-nitropyrazole-5-carboxylic acid (11.5 g, 39.63 mmol) was dissolved in 300 ml of a 1:1 mixture of CH₂Cl₂/THF followed by the addition of 5.18 ml (59.44 mmol) of oxalyl chloride and 1 drop of DMF. This mixture was stirred at ambient temperature for 2 h. The volatiles were removed and the crude acid chloride was dried under high vacuum for 1 h. The acid chloride was then dissolved in 200 ml of CH₂Cl₂ followed by the addition of 4-bromoaniline (6.13 g, 35.66 mmol) and DMAP (14.52 g, 118.89 mmol) and the resulting mixture was stirred at ambient temperature for 16 h. The solution was filtered through a plug of silica gel and the volatiles were removed. The crude product was dissolved in a minimal amount of EtOAc and triturated with ethyl ether to afford 8.98 g (78%) of the title compound. LRMS (ES⁻): 414.1 (M−H)⁻.

[0660] Part D. [1-(3-cyano-4-fluoro)phenyl]-3-methyl-4-amino-5-[(4-bromophenyl)aminocarbonyl]pyrazole

[0661] [1- (3-Cyano-4-fluoro)phenyl]-3-methyl-4-nitro-5-[(4-bromophenyl)aminocarbonyl]pyrazole (7.98 g, 17.96 mmol) was dissolved in 300 ml of methanol and cooled in an ice/water bath followed by the addition of CuCl (21.34 g, 215.59 mmol) and the slow addition of NaBH₄ (13.56 g, 251.52 mmol) and stirred with warming to ambient temperature over 2 h. The solution was poured through a pad of silica gel and the volatiles removed to yield 7.11 g (95%) of the title compound that was sufficiently pure to be used without purification.

[0662] Part E. [1-(3-cyano-4-fluoro)phenyl]-3,5-dimethyl-6-(4-bromophenyl)-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one

[0663] [1-(3-Cyano-4-fluoro)phenyl]-3-methyl-4-amino-5-[(4-bromophenyl)aminocarbonyl]pyrazole (4.00 g, 9.65 mmol) was refluxed in a neat solution of N,N-dimethylacetamide dimethyl acetal (50 ml) for 1 h. The volatiles were removed in vacuo and the crude intermediate was then refluxed in 100 ml of glacial acetic acid for 1 h. The volatiles were removed in vacuo and the residue was washed with ethyl ether and dried to afford 2.2 g (53%) of the title compound.

[0664] Part F. 1-[3-Aminobenzisoxazol-5′-yl]-3,5-dimethyl-6-[2′-formyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one

[0665] Following the procedures described in Example 47, Part C, [1-(3-cyano-4-fluoro)phenyl]-3,5-dimethyl-6-(4-bromophenyl)-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one was converted into the title compound.

[0666] Part G. 1-[3-Aminobenzisoxazol-5′-yl]-3,5-dimethyl-6-[2′-N-dimethylaminomethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one, trifluoroacetic acid salt

[0667] 1-[3-Aminobenzisoxazol-5′-yl]-3,5-dimethyl-6-[2′-formyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one (0.80 g, 1.67 mmol) was dissolved in 100 ml of 1:1 CHCl₃/THF followed by the addition of a 2.0 M solution of dimethyl amine in methanol (3.3 ml, 6.71 mmol) and 1 ml of HOAC. The solution was stirred at ambient temperature for 10 min followed by the addition of sodium triacetoxyborohydride (0.71 g, 3.35 mmol) and the solution was stirred at ambient temperature overnight. After 18 h at ambient temperature more CHCl₃ was added (100 mL) and the organics washed with water, dried (MgSO₄) and evaporated. The residue was purified by prep HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and lyophilized to afford the title compound of Example 71 as a white solid. LRMS (ES⁺): 506.2 (M+H)⁺.

Example 72 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-N,N -dimethylaminomethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one, trifluoroacetic acid salt

[0668]

[0669] Part A. [1-(3-cyano-4-fluoro)phenyl]-3-methyl-6-(4-bromophenyl)-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one

[0670] [1-(3-Cyano-4-fluoro)phenyl]-3-methyl-4-amino-5-[(4-bromophenyl)aminocarbonyl]pyrazole from Example 71, Part D (2.48 g, 5.58 mmol) was refluxed in 100 ml of 96% formic acid for 2 h. The volatiles were removed under vacuum, the crude product was washed with a small amount of methanol and the product was filtered and dried to afford 2.04 g (86%) of the title compound.

[0671] Part B. 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-formyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one

[0672] Following the procedures described in Example 47, Part C, [1-(3-cyano-4-fluoro)phenyl]-3-methyl-6-(4-bromophenyl)-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one was converted into the title compound.

[0673] Part G. 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-N,N-dimethylaminomethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one, trifluoroacetic acid salt

[0674] Following the procedure described in Example 71, Part G, 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-formyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one was converted into the title compound of Example 72 as a white solid. LRMS (ES⁺): 492.2 (M+H)⁺.

Example 73 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-N-isopropylaminomethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one, trifluoroacetic acid salt

[0675]

[0676] To a solution of 1-[(3-aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-(hydroxymethyl)-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one, an intermediate from Example 72, Part B, (0.70 g, 1.57 mmol) in 200 mL of methylene chloride was added phosphorous tribromide (2.85 ml, 4.71 mmol) and the solution was stirred at ambient temperature for 2 h. The reaction was quenched by the addition of saturated K₂CO₃ solution and the product extracted using EtOAc. The bromide was dried using MgSO₄, filtered and dried under vacuum. A portion of the crude bromide (0.14 g, 0.26 mmol) was dissolved in 100 ml of CH₃CN followed by the addition of isopropyl amine (0.22 mL, 2.5 mmol) and the resulting mixture was stirred overnight. The volatiles were removed in vacuum and the product purified by prep HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and lyophilized to afford the title compound of Example 73 as a white solid. LRMS (ES⁺): 506.2 (M+H)⁺.

Example 74 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one, trifluoroacetic acid salt

[0677]

[0678] To a portion of the crude bromide from Example 73 (0.14 g, 0.26 mmol) in 100 ml of CH₃CN was added (R)-3-hydroxypyrrolidine hydrochloride (0.32 g, 2.6 mmol) and potassium carbonate (0.88 g, 6.40 mmol) and the reaction stirred at ambient temperature overnight. The volatiles were removed in vacuo and the product purified by prep HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and lyophilized to afford the title compound of Example 74 as a white solid. LRMS (ES⁺): 534.2 (M+H)⁺.

Example 75 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[4-(4,5-dihydroimidazol-1′-yl)phenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one, trifluoroacetic acid salt

[0679]

[0680] Part A. [N-(4-nitrophenyl)-N′-tert-butyloxycarbonyl]ethylene diamine

[0681] To a solution of 4-fluoro-nitrobenzene (3.31 ml, 31.21 mmol) in 200 mL of THF was added 2-N-BOC ethylene diamine (5.0 g, 31.21 ml) and DMAP (5.72 g, 46.81 mmol) and the reaction was allowed to stir at ambient temperature overnight. The volatiles were removed and the residue was purified by flash column chromatography (elution with 1:1 hexane/EtOAc) to afford 4.17 g (47%) of the title compound.

[0682] Part B. [N-(4-aminophenyl)-N′-tert-butyloxycarbonyl]ethylene diamine

[0683] [N-(4-nitrophenyl)-N′-tert-butyloxycarbonyl]ethylene diamine (4.17 g, 14.82 mmol) was dissolved in 100 ml of MeOH followed by the addition of 10% Pd/C (0.42 g) and placed on a Parr shaker under 55 psi of H₂ for 1 h. The solution was filtered through a pad of Celite and the volatiles were removed to afford 3.35 g (90%) of the title compound. LRMS (ES⁺): 252.4 (M+H)⁺.

[0684] Part C. [1-(3-cyano-4-fluoro)phenyl]-3-methyl-4-nitro-5-[[4-(2-N-(tert-butoxycarbonyl)aminoethylamino)phenyl]aminocarbonyl]pyrazole

[0685] [1-(3-Cyano-4-fluoro)phenyl]-3-methyl-4-nitropyrazole-5-carboxylic acid from Example 71, Part B (1.00 g, 3.44 mmol) was dissolved in 100 ml of 1:1 CH₂Cl₂/THF followed by the addition of oxalyl chloride (0.45 ml, 5.16 mmol) and 1 ml of DMF and the reaction was stirred at ambient temperature for 2 h. The volatiles were removed under vacuum and the crude acid chloride was dried under high vacuum for 1 hr. The residue was then dissolved in 100 ml of CH₂Cl₂ followed by the addition [N-(4-aminophenyl)-N′-tert-butyloxycarbonyl]ethylene diamine (0.87 g, 3.44 mmol) and DMAP (1.26 g, 10.33 mmol). The solution was allowed to stir overnight. The volatiles were removed under reduced pressure and the residue was purified by flash column chromatography (eluting with 1:1 hexane/EtOAc) to afford 1.15 g (64%) of the title compound. LRMS (ES⁺): 524.2 (M+H)⁺.

[0686] Part D. 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[4-(4,5-dihydroimidazol-1′-yl)phenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one, trifluoroacetic acid salt

[0687] To a solution of the product of Part C (1.15 g, 2.19 mmol) in 100 ml of methanol was added CuCl (2.60 g, 26.63 mmol) and KBH₄ (1.66 g, 30.75 mmol). The reaction was stirred at rt for 2 h and the solution filtered through a pad of silica gel and the volatiles removed. The residue was dissolved in 100 ml of 96% formic acid and refluxed for 6 h. The volatiles were removed and the residue washed with a small amount of methanol and filtered. The residue was dissolved in 50 ml of DMF and 2 ml of H₂O and then there was added acetohydroxamic acid (0.14 g, 1.88 mmol) and potassium carbonate (0.35 g, 2.51 mmol) the reaction was stirred at rt overnight. Ethyl ether was added to the reaction and the product washed twice with brine and the product dried over MgSO₄ and the volatiles removed under vacuum. The product was purified using prep HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and lyophilized to afford the title compound of Example 75 as a white solid. LRMS (ES⁺): 427.1 (M+H)⁺.

Example 76 1-[3-Aminobenzisoxazol-5′-yl-3-methyl-6-[2′-N-(cyclopropylmethyl)aminomethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one, trifluoroacetic acid salt

[0688]

[0689] To the crude bromide from Example 73 (0.03 g, 0.056 mmol) in 100 ml of CH₃CN was added (aminomethyl)cyclopropane (0.005 mL, 0.056 mmol) and the reaction stirred at ambient temperature overnight. The volatiles were removed in vacuo and the product purified by prep HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and lyophilized to afford the title compound of Example 76 as a white solid. LRMS (ES⁺) 518.2 (M+H)⁺.

Example 77 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-4,3-d]-pyrimidin-7-one, trifluoroacetic acid salt

[0690]

[0691] Following the procedure described in Example 47, Part D, 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-formyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one from Example 72, Part B was converted into the title compound of Example 77. LRMS (ES⁺): 518.2 (M+H)⁺.

Example 78 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-(N-methyl-N-isopropyl)aminomethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one, trifluoroacetic acid salt

[0692]

[0693] To a solution of 1-[(3-aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-formyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one from Example 72, Part B (0.21 g, 0.44 mmol) in 100 ml of 1:1 CHCl₃/THF was added N-methyl-N-isopropyl amine (0.18 ml, 1.76 mmol) and 1 ml of HOAc. The solution was stirred at rt for 10 min followed by the addition of sodium triacetoxyborohydride (0.18 g, 0.88 mmol) and the solution was stirred at rt overnight. The reaction was quenched with water, extracted with ethyl acetate, and the extracts were washed with brine, dried (MgSO₄) and concentrated in vacuo. The residue was purified by prep HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and lyophilized to afford the title compound of Example 78 as a white solid. LRMS (ES⁺): 534.1 (M+H)⁺.

Example 79 1-[3-Aminobenzisoxazol-5′-yl]-3,5-dimethyl-6-[2′-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one, trifluoroacetic acid salt

[0694]

[0695] To a solution of 1-[(3-aminobenzisoxazol-5′-yl]-3,5-dimethyl-6-[2′-formyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one from Example 71, Part F (0.30 g, 0.63 mmol) in 100 ml of 50 mL of THF was added (R)-3-hydroxypyrrolidine (0.22 g, 2.52 mmol) and 1 ml of HOAc. The solution was stirred at rt for 10 min followed by the addition of sodium triacetoxyborohydride (0.27 g, 1.26 mmol) and the solution was stirred at rt overnight. The reaction was quenched with water, extracted with ethyl acetate, and the extracts were washed with brine, dried (MgSO₄) and concentrated in vacuo. The residue was purified by prep HPLC (C18 reverse phase column, elution with a H₂O/CH₃CN gradient with 0.5% TFA) and lyophilized to afford the title compound of Example 79 as a white solid. LRMS (ES⁺): 548.2 (M+H)⁺.

Example 80 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-N,N-dimethylaminomethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one, trifluoroacetic acid salt

[0696]

[0697] Part A. [1-(3-Cyano-4-fluorophenyl)]-3-trifluoromethyl-4-nitro-pyrazole-5-carboxylic acid

[0698] To a solution of ammonium nitrate (2.4 g, 0.03 mol) in 100 mL of trifluoroacetic acid at 0° C. was added 1-(4-fluoro-3-cyano)phenyl-3-trifluoromethyl-pyrazole-5-carboxylic acid (6.0 g, 0.02 mol). This mixture was stirred for 15 min to dissolve the acid and then there was added trifluoroacetic anhydride (14.1 mL, 0.10 mol). The resulting mixture was allowed to stir with warming to ambient temperature for 72 h. The reaction mixture was poured into water, extracted with ethyl acetate, washed with brine, dried (MgSO₄) and concentrated to afford an approximately 2:1 mixture of product and starting material, which were separated in the following way. The residue was stirred in 400 mL of water for several hours and the solids were filtered and dried, yielding a mixture of product and recovered starting material. The filtrate was extracted with ethyl acetate, washed with brine, dried (MgSO₄) and concentrated to afford 1.5 g (22%) of pure title compound. The solids were resubjected to the purification procedure to afford an additional 2.0 g (29%) of the title compound. ¹H NMR (CD₃OD): □ 8.13 (dd, 1H), 8.02 (m, 1H), 7.58 (t, 1H).

[0699] Part B. [1-(3-cyano-4-fluorophenyl)]-3-trifluoromethyl-6-[2′-formyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one

[0700] Following procedures described in Example 71, Part D, Example 72, Part A and Example 47, Part C, [1-(3-cyano-4-fluorophenyl)]-3-trifluoromethyl-4-nitro-pyrazole-5-carboxylic acid was converted into the title compound.

[0701] Part C. [1-(3-cyano-4-fluorophenyl)]-3-trifluoromethyl-6-[2′-hydroxymethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one and [1-(3-cyano-4-fluorophenyl)]-3-trifluoromethyl-6-[2′-hydroxymethyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[4,3-d]-pyrimidin-7-one

[0702] To a solution of [1-(3-cyano-4-fluorophenyl)]-3-trifluoromethyl-6-[2′-formyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one (0.59 g, 1.17 mmol) in 100 mL of THF was added sodium borohydride (0.04 g, 1.17 mmol). The reaction was stirred at ambient temperature for 3 h and then was filtered through Celite, diluted with ethyl acetate, washed with water and brine, dried (MgSO₄) and concentrated. Purification by flash chromatography (elution with 2:1 hexanes/ethyl acetate) afforded 0.13 g of [1-(3-cyano-4-fluorophenyl)]-3-trifluoromethyl-6-[2′-hydroxymethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one and 0.12 g of the over reduction product, [1-(3-cyano-4-fluorophenyl)]-3-trifluoromethyl-6-[2′-hydroxymethyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[4,3-d]-pyrimidin-7-one.

[0703] Part D. 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-N,N-dimethylaminomethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one, trifluoroacetic acid salt

[0704] Following procedures described in Example 47, Part C and Example 71, Part G, [1-(3-cyano-4-fluorophenyl)]-3-trifluoromethyl-6-[2′-hydroxymethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one was converted into the title compound of Example 80. LRMS (ES⁺): 546.3 (M+H)⁺.

Example 81 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-N,N-dimethylaminomethyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[4,3-d]-pyrimidin-7-one, trifluoroacetic acid salt

[0705]

[0706] Following procedures described in Example 47, Part C and Example 71, Part G, the over reduction product [1-(3-cyano-4-fluorophenyl)]-3-trifluoromethyl-6-[2′-hydroxymethyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[4,3-d]-pyrimidin-7-one from Example 80, Part C was converted into the title compound of Example 81. LRMS (ES⁺): 548.2 (M+H)⁺.

Example 82 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[4,3-d]-pyrimidin-7-one, trifluoroacetic acid salt

[0707]

[0708] Following procedures described in Example 47, Part C and Example 79, the over reduction product [1-(3-cyano-4-fluorophenyl)]-3-trifluoromethyl-6-[2′-hydroxymethyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[4,3-d]-pyrimidin-7-one from Example 80, Part C was converted into the title compound of Example 82. LRMS (ES⁺): 590.2 (M+H)⁺.

Example 83 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-(3-(S)-hydroxy-N-pyrrolidinyl)methyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one, trifluoroacetic acid salt

[0709]

[0710] Following the procedure described in Example 60, except that (S)-3-pyrrolidinol was used, the title compound of Example 83 was prepared. Purification by HPLC and freeze-drying afforded 37 mg (15%): ¹H NMR (DMSO-d6) □ 8.11 (d, j=1.9 Hz, 1H), 7.81 (d, j=9.9 Hz, 1H), 7.72 (m, 1H), 7.58 (d, j=9.2 Hz, 2H), 7.54 (m, 2H), 7.51 (d, j=8.4 Hz, 2H), 7.40 (d, j=8.4 Hz, 2H), 7.34 (m, 1H), 6.58 (brd s, 2H), 4.48 (d, j=5.5 Hz, 1H), 4.37-4.29 (m, 2H), 4.23 (t, j=5.9, 2H), 3.50 (m, 2H), 3.18 (t, j=5.9 Hz, 2H), 2.95-2.85 (m, 2H, ), 2.15-1.75 (m, 3H). LRMS (ES⁺): 589.2 (M+H)⁺.

Example 84 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-N-(pyrrolindinyl)methyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one, trifluoroacetic acid salt

[0711]

[0712] Following the procedure described in Example 60, except that pyrrolidine was used, the title compound of Example 84 was prepared. Purification by HPLC and freeze-drying afforded 25 mg (11%): ¹H NMR (DMSO-d6) .□ 8.11 (d, j=2.2 Hz, 1H), 7.81 (dd, j=2.2, 9.2 Hz, 1H), 7.73 (m, 1H), 7.58 (d, j=9.2 Hz, 2H), 7.54 (m, 2H), 7.51 (d, j=8.4 Hz, 2H), 7.41 (d, j=8.5 Hz, 2H), 7.35 (m, 1H), 6.57 (brd s, 2H), 4.38 (d, j=5.1 Hz, 2H), 4.23 (t, j=6.6, 2H), 3.34 (m, 2H), 3.19 (t, j=6.2 Hz, 2H), 2.81 (m, 2H, ), 1.78 (m, 4H) ppm. LRMS (ES⁺): 573.2 (M+H)⁺.

Example 85 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-N-(morpholino)methyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one, trifluoroacetic acid salt

[0713]

[0714] Following the procedure described in Example 60, except that morpholine was used, the title compound of Example 85 was prepared. Purification by HPLC and freeze-drying afforded 110 mg (45.8%): ¹H NMR (DMSO-d6) □ 8.11 (d, j=1.9 Hz, 1H), 7.81 (dd, j=2.2, 8.8 Hz, 1H), 7.76 (m, 1H), 7.58 (d, j=8.8 Hz, 2H), 7.54 (m, 1H), 7.51 (d, j=8.4 Hz, 2H), 7.40 (d, j=8.4 Hz, 2H), 7.34 (m, 1H), 6.60 (brd s, 2H), 4.36 (brd s, 2H), 4.24 (t, j=6.6, 2H), 3.77 (m, 2H), 3.59 (m, 2H), 3.21 (t, j=5.8 Hz, 2H), 3.17 (m, 2H, ), 2.78 (m, 2H)ppm. LRMS (ES⁺): 589.2 (M+H)⁺.

Example 86 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-N,N-dimethylaminomethyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one, trifluoroacetic acid salt

[0715]

[0716] Following the procedure described in Example 60, except that dimethylamine in methanol was used, the title compound of Example 86 was prepared. Purification by HPLC and freeze-drying afforded 180 mg (79%): ¹H NMR (DMSO-d6) □ 9.55 (s, 1H), 8.11 (d, j=2.2 Hz, 1H), 7.81 (dd, j=2.2, 8.7 Hz, 1H), 7.72 (dd, j=3.7, 5.5 Hz, 1H), 7.57 (d, j=8.8 Hz, 2H), 7.54 (dd, j=2.5, 5.8 Hz, 1H), 7.51 (d, j=8.8 Hz, 2H), 7.39 (d, j=8.5 Hz, 2H), 7.36 (dd, j=1.8, 5.4 Hz, 1H), 6.57 (s, 1H), 4.32 (d, j=4.8 Hz, 2H), 4.23 (t, j=6.6, 2H), 3.21 (t, j=6.2 Hz, 2H), 2.57 (s, 3H, ), 2.55 (s, 3H) ppm. LRMS (ES⁺): 547.2 (M+H)⁺.

Example 87 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-7-[(3′-N-dimethylaminomethyl)-3-fluoro-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]azepin-8-one trifluoroacetic acid salt

[0717]

[0718] The title compound of Example 87 was prepared by the same methods described in Example 40. LRMS (ES⁺): 579.3, (M+H)⁺. ¹H NMR (CD₃OD) δ 7.98 (t, 1H), 7.81 (d, 1H), 7.79 (s, 1H), 7.67 (t, 1H), 7.59 (m, 1H), 7.55 (m, 2H), 7.51 (m, 2H), 7.47 (t, 1H), 4.39 (s, 2H), 4.01 (t, 2H), 3.15 (t, 2H), 2.89 (S, 6H), 2.31 (m, 2H)

Example 88 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-7-[(3′-N-pyrrolidinylmethyl)-3-fluoro-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]azepin-8-one trifluoroacetic acid salt

[0719]

[0720] The title compound was prepared by the same methods described in Example 40. LRMS (ES⁺): 605.3, (M+H)⁺. ¹H NMR (DMSO-d₆) δ 8.10 (d, 1H) , 7.89 (s, 1H) , 7.81 (d, 1H) , 7.65 (m, 2H), 7.59 (m, 2H), 7.51 (m, 3H), 6.58 (bs, 2H), 4.41 (d, 2H), 3.97 (t, 2H), 3.39 (m, 2H), 3.11 (m, 2H), 3.01 (t, 2H), 2.19 (m, 2H), 2.03 (m, 2H), 1.85 (m, 2H).

Example 89 1-[4-Methoxyphenyl]-3-trifluoromethyl-7-[(3′-N-pyrrolidinylmethyl)-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]azepin-8-one trifluoroacetic acid salt

[0721]

[0722] The title compound was prepared by the same methods described in Example 35. LRMS (ES⁺): 579.3, (M+H)⁺. ¹H NMR (CDCl₃) δ 7.66 (s, 1H), 7.58 (d, 1H), 7.48 (t, 1H), 7.45-7.31 (m, 6H), 6.93 (d, 2H), 4.27 (d, 2H), 4.10 (bs, 2H), 3.91 (t, 2H), 3.80 (s, 3H), 3.72 (m, 2H), 3.10 (t, 2H), 2.90 (m, 2H), 2.24 (m, 2H), 2.10 (m, 4H).

Example 90 1-[4-Methoxyphenyl]-3-trifluoromethyl-7-[(3′-N-dimethylaminomethyl)-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]azepin-8-one trifluoroacetic acid salt

[0723]

[0724] The title compound was prepared by the same methods described in Example 35. LRMS (ES⁺): 553.3, (M+H)⁺. ¹H NMR (CDCl₃) δ 7.68 (s, 1H), 7.62 (d, 1H), 7.53 (t, 1H), 7.48-7.31 (m, 6H), 6.93 (d, 2H), 4.22 (s, 2H), 3.90 (m, 2H), 3.81 (s, 3H), 3.12 (t, 2H), 2.92 (bs, 2H), 2.81 (s, 62H), 2.25 (m, 2H).

Example 91 1-[4-Methoxyphenyl]-3-trifluoromethyl-7-[4-benzimidazol-1′-yl-3-fluorophenyl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]azepin-8-one trifluoroacetic acid salt

[0725]

[0726] The title compound was prepared by the same methods described in Example 44. LRMS (ES⁺) 536.3, (M+H)⁺. ¹H NMR (CDCl₃) δ 8.87 (bs, 1H), 8.02 (d, 1H), 7.59 (m, 4H), 7.45 (m, 4H), 6.95 (d, 2H), 3.87 (m, 2H), 3.82 (s, 3H), 3.12 (t, 2H), 2.30 (m, 2H).

Example 92 1-[3-Aminobenzisoxazo-5′-yl]-3-trifluoromethyl-7-[(2′-N-pyrrolidinylmethyl)-3-fluoro-[1,1′]-biphen-4-yl]-6,7-dihydropyrazolo-[3,4-c]azepin-8-one trifluoroacetic acid salt

[0727]

[0728] 1-(3-Cyano-4-fluorophenyl)-3-trifluoromethyl-7-(2-fluoro-4-iodophenyl)-4,5,6,7-tetrahydropyrazolo-[3,4-c]azepin-8-one prepared by the same methods as shown in Example 40 (0.50 g, 0.90 mmol), N-bromosuccinimide (0.19 g, 1.08 mmol), and AIBN (9.0 mg) were refluxed with 50 mL of CCl₄ under N₂ for 2 h. The reaction mixture was cooled and filtered through Celite. The filtrate was concentrated to a brown solid. It was then dissolved in 20 mL of THF and 1, 8-diazabicyclo[5,4,0]unden-7-ene (DBU, 0.14 mL) was added. The mixture was refluxed for 12 h. The solvent was removed. It was dissolved in EtOAc and washed with water and brine, dried over MgSO₄ and concentrated. Flash chromatography on silica gel with 15% EtOAc in hexane gave 0.21 g of 1-(3-Cyano-4-fluorophenyl)-3-trifluoromethyl-7-(2-fluoro-4-iodophenyl)-6,7-dihydropyrazolo-[3,4-c]azepin-8-one. The title compound was then prepared from 1-(3-Cyano-4-fluorophenyl)-3-trifluoromethyl-7-(2-fluoro-4-iodophenyl)-6,7-dihydropyrazolo-[3,4-c]azepin-8-one by the same methods shown in Example 40. LRMS (ES⁺): 603.2, (M+H)⁺. ¹H NMR (CDCl₃) 7.82 (d, 1H), 7.73 (m, 2H), 7.54-7.35 (m, 4H), 7.09 (dd, 4H), 6.46 (m, 1H), 4.34 (s, 2H), 4.32 (d, 2H), 3.86 (bs, 2H), 3.59 (m, 2H), 2.58 (m, 2H), 2.01 (m, 2H), 1.85 (m, 2H).

Example 93 1-[3-Aminobenzisoxazo-5′-yl]-3-trifluoromethyl-7-[(2′-N-dimethylaminomethyl)-3-fluoro-[1,1′]-biphen-4-yl]-6,7-dihydropyrazolo-[3,4-c]azepin-8-one trifluoroacetic acid salt

[0729]

[0730] The title compound was prepared by the same methods described in Example 92. LRMS (ES⁺): 577.2, (M+H)⁺. ¹H NMR (CDCl₃) 7.82 (d, 1H), 7.73 (m, 2H), 7.54-7.35 (m, 4H), 7.09 (dd, 4H), 6.46 (m, 1H), 4.33 (d, 2H), 4.29 (s, 2H), 3.89 (bs, 2H), 2.58 (s, 6H).

Example 94 1-[3-Aminobenzisoxazo-5′-yl]-3-trifluoromethyl-7-[(2′-N-(R)-3-hydroxypyrrolidinylmethyl)-3-fluoro-[1,1′]-biphen-4-yl]-6,7-dihydropyrazolo-[3,4-c]azepin-8-one

[0731]

[0732] The title compound was prepared by the same methods described in Example 92. LRMS (ES⁺): 619.3, (M+H)⁺, ¹H NMR (CDCl₃) 7.78-7.59 (m, 4H), 7.50-7.28 (m, 4H), 7.17-7.03 (m, 3H), 6.44 (m, 1H), 4.64 (S, 2H), 4.42-4.15 (m, 3H), 3.63-3.25 (m, 2H), 2.95-2.50 (m, 2H), 1.97-1.62 (m, 2H).

Example 95 1-[3-Aminobenzisoxazo-5′-yl]-3-trifluoromethyl-7-[(2′-N-(R)-3-hydroxypyrrolidinylmethyl)-[1,1′]-biphen-4-yl]-6,7-dihydropyrazolo-[3,4-c]azepin-8-one trifluoroacetic acid salt

[0733]

[0734] The title compound was prepared by the same methods described in Example 92. LRMS (ES⁺): 601.0, (M+H)⁺. ¹H NMR (CDCl₃) 7.79 (S, 1H), 7.68 (m, 2H), 7.50-7.22 (m, 8H), 7.14 (d, 1H), 6.49 (m, 1H), 4.64 (S, 2H), 4.42-4.15 (m, 3H), 3.63-3.25 (m, 2H), 2.95-2.50 (m, 2H), 1.97-1.62 (m, 2H).

Example 96 1-[3-Aminobenzisoxazo-5′-yl]-3-trifluoromethyl-7-[(2′-N-dimethylaminomethyl)-[1,1′]-biphen-4-yl]-6,7-dihydropyrazolo-[3,4-c]azepin-8-one trifluoroacetic acid salt

[0735]

[0736] The title compound was prepared by the same methods described in Example 92. LRMS (ES⁺): 559.2, (M+H)⁺. ¹H NMR (CDCl₃) 7.82 (d, 1H), 7.70 (m, 2H), 7.53-7.38 (m, 5H), 7.28 (m, 2H), 7.14 (d, 1H), 6.50 (m, 1H), 4.39 (d, 2H), 4.28 (s, 2H) , 2.55 (s, 6H).

Example 97 1- [4-Methoxyphenyl]-3-trifluoromethyl-7-[(2′-N-pyrrolidinylmethyl)-[1,1′]-biphen-4-yl]-6,7-dihydropyrazolo-[3,4-c]azepin-8-one trifluoroacetic acid salt

[0737]

[0738] The title compound was prepared by the same methods described in Example 92. LRMS (ES⁺): 577.4, (M+H)⁺. ¹H NMR (CDCl₃) 7.77 (d, 1H), 7.55-7.35 (m, 5H), 7.28 (m, 1H), 7.15-6.95 (m, 5H), 6.42 (m, 1H), 4.34 (s, 2H), 4.28 (d, 2H), 3.85 (s, 3H), 3.60 (m, 2H), 2.58 (m, 2H), 2.03 (m, 2H), 1.89 (m, 2B).

Example 98 1-[4-Methoxyphenyl]-3-trifluoromethyl-7-[(2′-N,N-dimethylaminomethyl)-[1,1′]-biphen-4-yl]-6,7-dihydropyrazolo-[3,4-c]azepin-8-one trifluoroacetic acid salt

[0739]

[0740] The title compound was prepared by the same methods described in Example 92. LRMS (ES⁺): 551.3, (M+H)⁺. ¹H NMR (CDCl₃) 7.77 (d, 1H), 7.55-7.35 (m, 5H), 7.28 (m, 1H), 7.15-6.95 (m, 5H), 6.42 (m, 1H), 4.29 (d, 2H), 4.27 (s, 2H), 3.84 (s, 3H), 2.60 (s, 6H).

Example 99 1[4-Methoxyphenyl]-3-trifluoromethyl-6-[(4-aminomethyl)phenyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]pyridin-7-one trifluoroacetic acid salt

[0741]

[0742] 1[-Methoxyphenyl]-3-trifluoromethyl-6-[(4-carbomethyoxy)phenyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]pyridin-7-one prepared by the same method as described in Park A of Example 66 (0.17 g, 0.38 mmol) was dissolved in 20 mL of THF. Aqueous LiOH (0.5 mL of 1M solution) was added. The mixture was stirred at room temperature under N₂ for 2 h. It was diluted with Et₂O and washed with water and brine. It was then dried over MgSO₄ and concentrated to give 0.16 g of the acid. It was then dissolve din 15 mL of THF and cooled at 0° C. under N₂. To it was added Et₃N (0.057 mL) and isobutylchloroformate (0.056 mL). The reaction mixture was stirred at 0° C. for 20 minutes. The precipitate was filtered off and washed with 15 mL of THF. The filtrate was transferred to another flask and to it was added NaBH₄ (28 mg) and a few drops of water. The mixture was stirred at 0° C. for 15 minute and then at room temperature for 1 h. The reaction was quenched with aqueous HCl and the solvent was removed. The residue was dissolved in EtOAc and washed with water and brine. It was dried over MgSO₄, concentrated, and chromatographed with 1:1 EtOAc to hexane to give 70 mg of the benzyl alcohol. LRMS (ES⁺): 418.1, (M+H)⁺.

[0743] The benzyl alcohol was dissolved in 7 mL of CH₂Cl₂ and PBr₃ (0.02 mL) was added. The mixture was stirred at room temperature for 30 minute. It was diluted with CH₂Cl₂ and washed with brine. After dried over MgSO₄, it was concentrated to a white solid. It was dissolved in 7 mL of DMF and NaN₃ (24 mg) was added. The mixture was stirred at 50° C. under N₂ for 2.5 h. It was poured into water and extracted with EtOAc. The EtOAc extract was washed with brine, dried over MgSO₄, concentrated to give the benzyl azide. The azide was dissolved in 10 mL of MeOH and refluxed with SnCl₂.H₂O (0.31 mg) for 45 minutes. The solvent was removed. The residue was dissolved in EtOAc and saturated NaHCO₃ (4 mL) was added. It was filtered through Celite, concentrated, and purified by reverse phase HPLC (C18 reverse phase column, eluted with a H₂O/CH₃CN gradient with 0.05% TFA) and lyophilized to afford 40 mg the title compound as the TFA salt (24%). LRMS (ES⁺): 417.2, (M+H)⁺, ¹H NMR (CDCl₃) δ 7.37 (d, 2H), 7.12 (s, 4H), 6.84 (d, 2H), 4.01 (t, 2H), 3.67 (s, 3H), 3.58 (bs, 2H), 3.11 (t, 2H).

Example 100 1-[3-Aminomethylphenyl]-3-methyl-6-[(2′-N-((3-(S)-hydroxy)pyrrolidinyl) methyl-[1,1′]-biphen-4-yl)]-1,4,5,6-tetrahydro-7H-pyrazolo-[3,4-c]-pyridin-7-one bis-trifluoroacetic acid salt

[0744]

[0745] Part A. 1-(3-Cyanophenyl)-3-methyl-6-(4-bromophenyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one

[0746] A mixture of 1-(4-bromophenyl)-3-hydroxy-4-acetyl-5,6-dihydropyridin-2-one (3.2 mmol, 1.0 g, Example 47, Part A) and 3-cyanophenylhydrazine (3.5 mmol, 0.60 g) in acetic acid (glacial, 40 mL) was heated at reflux for 3 h. The reaction was evaporated, applied to a column of flash silica gel (ca. 250 g) and eluted with gradient of 2:1 to 1:1 hexane:EtOAc. There was obtained 0.4 g of the title compound, 1-(3-cyanophenyl)-3-methyl-6-(4-bromophenyl)1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one. LRMS (ES⁺): 409/411 (M+H)⁺.

[0747] Part B. 1-(3-Cyanophenyl)-3-methyl-6-[(2′-N-((3-(S)-hydroxy)pyrrolidinyl) methyl-[1,1′]-biphen-4-yl)]-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one

[0748] 1-(3-Cyanophenyl)-3-methyl-6-(4-bromophenyl)1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one (0.49 mmol, 0.20 g), 2-formylphenylboronic acid (0.69 mmol, 0.10 g), and tetrabutylammonium bromide (0.024 mmol, 0.008 mmol) in benzene (12 mL) and 2N Na₂CO₃ (4 mL) was purged with N₂ gas for 15 min, then tetrakis (triphenylphosphine) palladium (0.031 mmol, 0.035 g) was added. This mixture was heated at reflux for 18 h. To this mixture was added brine and it was then extracted with EtOAc. The extract was dried (MgSO₄) and evaporated. The residue was purified further by flash chromatography using a gradient of 5:1 to 1:1 hexane:EtOAc as an eluant. There was obtained 0.12 g of the desired coupling product. LRMS (ES⁻): 431 (M−H)⁻.

[0749] This product (0.28 mmol, 0.12 g), 3 (S)-hydroxypyrrolidine (1.11 mmol, 0.097 g), acetic acid (glacial, 0.03 g) and sodium triacetoxyborohydride (0.56 mmol, 0.12 g) in CHCl₃ (5 mL) was stirred at ambient temperature for 18 h. The reaction was evaporated, dissolved in CH₂Cl₂, washed with water, dried (MgSO₄) and evaporated. There was obtained 0.13 g of the title compound. LRMS (ES⁺): 504 (M+H)⁺.

[0750] Part C. 1-(3-Methylaminophenyl)-3-methyl-6-[(2′-N-((3-(S)-hydroxy)pyrrolidinyl)methyl-[1,1′]-biphen-4-yl)]-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one bis-trifluoroacetic acid salt

[0751] 1-(3-Cyanophenyl)-3-methyl-6-[(2′-N-((3-(S)-hydroxy)pyrrolidinyl) methyl-[1,1′]-biphen-4-yl)]-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one (0.26 mmol, 0.13 g) in MeOH (20 mL) with TFA (1 mL) was shaken under an atmosphere of H2 gas (50 psi) in the presence of 10% Pd—C catalyst (50 mg) for 18 h. The reaction was purged with N2 gas, filtered through a pad of Celite then evaporated. The residue was purified by HPLC on a C₁₈ column by elution with a gradient of water (0.05% TFA, solvent A) and acetonitrile (0.05% TFA, solvent B). There was obtained 0.072 g of 1-[3-aminomethylphenyl]-3-methyl-6-[(2′-N-((3-(S)hydroxy)pyrrolidinyl) methyl-[1,1′]-biphenyl-4-yl)]-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one bis-trifluoroacetic acid salt with a purity of >90%; mp 79.2° C., HRMS (C₃₁H₃₄O₂N₅)⁺: 508.2773 m/z.

Example 101 1- [3-Aminomethylphenyl]-3-methyl-6-[(2′-methylsulfonyl-[1,1′]-biphen-4-yl)]-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one, trifluoroacetic acid salt

[0752]

[0753] Part A. 1-(3-cyanophenyl)-3-methyl-6-[(2′-methylsulfonyl-[1,1′]-biphen-4-yl)]-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one

[0754] 1-(3-Cyanophenyl)-3-methyl-6-(4-bromophenyl)1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one (Example 100, Part A; 0.17 g, 0.42 mmol), 2-thiomethylphenylboronic acid (0.098 g, 0.58 mmol) and BU₄NBr (0.008 g) in C₆H₆ (20 mL) and 2N Na₂CO₃ (4 mL) was purged with a stream of N₂ gas. Palladium tetrakis (triphenyl)phosphine (0.02 g, 0.02 mmol) was added and the mixture heated at reflux for 18 h. To the cooled reaction mixture, brine and EtOAc was added and the layers separated. The organic layer was dried (MgSO₄) and evaporated then the residue was purified by silica gel chromatography (100 g of SiO₂, eluted with 1:1 hexane EtOAc) to give 0.12 g (3.2 mmol) of 1-(3-cyanophenyl)-3-methyl-6-[(2′-thiomethyl-[1,1′]-biphen-4-yl)]-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one. LRMS (ES⁺): 451 (M+H)⁺.

[0755] A mixture of this product (0.12 g, 0.27 mmol) and m-chloroperbenzoic acid (0.14 g, 0.81 mmol) in CH2Cl2 were stirred for 18 h. Saturated NaHCO3 was added and the layers separated. The basic layer was extracted into CH2Cl2, then the organic layers were combined, dried (MgSO4) and evaporated to yield 0.14 g of the title compound. LRMS (ES⁺): 505 (M+Na)⁺.

[0756] Part B. 1-[3-Aminomethylphenyl]-3-methyl-6-[(2′-methylsulfonyl-[1,1′]-biphen-4-yl)]-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one, trifluoroacetic acid salt

[0757] The product from above was treated as in Example 100, Part C and the residue was purified by HPLC on a C₁₈ column by elution with a gradient of water (0.05% TFA, solvent A) and acetonitrile (0.05% TFA, solvent B). There was obtained 0.066 g of the title compound of Example 101, 1-[3-aminomethylphenyl]-3-methyl-6-[(2′-methylsulfonyl-[1,1′]-biphen-4-yl)]-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one, trifluoroacetic acid salt with a purity of >94%. mp 131° C., HRMS (C₂₇H₂₇O₃N₄S)⁺487.1819 m/z.

Example 102 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[(3-fluoro-2′-N-(3 (S)-hydroxy)pyrrolidinylmethyl-[1,1′]-biphen-4-yl)]-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one, trifluoroacetic acid salt

[0758]

[0759] This compound was prepared and purified by the same procedure outlined in Example 47, Part D from a mixture of 1-[(3-aminobenzisoxazol-5′-yl]-3-methyl-6-[(3-fluoro-2′-formyl-[1,1′]-biphen-4-yl)]-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one and 3 (S)-hydroxypyrrolidine. There was obtained 0.030 g of the title product with a purity >98%. mp 207.7° C.; HRMS (C₃₁H₃₀N₆O₃F)⁺553.2377 m/z.

Example 103 1-[3-Aminobenzisoxazol-5′-yl-3-methyl-6-[(3-fluoro-2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl)]-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one, trifluoroacetic acid salt

[0760]

[0761] This compound was prepared and purified by the same procedure outlined in Example 47, Part D from a mixture of 1-[(3-aminobenzisoxazol-5′-yl]-3-methyl-6-[(3-fluoro-2′-formyl-[1,1′]-biphen-4-yl)]-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one and pyrrolidine. There was obtained 0.029 g of the title product with a purity >97%. HRMS (C₃₁H₃₀N₆O₂F)⁺: 537.2421 m/z.

Example 104 1-[1-Aminoisoquinolin-7′-yl]-3-trifluoromethyl-6-[4-(2-methylimidazol-1′-yl)phenyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one bis-trifluoroacetic acid salt

[0762]

[0763] Part A. 1-(Isoquinolin-7′-yl)-3-trifluoromethyl-6-[4-bromophenyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one 1,5,6-Trihydro-1-(4-bromophenyl)-4-trifluoroacetyl-pyridin-2,3-dione (0.84 g, 1.87 mmol) and 7-hydrazinoisoquinoline (tin salt from SnCl₂ reduction of diazonium salt) (0.72 g, 1.87 mmol) were heated to reflux in acetic acid (30 ml) for 4 h. The solvents were removed and ethyl acetate/sodium bicarbonate (sat) was added. The product was extracted with ethyl acetate, washed with brine and dried on sodium sulfate. Purification by chromatography on silica with (1:1) hexane/ethyl acetate as eluant afforded 0.60 g (64%) of the title compound. LRMS (ES+): 505/507.0 (Br pattern) (M+H)⁺.

[0764] Part B. 1-(l-Aminoisoquinolin-7′-yl)-3-trifluoromethyl-6-[4-bromophenyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridine-7-one

[0765] 1-(Isoquinolin-7′-yl)-3-trifluoromethyl-6-[4-bromophenyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (0.50 g, 1 mmol) was mixed with MCPBA (65%) (0.45 g, 1.2 mmol) in methylene chloride. The mixture was stirred at RT overnight. The solvents were removed and ethyl acetate/sodium bicarbonate (sat) added. Organic layer was separated and washed with brine and dried on sodium sulfate. Filtered and concentrated to give isoquinoline N-oxide (0.51 g, 98%) . LRMS (ES+): 521.2/523 (Br pattern) (M+H)⁺. The N-oxide was mixed with p-TsCl (229 mg, 1.2 mmol) in pyridine (10 ml). The mixture was stirred at RT overnight. Pyridine was removed under reduced pressure and ethanolamine (8 ml) was added. The resulting mixture was stirred at RT 1 h. Cold water was added and product was extracted with ethyl acetate, washed with brine and dried over sodium sulfate. Purification by chromatography on silica with (2:3) hexane/ethyl acetate as eluent afforded 0.26 g (50%) of the title compound. LRMS (ES+): 520.2/522.2 (Br pattern) (M+H)⁺.

[0766] Part C. 1-[1-Aminoisoquinolin-7′-yl]-3-trifluoromethyl-6-[4-(2-methylimidazol-1′-yl)phenyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one bis-trifluoroacetic acid salt

[0767] 1-(1-aminoisoquinolin-7′-yl)-3-trifluoromethyl-6-[4-bromophenyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridine-7-one (0.25 g, 0.48 mmol) was mixed with 2-methylimidazole (59 mg, 0.72 mmol), potassium carbonate (133 mg, 0.96 mmol) and CuI (14 mg, 0.072) in DMSO. The mixture was degassed under argon for 15 min. The mixture was stirred at 125° C. for 10 h. The mixture was cooled to RT and partitioned between ethyl acetate and water, washed with water, brine and dried over sodium sulfate. Purification by HPLC (RP) gradient to give 29 mg (14%) of the title compound of Example 104. LRMS (ES+): 504.4 (M+H)⁺

Example 105 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[4-(2-methylimidazol-1′-yl)phenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one bis-trifluoroacetic acid salt

[0768]

[0769] The title compound of Example 105 was prepared following procedures described previously. LRMS (ES+): 439.4 (M+H)⁺

Example 106 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[4-(2-(dimethylaminomethyl)imidazol-1′-yl)-2-fluorophenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one bis-trifluoroacetic acid salt

[0770]

[0771] The title compound of Example 106 was prepared following procedures described previously. LRMS (ES+): 500.5 (M+H)⁺

Example 107 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[4-(2-(dimethylaminomethyl)imidazol-1′-yl)phenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one bis-trifluoroacetic acid salt

[0772]

[0773] The title compound of Example 107 was prepared following procedures described previously. LRMS (ES+): 536.4 (M+H)⁺

Example 108 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[4-(2-(dimethylaminomethyl)imidazol-1′-yl)-2-fluorophenyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one bis-trifluoroacetic acid salt

[0774]

[0775] The title compound of Example 108 was prepared following procedures described previously. LRMS (ES+): 501.5 (M+H)⁺.

Example 109 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-(4-bromophenyl)-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one, trifluoroacetic acid salt

[0776]

[0777] The title compound of Example 109 was prepared following procedures described previously. HRMS (C₂₀H₁₇N₅O₂Br)⁺: 438.0557 m/z.

[0778] The following tables contain representative examples of the present invention. Each entry in each table is intended to be paired with each formulae at the start of the table. For example, in Tables 1 and 2, example 1 is intended to be paired with each of the formulae.

[0779] The following nomenclature is intended for group A in the following tables.

TABLE 1

[0780] Z is CR^(1a);

[0781] G is selected from:

[0782] 4-(methoxy)phenyl;

[0783] 2-(aminomethyl)phenyl;

[0784] 3-(aminomethyl)phenyl;

[0785] 2-(aminomethyl)-3-fluorophenyl;

[0786] 2-(aminomethyl)-4-fluorophenyl;

[0787] 2-(aminomethyl)-5-fluorophenyl;

[0788] 2-(aminomethyl)-6-fluorophenyl;

[0789] 3-amino-phthalazin-5-yl;

[0790] 3-amino-phthalazin-6-yl;

[0791] 1-aminoisoquinolin-6-yl;

[0792] 1-aminoisoquinolin-7-yl;

[0793] 4-aminoquinazol-6-yl;

[0794] 4-aminoquinazol-7-yl;

[0795] 3-aminobenzisoxazol-5-yl;

[0796] 3-aminobenzisoxazol-6-yl;

[0797] 3-aminoisobenzazol-5-yl; and,

[0798] 3-aminoisobenzazol-6-yl; Ex# R^(1a) A B 1 CH3 phenyl 2-(aminosulfonyl)phenyl 2 CH3 phenyl 2-(methylaminosulfonyl)phenyl 3 CH3 phenyl 1-pyrrolidinocarbonyl 4 CH3 phenyl 2-(methylsulfonyl)phenyl 5 CH3 phenyl 2-(N,N- dimethylaminomethyl)phenyl 6 CH3 phenyl 2-(N-pyrrolidinylmethyl)phenyl 7 CH3 phenyl 1-methyl-2-imidazolyl 8 CH3 phenyl 2-methyl-1-imidazolyl 9 CH3 phenyl 2-(dimethylaminomethyl)-1- imidazolyl 10 CH3 phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 11 CH3 phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 12 CH3 phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 13 CH3 phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 14 CH3 2-pyridyl 2-(aminosulfonyl)phenyl 15 CH3 2-pyridyl 2-(methylaminosulfonyl)phenyl 16 CH3 2-pyridyl 1-pyrrolidinocarbonyl 17 CH3 2-pyridyl 2-(methylsulfonyl)phenyl 18 CH3 2-pyridyl 2-(N,N- dimethylaminomethyl)phenyl 19 CH3 2-pyridyl 2-(N-pyrrolidinylmethyl)phenyl 20 CH3 2-pyridyl 1-methyl-2-imidazolyl 21 CH3 2-pyridyl 2-methyl-1-imidazolyl 22 CH3 2-pyridyl 2-(dimethylaminomethyl)-1- imidazolyl 23 CH3 2-pyridyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 24 CH3 2-pyridyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 25 CH3 2-pyridyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 26 CH3 2-pyridyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 27 CH3 3-pyridyl 2-(aminosulfonyl)phenyl 28 CH3 3-pyridyl 2-(methylaminosulfonyl)phenyl 29 CH3 3-pyridyl 1-pyrrolidinocarbonyl 30 CH3 3-pyridyl 2-(methylsulfonyl)phenyl 31 CH3 3-pyridyl 2-(N,N- dimethylaminomethyl)phenyl 32 CH3 3-pyridyl 2-(N-pyrrolidinylmethyl)phenyl 33 CH3 3-pyridyl 1-methyl-2-imidazolyl 34 CH3 3-pyridyl 2-methyl-1-imidazolyl 35 CH3 3-pyridyl 2-(dimethylaminomethyl)-1- imidazoly 36 CH3 3-pyridyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 37 CH3 3-pyridyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 38 CH3 3-pyridyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 39 CH3 3-pyridyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 40 CH3 2-pyrimidyl 2-(aminosulfonyl)phenyl 41 CH3 2-pyrimidyl 2-(methylaminosulfonyl)phenyl 42 CH3 2-pyrimidyl 1-pyrrolidinocarbonyl 43 CH3 2-pyrimidyl 2-(methylsulfonyl)phenyl 44 CH3 2-pyrimidyl 2-(N,N- dimethylaminomethyl)phenyl 45 CH3 2-pyrimidyl 2-(N-pyrrolidinylmethyl)phenyl 46 CH3 2-pyrimidyl 1-methyl-2-imidazolyl 47 CH3 2-pyrimidyl 2-methyl-1-imidazolyl 48 CH3 2-pyrimidyl 2-(dimethylaminomethyl)-1- imidazolyl 49 CH3 2-pyrimidyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 50 CH3 2-pyrimidyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 51 CH3 2-pyrimidyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 52 CH3 2-pyrimidyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 53 CH3 5-pyrimidyl 2-(aminosulfonyl)phenyl 54 CH3 5-pyrimidyl 2-(methylaminosulfonyl)phenyl 55 CH3 5-pyrimidyl 1-pyrrolidinocarbonyl 56 CH3 5-pyrimidyl 2-(methylsulfonyl)phenyl 57 CH3 5-pyrimidyl 2-(N,N- dimethylaminomethyl)phenyl 58 CH3 5-pyrimidyl 2-(N-pyrrolidinylmethyl)phenyl 59 CH3 5-pyrimidyl 1-methyl-2-imidazolyl 60 CH3 5-pyrimidyl 2-methyl-1-imidazolyl 61 CH3 5-pyrimidyl 2-(dimethylaminomethyl)-1- imidazolyl 62 CH3 5-pyrimidyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 63 CH3 5-pyrimidyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 64 CH3 5-pyrimidyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 65 CH3 5-pyrimidyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 66 CH3 2-Cl-phenyl 2-(aminosulfonyl)phenyl 67 CH3 2-Cl-phenyl 2-(methylaminosulfonyl)phenyl 68 CH3 2-Cl-phenyl 1-pyrrolidinocarbonyl 69 CH3 2-Cl-phenyl 2-(methylsulfonyl)phenyl 70 CH3 2-Cl-phenyl 2-(N,N- dimethylaminomethyl)phenyl 71 CH3 2-Cl-phenyl 2-(N-pyrrolidinylmethyl)phenyl 72 CH3 2-Cl-phenyl 1-methyl-2-imidazolyl 73 CH3 2-Cl-phenyl 2-methyl-1-imidazolyl 74 CH3 2-Cl-phenyl 2-(dimethylaminomethyl)-1- imidazolyl 75 CH3 2-Cl-phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 76 CH3 2-Cl-phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 77 CH3 2-Cl-phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 78 CH3 2-Cl-phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 79 CH3 2-F-phenyl 2-(aminosulfonyl)phenyl 80 CH3 2-F-phenyl 2-(methylaminosulfonyl)phenyl 81 CH3 2-F-phenyl 1-pyrrolidinocarbonyl 82 CH3 2-F-phenyl 2-(methylsulfonyl)phenyl 83 CH3 2-F-phenyl 2-(N,N- dimethylaminomethyl)phenyl 84 CH3 2-F-phenyl 2-(N-pyrrolidinylmethyl)phenyl 85 CH3 2-F-phenyl 1-methyl-2-imidazolyl 86 CH3 2-F-phenyl 2-methyl-1-imidazolyl 87 CH3 2-F-phenyl 2-(dimethylaminomethyl)-1- imidazolyl 88 CH3 2-F-phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 89 CH3 2-F-phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 90 CH3 2-F-phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 91 CH3 2-F-phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 92 CH3 2,6-diF-phenyl 2-(aminosulfonyl)phenyl 93 CH3 2,6-diF-phenyl 2- (methylaminosulfonyl)phenyl 94 CH3 2,6-diF-phenyl 1-pyrrolidinocarbonyl 95 CH3 2,6-diF-phenyl 2-(methylsulfonyl)phenyl 96 CH3 2,6-diF-phenyl 2-(N,N- dimethylaminomethyl)phenyl 97 CH3 2,6-diF-phenyl 2-(N-pyrrolidinylmethyl)phenyl 98 CH3 2,6-diF-phenyl 1-methyl-2-imidazolyl 99 CH3 2,6-diF-phenyl 2-methyl-1-imidazolyl 100 CH3 2,6-diF-phenyl 2-(dimethylaminomethyl)-1- imidazolyl 101 CH3 2,6-diF-phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 102 CH3 2,6-diF-phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 103 CH3 2,6-diF-phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 104 CH3 2,6-diF-phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 105 CH2CH3 phenyl 2-(aminosulfonyl)phenyl 106 CH2CH3 phenyl 2-(methylaminosulfonyl)phenyl 107 CH2CH3 phenyl 1-pyrrolidinocarbonyl 108 CH2CH3 phenyl 2-(methylsulfonyl)phenyl 109 CH2CH3 phenyl 2-(N,N- dimethylaminomethyl)phenyl 110 CH2CH3 phenyl 2-(N-pyrrolidinylmethyl)phenyl 111 CH2CH3 phenyl 1-methyl-2-imidazolyl 112 CH2CH3 phenyl 2-methyl-1-imidazolyl 113 CH2CH3 phenyl 2-(dimethylaminomethyl)-1- imidazolyl 114 CH2CH3 phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 115 CH2CH3 phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 116 CH2CH3 phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 117 CH2CH3 phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 118 CH2CH3 2-pyridyl 2-(aminosulfonyl)phenyl 119 CH2CH3 2-pyridyl 2-(methylaminosulfonyl)phenyl 120 CH2CH3 2-pyridyl 1-pyrrolidinocarbonyl 121 CH2CH3 2-pyridyl 2-(methylsulfonyl)phenyl 122 CH2CH3 2-pyridyl 2-(N,N- dimethylaminomethyl)phenyl 123 CH2CH3 2-pyridyl 2-(N-pyrrolidinylmethyl)phenyl 124 CH2CH3 2-pyridyl 1-methyl-2-imidazolyl 125 CH2CH3 2-pyridyl 2-methyl-1-imidazolyl 126 CH2CH3 2-pyridyl 2-(dimethylaminomethyl)-1- imidazolyl 127 CH2CH3 2-pyridyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 128 CH2CH3 2-pyridyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 129 CH2CH3 2-pyridyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 130 CH2CH3 2-pyridyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 131 CH2CH3 3-pyridyl 2-(aminosulfonyl)phenyl 132 CH2CH3 3-pyridyl 2-(methylaminosulfonyl)phenyl 133 CH2CH3 3-pyridyl 1-pyrrolidinocarbonyl 134 CH2CH3 3-pyridyl 2-(methylsulfonyl)phenyl 135 CH2CH3 3-pyridyl 2-(N,N- dimethylaminomethyl)phenyl 136 CH2CH3 3-pyridyl 2-(N-pyrrolidinylmethyl)phenyl 137 CH2CH3 3-pyridyl 1-methyl-2-imidazolyl 138 CH2CH3 3-pyridyl 2-methyl-1-imidazolyl 139 CH2CH3 3-pyridyl 2-(dimethylaminomethyl)-1- imidazolyl 140 CH2CH3 3-pyridyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 141 CH2CH3 3-pyridyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 142 CH2CH3 3-pyridyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 143 CH2CH3 3-pyridyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 144 CH2CH3 2-pyrimidyl 2-(aminosulfonyl)phenyl 145 CH2CH3 2-pyrimidyl 2-(methylaminosulfonyl)phenyl 146 CH2CH3 2-pyrimidyl 1-pyrrolidinocarbonyl 147 CH2CH3 2-pyrimidyl 2-(methylsulfonyl)phenyl 148 CH2CH3 2-pyrimidyl 2-(N,N- dimethylaminomethyl)phenyl 149 CH2CH3 2-pyrimidyl 2-(N-pyrrolidinylmethyl)phenyl 150 CH2CH3 2-pyrimidyl 1-methyl-2-imidazolyl 151 CH2CH3 2-pyrimidyl 2-methyl-1-imidazolyl 152 CH2CH3 2-pyrimidyl 2-(dimethylaminomethyl)-1- imidazolyl 153 CH2CH3 2-pyrimidyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 154 CH2CH3 2-pyrimidyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 155 CH2CH3 2-pyrimidyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 156 CH2CH3 2-pyrimidyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 157 CH2CH3 5-pyrimidyl 2-(aminosulfonyl)phenyl 158 CH2CH3 5-pyrimidyl 2-(methylaminosulfonyl)phenyl 159 CH2CH3 5-pyrimidyl 1-pyrrolidinocarbonyl 160 CH2CH3 5-pyrimidyl 2-(methylsulfonyl)phenyl 161 CH2CH3 5-pyrimidyl 2-(N,N- dimethylaminomethyl)phenyl 162 CH2CH3 5-pyrimidyl 2-(N-pyrrolidinylmethyl)phenyl 163 CH2CH3 5-pyrimidyl 1-methyl-2-imidazolyl 164 CH2CH3 5-pyrimidyl 2-methyl-1-imidazolyl 165 CH2CH3 5-pyrimidyl 2-(dimethylaminomethyl)-1- imidazolyl 166 CH2CH3 5-pyrimidyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 167 CH2CH3 5-pyrimidyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 168 CH2CH3 5-pyrimidyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 169 CH2CH3 5-pyrimidyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 170 CH2CH3 2-Cl-phenyl 2-(aminosulfonyl)phenyl 171 CH2CH3 2-Cl-phenyl 2-(methylaminosulfonyl)phenyl 172 CH2CH3 2-Cl-phenyl 1-pyrrolidinocarbonyl 173 CH2CH3 2-Cl-phenyl 2-(methylsulfonyl)phenyl 174 CH2CH3 2-Cl-phenyl 2-(N,N- dimethylaminomethyl)phenyl 175 CH2CH3 2-Cl-phenyl 2-(N-pyrrolidinylmethyl)phenyl 176 CH2CH3 2-Cl-phenyl 1-methyl-2-imidazolyl 177 CH2CH3 2-Cl-phenyl 2-methyl-1-imidazolyl 178 CH2CH3 2-Cl-phenyl 2-(dimethylaminomethyl)-1- imidazolyl 179 CH2CH3 2-Cl-phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 180 CH2CH3 2-Cl-phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 181 CH2CH3 2-Cl-phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 182 CH2CH3 2-Cl-phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 183 CH2CH3 2-F-phenyl 2-(aminosulfonyl)phenyl 184 CH2CH3 2-F-phenyl 2-(methylaminosulfonyl)phenyl 185 CH2CH3 2-F-phenyl 1-pyrrolidinocarbonyl 186 CH2CH3 2-F-phenyl 2-(methylsulfonyl)phenyl 187 CH2CH3 2-F-phenyl 2-(N,N- dimethylaminomethyl)phenyl 188 CH2CH3 2-F-phenyl 2-(N-pyrrolidinylmethyl)phenyl 189 CH2CH3 2-F-phenyl 1-methyl-2-imidazolyl 190 CH2CH3 2-F-phenyl 2-methyl-1-imidazolyl 191 CH2CH3 2-F-phenyl 2-(dimethylaminomethyl)-1- imidazolyl 192 CH2CH3 2-F-phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 193 CH2CH3 2-F-phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 194 CH2CH3 2-F-phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 195 CH2CH3 2-F-phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 196 CH2CH3 2,6-diF-phenyl 2-(aminosulfonyl)phenyl 197 CH2CH3 2,6-diF-phenyl 2-(methylaminosulfonyl)phenyl 198 CH2CH3 2,6-diF-phenyl 1-pyrrolidinocarbonyl 199 CH2CH3 2,6-diF-phenyl 2-(methylsulfonyl)phenyl 200 CH2CH3 2,6-diF-phenyl 2-(N,N- dimethylaminomethyl)phenyl 201 CH2CH3 2,6-diF-phenyl 2-(N-pyrrolidinylmethyl)phenyl 202 CH2CH3 2,6-diF-phenyl 1-methyl-2-imidazolyl 203 CH2CH3 2,6-diF-phenyl 2-methyl-1-imidazolyl 204 CH2CH3 2,6-diF-phenyl 2-(dimethylaminomethyl)-1- imidazolyl 205 CH2CH3 2,6-diF-phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 206 CH2CH3 2,6-diF-phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 207 CH2CH3 2,6-diF-phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 208 CH2CH3 2,6-diF-phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 209 CF3 phenyl 2-(aminosulfonyl)phenyl 210 CF3 phenyl 2-(methylaminosulfonyl)phenyl 211 CF3 phenyl 1-pyrrolidinocarbonyl 212 CF3 phenyl 2-(methylsulfonyl)phenyl 213 CF3 phenyl 2-(N,N- dimethylaminomethyl)phenyl 214 CF3 phenyl 2-(N-pyrrolidinylmethyl)phenyl 215 CF3 phenyl 1-methyl-2-imidazolyl 216 CF3 phenyl 2-methyl-1-imidazolyl 217 CF3 phenyl 2-(dimethylaminomethyl)-1- imidazolyl 218 CF3 phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 219 CF3 phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 220 CF3 phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 221 CF3 phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 222 CF3 2-pyridyl 2-(aminosulfonyl)phenyl 223 CF3 2-pyridyl 2-(methylaminosulfonyl)phenyl 224 CF3 2-pyridyl 1-pyrrolidinocarbonyl 225 CF3 2-pyridyl 2-(methylsulfonyl)phenyl 226 CF3 2-pyridyl 2-(N,N- dimethylaminomethyl)phenyl 227 CF3 2-pyridyl 2-(N-pyrrolidinylmethyl)phenyl 228 CF3 2-pyridyl 1-methyl-2-imidazolyl 229 CF3 2-pyridyl 2-methyl-1-imidazolyl 230 CF3 2-pyridyl 2-(dimethylaminomethyl)-1- imidazolyl 231 CF3 2-pyridyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 232 CF3 2-pyridyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 233 CF3 2-pyridyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 234 CF3 2-pyridyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 235 CF3 3-pyridyl 2-(aminosulfonyl)phenyl 236 CF3 3-pyridyl 2-(methylaminosulfonyl)phenyl 237 CF3 3-pyridyl 1-pyrrolidinocarbonyl 238 CF3 3-pyridyl 2-(methylsulfonyl)phenyl 239 CF3 3-pyridyl 2-(N,N- dimethylaminomethyl)phenyl 240 CF3 3-pyridyl 2-(N-pyrrolidinylmethyl)phenyl 241 CF3 3-pyridyl 1-methyl-2-imidazolyl 242 CF3 3-pyridyl 2-methyl-1-imidazolyl 243 CF3 3-pyridyl 2-(dimethylaminomethyl)-1- imidazolyl 244 CF3 3-pyridyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 245 CF3 3-pyridyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 246 CF3 3-pyridyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 247 CF3 3-pyridyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 248 CF3 2-pyrimidyl 2-(aminosulfonyl)phenyl 249 CF3 2-pyrimidyl 2-(methylaminosulfonyl)phenyl 250 CF3 2-pyrimidyl 1-pyrrolidinocarbonyl 251 CF3 2-pyrimidyl 2-(methylsulfonyl)phenyl 252 CF3 2-pyrimidyl 2-(N,N- dimethylaminomethyl)phenyl 253 CF3 2-pyrimidyl 2-(N-pyrrolidinylmethyl)phenyl 254 CF3 2-pyrimidyl 1-methyl-2-imidazolyl 255 CF3 2-pyrimidyl 2-methyl-1-imidazolyl 256 CF3 2-pyrimidyl 2-(dimethylaminomethyl)-1- imidazolyl 257 CF3 2-pyrimidyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 258 CF3 2-pyrimidyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 259 CF3 2-pyrimidyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 260 CF3 2-pyrimidyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 261 CF3 5-pyrimidyl 2-(aminosulfonyl)phenyl 262 CF3 5-pyrimidyl 2-(methylaminosulfonyl)phenyl 263 CF3 5-pyrimidyl 1-pyrrolidinocarbonyl 264 CF3 5-pyrimidyl 2-(methylsulfonyl)phenyl 265 CF3 5-pyrimidyl 2-(N,N- dimethylaminomethyl)phenyl 266 CF3 5-pyrimidyl 2-(N-pyrrolidinylmethyl)phenyl 267 CF3 5-pyrimidyl 1-methyl-2-imidazolyl 268 CF3 5-pyrimidyl 2-methyl-1-imidazolyl 269 CF3 5-pyrimidyl 2-(dimethylaminomethyl)-1- imidazolyl 270 CF3 5-pyrimidyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 271 CF3 5-pyrimidyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 272 CF3 5-pyrimidyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 273 CF3 5-pyrimidyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 274 CF3 2-Cl-phenyl 2-(aminosulfonyl)phenyl 275 CF3 2-Cl-phenyl 2-(methylaminosulfonyl)phenyl 276 CF3 2-Cl-phenyl 1-pyrrolidinocarbonyl 277 CF3 2-Cl-phenyl 2-(methylsulfonyl)phenyl 278 CF3 2-Cl-phenyl 2-(N,N- dimethylaminomethyl)phenyl 279 CF3 2-Cl-phenyl 2-(N-pyrrolidinylmethyl)phenyl 280 CF3 2-Cl-phenyl 1-methyl-2-imidazolyl 281 CF3 2-Cl-phenyl 2-methyl-1-imidazolyl 282 CF3 2-Cl-phenyl 2-(dimethylaminomethyl)-1- imidazolyl 283 CF3 2-Cl-phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 284 CF3 2-Cl-phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 285 CF3 2-Cl-phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 286 CF3 2-Cl-phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 287 CF3 2-F-phenyl 2-(aminosulfonyl)phenyl 288 CF3 2-F-phenyl 2-(methylaminosulfonyl)phenyl 289 CF3 2-F-phenyl 1-pyrrolidinocarbonyl 290 CF3 2-F-phenyl 2-(methylsulfonyl)phenyl 291 CF3 2-F-phenyl 2-(N,N- dimethylaminomethyl)phenyl 292 CF3 2-F-phenyl 2-(N-pyrrolidinylmethyl)phenyl 293 CF3 2-F-phenyl 1-methyl-2-imidazolyl 294 CF3 2-F-phenyl 2-methyl-1-imidazolyl 295 CF3 2-F-phenyl 2-(dimethylaminomethyl)-1- imidazolyl 296 CF3 2-F-phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 297 CF3 2-F-phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 298 CF3 2-F-phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 299 CF3 2-F-phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 300 CF3 2,6-diF-phenyl 2-(aminosulfonyl)phenyl 301 CF3 2,6-diF-phenyl 2-(methylaminosulfonyl)phenyl 302 CF3 2,6-diF-phenyl 1-pyrrolidinocarbonyl 303 CF3 2,6-diF-phenyl 2-(methylsulfonyl)phenyl 304 CF3 2,6-diF-phenyl 2-(N,N- dimethylaminomethyl)phenyl 305 CF3 2,6-diF-phenyl 2-(N-pyrrolidinylmethyl)phenyl 306 CF3 2,6-diF-phenyl 1-methyl-2-imidazolyl 307 CF3 2,6-diF-phenyl 2-methyl-1-imidazolyl 308 CF3 2,6-diF-phenyl 2-(dimethylaminomethyl)-1- imidazolyl 309 CF3 2,6-diF-phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 310 CF3 2,6-diF-phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 311 CF3 2,6-diF-phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 312 CF3 2,6-diF-phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 313 SCH3 phenyl 2-(aminosulfonyl)phenyl 314 SCH3 phenyl 2-(methylaminosulfonyl)phenyl 315 SCH3 phenyl 1-pyrrolidinocarbonyl 316 SCH3 phenyl 2-(methylsulfonyl)phenyl 317 SCH3 phenyl 2-(N,N- dimethylaminomethyl)phenyl 318 SCH3 phenyl 2-(N-pyrrolidinylmethyl)phenyl 319 SCH3 phenyl 1-methyl-2-imidazolyl 320 SCH3 phenyl 2-methyl-1-imidazolyl 321 SCH3 phenyl 2-(dimethylaminomethyl)-1- imidazolyl 322 SCH3 phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 323 SCH3 phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 324 SCH3 phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 325 SCH3 phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 326 SCH3 2-pyridyl 2-(aminosulfonyl)phenyl 327 SCH3 2-pyridyl 2-(methylaminosulfonyl)phenyl 328 SCH3 2-pyridyl 1-pyrrolidinocarbonyl 329 SCH3 2-pyridyl 2-(methylsulfonyl)phenyl 330 SCH3 2-pyridyl 2-(N,N- dimethylaminomethyl)phenyl 331 SCH3 2-pyridyl 2-(N-pyrrolidinylmethyl)phenyl 332 SCH3 2-pyridyl 1-methyl-2-imidazolyl 333 SCH3 2-pyridyl 2-methyl-1-imidazolyl 334 SCH3 2-pyridyl 2-(dimethylaminomethyl)-1- imidazolyl 335 SCH3 2-pyridyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 336 SCH3 2-pyridyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 337 SCH3 2-pyridyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 338 SCH3 2-pyridyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 339 SCH3 3-pyridyl 2-(aminosulfonyl)phenyl 340 SCH3 3-pyridyl 2-(methylaminosulfonyl)phenyl 341 SCH3 3-pyridyl 1-pyrrolidinocarbonyl 342 SCH3 3-pyridyl 2-(methylsulfonyl)phenyl 343 SCH3 3-pyridyl 2-(N,N- dimethylaminomethyl)phenyl 344 SCH3 3-pyridyl 2-(N-pyrrolidinylmethyl)phenyl 345 SCH3 3-pyridyl 1-methyl-2-imidazolyl 346 SCH3 3-pyridyl 2-methyl-1-imidazolyl 347 SCH3 3-pyridyl 2-(dimethylaminomethyl)-1- imidazolyl 348 SCH3 3-pyridyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 349 SCH3 3-pyridyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 350 SCH3 3-pyridyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 351 SCH3 3-pyridyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 352 SCH3 2-pyrimidyl 2-(aminosulfonyl)phenyl 353 SCH3 2-pyrimidyl 2-(methylaminosulfonyl)phenyl 354 SCH3 2-pyrimidyl 1-pyrrolidinocarbonyl 355 SCH3 2-pyrimidyl 2-(methylsulfonyl)phenyl 356 SCH3 2-pyrimidyl 2-(N,N- dimethylaminomethyl)phenyl 357 SCH3 2-pyrimidyl 2-(N-pyrrolidinylmethyl)phenyl 358 SCH3 2-pyrimidyl 1-methyl-2-imidazolyl 359 SCH3 2-pyrimidyl 2-methyl-1-imidazolyl 360 SCH3 2-pyrimidyl 2-(dimethylaminomethyl)-1- imidazolyl 361 SCH3 2-pyrimidyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 362 SCH3 2-pyrimidyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 363 SCH3 2-pyrimidyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 364 SCH3 2-pyrimidyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 365 SCH3 5-pyrimidyl 2-(aminosulfonyl)phenyl 366 SCH3 5-pyrimidyl 2-(methylaminosulfonyl)phenyl 367 SCH3 5-pyrimidyl 1-pyrrolidinocarbonyl 368 SCH3 5-pyrimidyl 2-(methylsulfonyl)phenyl 369 SCH3 5-pyrimidyl 2-(N,N- dimethylaminomethyl)phenyl 370 SCH3 5-pyrimidyl 2-(N-pyrrolidinylmethyl)phenyl 371 SCH3 5-pyrimidyl 1-methyl-2-imidazolyl 372 SCH3 5-pyrimidyl 2-methyl-1-imidazolyl 373 SCH3 5-pyrimidyl 2-(dimethylaminomethyl)-1- imidazolyl 374 SCH3 5-pyrimidyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 375 SCH3 5-pyrimidyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 376 SCH3 5-pyrimidyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 377 SCH3 5-pyrimidyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 378 SCH3 2-Cl-phenyl 2-(aminosulfonyl)phenyl 379 SCH3 2-Cl-phenyl 2-(methylaminosulfonyl)phenyl 380 SCH3 2-Cl-phenyl 1-pyrrolidinocarbonyl 381 SCH3 2-Cl-phenyl 2-(methylsulfonyl)phenyl 382 SCH3 2-Cl-phenyl 2-(N,N- dimethylaminomethyl)phenyl 383 SCH3 2-Cl-phenyl 2-(N-pyrrolidinylmethyl)phenyl 384 SCH3 2-Cl-phenyl 1-methyl-2-imidazolyl 385 SCH3 2-Cl-phenyl 2-methyl-1-imidazolyl 386 SCH3 2-Cl-phenyl 2-(dimethylaminomethyl)-1- imidazolyl 387 SCH3 2-Cl-phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 388 SCH3 2-Cl-phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 389 SCH3 2-Cl-phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 390 SCH3 2-Cl-phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 391 SCH3 2-F-phenyl 2-(aminosulfonyl)phenyl 392 SCH3 2-F-phenyl 2-(methylaminosulfonyl)phenyl 393 SCH3 2-F-phenyl 1-pyrrolidinocarbonyl 394 SCH3 2-F-phenyl 2-(methylsulfonyl)phenyl 395 SCH3 2-F-phenyl 2-(N,N- dimethylaminomethyl)phenyl 396 SCH3 2-F-phenyl 2-(N-pyrrolidinylmethyl)phenyl 397 SCH3 2-F-phenyl 1-methyl-2-imidazolyl 398 SCH3 2-F-phenyl 2-methyl-1-imidazolyl 399 SCH3 2-F-phenyl 2-(dimethylaminomethyl)-1- imidazolyl 400 SCH3 2-F-phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 401 SCH3 2-F-phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 402 SCH3 2-F-phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 403 SCH3 2-F-phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 404 SCH3 2,6-diF-phenyl 2-(aminosulfonyl)phenyl 405 SCH3 2,6-diF-phenyl 2-(methylaminosulfonyl)phenyl 406 SCH3 2,6-diF-phenyl 1-pyrrolidinocarbonyl 407 SCH3 2,6-diF-phenyl 2-(methylsulfonyl)phenyl 408 SCH3 2,6-diF-phenyl 2-(N,N- dimethylaminomethyl)phenyl 409 SCH3 2,6-diF-phenyl 2-(N-pyrrolidinylmethyl)phenyl 410 SCH3 2,6-diF-phenyl 1-methyl-2-imidazolyl 411 SCH3 2,6-diF-phenyl 2-methyl-1-imidazolyl 412 SCH3 2,6-diF-phenyl 2-(dimethylaminomethyl)-1- imidazolyl 413 SCH3 2,6-diF-phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 414 SCH3 2,6-diF-phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 415 SCH3 2,6-diF-phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 416 SCH3 2,6-diF-phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 417 SOCH3 phenyl 2-(aminosulfonyl)phenyl 418 SOCH3 phenyl 2-(methylaminosulfonyl)phenyl 419 SOCH3 phenyl 1-pyrrolidinocarbonyl 420 SOCH3 phenyl 2-(methylsulfonyl)phenyl 421 SOCH3 phenyl 2-(N,N- dimethylaminomethyl)phenyl 422 SOCH3 phenyl 2-(N-pyrrolidinylmethyl)phenyl 423 SOCH3 phenyl 1-methyl-2-imidazolyl 424 SOCH3 phenyl 2-methyl-1-imidazolyl 425 SOCH3 phenyl 2-(dimethylaminomethyl)-1- imidazolyl 426 SOCH3 phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 427 SOCH3 phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 428 SOCH3 phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 429 SOCH3 phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 430 SOCH3 2-pyridyl 2-(aminosulfonyl)phenyl 431 SOCH3 2-pyridyl 2-(methylaminosulfonyl)phenyl 432 SOCH3 2-pyridyl 1-pyrrolidinocarbonyl 433 SOCH3 2-pyridyl 2-(methylsulfonyl)phenyl 434 SOCH3 2-pyridyl 2-(N,N- dimethylaminomethyl)phenyl 435 SOCH3 2-pyridyl 2-(N-pyrrolidinylmethyl)phenyl 436 SOCH3 2-pyridyl 1-methyl-2-imidazolyl 437 SOCH3 2-pyridyl 2-methyl-1-imidazolyl 438 SOCH3 2-pyridyl 2-(dimethylaminomethyl)-1- imidazolyl 439 SOCH3 2-pyridyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 440 SOCH3 2-pyridyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 441 SOCH3 2-pyridyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 442 SOCH3 2-pyridyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 443 SOCH3 3-pyridyl 2-(aminosulfonyl)phenyl 444 SOCH3 3-pyridyl 2-(methylaminosulfonyl)phenyl 445 SOCH3 3-pyridyl 1-pyrrolidinocarbonyl 446 SOCH3 3-pyridyl 2-(methylsulfonyl)phenyl 447 SOCH3 3-pyridyl 2-(N,N- dimethylaminomethyl)phenyl 448 SOCH3 3-pyridyl 2-(N-pyrrolidinylmethyl)phenyl 449 SOCH3 3-pyridyl 1-methyl-2-imidazolyl 450 SOCH3 3-pyridyl 2-methyl-1-imidazolyl 451 SOCH3 3-pyridyl 2-(dimethylaminomethyl)-1- imidazolyl 452 SOCH3 3-pyridyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 453 SOCH3 3-pyridyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 454 SOCH3 3-pyridyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 455 SOCH3 3-pyridyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 456 SOCH3 2-pyrimidyl 2-(aminosulfonyl)phenyl 457 SOCH3 2-pyrimidyl 2-(methylaminosulfonyl)phenyl 458 SOCH3 2-pyrimidyl 1-pyrrolidinocarbonyl 459 SOCH3 2-pyrimidyl 2-(methylsulfonyl)phenyl 460 SOCH3 2-pyrimidyl 2-(N,N- dimethylaminomethyl)phenyl 461 SOCH3 2-pyrimidyl 2-(N-pyrrolidinylmethyl)phenyl 462 SOCH3 2-pyrimidyl 1-methyl-2-imidazolyl 463 SOCH3 2-pyrimidyl 2-methyl-1-imidazolyl 464 SOCH3 2-pyrimidyl 2-(dimethylaminomethyl)-1- imidazolyl 465 SOCH3 2-pyrimidyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 466 SOCH3 2-pyrimidyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 467 SOCH3 2-pyrimidyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 468 SOCH3 2-pyrimidyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 469 SOCH3 5-pyrimidyl 2-(aminosulfonyl)phenyl 470 SOCH3 5-pyrimidyl 2-(methylaminosulfonyl)phenyl 471 SOCH3 5-pyrimidyl 1-pyrrolidinocarbonyl 472 SOCH3 5-pyrimidyl 2-(methylsulfonyl)phenyl 473 SOCH3 5-pyrimidyl 2-(N,N- dimethylaminomethyl)phenyl 474 SOCH3 5-pyrimidyl 2-(N-pyrrolidinylmethyl)phenyl 475 SOCH3 5-pyrimidyl 1-methyl-2-imidazolyl 476 SOCH3 5-pyrimidyl 2-methyl-1-imidazolyl 477 SOCH3 5-pyrimidyl 2-(dimethylaminomethyl)-1- imidazolyl 478 SOCH3 5-pyrimidyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 479 SOCH3 5-pyrimidyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 480 SOCH3 5-pyrimidyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 481 SOCH3 5-pyrimidyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 482 SOCH3 2-Cl-phenyl 2-(aminosulfonyl)phenyl 483 SOCH3 2-Cl-phenyl 2-(methylaminosulfonyl)phenyl 484 SOCH3 2-Cl-phenyl 1-pyrrolidinocarbonyl 485 SOCH3 2-Cl-phenyl 2-(methylsulfonyl)phenyl 486 SOCH3 2-Cl-phenyl 2-(N,N- dimethylaminomethyl)phenyl 487 SOCH3 2-Cl-phenyl 2-(N-pyrrolidinylmethyl)phenyl 488 SOCH3 2-Cl-phenyl 1-methyl-2-imidazolyl 489 SOCH3 2-Cl-phenyl 2-methyl-1-imidazolyl 490 SOCH3 2-Cl-phenyl 2-(dimethylaminomethyl)-1- imidazolyl 491 SOCH3 2-Cl-phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 492 SOCH3 2-Cl-phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 493 SOCH3 2-Cl-phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 494 SOCH3 2-Cl-phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 495 SOCH3 2-F-phenyl 2-(aminosulfonyl)phenyl 496 SOCH3 2-F-phenyl 2-(methylaminosulfonyl)phenyl 497 SOCH3 2-F-phenyl 1-pyrrolidinocarbonyl 498 SOCH3 2-F-phenyl 2-(methylsulfonyl)phenyl 499 SOCH3 2-F-phenyl 2-(N,N- dimethylaminomethyl)phenyl 500 SOCH3 2-F-phenyl 2-(N-pyrrolidinylmethyl)phenyl 501 SOCH3 2-F-phenyl 1-methyl-2-imidazolyl 502 SOCH3 2-F-phenyl 2-methyl-1-imidazolyl 503 SOCH3 2-F-phenyl 2-(dimethylaminomethyl)-1- imidazolyl 504 SOCH3 2-F-phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 505 SOCH3 2-F-phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 506 SOCH3 2-F-phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 507 SOCH3 2-F-phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 508 SOCH3 2,6-diF-phenyl 2-(aminosulfonyl)phenyl 509 SOCH3 2,6-diF-phenyl 2-(methylaminosulfonyl)phenyl 510 SOCH3 2,6-diF-phenyl 1-pyrrolidinocarbonyl 511 SOCH3 2,6-diF-phenyl 2-(methylsulfonyl)phenyl 512 SOCH3 2,6-diF-phenyl 2-(N,N- dimethylaminomethyl)phenyl 513 SOCH3 2,6-diF-phenyl 2-(N-pyrrolidinylmethyl)phenyl 514 SOCH3 2,6-diF-phenyl 1-methyl-2-imidazolyl 515 SOCH3 2,6-diF-phenyl 2-methyl-1-imidazolyl 516 SOCH3 2,6-diF-phenyl 2-(dimethylaminomethyl)-1- imidazolyl 517 SOCH3 2,6-diF-phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 518 SOCH3 2,6-diF-phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 519 SOCH3 2,6-diF-phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 520 SOCH3 2,6-diF-phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 521 SO2CH3 phenyl 2-(aminosulfonyl)phenyl 522 SO2CH3 phenyl 2-(methylaminosulfonyl)phenyl 523 SO2CH3 phenyl 1-pyrrolidinocarbonyl 524 SO2CH3 phenyl 2-(methylsulfonyl)phenyl 525 SO2CH3 phenyl 2-(N,N- dimethylaminomethyl)phenyl 526 SO2CH3 phenyl 2-(N-pyrrolidinylmethyl)phenyl 527 SO2CH3 phenyl 1-methyl-2-imidazolyl 528 SO2CH3 phenyl 2-methyl-1-imidazolyl 529 SO2CH3 phenyl 2-(dimethylaminomethyl)-1- imidazolyl 530 SO2CH3 phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 531 SO2CH3 phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 532 SO2CH3 phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 533 SO20H3 phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 534 SO2CH3 2-pyridyl 2-(aminosulfonyl)phenyl 535 SO2CH3 2-pyridyl 2-(methylaminosulfonyl)phenyl 536 SO2CH3 2-pyridyl 1-pyrrolidinocarbonyl 537 SO2CH3 2-pyridyl 2-(methylsulfonyl)phenyl 538 SO2CH3 2-pyridyl 2-(N,N- dimethylaminomethyl)phenyl 539 SO2CH3 2-pyridyl 2-(N-pyrrolidinylmethyl)phenyl 540 SO2CH3 2-pyridyl 1-methyl-2-imidazolyl 541 SO2CH3 2-pyridyl 2-methyl-1-imidazolyl 542 SO2CH3 2-pyridyl 2-(dimethylaminomethyl)-1- imidazolyl 543 SO2CH3 2-pyridyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 544 SO2CH3 2-pyridyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 545 SO2CH3 2-pyridyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 546 SO2CH3 2-pyridyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 547 SO2CH3 3-pyridyl 2-(aminosulfonyl)phenyl 548 SO2CH3 3-pyridyl 2-(methylaminosulfonyl)phenyl 549 SO2CH3 3-pyridyl 1-pyrrolidinocarbonyl 550 SO2CH3 3-pyridyl 2-(methylsulfonyl)phenyl 551 SO2CH3 3-pyridyl 2-(N,N- dimethylaminomethyl)phenyl 552 SO2CH3 3-pyridyl 2-(N-pyrrolidinylmethyl)phenyl 553 SO2CH3 3-pyridyl 1-methyl-2-imidazolyl 554 SO2CH3 3-pyridyl 2-methyl-1-imidazolyl 555 SO2CH3 3-pyridyl 2-(dimethylaminomethyl)-1- imidazolyl 556 SO2CH3 3-pyridyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 557 SO2CH3 3-pyridyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 558 SO2CH3 3-pyridyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 559 SO2CH3 3-pyridyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 560 SO2CH3 2-pyrimidyl 2-(aminosulfonyl)phenyl 561 SO2CH3 2-pyrimidyl 2-(methylaminosulfonyl)phenyl 562 SO2CH3 2-pyrimidyl 1-pyrrolidinocarbonyl 563 SO2CH3 2-pyrimidyl 2-(methylsulfonyl)phenyl 564 SO2CH3 2-pyrimidyl 2-(N,N- dimethylaminomethyl)phenyl 565 SO2CH3 2-pyrimidyl 2-(N-pyrrolidinylmethyl)phenyl 566 SO2CH3 2-pyrimidyl 1-methyl-2-imidazolyl 567 SO2CH3 2-pyrimidyl 2-methyl-1-imidazolyl 568 SO2CH3 2-pyrimidyl 2-(dimethylaminomethyl)-1- imidazolyl 569 SO2CH3 2-pyrimidyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 570 SO2CH3 2-pyrimidyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 571 SO2CH3 2-pyrimidyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 572 SO2CH3 2-pyrimidyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 573 SO2CH3 5-pyrimidyl 2-(aminosulfonyl)phenyl 574 SO2CH3 5-pyrimidyl 2-(methylaminosulfonyl)phenyl 575 SO2CH3 5-pyrimidyl 1-pyrrolidinocarbonyl 576 SO2CH3 5-pyrimidyl 2-(methylsulfonyl)phenyl 577 SO2CH3 5-pyrimidyl 2-(N,N- dimethylaminomethyl)phenyl 578 SO2CH3 5-pyrimidyl 2-(N-pyrrolidinylmethyl)phenyl 579 SO2CH3 5-pyrimidyl 1-methyl-2-imidazolyl 580 SO2CH3 5-pyrimidyl 2-methyl-1-imidazolyl 581 SO2CH3 5-pyrimidyl 2-(dimethylaminomethyl)-1- imidazolyl 582 SO2CH3 5-pyrimidyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 583 SO2CH3 5-pyrimidyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 584 SO2CH3 5-pyrimidyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 585 SO2CH3 5-pyrimidyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 586 SO2CH3 2-Cl-phenyl 2-(aminosulfonyl)phenyl 587 SO2CH3 2-Cl-phenyl 2-(methylaminosulfonyl)phenyl 588 SO2CH3 2-Cl-phenyl 1-pyrrolidinocarbonyl 589 SO2CH3 2-Cl-phenyl 2-(methylsulfonyl)phenyl 590 SO2CH3 2-Cl-phenyl 2-(N,N- dimethylaminomethyl)phenyl 591 SO2CH3 2-Cl-phenyl 2-(N-pyrrolidinylmethyl)phenyl 592 SO2CH3 2-Cl-phenyl 1-methyl-2-imidazolyl 593 SO2CH3 2-Cl-phenyl 2-methyl-1-imidazolyl 594 SO2CH3 2-Cl-phenyl 2-(dimethylaminomethyl)-1- imidazolyl 595 SO2CH3 2-Cl-phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 596 SO2CH3 2-Cl-phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 597 SO2CH3 2-Cl-phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 598 SO2CH3 2-Cl-phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 599 SO2CH3 2-F-phenyl 2-(aminosulfonyl)phenyl 600 SO2CH3 2-F-phenyl 2-(methylaminosulfonyl)phenyl 601 SO2CH3 2-F-phenyl 1-pyrrolidinocarbonyl 602 SO2CH3 2-F-phenyl 2-(methylsulfonyl)phenyl 603 SO2CH3 2-F-phenyl 2-(N,N- dimethylaminomethyl)phenyl 604 SO2CH3 2-F-phenyl 2-(N-pyrrolidinylmethyl)phenyl 605 SO2CH3 2-F-phenyl 1-methyl-2-imidazolyl 606 SO2CH3 2-F-phenyl 2-methyl-1-imidazolyl 607 SO2CH3 2-F-phenyl 2-(dimethylaminomethyl)-1- imidazolyl 608 SO2CH3 2-F-phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 609 SO2CH3 2-F-phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 610 SO2CH3 2-F-phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 611 SO2CH3 2-F-phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 612 SO2CH3 2,6-diF-phenyl 2-(aminosulfonyl)phenyl 613 SO2CH3 2,6-diF-phenyl 2-(methylaminosulfonyl)phenyl 614 SO2CH3 2,6-diF-phenyl 1-pyrrolidinocarbonyl 615 SO2CH3 2,6-diF-phenyl 2-(methylsulfonyl)phenyl 616 SO2CH3 2,6-diF-phenyl 2-(N,N- dimethylaminomethyl)phenyl 617 SO2CH3 2,6-diF-phenyl 2-(N-pyrrolidinylmethyl)phenyl 618 SO2CH3 2,6-diF-phenyl 1-methyl-2-imidazolyl 619 SO2CH3 2,6-diF-phenyl 2-methyl-1-imidazolyl 620 SO2CH3 2,6-diF-phenyl 2-(dimethylaminomethyl)-1- imidazolyl 621 SO2CH3 2,6-diF-phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 622 SO2CH3 2,6-diF-phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 623 SO2CH3 2,6-diF-phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 624 SO2CH3 2,6-diF-phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 625 Cl phenyl 2-(aminosulfonyl)phenyl 626 Cl phenyl 2-(methylaminosulfonyl)phenyl 627 Cl phenyl 1-pyrrolidinocarbonyl 628 Cl phenyl 2-(methylsulfonyl)phenyl 629 Cl phenyl 2-(N,N- dimethylaminomethyl)phenyl 630 Cl phenyl 2-(N-pyrrolidinylmethyl)phenyl 631 Cl phenyl 1-methyl-2-imidazolyl 632 Cl phenyl 2-methyl-1-imidazolyl 633 Cl phenyl 2-(dimethylaminomethyl)-1- imidazolyl 634 Cl phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 635 Cl phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 636 Cl phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 637 Cl phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 638 Cl 2-pyridyl 2-(aminosulfonyl)phenyl 639 Cl 2-pyridyl 2-(methylaminosulfonyl)phenyl 640 Cl 2-pyridyl 1-pyrrolidinocarbonyl 641 Cl 2-pyridyl 2-(methylsulfonyl)phenyl 642 Cl 2-pyridyl 2-(N,N- dimethylaminomethyl)phenyl 643 Cl 2-pyridyl 2-(N-pyrrolidinylmethyl)phenyl 644 Cl 2-pyridyl 1-methyl-2-imidazolyl 645 Cl 2-pyridyl 2-methyl-1-imidazolyl 646 Cl 2-pyridyl 2-(dimethylaminomethyl)-1- imidazolyl 647 Cl 2-pyridyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 648 Cl 2-pyridyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 649 Cl 2-pyridyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 650 Cl 2-pyridyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 651 Cl 3-pyridyl 2-(aminosulfonyl)phenyl 652 Cl 3-pyridyl 2-(methylaminosulfonyl)phenyl 653 Cl 3-pyridyl 1-pyrrolidinocarbonyl 654 Cl 3-pyridyl 2-(methylsulfonyl)phenyl 655 Cl 3-pyridyl 2-(N,N- dimethylaminomethyl)phenyl 656 Cl 3-pyridyl 2-(N-pyrrolidinylmethyl)phenyl 657 Cl 3-pyridyl 1-methyl-2-imidazolyl 658 Cl 3-pyridyl 2-methyl-1-imidazolyl 659 Cl 3-pyridyl 2-(dimethylaminomethyl)-1- imidazolyl 660 Cl 3-pyridyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 661 Cl 3-pyridyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 662 Cl 3-pyridyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 663 Cl 3-pyridyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 664 Cl 2-pyrimidyl 2-(aminosulfonyl)phenyl 665 Cl 2-pyrimidyl 2-(methylaminosulfonyl)phenyl 666 Cl 2-pyrimidyl 1-pyrrolidinocarbonyl 667 Cl 2-pyrimidyl 2-(methylsulfonyl)phenyl 668 Cl 2-pyrimidyl 2-(N,N- dimethylaminomethyl)phenyl 669 Cl 2-pyrimidyl 2-(N-pyrrolidinylmethyl)phenyl 670 Cl 2-pyrimidyl 1-methyl-2-imidazolyl 671 Cl 2-pyrimidyl 2-methyl-1-imidazolyl 672 Cl 2-pyrimidyl 2-(dimethylaminomethyl)-1- imidazolyl 673 Cl 2-pyrimidyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 674 Cl 2-pyrimidyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 675 Cl 2-pyrimidyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 676 Cl 2-pyrimidyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 677 Cl 5-pyrimidyl 2-(aminosulfonyl)phenyl 678 Cl 5-pyrimidyl 2-(methylaminosulfonyl)phenyl 679 Cl 5-pyrimidyl 1-pyrrolidinocarbonyl 680 Cl 5-pyrimidyl 2-(methylsulfonyl)phenyl 681 Cl 5-pyrimidyl 2-(N,N- dimethylaminomethyl)phenyl 682 Cl 5-pyrimidyl 2-(N-pyrrolidinylmethyl)phenyl 683 Cl 5-pyrimidyl 1-methyl-2-imidazolyl 684 Cl 5-pyrimidyl 2-methyl-1-imidazolyl 685 Cl 5-pyrimidyl 2-(dimethylaminomethyl)-1- imidazolyl 686 Cl 5-pyrimidyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 687 Cl 5-pyrimidyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 688 Cl 5-pyrimidyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 689 Cl 5-pyrimidyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 690 Cl 2-Cl-phenyl 2-(aminosulfonyl)phenyl 691 Cl 2-Cl-phenyl 2-(methylaminosulfonyl)phenyl 692 Cl 2-Cl-phenyl 1-pyrrolidinocarbonyl 693 Cl 2-Cl-phenyl 2-(methylsulfonyl)phenyl 694 Cl 2-Cl-phenyl 2-(N,N- dimethylaminomethyl)phenyl 695 Cl 2-Cl-phenyl 2-(N-pyrrolidinylmethyl)phenyl 696 Cl 2-Cl-phenyl 1-methyl-2-imidazolyl 697 Cl 2-Cl-phenyl 2-methyl-1-imidazolyl 698 Cl 2-Cl-phenyl 2-(dimethylaminomethyl)-1- imidazolyl 699 Cl 2-Cl-phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 700 Cl 2-Cl-phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 701 Cl 2-Cl-phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 702 Cl 2-Cl-phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 703 Cl 2-F-phenyl 2-(aminosulfonyl)phenyl 704 Cl 2-F-phenyl 2-(methylaminosulfonyl)phenyl 705 Cl 2-F-phenyl 1-pyrrolidinocarbonyl 706 Cl 2-F-phenyl 2-(methylsulfonyl)phenyl 707 Cl 2-F-phenyl 2-(N,N- dimethylaminomethyl)phenyl 708 Cl 2-F-phenyl 2-(N-pyrrolidinylmethyl)phenyl 709 Cl 2-F-phenyl 1-methyl-2-imidazolyl 710 Cl 2-F-phenyl 2-methyl-1-imidazolyl 711 Cl 2-F-phenyl 2-(dimethylaminomethyl)-1- imidazolyl 712 Cl 2-F-phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 713 Cl 2-F-phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 714 Cl 2-F-phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 715 Cl 2-F-phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 716 Cl 2,6-diF-phenyl 2-(aminosulfonyl)phenyl 717 Cl 2,6-diF-phenyl 2-(methylaminosulfonyl)phenyl 718 Cl 2,6-diF-phenyl 1-pyrrolidinocarbonyl 719 Cl 2,6-diF-phenyl 2-(methylsulfonyl)phenyl 720 Cl 2,6-diF-phenyl 2-(N,N- dimethylaminomethyl)phenyl 721 Cl 2,6-diF-phenyl 2-(N-pyrrolidinylmethyl)phenyl 722 Cl 2,6-diF-phenyl 1-methyl-2-imidazolyl 723 Cl 2,6-diF-phenyl 2-methyl-1-imidazolyl 724 Cl 2,6-diF-phenyl 2-(dimethylaminomethyl)-1- imidazolyl 725 Cl 2,6-diF-phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 726 Cl 2,6-diF-phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 727 Cl 2,6-diF-phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 728 Cl 2,6-diF-phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 729 F phenyl 2-(aminosulfonyl)phenyl 730 F phenyl 2-(methylaminosulfonyl)phenyl 731 F phenyl 1-pyrrolidinocarbonyl 732 F phenyl 2-(methylsulfonyl)phenyl 733 F phenyl 2-(N,N- dimethylaminomethyl)phenyl 734 F phenyl 2-(N-pyrrolidinylmethyl)phenyl 735 F phenyl 1-methyl-2-imidazolyl 736 F phenyl 2-methyl-1-imidazolyl 737 F phenyl 2-(dimethylaminomethyl)-1- imidazolyl 738 F phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 739 F phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 740 F phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 741 F phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 742 F 2-pyridyl 2-(aminosulfonyl)phenyl 743 F 2-pyridyl 2-(methylaminosulfonyl)phenyl 744 F 2-pyridyl 1-pyrrolidinocarbonyl 745 F 2-pyridyl 2-(methylsulfonyl)phenyl 746 F 2-pyridyl 2-(N,N- dimethylaminomethyl)phenyl 747 F 2-pyridyl 2-(N-pyrrolidinylmethyl)phenyl 748 F 2-pyridyl 1-methyl-2-imidazolyl 749 F 2-pyridyl 2-methyl-1-imidazolyl 750 F 2-pyridyl 2-(dimethylaminomethyl)-1- imidazolyl 751 F 2-pyridyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 752 F 2-pyridyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 753 F 2-pyridyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 754 F 2-pyridyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 755 F 3-pyridyl 2-(aminosulfonyl)phenyl 756 F 3-pyridyl 2-(methylaminosulfonyl)phenyl 757 F 3-pyridyl 1-pyrrolidinocarbonyl 758 F 3-pyridyl 2-(methylsulfonyl)phenyl 759 F 3-pyridyl 2-(N,N- dimethylaminomethyl)phenyl 760 F 3-pyridyl 2-(N-pyrrolidinylmethyl)phenyl 761 F 3-pyridyl 1-methyl-2-imidazolyl 762 F 3-pyridyl 2-methyl-1-imidazolyl 763 F 3-pyridyl 2-(dimethylaminomethyl)-1- imidazolyl 764 F 3-pyridyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 765 F 3-pyridyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 766 F 3-pyridyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 767 F 3-pyridyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 768 F 2-pyrimidyl 2-(aminosulfonyl)phenyl 769 F 2-pyrimidyl 2-(methylaminosulfonyl)phenyl 770 F 2-pyrimidyl 1-pyrrolidinocarbonyl 771 F 2-pyrimidyl 2-(methylsulfonyl)phenyl 772 F 2-pyrimidyl 2-(N,N- dimethylaminomethyl)phenyl 773 F 2-pyrimidyl 2-(N-pyrrolidinylmethyl)phenyl 774 F 2-pyrimidyl 1-methyl-2-imidazolyl 775 F 2-pyrimidyl 2-methyl-1-imidazolyl 776 F 2-pyrimidyl 2-(dimethylaminomethyl)-1- imidazolyl 777 F 2-pyrimidyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 778 F 2-pyrimidyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 779 F 2-pyrimidyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 780 F 2-pyrimidyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 781 F 5-pyrimidyl 2-(aminosulfonyl)phenyl 782 F 5-pyrimidyl 2-(methylaminosulfonyl)phenyl 783 F 5-pyrimidyl 1-pyrrolidinocarbonyl 784 F 5-pyrimidyl 2-(methylsulfonyl)phenyl 785 F 5-pyrimidyl 2-(N,N- dimethylaminomethyl)phenyl 786 F 5-pyrimidyl 2-(N-pyrrolidinylmethyl)phenyl 787 F 5-pyrimidyl 1-methyl-2-imidazolyl 788 F 5-pyrimidyl 2-methyl-1-imidazolyl 789 F 5-pyrimidyl 2-(dimethylaminomethyl)-1- imidazolyl 790 F 5-pyrimidyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 791 F 5-pyrimidyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 792 F 5-pyrimidyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 793 F 5-pyrimidyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 794 F 2-F-phenyl 2-(aminosulfonyl)phenyl 795 F 2-F-phenyl 2-(methylaminosulfonyl)phenyl 796 F 2-F-phenyl 1-pyrrolidinocarbonyl 797 F 2-F-phenyl 2-(methylsulfonyl)phenyl 798 F 2-F-phenyl 2-(N,N- dimethylaminomethyl)phenyl 799 F 2-F-phenyl 2-(N-pyrrolidinylmethyl)phenyl 800 F 2-F-phenyl 1-methyl-2-imidazolyl 801 F 2-F-phenyl 2-methyl-1-imidazolyl 802 F 2-F-phenyl 2-(dimethylaminomethyl)-1- imidazolyl 803 F 2-F-phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 804 F 2-F-phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 805 F 2-F-phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 806 F 2-F-phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 807 F 2-F-phenyl 2-(aminosulfonyl)phenyl 808 F 2-F-phenyl 2-(methylaminosulfonyl)phenyl 809 F 2-F-phenyl 1-pyrrolidinocarbonyl 810 F 2-F-phenyl 2-(methylsulfonyl)phenyl 811 F 2-F-phenyl 2-(N,N- dimethylaminomethyl)phenyl 812 F 2-F-phenyl 2-(N-pyrrolidinylmethyl)phenyl 813 F 2-F-phenyl 1-methyl-2-imidazolyl 814 F 2-F-phenyl 2-methyl-1-imidazolyl 815 F 2-F-phenyl 2-(dimethylaminomethyl)-1- imidazolyl 816 F 2-F-phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 817 F 2-F-phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 818 F 2-F-phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 819 F 2-F-phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 820 F 2,6-diF-phenyl 2-(aminosulfonyl)phenyl 821 F 2,6-diF-phenyl 2-(methylaminosulfonyl)phenyl 822 F 2,6-diF-phenyl 1-pyrrolidinocarbonyl 823 F 2,6-diF-phenyl 2-(methylsulfonyl)phenyl 824 F 2,6-diF-phenyl 2-(N,N- dimethylaminomethyl)phenyl 825 F 2,6-diF-phenyl 2-(N-pyrrolidinylmethyl)phenyl 826 F 2,6-diF-phenyl 1-methyl-2-imidazolyl 827 F 2,6-diF-phenyl 2-methyl-1-imidazolyl 828 F 2,6-diF-phenyl 2-(dimethylaminomethyl)-1- imidazolyl 829 F 2,6-diF-phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 830 F 2,6-diF-phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 831 F 2,6-diF-phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 832 F 2,6-diF-phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 833 CO2CH3 phenyl 2-(aminosulfonyl)phenyl 834 CO2CH3 phenyl 2-(methylaminosulfonyl)phenyl 835 CO2CH3 phenyl 1-pyrrolidinocarbonyl 836 CO2CH3 phenyl 2-(methylsulfonyl)phenyl 837 CO2CH3 phenyl 2-(N,N- dimethylaminomethyl)phenyl 838 CO2CH3 phenyl 2-(N-pyrrolidinylmethyl)phenyl 839 CO2CH3 phenyl 1-methyl-2-imidazolyl 840 CO2CH3 phenyl 2-methyl-1-imidazolyl 841 CO2CH3 phenyl 2-(dimethylaminomethyl)-1- imidazolyl 842 CO2CH3 phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 843 CO2CH3 phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 844 CO2CH3 phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 845 CO2CH3 phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 846 CO2CH3 2-pyridyl 2-(aminosulfonyl)phenyl 847 CO2CH3 2-pyridyl 2-(methylaminosulfonyl)phenyl 848 CO2CH3 2-pyridyl 1-pyrrolidinocarbonyl 849 CO2CH3 2-pyridyl 2-(methylsulfonyl)phenyl 850 CO2CH3 2-pyridyl 2-(N,N- dimethylaminomethyl)phenyl 851 CO2CH3 2-pyridyl 2-(N-pyrrolidinylmethyl)phenyl 852 CO2CH3 2-pyridyl 1-methyl-2-imidazolyl 853 CO2CH3 2-pyridyl 2-methyl-1-imidazolyl 854 CO2CH3 2-pyridyl 2-(dimethylaminomethyl)-1- imidazolyl 855 CO2CH3 2-pyridyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 856 CO2CH3 2-pyridyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 857 CO2CH3 2-pyridyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 858 CO2CH3 2-pyridyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 859 CO2CH3 3-pyridyl 2-(aminosulfonyl)phenyl 860 CO2CH3 3-pyridyl 2-(methylaminosulfonyl)phenyl 861 CO2CH3 3-pyridyl 1-pyrrolidinocarbonyl 862 CO2CH3 3-pyridyl 2-(methylsulfonyl)phenyl 863 CO2CH3 3-pyridyl 2-(N,N- dimethylaminomethyl)phenyl 864 CO2CH3 3-pyridyl 2-(N-pyrrolidinylmethyl)phenyl 865 CO2CH3 3-pyridyl 1-methyl-2-imidazolyl 866 CO2CH3 3-pyridyl 2-methyl-1-imidazolyl 867 CO2CH3 3-pyridyl 2-(dimethylaminomethyl)-1- imidazolyl 868 CO2CH3 3-pyridyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 869 CO2CH3 3-pyridyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 870 CO2CH3 3-pyridyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 871 CO2CH3 3-pyridyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 872 CO2CH3 2-pyrimidyl 2-(aminosulfonyl)phenyl 873 CO2CH3 2-pyrimidyl 2-(methylaminosulfonyl)phenyl 874 CO2CH3 2-pyrimidyl 1-pyrrolidinocarbonyl 875 CO2CH3 2-pyrimidyl 2-(methylsulfonyl)phenyl 876 CO2CH3 2-pyrimidyl 2-(N,N- dimethylaminomethyl)phenyl 877 CO2CH3 2-pyrimidyl 2-(N-pyrrolidinylmethyl)phenyl 878 CO2CH3 2-pyrimidyl 1-methyl-2-imidazolyl 879 CO2CH3 2-pyrimidyl 2-methyl-1-imidazolyl 880 CO2CH3 2-pyrimidyl 2-(dimethylaminomethyl)-1- imidazolyl 881 CO2CH3 2-pyrimidyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 882 CO2CH3 2-pyrimidyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 883 CO2CH3 2-pyrimidyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 884 CO2CH3 2-pyrimidyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 885 CO2CH3 5-pyrimidyl 2-(aminosulfonyl)phenyl 886 CO2CH3 5-pyrimidyl 2-(methylaminosulfonyl)phenyl 887 CO2CH3 5-pyrimidyl 1-pyrrolidinocarbonyl 888 CO2CH3 5-pyrimidyl 2-(methylsulfonyl)phenyl 889 CO2CH3 5-pyrimidyl 2-(N,N- dimethylaminomethyl)phenyl 890 CO2CH3 5-pyrimidyl 2-(N-pyrrolidinylmethyl)phenyl 891 CO2CH3 5-pyrimidyl 1-methyl-2-imidazolyl 892 CO2CH3 5-pyrimidyl 2-methyl-1-imidazolyl 893 CO2CH3 5-pyrimidyl 2-(dimethylaminomethyl)-1- imidazolyl 894 CO2CH3 5-pyrimidyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 895 CO2CH3 5-pyrimidyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 896 CO2CH3 5-pyrimidyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 897 CO2CH3 5-pyrimidyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 898 CO2CH3 2-F-phenyl 2-(aminosulfonyl)phenyl 899 CO2CH3 2-F-phenyl 2-(methylaminosulfonyl)phenyl 900 CO2CH3 2-F-phenyl 1-pyrrolidinocarbonyl 901 CO2CH3 2-F-phenyl 2-(methylsulfonyl)phenyl 902 CO2CH3 2-F-phenyl 2-(N,N- dimethylaminomethyl)phenyl 903 CO2CH3 2-F-phenyl 2-(N-pyrrolidinylmethyl)phenyl 904 CO2CH3 2-F-phenyl 1-methyl-2-imidazolyl 905 CO2CH3 2-F-phenyl 2-methyl-1-imidazolyl 906 CO2CH3 2-F-phenyl 2-(dimethylaminomethyl)-1- imidazolyl 907 CO2CH3 2-F-phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 908 CO2CH3 2-F-phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 909 CO2CH3 2-F-phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 910 CO2CH3 2-F-phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 911 CO2CH3 2-F-phenyl 2-(aminosulfonyl)phenyl 912 CO2CH3 2-F-phenyl 2-(methylaminosulfonyl)phenyl 913 CO2CH3 2-F-phenyl 1-pyrrolidinocarbonyl 914 CO2CH3 2-F-phenyl 2-(methylsulfonyl)phenyl 915 CO2CH3 2-F-phenyl 2-(N,N- dimethylaminomethyl)phenyl 916 CO2CH3 2-F-phenyl 2-(N-pyrrolidinylmethyl)phenyl 917 CO2CH3 2-F-phenyl 1-methyl-2-imidazolyl 918 CO2CH3 2-F-phenyl 2-methyl-1-imidazolyl 919 CO2CH3 2-F-phenyl 2-(dimethylaminomethyl)-1- imidazolyl 920 CO2CH3 2-F-phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 921 CO2CH3 2-F-phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 922 CO2CH3 2-F-phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 923 CO2CH3 2-F-phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 924 CO2CH3 2,6-diF-phenyl 2-(aminosulfonyl)phenyl 925 CO2CH3 2,6-diF-phenyl 2-(methylaminosulfonyl)phenyl 926 CO2CH3 2,6-diF-phenyl 1-pyrrolidinocarbonyl 927 CO2CH3 2,6-diF-phenyl 2-(methylsulfonyl)phenyl 928 CO2CH3 2,6-diF-phenyl 2-(N,N- dimethylaminomethyl)phenyl 929 CO2CH3 2,6-diF-phenyl 2-(N-pyrrolidinylmethyl)phenyl 930 CO2CH3 2,6-diF-phenyl 1-methyl-2-imidazolyl 931 CO2CH3 2,6-diF-phenyl 2-methyl-1-imidazolyl 932 CO2CH3 2,6-diF-phenyl 2-(dimethylaminomethyl)-1- imidazolyl 933 CO2CH3 2,6-diF-phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 934 CO2CH3 2,6-diF-phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 935 CO2CH3 2,6-diF-phenyl 2-(N-(cyclopentyl)- aminomethyl )phenyl 936 CO2CH3 2,6-diF-phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 937 CH2OCH3 phenyl 2-(aminosulfonyl)phenyl 938 CH2OCH3 phenyl 2-(methylaminosulfonyl)phenyl 939 CH2OCH3 phenyl 1-pyrrolidinocarbonyl 940 CH2OCH3 phenyl 2-(methylsulfonyl)phenyl 941 CH2OCH3 phenyl 2-(N,N- dimethylaminomethyl)phenyl 942 CH2OCH3 phenyl 2-(N-pyrrolidinylmethyl)phenyl 943 CH2OCH3 phenyl 1-methyl-2-imidazolyl 944 CH2OCH3 phenyl 2-methyl-1-imidazolyl 945 CH2OCH3 phenyl 2-(dimethylaminomethyl)-1- imidazolyl 946 CH2OCH3 phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 947 CH2OCH3 phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 948 CH2OCH3 phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 949 CH2OCH3 phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 950 CH2OCH3 2-pyridyl 2-(aminosulfonyl)phenyl 951 CH2OCH3 2-pyridyl 2-(methylaminosulfonyl)phenyl 952 CH2OCH3 2-pyridyl 1-pyrrolidinocarbonyl 953 CH2OCH3 2-pyridyl 2-(methylsulfonyl)phenyl 954 CH2OCH3 2-pyridyl 2-(N,N- dimethylaminomethyl)phenyl 955 CH2OCH3 2-pyridyl 2-(N-pyrrolidinylmethyl)phenyl 956 CH2OCH3 2-pyridyl 1-methyl-2-imidazolyl 957 CH2OCH3 2-pyridyl 2-methyl-1-imidazolyl 958 CH2OCH3 2-pyridyl 2-(dimethylaminomethyl)-1- imidazolyl 959 CH2OCH3 2-pyridyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 960 CH2OCH3 2-pyridyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 961 CH2OCH3 2-pyridyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 962 CH2OCH3 2-pyridyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 963 CH2OCH3 3-pyridyl 2-(aminosulfonyl)phenyl 964 CH2OCH3 3-pyridyl 2-(methylaminosulfonyl)phenyl 965 CH2OCH3 3-pyridyl 1-pyrrolidinocarbonyl 966 CH2OCH3 3-pyridyl 2-(methylsulfonyl)phenyl 967 CH2OCH3 3-pyridyl 2-(N,N- dimethylaminomethyl)phenyl 968 CH2OCH3 3-pyridyl 2-(N-pyrrolidinylmethyl)phenyl 969 CH2OCH3 3-pyridyl 1-methyl-2-imidazolyl 970 CH2OCH3 3-pyridyl 2-methyl-1-imidazolyl 971 CH2OCH3 3-pyridyl 2-(dimethylaminomethyl)-1- imidazolyl 972 CH2OCH3 3-pyridyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 973 CH2OCH3 3-pyridyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 974 CH2OCH3 3-pyridyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 975 CH2OCH3 3-pyridyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 976 CH2OCH3 2-pyrimidyl 2-(aminosulfonyl)phenyl 977 CH2OCH3 2-pyrimidyl 2-(methylaminosulfonyl)phenyl 978 CH2OCH3 2-pyrimidyl 1-pyrrolidinocarbonyl 979 CH2OCH3 2-pyrimidyl 2-(methylsulfonyl)phenyl 980 CH2OCH3 2-pyrimidyl 2-(N,N- dimethylaminomethyl)phenyl 981 CH2OCH3 2-pyrimidyl 2-(N-pyrrolidinylmethyl)phenyl 982 CH2OCH3 2-pyrimidyl 1-methyl-2-imidazolyl 983 CH2OCH3 2-pyrimidyl 2-methyl-1-imidazolyl 984 CH2OCH3 2-pyrimidyl 2-(dimethylaminomethyl)-1- imidazolyl 985 CH2OCH3 2-pyrimidyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 986 CH2OCH3 2-pyrimidyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 987 CH2OCH3 2-pyrimidyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 988 CH2OCH3 2-pyrimidyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 989 CH2OCH3 5-pyrimidyl 2-(aminosulfonyl)phenyl 990 CH2OCH3 5-pyrimidyl 2-(methylaminosulfonyl)phenyl 991 CH2OCH3 5-pyrimidyl 1-pyrrolidinocarbonyl 992 CH2OCH3 5-pyrimidyl 2-(methylsulfonyl)phenyl 993 CH2OCH3 5-pyrimidyl 2-(N,N- dimethylaminomethyl)phenyl 994 CH2OCH3 5-pyrimidyl 2-(N-pyrrolidinylmethyl)phenyl 995 CH2OCH3 5-pyrimidyl 1-methyl-2-imidazolyl 996 CH2OCH3 5-pyrimidyl 2-methyl-1-imidazolyl 997 CH2OCH3 5-pyrimidyl 2-(dimethylaminomethyl)-1- imidazolyl 998 CH2OCH3 5-pyrimidyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 999 CH2OCH3 5-pyrimidyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 1000 CH2OCH3 5-pyrimidyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 1001 CH2OCH3 5-pyrimidyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 1002 CH2OCH3 2-F-phenyl 2-(aminosulfonyl)phenyl 1003 CH2OCH3 2-F-phenyl 2-(methylaminosulfonyl)phenyl 1004 CH2OCH3 2-F-phenyl 1-pyrrolidinocarbonyl 1005 CH2OCH3 2-F-phenyl 2-(methylsulfonyl)phenyl 1006 CH2OCH3 2-F-phenyl 2-(N,N- dimethylaminomethyl)phenyl 1007 CH2OCH3 2-F-phenyl 2-(N-pyrrolidinylmethyl)phenyl 1008 CH2OCH3 2-F-phenyl 1-methyl-2-imidazolyl 1009 CH2OCH3 2-F-phenyl 2-methyl-1-imidazolyl 1010 CH2OCH3 2-F-phenyl 2-(dimethylaminomethyl)-1- imidazolyl 1011 CH2OCH3 2-F-phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 1012 CH2OCH3 2-F-phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 1013 CH2OCH3 2-F-phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 1014 CH2OCH3 2-F-phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 1015 CH2OCH3 2-F-phenyl 2-(aminosulfonyl)phenyl 1016 CH2OCH3 2-F-phenyl 2-(methylaminosulfonyl)phenyl 1017 CH2OCH3 2-F-phenyl 1-pyrrolidinocarbonyl 1018 CH2OCH3 2-F-phenyl 2-(methylsulfonyl)phenyl 1019 CH2OCH3 2-F-phenyl 2-(N,N- dimethylaminomethyl)phenyl 1020 CH2OCH3 2-F-phenyl 2-(N-pyrrolidinylmethyl)phenyl 1021 CH2OCH3 2-F-phenyl 1-methyl-2-imidazolyl 1022 CH2OCH3 2-F-phenyl 2-methyl-1-imidazolyl 1023 CH2OCH3 2-F-phenyl 2-(dimethylaminomethyl)-1- imidazolyl 1024 CH2OCH3 2-F-phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 1025 CH2OCH3 2-F-phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 1026 CH2OCH3 2-F-phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 1027 CH2OCH3 2-F-phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 1028 CH2OCH3 2,6-diF-phenyl 2-(aminosulfonyl)phenyl 1029 CH2OCH3 2,6-diF-phenyl 2-(methylaminosulfonyl)phenyl 1030 CH2OCH3 2,6-diF-phenyl 1-pyrrolidinocarbonyl 1031 CH2OCH3 2,6-diF-phenyl 2-(methylsulfonyl)phenyl 1032 CH2OCH3 2,6-diF-phenyl 2-(N,N- dimethylaminomethyl)phenyl 1033 CH2OCH3 2,6-diF-phenyl 2-(N-pyrrolidinylmethyl)phenyl 1034 CH2OCH3 2,6-diF-phenyl 1-methyl-2-imidazolyl 1035 CH2OCH3 2,6-diF-phenyl 2-methyl-1-imidazolyl 1036 CH2OCH3 2,6-diF-phenyl 2-(dimethylaminomethyl)-1- imidazolyl 1037 CH2OCH3 2,6-diF-phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 1038 CH2OCH3 2,6-diF-phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 1039 CH2OCH3 2,6-diF-phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 1040 CH2OCH3 2,6-diF-phenyl 2-(N-(3-hydroxypyrrolidinyl) - methyl)phenyl 1041 CONH2 phenyl 2-(aminosulfonyl)phenyl 1042 CONH2 phenyl 2-(methylaminosulfonyl)phenyl 1043 CONH2 phenyl 1-pyrrolidinocarbonyl 1044 CONH2 phenyl 2-(methylsulfonyl)phenyl 1045 CONH2 phenyl 2-(N,N- dimethylaminomethyl)phenyl 1046 CONH2 phenyl 2-(N-pyrrolidinylmethyl)phenyl 1047 CONH2 phenyl 1-methyl-2-imidazolyl 1048 CONH2 phenyl 2-methyl-1-imidazolyl 1049 CONH2 phenyl 2-(dimethylaminomethyl)-1- imidazolyl 1050 CONH2 phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 1051 CONH2 phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 1052 CONH2 phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 1053 CONH2 phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 1054 CONH2 2-pyridyl 2-(aminosulfonyl)phenyl 1055 CONH2 2-pyridyl 2-(methylaminosulfonyl)phenyl 1056 CONH2 2-pyridyl 1-pyrrolidinocarbonyl 1057 CONH2 2-pyridyl 2-(methylsulfonyl)phenyl 1058 CONH2 2-pyridyl 2-(N,N- dimethylaminomethyl)phenyl 1059 CONH2 2-pyridyl 2-(N-pyrrolidinylmethyl)phenyl 1060 CONH2 2-pyridyl 1-methyl-2-imidazolyl 1061 CONH2 2-pyridyl 2-methyl-1-imidazolyl 1062 CONH2 2-pyridyl 2-(dimethylaminomethyl)-1- imidazolyl 1063 CONH2 2-pyridyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 1064 CONH2 2-pyridyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 1065 CONH2 2-pyridyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 1066 CONH2 2-pyridyl 2-(N-(3-hydroxypyrrolidinyl) - methyl)phenyl 1067 CONH2 3-pyridyl 2-(aminosulfonyl)phenyl 1068 CONH2 3-pyridyl 2-(methylaminosulfonyl)phenyl 1069 CONH2 3-pyridyl 1-pyrrolidinocarbonyl 1070 CONH2 3-pyridyl 2-(methylsulfonyl)phenyl 1071 CONH2 3-pyridyl 2-(N,N- dimethylaminomethyl)phenyl 1072 CONH2 3-pyridyl 2-(N-pyrrolidinylmethyl)phenyl 1073 CONH2 3-pyridyl 1-methyl-2-imidazolyl 1074 CONH2 3-pyridyl 2-methyl-1-imidazolyl 1075 CONH2 3-pyridyl 2-(dimethylaminomethyl)-1- imidazolyl 1076 CONH2 3-pyridyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 1077 CONH2 3-pyridyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 1078 CONH2 3-pyridyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 1079 CONH2 3-pyridyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 1080 CONH2 2-pyrimidyl 2-(aminosulfonyl)phenyl 1081 CONH2 2-pyrimidyl 2-(methylaminosulfonyl)phenyl 1082 CONH2 2-pyrimidyl 1-pyrrolidinocarbonyl 1083 CONH2 2-pyrimidyl 2-(methylsulfonyl)phenyl 1084 CONH2 2-pyrimidyl 2-(N,N- dimethylaminomethyl)phenyl 1085 CONH2 2-pyrimidyl 2-(N-pyrrolidinylmethyl)phenyl 1086 CONH2 2-pyrimidyl 1-methyl-2-imidazolyl 1087 CONH2 2-pyrimidyl 2-methyl-1-imidazolyl 1088 CONH2 2-pyrimidyl 2-(dimethylaminomethyl)-1- imidazolyl 1089 CONH2 2-pyrimidyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 1090 CONH2 2-pyrimidyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 1091 CONH2 2-pyrimidyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 1092 CONH2 2-pyrimidyl 2-(N-(3-hydroxypyrrolidinyl) methyl)phenyl 1093 CONH2 5-pyrimidyl 2-(aminosulfonyl)phenyl 1094 CONH2 5-pyrimidyl 2-(methylaminosulfonyl)phenyl 1095 CONH2 5-pyrimidyl 1-pyrrolidinocarbonyl 1096 CONH2 5-pyrimidyl 2-(methylsulfonyl)phenyl 1097 CONH2 5-pyrimidyl 2-(N,N- dimethylaminomethyl)phenyl 1098 CONH2 5-pyrimidyl 2-(N-pyrrolidinylmethyl)phenyl 1099 CONH2 5-pyrimidyl 1-methyl-2-imidazolyl 1100 CONH2 5-pyrimidyl 2-methyl-1-imidazolyl 1101 CONH2 5-pyrimidyl 2-(dimethylaminomethyl)-1- imidazolyl 1102 CONH2 5-pyrimidyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 1103 CONH2 5-pyrimidyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 1104 CONH2 5-pyrimidyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 1105 CONH2 5-pyrimidyl 2-(N-(3-hydroxypyrrolidinyl) - methyl)phenyl 1106 CONH2 2-F-phenyl 2-(aminosulfonyl)phenyl 1107 CONH2 2-F-phenyl 2-(methylaminosulfonyl)phenyl 1108 CONH2 2-F-phenyl 1-pyrrolidinocarbonyl 1109 CONH2 2-F-phenyl 2-(methylsulfonyl)phenyl 1110 CONH2 2-F-phenyl 2-(N,N- dimethylaminomethyl)phenyl 1111 CONH2 2-F-phenyl 2-(N-pyrrolidinylmethyl)phenyl 1112 CONH2 2-F-phenyl 1-methyl-2-imidazolyl 1113 CONH2 2-F-phenyl 2-methyl-1-imidazolyl 1114 CONH2 2-F-phenyl 2-(dimethylaminomethyl)-1- imidazolyl 1115 CONH2 2-F-phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 1116 CONH2 2-F-phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 1117 CONH2 2-F-phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 1118 CONH2 2-F-phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 1119 CONH2 2-F-phenyl 2-(aminosulfonyl)phenyl 1120 CONH2 2-F-phenyl 2-(methylaminosulfonyl)phenyl 1121 CONH2 2-F-phenyl 1-pyrrolidinocarbonyl 1122 CONH2 2-F-phenyl 2-(methylsulfonyl)phenyl 1123 CONH2 2-F-phenyl 2-(N,N- dimethylaminomethyl)phenyl 1124 CONH2 2-F-phenyl 2-(N-pyrrolidinylmethyl)phenyl 1125 CONH2 2-F-phenyl 1-methyl-2-imidazolyl 1126 CONH2 2-F-phenyl 2-methyl-1-imidazolyl 1127 CONH2 2-F-phenyl 2-(dimethylaminomethyl)-1- imidazolyl 1128 CONH2 2-F-phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 1129 CONH2 2-F-phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 1130 CONH2 2-F-phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 1131 CONH2 2-F-phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 1132 CONH2 2,6-diF-phenyl 2-(aminosulfonyl)phenyl 1133 CONH2 2,6-diF-phenyl 2-(methylaminosulfonyl)phenyl 1134 CONH2 2,6-diF-phenyl 1-pyrrolidinocarbonyl 1135 CONH2 2,6-diF-phenyl 2-(methylsulfonyl)phenyl 1136 CONH2 2,6-diF-phenyl 2-(N,N- dimethylaminomethyl)phenyl 1137 CONH2 2,6-diF-phenyl 2-(N-pyrrolidinylmethyl)phenyl 1138 CONH2 2,6-diF-phenyl 1-methyl-2-imidazolyl 1139 CONH2 2,6-diF-phenyl 2-methyl-1-imidazolyl 1140 CONH2 2,6-diF-phenyl 2-(dimethylaminomethyl)-1- imidazolyl 1141 CONH2 2,6-diF-phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 1142 CONH2 2,6-diF-phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 1143 CONH2 2,6-diF-phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 1144 CONH2 2,6-diF-phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 1145 CN phenyl 2-(aminosulfonyl)phenyl 1146 CN phenyl 2-(methylaminosulfonyl)phenyl 1147 CN phenyl 1-pyrrolidinocarbonyl 1148 CN phenyl 2-(methylsulfonyl)phenyl 1149 CN phenyl 2-(N,N- dimethylaminomethyl)phenyl 1150 CN phenyl 2-(N-pyrrolidinylmethyl)phenyl 1151 CN phenyl 1-methyl-2-imidazolyl 1152 CN phenyl 2-methyl-1-imidazolyl 1153 CN phenyl 2-(dimethylaminomethyl)-1- imidazolyl 1154 CN phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 1155 CN phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 1156 CN phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 1157 CN phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 1158 CN 2-pyridyl 2-(aminosulfonyl)phenyl 1159 CN 2-pyridyl 2-(methylaminosulfonyl)phenyl 1160 CN 2-pyridyl 1-pyrrolidinocarbonyl 1161 CN 2-pyridyl 2-(methylsulfonyl)phenyl 1162 CN 2-pyridyl 2-(N,N- dimethylaminomethyl)phenyl 1163 CN 2-pyridyl 2-(N-pyrrolidinylmethyl)phenyl 1164 CN 2-pyridyl 1-methyl-2-imidazolyl 1165 CN 2-pyridyl 2-methyl-1-imidazolyl 1166 CN 2-pyridyl 2-(dimethylaminomethyl)-1- imidazolyl 1167 CN 2-pyridyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 1168 CN 2-pyridyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 1169 CN 2-pyridyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 1170 CN 2-pyridyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 1171 CN 3-pyridyl 2-(aminosulfonyl)phenyl 1172 CN 3-pyridyl 2-(methylaminosulfonyl)phenyl 1173 CN 3-pyridyl 1-pyrrolidinocarbonyl 1174 CN 3-pyridyl 2-(methylsulfonyl)phenyl 1175 CN 3-pyridyl 2-(N,N- dimethylaminomethyl)phenyl 1176 CN 3-pyridyl 2-(N-pyrrolidinylmethyl)phenyl 1177 CN 3-pyridyl 1-methyl-2-imidazolyl 1178 CN 3-pyridyl 2-methyl-1-imidazolyl 1179 CN 3-pyridyl 2-(dimethylaminomethyl)-1- imidazolyl 1180 CN 3-pyridyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 1181 CN 3-pyridyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 1182 CN 3-pyridyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 1183 CN 3-pyridyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 1184 CN 2-pyrimidyl 2-(aminosulfonyl)phenyl 1185 CN 2-pyrimidyl 2-(methylaminosulfonyl)phenyl 1186 CN 2-pyrimidyl 1-pyrrolidinocarbonyl 1187 CN 2-pyrimidyl 2-(methylsulfonyl)phenyl 1188 CN 2-pyrimidyl 2-(N,N- dimethylaminomethyl)phenyl 1189 CN 2-pyrimidyl 2-(N-pyrrolidinylmethyl)phenyl 1190 CN 2-pyrimidyl 1-methyl-2-imidazolyl 1191 CN 2-pyrimidyl 2-methyl-1-imidazolyl 1192 CN 2-pyrimidyl 2-(dimethylaminomethyl)-1- imidazolyl 1193 CN 2-pyrimidyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 1194 CN 2-pyrimidyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 1195 CN 2-pyrimidyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 1196 CN 2-pyrimidyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 1197 CN 5-pyrimidyl 2-(aminosulfonyl)phenyl 1198 CN 5-pyrimidyl 2-(methylaminosulfonyl)phenyl 1199 CN 5-pyrimidyl 1-pyrrolidinocarbonyl 1200 CN 5-pyrimidyl 2-(methylsulfonyl)phenyl 1201 CN 5-pyrimidyl 2-(N,N- dimethylaminomethyl)phenyl 1202 CN 5-pyrimidyl 2-(N-pyrrolidinylmethyl)phenyl 1203 CN 5-pyrimidyl 1-methyl-2-imidazolyl 1204 CN 5-pyrimidyl 2-methyl-1-imidazolyl 1205 CN 5-pyrimidyl 2-(dimethylaminomethyl)-1- imidazolyl 1206 CN 5-pyrimidyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 1207 CN 5-pyrimidyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 1208 CN 5-pyrimidyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 1209 CN 5-pyrimidyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 1210 CN 2-F-phenyl 2-(aminosulfonyl)phenyl 1211 CN 2-F-phenyl 2-(methylaminosulfonyl)phenyl 1212 CN 2-F-phenyl 1-pyrrolidinocarbonyl 1213 CN 2-F-phenyl 2-(methylsulfonyl)phenyl 1214 CN 2-F-phenyl 2-(N,N- dimethylaminomethyl)phenyl 1215 CN 2-F-phenyl 2-(N-pyrrolidinylmethyl)phenyl 1216 CN 2-F-phenyl 1-methyl-2-imidazolyl 1217 CN 2-F-phenyl 2-methyl-1-imidazolyl 1218 CN 2-F-phenyl 2-(dimethylaminomethyl)-1- imidazolyl 1219 CN 2-F-phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 1220 CN 2-F-phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 1221 CN 2-F-phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 1222 CN 2-F-phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 1223 CN 2-F-phenyl 2-(aminosulfonyl)phenyl 1224 CN 2-F-phenyl 2-(methylaminosulfonyl)phenyl 1225 CN 2-F-phenyl 1-pyrrolidinocarbonyl 1226 CN 2-F-phenyl 2-(methylsulfonyl)phenyl 1227 CN 2-F-phenyl 2-(N,N- dimethylaminomethyl)phenyl 1228 CN 2-F-phenyl 2-(N-pyrrolidinylmethyl)phenyl 1229 CN 2-F-phenyl 1-methyl-2-imidazolyl 1230 CN 2-F-phenyl 2-methyl-1-imidazolyl 1231 CN 2-F-phenyl 2-(dimethylaminomethyl)-1- imidazolyl 1232 CN 2-F-phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 1233 CN 2-F-phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 1234 CN 2-F-phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 1235 CN 2-F-phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 1236 CN 2,6-diF-phenyl 2-(aminosulfonyl)phenyl 1237 CN 2,6-diF-phenyl 2-(methylaminosulfonyl)phenyl 1238 CN 2,6-diF-phenyl 1-pyrrolidinocarbonyl 1239 CN 2,6-diF-phenyl 2-(methylsulfonyl)phenyl 1240 CN 2,6-diF-phenyl 2-(N,N- dimethylaminomethyl)phenyl 1241 CN 2,6-diF-phenyl 2-(N-pyrrolidinylmethyl)phenyl 1242 CN 2,6-diF-phenyl 1-methyl-2-imidazolyl 1243 CN 2,6-diF-phenyl 2-methyl-1-imidazolyl 1244 CN 2,6-diF-phenyl 2-(dimethylaminomethyl)-1- imidazolyl 1245 CN 2,6-diF-phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 1246 CN 2,6-diF-phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 1247 CN 2,6-diF-phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 1248 CN 2,6-diF-phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 1249 CH2NH2 phenyl 2-(aminosulfonyl)phenyl 1250 CH2NH2 phenyl 2-(methylaminosulfonyl)phenyl 1251 CH2NH2 phenyl 1-pyrrolidinocarbonyl 1252 CH2NH2 phenyl 2-(methylsulfonyl)phenyl 1253 CH2NH2 phenyl 2-(N,N- dimethylaminomethyl)phenyl 1254 CH2NH2 phenyl 2-(N-pyrrolidinylmethyl)phenyl 1255 CH2NH2 phenyl 1-methyl-2-imidazolyl 1256 CH2NH2 phenyl 2-methyl-1-imidazolyl 1257 CH2NH2 phenyl 2-(dimethylaminomethyl)-1- imidazolyl 1258 CH2NH2 phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 1259 CH2NH2 phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 1260 CH2NH2 phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 1261 CH2NH2 phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 1262 CH2NH2 2-pyridyl 2-(aminosulfonyl)phenyl 1263 CH2NH2 2-pyridyl 2-(methylaminosulfonyl)phenyl 1264 CH2NH2 2-pyridyl 1-pyrrolidinocarbonyl 1265 CH2NH2 2-pyridyl 2-(methylsulfonyl)phenyl 1266 CH2NH2 2-pyridyl 2-(N,N- dimethylaminomethyl)phenyl 1267 CH2NH2 2-pyridyl 2-(N-pyrrolidinylmethyl)phenyl 1268 CH2NH2 2-pyridyl 1-methyl-2-imidazolyl 1269 CH2NH2 2-pyridyl 2-methyl-1-imidazolyl 1270 CH2NH2 2-pyridyl 2-(dimethylaminomethyl)-1- imidazolyl 1271 CH2NH2 2-pyridyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 1272 CH2NH2 2-pyridyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 1273 CH2NH2 2-pyridyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 1274 CH2NH2 2-pyridyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 1275 CH2NH2 3-pyridyl 2-(aminosulfonyl)phenyl 1276 CH2NH2 3-pyridyl 2-(methylaminosulfonyl)phenyl 1277 CH2NH2 3-pyridyl 1-pyrrolidinocarbonyl 1278 CH2NH2 3-pyridyl 2-(methylsulfonyl)phenyl 1279 CH2NH2 3-pyridyl 2-(N,N- dimethylaminomethyl)phenyl 1280 CH2NH2 3-pyridyl 2-(N-pyrrolidinylmethyl)phenyl 1281 CH2NH2 3-pyridyl 1-methyl-2-imidazolyl 1282 CH2NH2 3-pyridyl 2-methyl-1-imidazolyl 1283 CH2NH2 3-pyridyl 2-(dimethylaminomethyl)-1- imidazolyl 1284 CH2NH2 3-pyridyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 1285 CH2NH2 3-pyridyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 1286 CH2NH2 3-pyridyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 1287 CH2NH2 3-pyridyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 1288 CH2NH2 2-pyrimidyl 2-(aminosulfonyl)phenyl 1289 CH2NH2 2-pyrimidyl 2-(methylaminosulfonyl)phenyl 1290 CH2NH2 2-pyrimidyl 1-pyrrolidinocarbonyl 1291 CH2NH2 2-pyrimidyl 2-(methylsulfonyl)phenyl 1292 CH2NH2 2-pyrimidyl 2-(N,N- dimethylaminomethyl)phenyl 1293 CH2NH2 2-pyrimidyl 2-(N-pyrrolidinylmethyl)phenyl 1294 CH2NH2 2-pyrimidyl 1-methyl-2-imidazolyl 1295 CH2NH2 2-pyrimidyl 2-methyl-1-imidazolyl 1296 CH2NH2 2-pyrimidyl 2-(dimethylaminomethyl)-1- imidazolyl 1297 CH2NH2 2-pyrimidyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 1298 CH2NH2 2-pyrimidyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 1299 CH2NH2 2-pyrimidyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 1300 CH2NH2 2-pyrimidyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 1301 CH2NH2 5-pyrimidyl 2-(aminosulfonyl)phenyl 1302 CH2NH2 5-pyrimidyl 2-(methylaminosulfonyl)phenyl 1303 CH2NH2 5-pyrimidyl 1-pyrrolidinocarbonyl 1304 CH2NH2 5-pyrimidyl 2-(methylsulfonyl)phenyl 1305 CH2NH2 5-pyrimidyl 2-(N,N- dimethylaminomethyl)phenyl 1306 CH2NH2 5-pyrimidyl 2-(N-pyrrolidinylmethyl)phenyl 1307 CH2NH2 5-pyrimidyl 1-methyl-2-imidazolyl 1308 CH2NH2 5-pyrimidyl 2-methyl-1-imidazolyl 1309 CH2NH2 5-pyrimidyl 2-(dimethylaminomethyl)-1- imidazolyl 1310 CH2NH2 5-pyrimidyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 1311 CH2NH2 5-pyrimidyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 1312 CH2NH2 5-pyrimidyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 1313 CH2NH2 5-pyrimidyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 1314 CH2NH2 2-F-phenyl 2-(aminosulfonyl)phenyl 1315 CH2NH2 2-F-phenyl 2-(methylaminosulfonyl)phenyl 1316 CH2NH2 2-F-phenyl 1-pyrrolidinocarbonyl 1317 CH2NH2 2-F-phenyl 2-(methylsulfonyl)phenyl 1318 CH2NH2 2-F-phenyl 2-(N,N- dimethylaminomethyl)phenyl 1319 CH2NH2 2-F-phenyl 2-(N-pyrrolidinylmethyl)phenyl 1320 CH2NH2 2-F-phenyl 1-methyl-2-imidazolyl 1321 CH2NH2 2-F-phenyl 2-methyl-1-imidazolyl 1322 CH2NH2 2-F-phenyl 2-(dimethylaminomethyl)-1- imidazolyl 1323 CH2NH2 2-F-phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 1324 CH2NH2 2-F-phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 1325 CH2NH2 2-F-phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 1326 CH2NH2 2-F-phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 1327 CH2NH2 2-F-phenyl 2-(aminosulfonyl)phenyl 1328 CH2NH2 2-F-phenyl 2-(methylaminosulfonyl)phenyl 1329 CH2NH2 2-F-phenyl 1-pyrrolidinocarbonyl 1330 CH2NH2 2-F-phenyl 2-(methylsulfonyl)phenyl 1331 CH2NH2 2-F-phenyl 2-(N,N- dimethylaminomethyl)phenyl 1332 CH2NH2 2-F-phenyl 2-(N-pyrrolidinylmethyl)phenyl 1333 CH2NH2 2-F-phenyl 1-methyl-2-imidazolyl 1334 CH2NH2 2-F-phenyl 2-methyl-1-imidazolyl 1335 CH2NH2 2-F-phenyl 2-(dimethylaminomethyl)-1- imidazolyl 1336 CH2NH2 2-F-phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 1337 CH2NH2 2-F-phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 1338 CH2NH2 2-F-phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 1339 CH2NH2 2-F-phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 1340 CH2NH2 2,6-diF-phenyl 2-(aminosulfonyl)phenyl 1341 CH2NH2 2,6-diF-phenyl 2-(methylaminosulfonyl)phenyl 1342 CH2NH2 2,6-diF-phenyl 1-pyrrolidinocarbonyl 1343 CH2NH2 2,6-diF-phenyl 2-(methylsulfonyl)phenyl 1344 CH2NH2 2,6-diF-phenyl 2-(N,N- dimethylaminomethyl)phenyl 1345 CH2NH2 2,6-diF-phenyl 2-(N-pyrrolidinylmethyl)phenyl 1346 CH2NH2 2,6-diF-phenyl 1-methyl-2-imidazolyl 1347 CH2NH2 2,6-diF-phenyl 2-methyl-1-imidazolyl 1348 CH2NH2 2,6-diF-phenyl 2-(dimethylaminomethyl)-1- imidazolyl 1349 CH2NH2 2,6-diF-phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 1350 CH2NH2 2,6-diF-phenyl 2-(N-(cyclobutyl)- aminomethyl)phenyl 1351 CH2NH2 2,6-diF-phenyl 2-(N-(cyclopentyl)- aminomethyl)phenyl 1352 CH2NH2 2,6-diF-phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 1353 CH2NH— phenyl 2-(aminosulfonyl)phenyl SO2CH3 1354 CH2NH— phenyl 2-(methylaminosulfonyl)phenyl SO2CH3 1355 CH2NH— phenyl 1-pyrrolidinocarbonyl SO2CH3 1356 CH2NH— phenyl 2-(methylsulfonyl)phenyl SO2CH3 1357 CH2NH— phenyl 2-(N,N- SO2CH3 dimethylaminomethyl)phenyl 1358 CH2NH— phenyl 2-(N-pyrrolidinylmethyl)phenyl SO2CH3 1359 CH2NH— phenyl 1-methyl-2-imidazolyl SO2CH3 1360 CH2NH— phenyl 2-methyl-1-imidazolyl SO2CH3 1361 CH2NH— phenyl 2-(dimethylaminomethyl)-1- SO2CH3 imidazolyl 1362 CH2NH— phenyl 2-(N-(cyclopropyl- SO2CH3 methyl)aminomethyl)phenyl 1363 CH2NH— phenyl 2-(N-(cyclobutyl)- SO2CH3 aminomethyl)phenyl 1364 CH2NH— phenyl 2-(N-(cyclopentyl)- SO2CH3 aminomethyl)phenyl 1365 CH2NH— phenyl 2-(N-(3-hydroxypyrrolidinyl)- SO2CH3 methyl)phenyl 1366 CH2NH— 2-pyridyl 2-(aminosulfonyl)phenyl SO2CH3 1367 CH2NH— 2-pyridyl 2-(methylaminosulfonyl)phenyl SO2CH3 1368 CH2NH— 2-pyridyl 1-pyrrolidinocarbonyl SO2CH3 1369 CH2NH— 2-pyridyl 2-(methylsulfonyl)phenyl SO2CH3 1370 CH2NH— 2-pyridyl 2-(N,N- SO2CH3 dimethylaminomethyl)phenyl SO2CH3 1371 CH2NH— 2-pyridyl 2-(N-pyrrolidinylmethyl)phenyl SO2CH3 1372 CH2NH— 2-pyridyl 1-methyl-2-imidazolyl SO2CH3 1373 CH2NH— 2-pyridyl 2-methyl-1-imidazolyl SO2CH3 1374 CH2NH— 2-pyridyl 2-(dimethylaminomethyl)-1- SO2CH3 imidazolyl 1375 CH2NH— 2-pyridyl 2-(N-(cyclopropyl- SO2CH3 methyl)aminomethyl)phenyl 1376 CH2NH— 2-pyridyl 2-(N-(cyclobutyl)- SO2CH3 aminomethyl)phenyl 1377 CH2NH— 2-pyridyl 2-(N-(cyclopentyl)- SO2CH3 aminomethyl)phenyl 1378 CH2NH— 2-pyridyl 2-(N-(3-hydroxypyrrolidinyl)- SO2CH3 methyl)phenyl 1379 CH2NH— 3-pyridyl 2-(aminosulfonyl)phenyl SO2CH3 1380 CH2NH— 3-pyridyl 2-(methylaminosulfonyl)phenyl SO2CH3 1381 CH2NH— 3-pyridyl 1-pyrrolidinocarbonyl SO2CH3 1382 CH2NH— 3-pyridyl 2-(methylsulfonyl)phenyl SO2CH3 1383 CH2NH— 3-pyridyl 2-(N,N- SO2CH3 dimethylaminomethyl)phenyl 1384 CH2NH— 3-pyridyl 2-(N-pyrrolidinylmethyl)phenyl SO2CH3 1385 CH2NH— 3-pyridyl 1-methyl-2-imidazolyl SO2CH3 1386 CH2NH— 3-pyridyl 2-methyl-1-imidazolyl SO2CH3 1387 CH2NH— 3-pyridyl 2-(dimethylaminomethyl)-1- SO2CH3 imidazolyl 1388 CH2NH— 3-pyridyl 2-(N-(cyclopropyl- SO2CH3 methyl)aminomethyl)phenyl 1389 CH2NH— 3-pyridyl 2-(N-(cyclobutyl)- SO2CH3 aminomethyl)phenyl 1390 CH2NH— 3-pyridyl 2-(N-(cyclopentyl)- SO2CH3 aminomethyl)phenyl 1391 CH2NH— 3-pyridyl 2-(N-(3-hydroxypyrrolidinyl)- SO2CH3 methyl)phenyl 1392 CH2NH— 2-pyrimidyl 2-(aminosulfonyl)phenyl SO2CH3 1393 CH2NH— 2-pyrimidyl 2-(methylaminosulfonyl)phenyl SO2CH3 1394 CH2NH— 2-pyrimidyl 1-pyrrolidinocarbonyl SO2CH3 1395 CH2NH— 2-pyrimidyl 2-(methylsulfonyl)phenyl SO2CH3 1396 CH2NH— 2-pyrimidyl 2-(N,N- SO2CH3 dimethylaminomethyl)phenyl 1397 CH2NH— 2-pyrimidyl 2-(N-pyrrolidinylmethyl)phenyl SO2CH3 1398 CH2NH— 2-pyrimidyl 1-methyl-2-imidazolyl SO2CH3 1399 CH2NH— 2-pyrimidyl 2-methyl-1-imidazolyl SO2CH3 1400 CH2NH— 2-pyrimidyl 2-(dimethylaminomethyl)-1- SO2CH3 imidazolyl 1401 CH2NH— 2-pyrimidyl 2-(N-(cyclopropyl- SO2CH3 methyl)aminomethyl)phenyl 1402 CH2NH— 2-pyrimidyl 2-(N-(cyclobutyl)- SO2CH3 aminomethyl)phenyl 1403 CH2NH— 2-pyrimidyl 2-(N-(cyclopentyl)- SO2CH3 aminomethyl)phenyl 1404 CH2NH— 2-pyrimidyl 2-(N-(3-hydroxypyrrolidinyl)- SO2CH3 methyl)phenyl 1405 CH2NH— 5-pyrimidyl 2-(aminosulfonyl)phenyl SO2CH3 1406 CH2NH— 5-pyrimidyl 2-(methylaminosulfonyl)phenyl SO2CH3 1407 CH2NH— 5-pyrimidyl 1-pyrrolidinocarbonyl SO2CH3 1408 CH2NH— 5-pyrimidyl 2-(methylsulfonyl)phenyl SO2CH3 1409 CH2NH— 5-pyrimidyl 2-(N,N- SO2CH3 dimethylaminomethyl)phenyl 1410 CH2NH— 5-pyrimidyl 2-(N-pyrrolidinylmethyl)phenyl SO2CH3 1411 CH2NH— 5-pyrimidyl 1-methyl-2-imidazolyl SO2CH3 1412 CH2NH— 5-pyrimidyl 2-methyl-1-imidazolyl SO2CH3 1413 CH2NH— 5-pyrimidyl 2-(dimethylaminomethyl)-1- SO2CH3 imidazolyl 1414 CH2NH— 5-pyrimidyl 2-(N-(cyclopropyl- SO2CH3 methyl)aminomethyl)phenyl 1415 CH2NH— 5-pyrimidyl 2-(N-(cyclobutyl)- SO2CH3 aminomethyl)phenyl 1416 CH2NH— 5-pyrimidyl 2-(N-(cyclopentyl)- SO2CH3 aminomethyl)phenyl 1417 CH2NH— 5-pyrimidyl 2-(N-(3-hydroxypyrrolidinyl)- SO2CH3 methyl)phenyl 1418 CH2NH— 2-Cl-phenyl 2-(aminosulfonyl)phenyl SO2CH3 1419 CH2NH— 2-Cl-phenyl 2-(methylaminosulfonyl)phenyl SO2CH3 1420 CH2NH— 2-Cl-phenyl 1-pyrrolidinocarbonyl SO2CH3 1421 CH2NH— 2-Cl-phenyl 2-(methylsulfonyl)phenyl SO2CH3 1422 CH2NH— 2-Cl-phenyl 2-(N,N- SO2CH3 dimethylaminomethyl)phenyl 1423 CH2NH— 2-Cl-phenyl 2-(N-pyrrolidinylmethyl)phenyl SO2CH3 1424 CH2NH— 2-Cl-phenyl 1-methyl-2-imidazolyl SO2CH3 1425 CH2NH— 2-Cl-phenyl 2-methyl-1-imidazolyl SO2CH3 1426 CH2NH— 2-Cl-phenyl 2-(dimethylaminomethyl)-1- SO2CH3 imidazolyl 1427 CH2NH— 2-Cl-phenyl 2-(N-(cyclopropyl- SO2CH3 methyl)aminomethyl)phenyl 1428 CH2NH— 2-Cl-phenyl 2-(N-(cyclobutyl)- SO2CH3 aminomethyl)phenyl 1429 CH2NH— 2-Cl-phenyl 2-(N-(cyclopentyl)- SO2CH3 aminomethyl)phenyl 1430 CH2NH— 2-Cl-phenyl 2-(N-(3-hydroxypyrrolidinyl)- SO2CH3 methyl)phenyl 1431 CH2NH— 2-F-phenyl 2-(aminosulfonyl)phenyl SO2CH3 1432 CH2NH— 2-F-phenyl 2-(methylaminosulfonyl)phenyl SO2CH3 1433 CH2NH— 2-F-phenyl 1-pyrrolidinocarbonyl SO2CH3 1434 CH2NH— 2-F-phenyl 2-(methylsulfonyl)phenyl SO2CH3 1435 CH2NH— 2-F-phenyl 2-(N,N- SO2CH3 dimethylaminomethyl)phenyl 1436 CH2NH— 2-F-phenyl 2-(N-pyrrolidinylmethyl)phenyl SO2CH3 1437 CH2NH— 2-F-phenyl 1-methyl-2-imidazolyl SO2CH3 1438 CH2NH— 2-F-phenyl 2-methyl-1-imidazolyl SO2CH3 1439 CH2NH— 2-F-phenyl 2-(dimethylaminomethyl)-1- SO2CH3 imidazolyl 1440 CH2NH— 2-F-phenyl 2-(N-(cyclopropyl- SO2CH3 methyl)aminomethyl)phenyl 1441 CH2NH— 2-F-phenyl 2-(N-(cyclobutyl)- SO2CH3 aminomethyl)phenyl 1442 CH2NH— 2-F-phenyl 2-(N-(cyclopentyl)- SO2CH3 aminomethyl)phenyl 1443 CH2NH— 2-F-phenyl 2-(N-(3-hydroxypyrrolidinyl)- SO2CH3 methyl)phenyl 1444 CH2NH— 2,6-diF-phenyl 2-(aminosulfonyl)phenyl SO2CH3 1445 CH2NH— 2,6-diF-phenyl 2-(methylaminosulfonyl)phenyl SO2CH3 1446 CH2NH— 2,6-diF-phenyl 1-pyrrolidinocarbonyl SO2CH3 1447 CH2NH— 2,6-diF-phenyl 2-(methylsulfonyl)phenyl SO2CH3 1448 CH2NH— 2,6-diF-phenyl 2-(N,N- SO2CH3 dimethylaminomethyl)phenyl 1449 CH2NH— 2,6-diF-phenyl 2-(N-pyrrolidinylmethyl)phenyl SO2CH3 1450 CH2NH— 2,6-diF-phenyl 1-methyl-2-imidazolyl SO2CH3 1451 CH2NH— 2,6-diF-phenyl 2-methyl-1-imidazolyl SO2CH3 1452 CH2NH— 2,6-diF-phenyl 2-(dimethylaminomethyl)-1- SO2CH3 imidazolyl 1453 CH2NH— 2,6-diF-phenyl 2-(N-(cyclopropyl- SO2CH3 methyl)aminomethyl)phenyl 1454 CH2NH— 2,6-diF-phenyl 2-(N-(cyclobutyl)- SO2CH3 aminomethyl)phenyl 1455 CH2NH— 2,6-diF-phenyl 2-(N-(cyclopentyl)- SO2CH3 aminomethyl)phenyl 1456 CH2NH— 2,6-diF-phenyl 2-(N-(3-hydroxypyrrolidinyl)- SO2CH3 methyl)phenyl

[0799] TABLE 2

Z is N;

Z is N;

Z is N;

Z is N;

Z is N;

Z¹ is O;

Z¹ is O;

Z¹ is O;

Z¹ is O;

Z¹ is O;

Z¹ is S;

Z¹ is S;

Z¹ is S;

Z¹ is S;

Z¹ is S;

Z¹ is NH;

Z¹ is NH;

Z¹ is NH;

Z¹ is NH;

Z¹ is NH;

Z¹ is NCH₃;

Z¹ is NCH₃;

Z¹ is NCH₃;

Z¹ is NCH₃;

Z¹ is NCH₃;

[0800] G is selected from:

[0801] 4-(methoxy)phenyl;

[0802] 2-(aminomethyl)phenyl;

[0803] 3-(aminomethyl)phenyl;

[0804] 2-(aminomethyl)-3-fluorophenyl;

[0805] 2-(aminomethyl)-4-fluorophenyl;

[0806] 2-(aminomethyl)-5-fluorophenyl;

[0807] 2-(aminomethyl)-6-fluorophenyl;

[0808] 3-amino-phthalazin-5-yl;

[0809] 3-amino-phthalazin-6-yl;

[0810] 1-aminoisoquinolin-6-yl;

[0811] 1-aminoisoquinolin-7-yl;

[0812] 4-aminoquinazol-6-yl;

[0813] 4-aminoquinazol-7-yl;

[0814] 3-aminobenzisoxazol-5-yl ;

[0815] 3-aminobenzisoxazol-6-yl;

[0816] 3-aminoisobenzazol-5-yl; and,

[0817] 3-aminoisobenzazol-6-yl; Ex # A B  1 phenyl 2-(aminosulfonyl)phenyl  2 phenyl 2-(methylaminosulfonyl)phenyl  3 phenyl 1-pyrrolidinocarbonyl  4 phenyl 2-(methylsulfonyl)phenyl  5 phenyl 2-(N,N-dimethylaminomethyl)phenyl  6 phenyl 2-(N-pyrrolidinylmethyl)phenyl  7 phenyl 1-methyl-2-imidazolyl  8 phenyl 2-methyl-1-imidazolyl  9 phenyl 2-(dimethylaminomethyl)-1-imidazolyl 10 phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 11 phenyl 2-(N-(cyclobutyl)-aminomethyl)phenyl 12 phenyl 2-(N-(cyclopentyl)-aminomethyl)phenyl 13 phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 14 2-pyridyl 2-(aminosulfonyl)phenyl 15 2-pyridyl 2-(methylaminosulfonyl)phenyl 16 2-pyridyl 1-pyrrolidinocarbonyl 17 2-pyridyl 2-(methylsulfonyl)phenyl 18 2-pyridyl 2-(N,N-dimethylaminomethyl)phenyl 19 2-pyridyl 2-(N-pyrrolidinylmethyl)phenyl 20 2-pyridyl 1-methyl-2-imidazolyl 21 2-pyridyl 2-methyl-1-imidazolyl 22 2-pyridyl 2-(dimethylaminomethyl)-1-imidazolyl 23 2-pyridyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 24 2-pyridyl 2-(N-(cyclobutyl)-aminomethyl)phenyl 25 2-pyridyl 2-(N-(cyclopentyl)-aminomethyl)phenyl 26 2-pyridyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 27 3-pyridyl 2-(aminosulfonyl)phenyl 28 3-pyridyl 2-(methylaminosulfonyl)phenyl 29 3-pyridyl 1-pyrrolidinocarbonyl 30 3-pyridyl 2-(methylsulfonyl)phenyl 31 3-pyridyl 2-(N,N-dimethylaminomethyl)phenyl 32 3-pyridyl 2-(N-pyrrolidinylmethyl)phenyl 33 3-pyridyl 1-methyl-2-imidazolyl 34 3-pyridyl 2-methyl-1-imidazolyl 35 3-pyridyl 2-(dimethylaminomethyl)-1-imidazolyl 36 3-pyridyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 37 3-pyridyl 2-(N-(cyclobutyl)-aminomethyl)phenyl 38 3-pyridyl 2-(N-(cyclopentyl)-aminomethyl)phenyl 39 3-pyridyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 40 2-pyrimidyl 2-(aminosulfonyl)phenyl 41 2-pyrimidyl 2-(methylaminosulfonyl)phenyl 42 2-pyrimidyl 1-pyrrolidinocarbonyl 43 2-pyrimidyl 2-(methylsulfonyl)phenyl 44 2-pyrimidyl 2-(N,N-dimethylaminomethyl)phenyl 45 2-pyrimidyl 2-(N-pyrrolidinylmethyl)phenyl 46 2-pyrimidyl 1-methyl-2-imidazolyl 47 2-pyrimidyl 2-methyl-1-imidazolyl 48 2-pyrimidyl 2-(dimethylaminomethyl)-1-imidazolyl 49 2-pyrimidyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 50 2-pyrimidyl 2-(N-(cyclobutyl)-aminomethyl)phenyl 51 2-pyrimidyl 2-(N-(cyclopentyl)-aminomethyl)phenyl 52 2-pyrimidyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 53 5-pyrimidyl 2-(aminosulfonyl)phenyl 54 5-pyrimidyl 2-(methylaminosulfonyl)phenyl 55 5-pyrimidyl 1-pyrrolidinocarbonyl 56 5-pyrimidyl 2-(methylsulfonyl)phenyl 57 5-pyrimidyl 2-(N,N-dimethylaminomethyl)phenyl 58 5-pyrimidyl 2-(N-pyrrolidinylmethyl)phenyl 59 5-pyrimidyl 1-methyl-2-imidazolyl 60 5-pyrimidyl 2-methyl-1-imidazolyl 61 5-pyrimidyl 2-(dimethylaminomethyl)-1-imidazolyl 62 5-pyrimidyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 63 5-pyrimidyl 2-(N-(cyclobutyl)-aminomethyl)phenyl 64 5-pyrimidyl 2-(N-(cyclopentyl)-aminomethyl)phenyl 65 5-pyrimidyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 66 2-Cl-phenyl 2-(aminosulfonyl)phenyl 67 2-Cl-phenyl 2-(methylaminosulfonyl)phenyl 68 2-Cl-phenyl 1-pyrrolidinocarbonyl 69 2-Cl-phenyl 2-(methylsulfonyl)phenyl 70 2-Cl-phenyl 2-(N,N-dimethylaminomethyl)phenyl 71 2-Cl-phenyl 2-(N-pyrrolidinylmethyl)phenyl 72 2-Cl-phenyl 1-methyl-2-imidazolyl 73 2-Cl-phenyl 2-methyl-1-imidazolyl 74 2-Cl-phenyl 2-(dimethylaminomethyl)-1-imidazolyl 75 2-Cl-phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 76 2-Cl-phenyl 2-(N-(cyclobutyl)-aminomethyl)phenyl 77 2-Cl-phenyl 2-(N-(cyclopentyl)-aminomethyl)phenyl 78 2-Cl-phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 79 2-F-phenyl 2-(aminosulfonyl)phenyl 80 2-F-phenyl 2-(methylaminosulfonyl)phenyl 81 2-F-phenyl 1-pyrrolidinocarbonyl 82 2-F-phenyl 2-(methylsulfonyl)phenyl 83 2-F-phenyl 2-(N,N-dimethylaminomethyl)phenyl 84 2-F-phenyl 2-(N-pyrrolidinylmethyl)phenyl 85 2-F-phenyl 1-methyl-2-imidazolyl 86 2-F-phenyl 2-methyl-1-imidazolyl 87 2-F-phenyl 2-(dimethylaminomethyl)-1-imidazolyl 88 2-F-phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 89 2-F-phenyl 2-(N-(cyclobutyl)-aminomethyl)phenyl 90 2-F-phenyl 2-(N-(cyclopentyl)-aminomethyl)phenyl 91 2-F-phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl 92 2,6-diF-phenyl 2-(aminosulfonyl)phenyl 93 2,6-diF-phenyl 2-(methylaminosulfonyl)phenyl 94 2,6-diF-phenyl 1-pyrrolidinocarbonyl 95 2,6-diF-phenyl 2-(methylsulfonyl)phenyl 96 2,6-diF-phenyl 2-(N,N-dimethylaminomethyl)phenyl 97 2,6-diF-phenyl 2-(N-pyrrolidinylmethyl)phenyl 98 2,6-diF-phenyl 1-methyl-2-imidazolyl 99 2,6-diF-phenyl 2-methyl-1-imidazolyl 100  2,6-diF-phenyl 2-(dimethylaminomethyl)-1-imidazolyl 101  2,6-diF-phenyl 2-(N-(cyclopropyl- methyl)aminomethyl)phenyl 102  2,6-diF-phenyl 2-(N-(cyclobutyl)-aminomethyl)phenyl 103  2,6-diF-phenyl 2-(N-(cyclopentyl)-aminomethyl)phenyl 104  2,6-diF-phenyl 2-(N-(3-hydroxypyrrolidinyl)- methyl)phenyl

Utility

[0818] The compounds of this invention are useful as anticoagulants for the treatment or prevention of thromboembolic disorders in mammals. The term “thromboembolic disorders” as used herein includes arterial or venous cardiovascular or cerebrovascular thromboembolic disorders, including, for example, unstable angina, first or recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary and cerebral arterial thrombosis, cerebral embolism, kidney embolisms, and pulmonary embolisms. The anticoagulant effect of compounds of the present invention is believed to be due to inhibition of factor Xa or thrombin.

[0819] The effectiveness of compounds of the present invention as inhibitors of factor Xa was determined using purified human factor Xa and synthetic substrate. The rate of factor Xa hydrolysis of chromogenic substrate S2222 (Kabi Pharmacia, Franklin, Ohio) was measured both in the absence and presence of compounds of the present invention. Hydrolysis of the substrate resulted in the release of pNA, which was monitored spectrophotometrically by measuring the increase in absorbance at 405 nm. A decrease in the rate of absorbance change at 405 nm in the presence of inhibitor is indicative of enzyme inhibition. The results of this assay are expressed as inhibitory constant, K_(i).

[0820] Factor Xa determinations were made in 0.10 M sodium phosphate buffer, pH 7.5, containing 0.20 M NaCl, and 0.5% PEG 8000. The Michaelis constant, K_(m), for substrate hydrolysis was determined at 25° C. using the method of Lineweaver and Burk. Values of K_(i) were determined by allowing 0.2-0.5 nM human factor Xa (Enzyme Research Laboratories, South Bend, Ind.) to react with the substrate (0.20 mM-1 mM) in the presence of inhibitor. Reactions were allowed to go for 30 minutes and the velocities (rate of absorbance change vs time) were measured in the time frame of 25-30 minutes. The following relationship was used to calculate K_(i) values:

(v _(o)-v _(s))/v _(s) =I/(K _(i)(1+S/K _(m)))

[0821] where:

[0822] v_(o) is the velocity of the control in the absence of inhibitor;

[0823] v_(s) is the velocity in the presence of inhibitor;

[0824] I is the concentration of inhibitor;

[0825] K_(i) is the dissociation constant of the enzyme:inhibitor complex;

[0826] S is the concentration of substrate;

[0827] K_(m) is the Michaelis constant.

[0828] Using the methodology described above, a number of compounds of the present invention were found to exhibit a K_(i) of ≦10 μM, thereby confirming the utility of the compounds of the present invention as effective Xa inhibitors.

[0829] Compounds tested in the above assay are considered to be active if they exhibit a K_(i) of ≦10 μM. Preferred compounds of the present invention have K_(i)'s of ≦1 μM. More preferred compounds of the present invention have K_(i)'s of ≦0.1 μM. Even more preferred compounds of the present invention have K_(i)'s of ≦0.01 μM. Still more preferred compounds of the present invention have K_(i)'s of ≦0.001 μM.

[0830] The antithrombotic effect of compounds of the present invention can be demonstrated in a rabbit arterio-venous (AV) shunt thrombosis model. In this model, rabbits weighing 2-3 kg anesthetized with a mixture of xylazine (10 mg/kg i.m.) and ketamine (50 mg/kg i.m.) are used. A saline-filled AV shunt device is connected between the femoral arterial and the femoral venous cannulae. The AV shunt device consists of a piece of 6-cm tygon tubing that contains a piece of silk thread. Blood will flow from the femoral artery via the AV-shunt into the femoral vein. The exposure of flowing blood to a silk thread will induce the formation of a significant thrombus. After forty minutes, the shunt is disconnected and the silk thread covered with thrombus is weighed. Test agents or vehicle will be given (i.v., i.p., s.c., or orally) prior to the opening of the AV shunt. The percentage inhibition of thrombus formation is determined for each treatment group. The ID50 values (dose which produces 50% inhibition of thrombus formation) are estimated by linear regression.

[0831] The compounds of formula (I) may also be useful as inhibitors of serine proteases, notably human thrombin, plasma kallikrein and plasmin. Because of their inhibitory action, these compounds are indicated for use in the prevention or treatment of physiological reactions, blood coagulation and inflammation, catalyzed by the aforesaid class of enzymes. Specifically, the compounds have utility as drugs for the treatment of diseases arising from elevated thrombin activity such as myocardial infarction, and as reagents used as anticoagulants in the processing of blood to plasma for diagnostic and other commercial purposes.

[0832] Some compounds of the present invention were shown to be direct acting inhibitors of the serine protease thrombin by their ability to inhibit the cleavage of small molecule substrates by thrombin in a purified system. In vitro inhibition constants were determined by the method described by Kettner et al. in J. Biol. Chem. 1990, 265, 18289-18297, herein incorporated by reference. In these assays, thrombin-mediated hydrolysis of the chromogenic substrate S2238 (Helena Laboratories, Beaumont, Tex.) was monitored spectrophotometrically. Addition of an inhibitor to the assay mixture results in decreased absorbance and is indicative of thrombin inhibition. Human thrombin (Enzyme Research Laboratories, Inc., South Bend, Ind.) at a concentration of 0.2 nM in 0.10 M sodium phosphate buffer, pH 7.5, 0.20 M NaCl, and 0.5% PEG 6000, was incubated with various substrate concentrations ranging from 0.20 to 0.02 mM. After 25 to 30 minutes of incubation, thrombin activity was assayed by monitoring the rate of increase in absorbance at 405 nm that arises owing to substrate hydrolysis. Inhibition constants were derived from reciprocal plots of the reaction velocity as a function of substrate concentration using the standard method of Lineweaver and Burk. Using the methodology described above, some compounds of this invention were evaluated and found to exhibit a K_(i) of less than 10 μm, thereby confirming the utility of the compounds of the present invention as effective thrombin inhibitors.

[0833] The compounds of the present invention can be administered alone or in combination with one or more additional therapeutic agents. These include other anti-coagulant or coagulation inhibitory agents, anti-platelet or platelet inhibitory agents, thrombin inhibitors, or thrombolytic or fibrinolytic agents.

[0834] The compounds are administered to a mammal in a therapeutically effective amount. By “therapeutically effective amount” it is meant an amount of a compound of Formula I that, when administered alone or in combination with an additional therapeutic agent to a mammal, is effective to prevent or ameliorate the thromboembolic disease condition or the progression of the disease.

[0835] By “administered in combination” or “combination therapy” it is meant that the compound of Formula I and one or more additional therapeutic agents are administered concurrently to the mammal being treated. When administered in combination each component may be administered at the same time or sequentially in any order at different points in time. Thus, each component may be administered separately but sufficiently closely in time so as to provide the desired therapeutic effect. Other anticoagulant agents (or coagulation inhibitory agents) that may be used in combination with the compounds of this invention include warfarin and heparin, as well as other factor Xa inhibitors such as those described in the publications identified above under Background of the Invention.

[0836] The term anti-platelet agents (or platelet inhibitory agents), as used herein, denotes agents that inhibit platelet function such as by inhibiting the aggregation, adhesion or granular secretion of platelets. Such agents include, but are not limited to, the various known non-steroidal anti-inflammatory drugs (NSAIDS) such as aspirin, ibuprofen, naproxen, sulindac, indomethacin, mefenamate, droxicam, diclofenac, sulfinpyrazone, and piroxicam, including pharmaceutically acceptable salts or prodrugs thereof. Of the NSAIDS, aspirin (acetylsalicyclic acid or ASA), and piroxicam are preferred. Other suitable anti-platelet agents include ticlopidine, including pharmaceutically acceptable salts or prodrugs thereof. Ticlopidine is also a preferred compound since it is known to be gentle on the gastro-intestinal tract in use. Still other suitable platelet inhibitory agents include IIb/IIIa antagonists, thromboxane-A2-receptor antagonists and thromboxane-A2-synthetase inhibitors, as well as pharmaceutically acceptable salts or prodrugs thereof.

[0837] The term thrombin inhibitors (or anti-thrombin agents), as used herein, denotes inhibitors of the serine protease thrombin. By inhibiting thrombin, various thrombin-mediated processes, such as thrombin-mediated platelet activation (that is, for example, the aggregation of platelets, and/or the granular secretion of plasminogen activator inhibitor-1 and/or serotonin) and/or fibrin formation are disrupted. A number of thrombin inhibitors are known to one of skill in the art and these inhibitors are contemplated to be used in combination with the present compounds. Such inhibitors include, but are not limited to, boroarginine derivatives, boropeptides, heparins, hirudin and argatroban, including pharmaceutically acceptable salts and prodrugs thereof. Boroarginine derivatives and boropeptides include N-acetyl and peptide derivatives of boronic acid, such as C-terminal a-aminoboronic acid derivatives of lysine, ornithine, arginine, homoarginine and corresponding isothiouronium analogs thereof. The term hirudin, as used herein, includes suitable derivatives or analogs of hirudin, referred to herein as hirulogs, such as disulfatohirudin. Boropeptide thrombin inhibitors include compounds described in Kettner et al., U.S. Pat. No. 5,187,157 and European Patent Application Publication Number 293 881 A2, the disclosures of which are hereby incorporated herein by reference. Other suitable boroarginine derivatives and boropeptide thrombin inhibitors include those disclosed in PCT Application Publication Number 92/07869 and European Patent Application Publication Number 471,651 A2, the disclosures of which are hereby incorporated herein by reference.

[0838] The term thrombolytics (or fibrinolytic) agents (or thrombolytics or fibrinolytics), as used herein, denotes agents that lyse blood clots (thrombi). Such agents include tissue plasminogen activator, anistreplase, urokinase or streptokinase, including pharmaceutically acceptable salts or prodrugs thereof. The term anistreplase, as used herein, refers to anisoylated plasminogen streptokinase activator complex, as described, for example, in European Patent Application No. 028,489, the disclosure of which is hereby incorporated herein by reference herein. The term urokinase, as used herein, is intended to denote both dual and single chain urokinase, the latter also being referred to herein as prourokinase.

[0839] Administration of the compounds of Formula I of the invention in combination with such additional therapeutic agent, may afford an efficacy advantage over the compounds and agents alone, and may do so while permitting the use of lower doses of each. A lower dosage minimizes the potential of side effects, thereby providing an increased margin of safety.

[0840] The compounds of the present invention are also useful as standard or reference compounds, for example as a quality standard or control, in tests or assays involving the inhibition of factor Xa. Such compounds may be provided in a commercial kit, for example, for use in pharmaceutical research involving factor Xa. For example, a compound of the present invention could be used as a reference in an assay to compare its known activity to a compound with an unknown activity. This would ensure the experimenter that the assay was being performed properly and provide a basis for comparison, especially if the test compound was a derivative of the reference compound. When developing new assays or protocols, compounds according to the present invention could be used to test their effectiveness.

[0841] The compounds of the present invention may also be used in diagnostic assays involving factor Xa. For example, the presence of factor Xa in an unknown sample could be determined by addition of chromogenic substrate S2222 to a series of solutions containing test sample and optionally one of the compounds of the present invention. If production of pNA is observed in the solutions containing test sample, but not in the presence of a compound of the present invention, then one would conclude factor Xa was present.

Dosage and Formulation

[0842] The compounds of this invention can be administered in such oral dosage forms as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups, and emulsions. They may also be administered in intravenous (bolus or infusion), intraperitoneal, subcutaneous, or intramuscular form, all using dosage forms well known to those of ordinary skill in the pharmaceutical arts. They can be administered alone, but generally will be administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.

[0843] The dosage regimen for the compounds of the present invention will, of course, vary depending upon known factors, such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration; the species, age, sex, health, medical condition, and weight of the recipient; the nature and extent of the symptoms; the kind of concurrent treatment; the frequency of treatment; the route of administration, the renal and hepatic function of the patient, and the effect desired. A physician or veterinarian can determine and prescribe the effective amount of the drug required to prevent, counter, or arrest the progress of the thromboembolic disorder.

[0844] By way of general guidance, the daily oral dosage of each active ingredient, when used for the indicated effects, will range between about 0.001 to 1000 mg/kg of body weight, preferably between about 0.01 to 100 mg/kg of body weight per day, and most preferably between about 1.0 to 20 mg/kg/day. Intravenously, the most preferred doses will range from about 1 to about 10 mg/kg/minute during a constant rate infusion. Compounds of this invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three, or four times daily.

[0845] Compounds of this invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using transdermal skin patches. When administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.

[0846] The compounds are typically administered in admixture with suitable pharmaceutical diluents, excipients, or carriers (collectively referred to herein as pharmaceutical carriers) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with conventional pharmaceutical practices.

[0847] For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl callulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like; for oral administration in liquid form, the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents, and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth, or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like.

[0848] The compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine, or phosphatidylcholines.

[0849] Compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol, polyhydroxyethylaspartamidephenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues. Furthermore, the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacylates, and crosslinked or amphipathic block copolymers of hydrogels.

[0850] Dosage forms (pharmaceutical compositions) suitable for administration may contain from about 1 milligram to about 100 milligrams of active ingredient per dosage unit. In these pharmaceutical compositions the active ingredient will ordinarily be present in an amount of about 0.5-95% by weight based on the total weight of the composition.

[0851] Gelatin capsules may contain the active ingredient and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.

[0852] Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance.

[0853] In general, water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions. Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances. Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents. Also used are citric acid and its salts and sodium EDTA. In addition, parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol.

[0854] Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, Mack Publishing Company, a standard reference text in this field.

[0855] Representative useful pharmaceutical dosage-forms for administration of the compounds of this invention can be illustrated as follows:

[0856] Capsules

[0857] A large number of unit capsules can be prepared by filling standard two-piece hard gelatin capsules each with 100 milligrams of powdered active ingredient, 150 milligrams of lactose, 50 milligrams of cellulose, and 6 milligrams magnesium stearate.

[0858] Soft Gelatin Capsules

[0859] A mixture of active ingredient in a digestable oil such as soybean oil, cottonseed oil or olive oil may be prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin capsules containing 100 milligrams of the active ingredient. The capsules should be washed and dried.

[0860] Tablets

[0861] Tablets may be prepared by conventional procedures so that the dosage unit is 100 milligrams of active ingredient, 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 milligrams of microcrystalline cellulose, 11 milligrams of starch and 98.8 milligrams of lactose. Appropriate coatings may be applied to increase palatability or delay absorption.

[0862] Injectable

[0863] A parenteral composition suitable for administration by injection may be prepared by stirring 1.5% by weight of active ingredient in 10% by volume propylene glycol and water. The solution should be made isotonic with sodium chloride and sterilized.

[0864] Suspension

[0865] An aqueous suspension can be prepared for oral administration so that each 5 mL contain 100 mg of finely divided active ingredient, 200 mg of sodium carboxymethyl cellulose, 5 mg of sodium benzoate, 1.0 g of sorbitol solution, U.S.P., and 0.025 mL of vanillin.

[0866] Where the compounds of this invention are combined with other anticoagulant agents, for example, a daily dosage may be about 0.1 to 100 milligrams of the compound of Formula I and about 1 to 7.5 milligrams of the second anticoagulant, per kilogram of patient body weight. For a tablet dosage form, the compounds of this invention generally may be present in an amount of about 5 to 10 milligrams per dosage unit, and the second anti-coagulant in an amount of about 1 to 5 milligrams per dosage unit.

[0867] Where the compounds of Formula I are administered in combination with an anti-platelet agent, by way of general guidance, typically a daily dosage may be about 0.01 to 25 milligrams of the compound of Formula I and about 50 to 150 milligrams of the anti-platelet agent, preferably about 0.1 to 1 milligrams of the compound of Formula I and about 1 to 3 milligrams of antiplatelet agents, per kilogram of patient body weight.

[0868] Where the compounds of Formula I are adminstered in combination with thrombolytic agent, typically a daily dosage may be about 0.1 to 1 milligrams of the compound of Formula I, per kilogram of patient body weight and, in the case of the thrombolytic agents, the usual dosage of the thrombolyic agent when administered alone may be reduced by about 70-80% when administered with a compound of Formula I.

[0869] Where two or more of the foregoing second therapeutic agents are administered with the compound of Formula I, generally the amount of each component in a typical daily dosage and typical dosage form may be reduced relative to the usual dosage of the agent when administered alone, in view of the additive or synergistic effect of the therapeutic agents when administered in combination.

[0870] Particularly when provided as a single dosage unit, the potential exists for a chemical interaction between the combined active ingredients. For this reason, when the compound of Formula I and a second therapeutic agent are combined in a single dosage unit they are formulated such that although the active ingredients are combined in a single dosage unit, the physical contact between the active ingredients is minimized (that is, reduced). For example, one active ingredient may be enteric coated. By enteric coating one of the active ingredients, it is possible not only to minimize the contact between the combined active ingredients, but also, it is possible to control the release of one of these components in the gastrointestinal tract such that one of these components is not released in the stomach but rather is released in the intestines. One of the active ingredients may also be coated with a material that effects a sustained-release throughout the gastrointestinal tract and also serves to minimize physical contact between the combined active ingredients. Furthermore, the sustained-released component can be additionally enteric coated such that the release of this component occurs only in the intestine. Still another approach would involve the formulation of a combination product in which the one component is coated with a sustained and/or enteric release polymer, and the other component is also coated with a polymer such as a lowviscosity grade of hydroxypropyl methylcellulose (HPMC) or other appropriate materials as known in the art, in order to further separate the active components. The polymer coating serves to form an additional barrier to interaction with the other component.

[0871] These as well as other ways of minimizing contact between the components of combination products of the present invention, whether administered in a single dosage form or administered in separate forms but at the same time by the same manner, will be readily apparent to those skilled in the art, once armed with the present disclosure.

[0872] Obviously, numerous modifications and variations of the present invention are possible in light of the above teachings. It is therefore to be understood that within the scope of the appended claims, the invention may be practiced otherwise that as specifically described herein. 

What is claimed is:
 1. A compound selected from the group:

or a stereoisomer or pharmaceutically acceptable salt thereof, wherein compounds of the above formulas are substituted with 0-2 R³; G is a group of formula I or II:

ring D is selected from —(CH₂)₃—, —(CH₂)₄—, —CH₂N═CH—, —CH₂CH₂N═CH—, and a 5-6 membered aromatic system containing from 0-2 heteroatoms selected from the group N, O, and S, provided that from 0-10 and S atoms are present; ring D, when present, is substituted with 0-2 R; E is selected from phenyl, pyridyl, pyrimidyl, pyrazinyl, and pyridazinyl, substituted with 0-1 R; R is selected from Cl, F, Br, I, OH, C₁₋₃ alkoxy, NH₂, NH(C₁₋₃ alkyl), N(C₁₋₃ alkyl)₂, CH₂NH₂, CH₂NH(C₁₋₃ alkyl), CH₂N(C₁₋₃ alkyl)₂, CH₂CH₂NH₂, CH₂CH₂NH(C₁₋₃ alkyl), and CH₂CH₂N(C₁₋₃ alkyl)₂; alternatively, ring D is absent; when ring D is absent, ring E is selected from phenyl, pyridyl, pyrimidyl, pyrazinyl, and pyridazinyl, and ring E is substituted with R″ and R′; R″ is selected from F, Cl, Br, I, OH, C₁₋₃ alkoxy, CN, C(═NR⁸)NR⁷R⁹, NHC(═NR⁸)NR⁷R⁹, NR⁸CH(=NR⁷), C(O)NR⁷R⁸, (CR⁸R⁹)_(t)NR⁷R⁸, SH, C₁₋₃ alkyl-S, S(O)R^(3b), S(O)₂R^(3a), S(O)₂NR²R^(2a), and OCF₃; R′ is selected from H, F, Cl, Br, I, SR³, CO₂R³, NO₂, (CH₂)_(t)OR³, C₁₋₄ alkyl, OCF₃, CF₃, C(O)NR⁷R⁸, and (CR⁸R⁹)_(t)NR⁷R⁸; alternatively, R″ and R′ combine to form methylenedioxy or ethylenedioxy; Z is N or CR^(1a); Z¹ is S, O, or NR³; Z² is selected from H, C₁₋₄ alkyl, phenyl, benzyl, C(O)R³, and S(O)_(p)R^(3c); R^(1a) is selected from H, —(CH₂)_(r)—R^(1′), —CH═CH—R^(1′), NHCH₂R^(1″), OCH₂R^(1″), SCH₂R^(1″), NH(CH₂)₂(CH₂)_(t)R^(1″), O(CH₂)₂(CH₂)_(t)R^(1′), and S(CH₂)₂ (CH₂)_(t)R^(1′); R^(1′) is selected from H, C₁₋₃ alkyl, F, Cl, Br, I, —CN, —CHO, (CF₂)_(r)CF₃, (CH₂)_(r)OR², NR²R^(2a), C(O)R^(2c), OC(O)R², (CF₂)_(r)CO₂R^(2c), S(O)_(p)R^(2b), NR²(CH₂)_(r)OR², C(═NR^(2c))NR²R^(2a), NR²C(O)R^(2b), NR²C(O)R³, NR²C(O)NHR^(2b), NR²C(O)₂R^(2a), OC(O)NR^(2a)R^(2b), C(O)NR²R^(2a), C(O)NR²(CH₂)_(r)OR², SO₂NR²R^(2a), NR²SO₂R^(2b), C₃₋₆ carbocyclic residue substituted with 0-2 R^(4a), and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R^(4a); R^(1″) is selected from H, CH(CH₂OR²)₂, C(O)R^(2c), C(O)NR²R^(2a), S(O)R^(2b), S(O)₂R^(2b), and SO₂NR²R^(2a); R², at each occurrence, is selected from H, CF₃, C₁₋₆ alkyl, benzyl, C₃₋₆ carbocyclic residue substituted with 0-2 R^(4b), a C₃₋₆ carbocyclic-CH₂- residue substituted with 0-2 R^(4b), and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R^(4b); R^(2a), at each occurrence, is selected from H, CF₃, C₁₋₆ alkyl, benzyl, C₃₋₆ carbocyclic residue substituted with 0-2 R^(4b), and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R^(4b); R^(2b), at each occurrence, is selected from CF₃, C₁₋₄ alkoxy, C₁₋₆ alkyl, benzyl, C₃₋₆ carbocyclic residue substituted with 0-2 R^(4b), and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R^(4b); R^(2c), at each occurrence, is selected from CF₃, OH, C₁₋₄ alkoxy, C₁₋₆ alkyl, benzyl, C₃₋₆ carbocyclic residue substituted with 0-2 R^(4b), and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R^(4b); alternatively, R² and R^(2a), together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R^(4b) and containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S; R³, at each occurrence, is selected from H, C₁₋₄ alkyl, and phenyl; R^(3a), at each occurrence, is selected from H, C₁₋₄ alkyl, and phenyl; R^(3b), at each occurrence, is selected from H, C₁₋₄ alkyl, and phenyl; R^(3c), at each occurrence, is selected from C₁₋₄ alkyl, and phenyl; A is selected from: C₃₋₁₀ carbocyclic residue substituted with 0-2 R⁴, and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R⁴; B is selected from: X—Y, C(═NR²)NR²R^(2a), NR²C(═NR²)NR²R^(2a), C₃₋₁₀ carbocyclic residue substituted with 0-2 R^(4a), and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R^(4a); X is selected from C₁₋₄ alkylene, —CR²(CR²R^(2b)) (CH₂)_(t)—, —C(O)—, —CO(═NR^(1″))—, —CR²(NR^(1″)R²)—, —CR²(OR²)—, —CR²(SR²)—, —C(O)CR²R^(2a)—, —CR²R^(2a)C(O), —S(O)_(p)—, —S(O)_(p)CR²R^(2a)—, —CR²R^(2a)S(O)_(p)—, —S(O)₂NR²—, —NR²S(O)₂—, —NR²S(O)₂CR²R^(2a)—, —CR²R^(2a)S(O)₂NR²—, —NR²S(O)₂NR²—, —C(O)NR²—, —NR²C(O)—, —C(O)NR²CR²R^(2a)—, —NR²C(O)CR²R^(2a)—, —CR²R^(2a)C(O)NR²—, —CR²R^(2a)NR²C(O)—, —NR²C(O)O—, —OC(O)NR²—, —NR²C(O)NR²—, —NR²—, —NR²CR²R^(2a)—, —CR²R^(2a)NR²—, O, —CR²R^(2a)O—, and —OCR²R^(2a)—; Y is selected from: CH₂NR²R^(2a); CH₂CH₂NR²R^(2a); C₃₋₁₀ carbocyclic residue substituted with 0-2 R^(4a), and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R^(4a); R⁴, at each occurrence, is selected from H, ═O, (CH₂)_(r)OR², F, Cl, Br, I, C₁₋₄ alkyl, —CN, NO₂, (CH₂)_(r)NR^(2a)R^(2a), (CH₂)_(r)C(O)R^(2c), NR²C(O)R^(2b), C(O)NR²R^(2a), NR²C(O)NR²R^(2a), C(═NR²)NR²R^(2a), C(═NS(O)₂R⁵)NR²R^(2a), NHC(═NR²)NR²R^(2a), C(O)NHC(═NR²)NR²R^(2a), SO₂NR²R^(2a), NR²SO₂NR²R^(2a), NR²SO₂—C₁₋₄ alkyl, NR²SO₂R⁵, S(O)_(p)R⁵, (CF₂)_(r)CF₃, NCH₂R^(1″), OCH₂R^(1″), SCH₂R^(1″), N(CH₂)₂(CH₂)_(t)R^(1′), O(CH₂)₂(CH₂)_(t)R^(1′), and S(CH₂)₂ (CH₂)_(t)R^(1′); alternatively, one R⁴ is a 5-6 membered aromatic heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, O, and S; R^(4a), at each occurrence, is selected from H, ═O, (CH₂)_(r)OR², (CH₂)_(r)—F, (CH₂)_(r)—Br, (CH₂)_(r)—Cl, Cl, Br, F, I, C₁₋₄ alkyl, —CN, NO₂, (CH₂)_(r)NR²R^(2a), (CH₂)_(r)C(O)R^(2c), NR²C(O)R^(2b), C(O)NR²R^(2a), (CH₂)_(r)N═CHOR³, C(O)NH(CH₂)₂NR²R^(2a), NR²C (O)NR²R^(2a), C(═NR²)NR²R^(2a), NHC(═NR²)NR²R^(2a), SO₂NR²R^(2a), NR²SO₂NR²R^(2a), NR²SO₂—C₁₋₄ alkyl, C(O)NHSO₂—C₁₋₄ alkyl, NR²SO₂R⁵, S(O)_(p)R⁵, and (CF₂)_(r)CF₃; alternatively, one R^(4a) is a 5-6 membered aromatic heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-1 R⁵; R^(4b), at each occurrence, is selected from H, ═O, (CH₂)_(r)OR³, F, Cl, Br, I, C₁₋₄ alkyl, —CN, NO₂, (CH₂)_(r)NR³R^(3a), (CH₂)_(r)C(O)R³, (CH₂)_(r)C(O)OR^(3c), NR³C(O)R^(3a), C(O)NR³R^(3a), NR³C(O)NR³R^(3a), C(═NR³)NR³R^(3a), NR³C(═NR³)NR³R^(3a), SO₂NR³R^(3a), NR³SO₂NR³R^(3a), NR³SO₂—C₁₋₄ alkyl, NR³SOCF₃, NR³SO₂-phenyl, S(O)_(p)CF₃, S(O)_(p)—C₁₋₄ alkyl, S(O)_(p)-phenyl, and (CF₂)_(r)CF₃; R⁵, at each occurrence, is selected from CF₃, C₁₋₆ alkyl, phenyl substituted with 0-2 R⁶, and benzyl substituted with 0-2 R⁶; R⁶, at each occurrence, is selected from H, OH, (CH₂)_(r)OR², halo, C₁₋₄ alkyl, CN, NO₂, (CH₂)_(r)NR²R^(2a), (CH₂)_(r)C(O)R^(2b), NR²C(O)R^(2b), NR²C(O)NR²R^(2a), C(═NH)NH₂, NHC(═NH)NH₂, SO₂NR²R^(2a), NR²SO₂NR²R^(2a), and NR²SO₂C₁₋₄ alkyl; R⁷, at each occurrence, is selected from H, OH, C₁₋₆ alkyl, C₁₋₆ alkylcarbonyl, C₁₋₆ alkoxy, C₁₋₄ alkoxycarbonyl, (CH₂)_(n)-phenyl, C₆₋₁₀ aryloxy, C₆₋₁₀ aryloxycarbonyl, C₆₋₁₀ arylmethylcarbonyl, C₁₋₄ alkylcarbonyloxy C₁₋₄ alkoxycarbonyl, C₆₋₁₀ arylcarbonyloxy C₁₋₄ alkoxycarbonyl, C₁₋₆ alkylaminocarbonyl, phenylaminocarbonyl, and phenyl C₁₋₄ alkoxycarbonyl; R⁸, at each occurrence, is selected from H, C₁₋₆ alkyl and (CH₂)_(n)-phenyl; alternatively, R⁷ and R⁸ combine to form a 5 or 6 membered saturated, ring which contains from 0-1 additional heteroatoms selected from the group consisting of N, O, and S; R⁹, at each occurrence, is selected from H, C₁₋₆ alkyl and (CH₂)_(n)-phenyl; n, at each occurrence, is selected from 0, 1, 2, and 3; m, at each occurrence, is selected from 0, 1, and 2; p, at each occurrence, is selected from 0, 1, and 2; r, at each occurrence, is selected from 0, 1, 2, and 3; s, at each occurrence, is selected from 0, 1, and 2; and, t, at each occurrence, is selected from 0, 1, 2, and
 3. 2. A compound of claim 1, wherein the compound is selected from the group:

wherein compounds of the above formulas are substituted with 0-2 R³; G is selected from the group:

A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R⁴; phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, benzofuranyl, benzothiofuranyl, indolyl, benzimidazolyl, benzoxazolyl, benzthiazolyl, indazolyl, benzisoxazolyl, benzisothiazolyl, and isoindazolyl; B is selected from: H, Y, and X—Y; X is selected from C₁₋₄ alkylene, —C(O)—, —C(═NR)—, —CR²(NR²R^(2a))—, —C(O)CR²R^(2a)—, —CR²R^(2a)C(O), —C(O)NR²—, —NR²C(O)—, —C(O)NR²CR²R^(2a)—, —NR²C(O)CR²R^(2a)—, —CR²R^(2a)C(O)NR²—, —CR²R^(2a)NR²C(O)—, —NR²C(O)NR²—, —NR²—, —NR²CR²R^(2a)—, —CR²R^(2a)NR²—, O, —CR²R^(2a)—, and —OCR²R^(2a); Y is CH₂NR²R^(2a) or CH₂CH₂NR²R^(2a); alternatively, Y is selected from one of the following carbocyclic and heterocyclic systems that are substituted with 0-2 R^(4a); cyclopropyl, cyclopentyl, cyclohexyl, phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, isoxazolinyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, benzofuranyl, benzothiofuranyl, indolyl, benzimidazolyl, benzoxazolyl, benzthiazolyl, indazolyl, benzisoxazolyl, benzisothiazolyl, and isoindazolyl; alternatively, Y is selected from the following bicyclic heteroaryl ring systems:

K is selected from O, S, NH, and N; and, s is
 0. 3. A compound of claim 2, wherein the compound is selected from the group:

wherein compounds of the above formulas are substituted with 0-2 R³; G is selected from the group:


4. A compound of claim 3, wherein: G is selected from:


5. A compound of claim 4, wherein: A is selected from phenyl, pyridyl, and pyrimidyl, and is substituted with 0-2 R⁴; and, B is selected from X—Y, phenyl, pyrrolidino, morpholino, 1,2,3-triazolyl, and imidazolyl, and is substituted with 0-1 R^(4a); R², at each occurrence, is selected from H, CH₃, CH₂CH₃, cyclopropylmethyl, cyclobutyl, and cyclopentyl; R^(2a), at each occurrence, is H or CH₃; alternatively, R² and R^(2a), together with the atom to which they are attached, combine to form pyrrolidine substituted with 0-2 R^(4b); R⁴, at each occurrence, is selected from OH, (CH₂)_(r)OR², halo, C₁₋₄ alkyl, (CH₂)_(r)NR²R^(2a), and (CF₂)_(r)CF₃; R^(4a) is selected from C₁₋₄ alkyl, CF₃, (CH₂)_(r)OR², (CH₂)_(r)NR²R^(2a), S(O)_(p)R⁵, SO₂NR²R^(2a), and 1-CF₃-tetrazol-2-yl; R^(4b), at each occurrence, is selected from H, CH₃, and OH; R⁵, at each occurrence, is selected from CF₃, C₁₋₆ alkyl, phenyl, and benzyl; X is CH₂ or C(O); Y is selected from pyrrolidino and morpholino; and, r, at each occurrence, is selected from 0, 1, and
 2. 6. A compound of claim 5, wherein: A is selected from the group: phenyl, 2-pyridyl, 3-pyridyl, 2-pyrimidyl, 2-Cl-phenyl, 3-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 2-methylphenyl, 2-aminophenyl, and 2-methoxyphenyl; and, B is selected from the group: 2-(aminosulfonyl)phenyl, 2-(methylaminosulfonyl)phenyl, 1-pyrrolidinocarbonyl, 2-(methylsulfonyl)phenyl, 2-(N,N-dimethylaminomethyl) phenyl, 2-(N-pyrrolidinylmethyl)phenyl, 1-methyl-2-imidazolyl, 2-methyl-1-imidazolyl, 2-(dimethylaminomethyl)-1-imidazolyl, 2-(N-(cyclopropylmethyl)aminomethyl)phenyl, 2-(N-(cyclobutyl)aminomethyl)phenyl, 2-(N-(cyclopentyl)aminomethyl)phenyl, and 2-(N-(3-hydroxypyrrolidinyl)methyl)phenyl.
 7. A compound of claim 1, wherein the compound is selected from: 1-[4-Methoxyphenyl]-3-cyano-6-[2′-methylsulfonyl-3-fluoro-[1,1′]-biphen-4-yl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione; 1-[4-Methoxyphenyl]-3-(methoxycarbonyl)-6-[2′-aminosulfonyl-3-fluoro-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[4-Methoxyphenyl]-3-(aminocarbonyl)-6-[2′-aminosulfonyl-3-fluoro-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[4-Methoxyphenyl]-3-(methoxycarbonyl)-6-[2′-aminosulfonyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[4-Methoxyphenyl]-6-[2′-aminosulfonyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one-3-carboxylic acid; 1-[4-Methoxyphenyl]-3-(aminocarbonyl)-6-[2′-aminosulfonyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[4-Methoxyphenyl]-3-cyano-6-[2′-aminosulfonyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[4-Methoxyphenyl]-3-(aminomethyl)-6-[2′-aminosulfonyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[4-Methoxyphenyl]-3-(ethoxycarbonyl)-6-[4-(2-methylimidazol-1′-yl)phenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[4-Methoxyphenyl]-3-(aminocarbonyl)-6-[4-(2-methylimidazol-1′-yl)phenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[4-Methoxyphenyl]-3-(ethoxycarbonyl)-6-[2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[4-Methoxyphenyl]-3-(ethoxycarbonyl)-6-[2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[4-Methoxyphenyl]-3-(aminocarbonyl)-6-[2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[4-Methoxyphenyl]-3-cyano-6-[2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[4-Methoxyphenyl]-3-(ethoxycarbonyl)-6-[2-fluoro-4-(2-dimethylaminomethylimidazol-1′-yl)phenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[2-Aminomethylphenyl]-3-(ethoxycarbonyl)-6-[2′-methylsulfonyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[4-Methoxyphenyl]-3-cyano-6-[2′-N,N-dimethylaminomethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[4-Methoxyphenyl]-3-cyano-5-methyl-6-[2′-N,N-dimethylaminomethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[2-Aminomethylphenyl]-3-cyano-6-[2′-methylsulfonyl-3-fluoro-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[4-Methoxyphenyl]-3-trifluoromethyl-4-methyl-6-(2′-aminosulfonyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[3,4-d]-pyridazin-7-one; 1-[4-Methoxyphenyl]-3-trifluoromethyl-4-methyl-6-[2′-pyrrolidinylmethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[3,4-d]-pyridazin-7-one, 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[4-(1-methylimidazol-2′-yl)phenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[4-Methoxyphenyl]-3-(ethoxycarbonyl)-6-[2′-hydroxymethyl-3-fluoro-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[4-Methoxyphenyl]-3-(ethoxycarbonyl)-6-[2′-N-pyrrolidinylmethyl-3-fluoro-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[4-Methoxyphenyl]-3-(aminocarbonyl)-6-[2′-N-pyrrolidinylmethyl-3-fluoro-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[4-Methoxyphenyl]-3-(aminocarbonyl)-6-[2′-(3-(R)-hydroxy-N-pyrrolidinylmethyl)-3-fluoro-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[4-Methoxyphenyl]-3-(N-formylaminomethyl)-6-[2′-methylsulfonyl-3-fluoro-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[3-Aminobenzisoxazol-5′-yl]-3-(ethoxycarbonyl)-6-[2′-hydroxymethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[3-Aminobenzisoxazol-5′-yl]-3-(ethoxycarbonyl)-6-[2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[4-Methoxyphenyl]-3-trifluoromethyl-7-[2′-methylsulfonyl-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one; 1-[4-Methoxyphenyl]-3-trifluoromethyl-7-[2′-aminosulfonyl-3-fluoro-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one; 1-[4-Methoxyphenyl]-3-trifluoromethyl-7-[2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one; 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-7-[2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one; 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-7-[2′-N-dimethylaminomethyl-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one; 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-7-[2′-N-isopropylaminomethyl-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one; 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-7-[2′-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one; 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-7-[2′-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-3-fluoro-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one; 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-7-[2′-N-pyrrolidinylmethyl-3-fluoro-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one; 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-7-[2′-N-dimethylaminomethyl-3-fluoro-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one; 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-7-[2′-N-isopropylaminomethyl-3-fluoro-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one; 1-[4-Methoxyphenyl]-3-trifluoromethyl-7-[4-(2-dimethylaminomethylimidazol-1′-yl)-3-fluorophenyl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one; 1-[4-Methoxyphenyl]-3-trifluoromethyl-7-[4-(imidazol-1′-yl)-3-fluorophenyl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one; 1-[2-Aminomethylphenyl]-3-trifluoromethyl-7-[2′-methylsulfonyl-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]-azepin-8-one; 1-[4-Methoxyphenyl]-3-[(imidazol-1-yl)methyl]-5-methyl-6-[(2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl)]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[4-Methoxyphenyl]-3-[(tetrazol-1-yl)methyl]-5-methyl-6-[(2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl)]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[4-Methoxyphenyl]-3-[(tetrazol-2-yl)methyl]-5-methyl-6-[(2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl)]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[3-Aminobenzisoxazol-5′-yl]-3,5-dimethyl-6-[2′-N-dimethylaminomethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-N,N-dimethylaminomethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-N-isopropylaminomethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[4-(4 5-dihydroimidazol-1′-yl)phenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-N-(cyclopropylmethyl)aminomethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-N-pyrrolidinylmethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[2′-(N-methyl-N-isopropyl)aminomethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[3-Aminobenzisoxazol-5′-yl]-3,5-dimethyl-6-[2′-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-N,N-dimethylaminomethyl-[1,1′]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-N,N-dimethylaminomethyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-7-[(3′-N-dimethylaminomethyl)-3-fluoro-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]azepin-8-one; 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-7-[(3′-N-pyrrolidinylmethyl)-3-fluoro-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]azepin-8-one; 1-[4-Methoxyphenyl]-3-trifluoromethyl-7-[(3′-N-pyrrolidinylmethyl)-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]azepin-8-one; 1-[4-Methoxyphenyl]-3-trifluoromethyl-7-[(3′-N-dimethylaminomethyl)-[1,1′]-biphen-4-yl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]azepin-8-one; 1-[4-Methoxyphenyl]-3-trifluoromethyl-7-[4-benzimidazol-1′-yl-3-fluorophenyl]-4,5,6,7-tetrahydropyrazolo-[3,4-c]azepin-8-one; 1-[3-Aminobenzisoxazo-5′-yl]-3-trifluoromethyl-7-[(2′-N-pyrrolidinylmethyl)-3-fluoro-[1,1′]-biphen-4-yl]-6,7-dihydropyrazolo-[3,4-c]azepin-8-one; 1-[3-Aminobenzisoxazo-5′-yl]-3-trifluoromethyl-7-[(2′-N-dimethylaminomethyl)-3-fluoro-[1,1′]-biphen-4-yl]-6,7-dihydropyrazolo-[3,4-c]azepin-8-one; 1-[3-Aminobenzisoxazo-5′-yl]-3-trifluoromethyl-7-[(2′-N-(R)-3-hydroxypyrrolidinylmethyl)-3-fluoro-[1,1′]-biphen-4-yl]-6,7-dihydropyrazolo-[3,4-c]azepin-8-one; 1-[3-Aminobenzisoxazo-5′-yl]-3-trifluoromethyl-7-[(2′-N-(R)-3-hydroxypyrrolidinylmethyl)-[1,1′]-biphen-4-yl]-6,7-dihydropyrazolo-[3,4-c]azepin-8-one; 1-[3-Aminobenzisoxazo-5′-yl]-3-trifluoromethyl-7-[(2′-N-dimethylaminomethyl)-[1,1′]-biphen-4-yl]-6,7-dihydropyrazolo-[3,4-c]azepin-8-one; 1-[4-Methoxyphenyl]-3-trifluoromethyl-7-[(2′-N-pyrrolidinylmethyl)-[1,1′]-biphen-4-yl]-6,7-dihydropyrazolo-[3,4-c]azepin-8-one; 1-[4-Methoxyphenyl]-3-trifluoromethyl-7-[(2′-N,N-dimethylaminomethyl)-[1,1′]-biphen-4-yl]-6,7-dihydropyrazolo-[3,4-c]azepin-8-one; 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[4-(2-methylimidazol-1′-yl)phenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[3-Aminobenzisoxazol-5′-yl]-3-methyl-6-[4-(2-(dimethylaminomethyl)imidazol-1′-yl)-2-fluorophenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; and, 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[4-(2-(dimethylaminomethyl)imidazol-1′-yl)phenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; or a pharmaceutically acceptable salt form thereof.
 8. A pharmaceutical compositions, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt form thereof.
 9. A method for treating or preventing a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt form thereof. 